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ABSTRACT 
 
Delivery and activity of toxic effector domains from contact-dependent growth inhibition 
systems in Escherichia coli 
 
by 
 
Julia Laura Elizabeth Willett 
 
Bacteria are ubiquitous in nature and have evolved a variety of communication and 
competition systems to survive in dense, complex environments.  Contact-dependent growth 
inhibition (CDI) is a microbial competition system that is widespread throughout Gram-
negative bacteria.  CDI is mediated by the CdiB/CdiA two-partner secretion system, which 
displays the large CdiA exoprotein on the surface of CDI
+
 inhibitor cells.  The C-terminal 
domain of CdiA (CdiA-CT) is toxic and inhibits cell growth after delivery into target 
bacteria.  CDI
+
 cells are protected from auto-inhibition by expression of a cognate immunity 
protein (CdiI), which binds to the CdiA-CT and inactivates toxicity.  CdiA-CT/CdiI pairs are 
highly divergent across species, indicating that CDI systems are capable of deploying a 
variety of toxins. 
This thesis explores several aspects of CDI, including delivery of CdiA-CTs into target 
cells, the toxic activities that lead to growth inhibition by CdiA-CT domains, and target cell 
stress responses that may influence CDI populations in natural environments.  In Chapter I, 
we provide a general introduction to both diffusible and contact-dependent bacterial 
xiii 
 
competition systems.  This provides an overview of our current knowledge of CDI systems 
and also highlights key features of other secretion systems that contribute to population 
dynamics within bacterial communities.  We then present a genetic study characterizing 
pathways of CdiA-CT translocation into target cells in Chapter II.  In Chapter III, we focus 
on one protein, YciB, which is required for translocation of CdiA-CTo11
EC869
, a DNase toxin 
from E. coli, and examine the role of YciB in E. coli physiology outside of CDI.  Chapter IV 
explores genetic responses that occur inside target cells after delivery of CdiA-CTo11
EC869
; in 
Chapter V, we present a study characterizing CdiA-CT/CdiI modules related to CdiA-
CT/CdiIo11
EC869
.  In Chapter VI, we discuss unpublished work examining the role of the 
translation factor EF-Tu as a co-factor required for activity by numerous CdiA-CT toxins.  
Chapter VII describes a collaborative project that utilized principle components of CDI 
systems as synthetic biology tools.  Finally, we discuss research questions of significant 
interest in the field of CDI in Chapter VIII. 
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I. Introduction 
Bacteria are unicellular organisms that exist and thrive in complex multicellular 
communities.  They form intricate microbial networks in the rhizosphere and in the ocean  
(1), have important host-associated roles on plants and in insects (2), and are commensal 
organisms on skin, in the nose, and in gut microbiomes (3).  Historical research has 
appreciated a pathogenic role for these microbes in disease states in plants and animals, but 
recent research demonstrates that bacterial populations influence a plethora of physiological 
behaviors.  Microbial communities can influence a variety of host behaviors and phenotypes, 
including gene expression and metabolism in Drosophila (4); light organ development in the 
squid Euprymna scolopes (5, 6); maturation, differentiation, and morphology of gut and 
immune cells (4, 7); vasculature remodeling (8); endocrine, neurological, and immune 
signaling (4, 9); brain and nervous system diseases (10-13); and social behavior and mating 
(14).  Within these niches, microbes must communicate and compete with each other and the 
surrounding host environment in order to survive.  A great body of work has characterized 
secreted factors that govern the behaviors of bacterial communication, including quorum 
sensing pathways involving production and recognition of N-acyl homoserine lactones or 
thiolactones (15-19); competition for nutrient acquisition using siderophores or manipulation 
of host machinery (20-22); and bacterial competition via killing of surrounding cells using 
molecular tools such as colicins and anti-microbial peptides (23-26), yet relatively little is 
known about systems that require direct physical contact to control neighboring cells in 
dense microbial environments. 
This introduction will provide a review of bacterial secretion systems and inhibition 
mechanisms and will also introduce the contact-dependent growth inhibition (CDI) system, 
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the study of which is the focus of this thesis.  First, colicins will be discussed as a means of 
providing background information on perhaps the best-studied group of bacterial toxins.  An 
understanding of the fundamentals of colicin biology is helpful when considering the 
complexities of CDI systems.  Next, we briefly introduce bacterial secretion systems to 
examine the different ways in which prokaryotes export toxins and other effector molecules 
to target cells.  We then discuss the history of CDI and our current understanding of the 
mechanisms by which CDI systems deploy toxins, recognize target cells, and carry out 
inhibitory activities.  Finally, we provide a short review of additional competition systems to 
contextualize CDI within a larger group of “contact-dependent” inhibition systems. 
A. Colicins 
In addition to being one of the best-studied Gram-negative organisms, Escherichia coli is 
a coliform and is present in the human intestinal microbiome (27).  In the gut, E. coli is in 
constant competition with surrounding host cells and other microbes for space and nutrients.  
As such, E. coli has evolved many ways to gain a competitive advantage in a dense microbial 
environment.  These competitive tools include secreted compounds that aid in nutrient 
acquisition, secreted proteins and nonribosomal peptides that inhibit the growth of nearby 
cells, or systems that require physical contact between cells and result in cell death (which 
will be discussed later in this chapter).  Bacteriocins are secreted proteins that inhibit the 
growth of surrounding cells.  These include the small peptide lantibiotics produced by Gram-
positive bacteria, small cyclic peptides and microcins, non-ribosomal peptides, and larger 
ribosomally-produced toxins (23).  The best studied toxins in the latter class are colicins, 
which are toxins produced by E. coli for the purpose of inhibiting other E. coli strains.  
Analogous toxins exist in other Gram-negative bacteria and are named accordingly (klebicins 
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are produced by Klebsiella pneumoniae, cloacins by Enterobacter cloacae, and so forth).  
For a comprehensive review of colicins, the 2007 review by Cascales et al. (23) is an 
excellent resource. 
1. Colicin production and release 
Colicins are 40-80 kDa peptides produced by strains carrying a pCol plasmid (28-31).  
Most colicins inhibit cells by degrading nucleic acids or forming pores in cell membranes.  A 
smaller number have other activities, such as peptidoglycan degradation in the case of colicin 
M (23).  Colicin operons contain two to three genes that encode the toxin, an immunity 
protein that inactives the peptide, and in some cases, a lysis protein required for release into 
the environment (32-39).  Some colicin operons contain multiple immunity or lysis genes, 
suggesting these genetic domains can be mobile and may have evolved from common 
ancestors (33, 36, 40).  Expression of colicin operons is typically repressed by the LexA 
protein, which is the canonical repressor of genes involved in the SOS response pathway 
induced by DNA damage (41).  As such, colicin production can be induced by DNA damage 
from UV light or other mutagens as well as other stress or nutrient starvation conditions (23).  
Upon alleviation of LexA repression, colicin and immunity genes are co-transcribed and 
translated, although the immunity genes typically have their own promoters to prevent auto-
inhibition during colicin production (42).  Expression of the lysis protein ultimately leads to 
death of the colicinogenic cell and expulsion of the colicin-immunity dimers into the 
environment, where they can interact with and inhibit target cells (43, 44). 
2. Structure and function of colicin domains 
Colicins carry out a variety of discrete steps during the process of inhibition.  After 
release from colicin-producing cells, the toxins first bind a receptor at the surface of target 
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cells.  Sequence homology was used to map this to the central region of the primary sequence 
of colicins.  The primary colicin receptors are the outer membrane proteins BtuB (utilized for 
uptake of vitamin B12) and FepA (also involved in iron uptake via transport of siderophores), 
and to a lesser extent, OmpF, OmpA, Cir, and Tsx (23).  Some colicins compete with the 
natural ligand for these outer membrane proteins, suggesting that the toxins and the natural 
substrate share overlapping binding sites (45, 46). 
Though colicins can interact with these outer membrane receptors in an energy-
independent manner, they require a source of cellular energy in order to translocate through 
the membrane (23).  This activity is mediated by the N-terminal translocation domain of 
colicins, and colicins are separated into two groups based on the protein complex utilized for 
this process.  Group A colicins utilize the Tol machinery while group B colicins hijack the 
Ton complex to move across the outer membrane.  Translocation of group A colicins has 
been best studied using the DNase colicin E9.  After binding BtuB at the outer membrane, a 
secondary outer membrane protein (OmpF) is engaged, where it interacts with the 
unstructured N-terminal domain of colicin E9.  Part of this N-terminal domain then enters the 
periplasm and recruits TolB, a membrane-associated periplasmic protein involved in 
maintaining outer membrane integrity (47-51).  Group A colicins require varying subsets of 
the TolABQR proteins for translocation (23, 52, 53).  In contrast to group A colicins, group 
B colicins require just a single outer membrane protein for translocation across this barrier.  
Instead, it appears that the outer membrane receptor is also utilized for translocation.  Instead 
of Tol proteins, group B colicins interact with TonB via a small motif termed the TonB box 
(54, 55).  In normal E. coli physiology, TonB interacts with ExbB and ExbD to transduce 
energy of the proton motive force for active transport (23). 
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3. Cytotoxic activities of colicins 
Once inside the cell, inhibitory activities are conferred by the C-terminal cytotoxic 
domain of colicins (23).  Almost all colicins kill cells in one of two basic ways:  1) by pore 
formation in the inner membrane or 2) through degradation of nucleic acids.  One exception 
is colicin M, which degrades peptidoglycan precursor molecules and blocks cell wall 
synthesis (56).  After translocation across the outer membrane, pore-forming toxins insert 
themselves into the inner membrane of E. coli target cells, converting the 10-helix bundle it 
maintains as a secreted toxin into a lipid-soluble voltage-gated channel (57-62).  Toxicity of 
these proteins is orientation-dependent, as pore-forming colicins that insert into the 
membrane from the intracellular compartment are not toxic and do not require the presence 
of immunity protein for survival.  The immunity proteins associated with these toxins 
typically block activity by “plugging” the pore formed by these ionophoric colicins and do 
not block pore formation in the membrane (23). 
Nucleases are the other major class of colicins.  These toxins cleave a variety of nucleic 
acid substrates, including DNA (colicins E2, E7, E8, and E9), 16S RNA (colicins E3, E4, and 
E6), and tRNA (colicins D and E5) (23, 34, 63-70).  DNase colicins coordinate a transition 
metal cofactor and stochastically make cuts in genomic DNA, eventually creating double-
stranded breaks that lead to cell death (23).  Studies of colicin E7, colicin E9, and related 
DNases show that these toxins bind the minor groove of double-stranded DNA (71, 72), 
distorting the phosphodiester backbone towards the coordinated metal ion.  The relevant 
metal ion in vivo is unknown due to conflicting purification and activity assay results, but 
Zn
2+
, Mg
2+
, and Ca
2+
 have supported DNase activity in vitro (73-75).  Colicins that cleave 
RNA target one of two sets of substrates:  16S RNA or tRNA.  Colicin E3 attacks the 30S 
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ribosomal subunit and cleaves 16S RNA near the A site of the ribosome (69).  Colicins E5 
and D each cleave the anticodon loops of a different subset of tRNA molecules (68, 70).  
ColE5 cleaves tRNA
His
, tRNA
Asn
, tRNA
Tyr
, and tRNA
Asp
, while colicin D cleaves all 4 
arginine isoacceptors.  The immunity proteins that correspond to the DNase and RNase 
colicins physically bind the C-terminal cytotoxic domain of these toxins, as opposed to the 
pore-forming immunities that interact with the inner membrane of cells.  ImmE5 and ImmD 
directly block the active site of their cognate colicins (76, 77), while the immunities for the 
DNase colicins as well as colicins E3, E4, and E6 bind exosite locations outside of the active 
site residues (71, 72, 78, 79).  Mechanisms of immunity inactivation will be discussed in 
Chapter V of this thesis. 
A fundamental difference between nuclease and pore-forming colicins is the location of 
the cellular compartment containing their substrates.  Nucleases cleave RNA and DNA, 
meaning that these colicins must necessarily cross both the outer and inner membranes in 
order to reach the cytoplasmic compartment.  This makes the delivery pathway of these 
toxins distinct from pore-forming colicins, which exert their toxic effect at the inner 
membrane.  A major interest in the colicin field is elucidating how nuclease colicins carry out 
the nontrivial task of crossing the inner membrane.  Studies have shown that the cytotoxic 
domains of colicins E3 and E9 associate with anionic lipid vesicles in a charge-dependent 
manner (80-84), suggesting that these toxins may interact with the inner membrane of cells in 
a similar fashion, perhaps facilitating their translocation across this barrier.  This hypothesis 
was tested by Walker et al., who examined cytotoxicity in cells with variable anionic 
phospholipid levels (85).  They utilized a cell line in which the phospholipid composition of 
the inner membrane could be altered by regulating the expression of pgsA (and thus the 
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production of the anionic phospholipid phosphatidylglycerol) and found a positive 
correlation between the levels of phosphatidylglycerol and inhibition by colicin E9 (85).  
Additionally, constructing mutant variants of colicin E9 with increased or reduced positive 
charges in the DNase domain enhanced or decreased cytotoxicity, respectively (85).  Taken 
together, this data suggests that charge-mediated interactions with the inner membrane may 
be required for nuclease toxins to access the cytoplasm of cells.   
4. Colicins undergo processing during translocation into target cells 
A number of processing steps have been identified as essential for colicin translocation.  
The first involves the immunity protein, which is bound to the toxin during synthesis to 
prevent auto-inhibition of the colicinogenic cell.  Therefore, the colicin/immunity complex is 
intact when producing cells lyse and release the toxins into the extracellular milieu.  The 
immunity protein is necessarily lost during translocation into susceptible cells in order to 
liberate the toxin and allow it to carry out toxic function upon reaching its intended 
destination.  Given the extremely strong binding affinities measured for colicin-immunity 
complexes (Kd = 10
-12
 – 10-14 (23)), it is unlikely that they simply dissociate upon release 
from a lysed cell.  Therefore, stripping away the immunity protein must be an active process 
that occurs during colicin binding or translocation instead of simply a stochastic event. 
The first step at which removal of the immunity protein could occur is during interaction 
with the outer membrane receptor.  If receptor binding induces a conformational change in 
the colicin, this could promote dissociation of the toxin-immunity complex upon binding.  
However, binding studies show that colicins do not unfold upon receptor binding and that 
immunity release does not occur at this step (86-88).  In the case of colicin E9, which binds 
BtuB at the outer membrane and requires OmpF for translocation, the entire BtuB-E9-
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ImmE9-OmpF complex can be isolated from the outer membrane of cells via nickel-affinity 
purification using His-tagged ImmE9, indicating that the immunity protein does not 
dissociate at this step (87).  Instead, translocation across the outer membrane may be a 
requirement for immunity dissociation.  Crystal structure analysis of colicin E3 reveals that 
the immunity protein interacts with both the C-terminal cytotoxic domain as well as the N-
terminal translocation domain, which is required for release of ImmE3 (79, 89).  
Additionally, the Tol machinery involved in translocation is required for the release of 
ImmE2 from colicin E2 (90).  Changes that occur in the toxin itself may also be important for 
release of the immunity.  Some models suggest that colicins become unfolded as they 
translocate across the outer membrane.  Unfolding of the domains that interact with 
immunity proteins would presumably facilitate dissociation of the colicin-immunity complex, 
liberating the toxin and enabling it to carry out toxic activity once refolded inside the cell.   
Several colicins, including pore-formers and nucleases, undergo proteolytic processing 
events during delivery.  Accordingly, only the C-terminal cytotoxic domains and not full-
length toxin are detected in cells treated with both DNase and RNase colicins (91, 92).  Many 
are processed either in vitro or in vivo by OmpT, although interpreting the relevance of this 
event is not always straightforward (93-97).  OmpT is a surface-associated serine protease 
that cleaves cationic antibiotic peptides and may be involved in processing secreted proteins 
(98, 99).  Interestingly, although OmpT processes colicin D and E3 in vitro, this cleavage is 
not required for inhibition.  E3 is still processed by lysates made from cells expressing an 
inactive form of OmpT, suggesting that another component cleaves colicin E3 in vivo (23, 
91).  OmpT processing of colicins D and E2 may be a defense mechanism to protect the cell 
from inhibition, as the presence of ImmE2 blocks OmpT-dependent cleavage, and over-
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expression of OmpT increases resistance to both toxins (91, 100). 
Additional colicin processing steps have been found to require essential proteins.  de 
Zamaroczy and colleages identified a single point mutation in LepB that prevents processing 
of colicin D and confers resistance to this toxin (101).  LepB is an essential inner membrane 
peptidase that removes signal peptides from secreted proteins, such as OmpA (102).  The 
mutation (N274K) is in a conserved domain that is required for activity of LepB, but this 
specific asparagine does not contribute to canonical peptidase function (101).  It is 
hypothesized that the LepB-dependent processing event is not required for translocation 
across the outer membrane into the periplasm, but simply to remove the C-terminal cytotoxic 
domain such that it can continue on into the cytoplasm.  Furthermore, ImmD protects against 
in vitro cleavage of colicin D by LepB (101), suggesting that the processing event takes place 
after the immunity protein is stripped away at the outer membrane.  LepB interacts with 
colicin D in vitro, and Mora et al. recently identified a LepB recognition motif in colicin D 
and two related toxins from Klebsiella pneumoniae (103).  However, purified LepB is 
insufficient to cleave colicin D, suggesting that perhaps another cellular component is 
required for this processing to take place (91, 101).  Interestingly, OmpT processes colicin D 
in vitro, but this does not require the catalytic activity of LepB, and OmpT-dependent 
processing is not required for inhibition of cells in vivo (91).  Unlike the E group colicins that 
contain patches of positively-charged residues that presumably interact with the inner 
membrane and facilitate delivery, colicin D and related klebicins do not have this charge 
distribution in their cytotoxic domains.  Therefore, it has been proposed that a direct 
interaction with LepB helps bring these toxins close to the membrane, where they can be 
subsequently processed and translocated into the cytoplasm (103).   
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Early reports on colicin resistance found that cells with mutations in tolZ (ftsH) were 
resistant to both nuclease and pore-forming colicins (104-107).  Further tests with rigorously-
characterized mutant backgrounds determined that FtsH is required for inhibition by all 
nuclease toxins but not pore-formers or colicin M (85).  The FtsH-dependent step is 
presumably downstream of receptor binding and translocation across the outer membrane, as 
both Tol- and Ton-dependent nuclease toxins require FtsH for inhibition (85).  FtsH is an 
essential AAA+ ATPase that contains a cytoplasmic protease domain and is involved in the 
degradation of aberrant proteins and the heat shock response (108-111).  Because FtsH 
typically degrades substrates into small peptides, its role in colicin processing is not 
immediately clear.  The involvement of FtsH in processing cytotoxic fragments in other 
toxin-immunity systems will be discussed in Chapter II. 
B. Bacterial secretion systems 
Secretion of effector molecules is critical for bacteria survival.  Microbes produce and 
export a number of secreted compounds used for nutrient acquisition, transfer of genetic 
materials, and inhibition of other cells.  To date, seven secretion systems that accomplish 
these tasks have been described (T1SS through T7SS).  Additional systems utilized for the 
biogenesis of extracellular structures like pili and curli have also been identified.  Here, we 
will briefly introduce the seven well-described secretion systems with the exception of T6SS, 
which will be discussed in section D.  
1. One-step transport systems (T1SS, T3SS, and T4SS) 
One-step secretion pathways transport effector molecules from Gram-negative bacteria 
across both the inner and outer membranes, and include the type 1, type 3, and type 4 
secretions systems (T1SS, T3SS, and T4SS, respectively).  The best-studied T1SS effector is 
E. coli α-hemolysin (HlyA), a toxin that forms pores in plasma membranes of red blood cells 
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and is commonly produced by uropathogenic strains of E. coli (112).  The suite of proteins 
secreted by the T1SS is broad and ranges from the 5.8kDa colicin V up to ~900 kDa 
RTX/MARTX toxins (113, 114).  T1SS loci are regulated in a variety of ways, including cis-
acting regulatory elements, mRNA structure, H-NS binding, and the Fur transcriptional 
regulator (115), and many T1SS substrates are involved in inhibiting the growth of 
surrounding cells or acquiring resources for the producing cell (116).  T1SS structures are 
composed of an outer membrane protein, a membrane fusion protein, and an ABC transport 
system.  Together, these span from the cytoplasm to the extracellular space of Gram-negative 
organisms, enabling transport of effectors across both membranes and eventual secretion 
from the cell.  The ABC transporter permits transport across the inner membrane using 
energy from ATP hydrolysis, and the outer membrane factor is typically a protein pore that 
facilitates the final step of secretion (117).  ABC transport components are highly specific for 
their substrates, but the outer membrane proteins involved in T1SS activity are more 
promiscuous.  For example, HlyA secretion requires the outer membrane factor TolC, which 
is also involved in colicin V secretion and works with the inner membrane protein AcrB to 
export small cytotoxic drug molecules (116, 118, 119). 
Secreted proteins are targeted for export via the T1SS in both signal peptide-dependent 
and signal peptide-independent manners.  Low molecular weight bacteriocins (microcins) 
contain an N-terminal signal peptide that is cleaved by a C39-like peptidase domain in their 
associated ABC transporters.  It is thought that the C39 peptidase domain/signal peptide 
interaction may help retain substrates in a conformation that permits membrane translocation 
(116).  Interestingly, the ABC transporters required for export of signal peptide-independent 
T1SS effectors contain an N-terminal domain that resembles C39 peptidase in both sequence 
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and structure.  These peptidase-like domains lack a conserved cysteine required for activity 
and are not involved in processing, but they are nevertheless required for the export of their 
T1SS effector molecules (116).  Other well-studied proteins secreted by T1SS have C-
terminal secretion signals that are not proteolytically cleaved during export but are required 
for targeting to T1SS machinery (116).  T1SS substrates are exported in an unfolded state 
(120).  The HasB iron-binding protein produced by Serratia marcescens interacts with the 
SecB chaperone to remain in an unfolded state and facilitate export, but not via interaction 
with the same residues involved in the canonical SecB/SecA chaperone pathway.  This is the 
only T1SS substrate exported using this chaperone, and it hypothesized that others have 
intramolecular motifs that help retain them in an unfolded or secretion-competent state (120). 
In contrast to the simple three-partner T1SS export machinery, type 3 secretion systems 
(T3SS) are composed of a complex assemblage termed the injectosome, which contains 
approximately 25 unique proteins and allows bacteria to deliver proteins to eukaryotic cells 
(121, 122).  The T3SS injectosome apparatus is structurally conserved and resembles 
flagella.  Flagella are anchored to the inner membrane by a ring composed of FliF subunits 
and span the periplasmic space to the outer membrane.  They elaborate a curved “hook” on 
the cell surface, from which the filament extends away from the cell (121).  Turning of the 
flagella is achieved by a cytosolic ATPase motor.  Similarly, T3SS injectosomes are 
anchored to both the inner and outer membrane by ring structures and include a cytosolic 
ATPase required for export of effectors.  The injectosome needle is analogous to the flagellar 
filament and is a hollow protein tube that extends away from the cell surface.  Electron 
microscopy studies show that the width of the tube cannot accommodate folded proteins; as 
such, T3SS effectors are exported in an unfolded state.  T3SS needles have evolved to best 
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deliver effector molecules to unique environments of their hosts.  T3SS systems from 
enteropathogenic E. coli must move effectors across the intestinal mucosa, but plant 
pathogens must transport their T3SS effectors across plant cell walls.  To accomplish these 
similar but distinct tasks, T3SS needles produced by enteropathogenic E. coli are more 
flexible than the thin pilus produced by T3SS loci in plant pathogens (123, 124).  Both 
flagella and the T3SS injectosome have molecular “rulers” to regulate the length of these 
structures, which ensures that T3SS effectors are properly deployed from one cell cytoplasm 
to another. 
Though the injectosome machinery is highly conserved, T3SS effectors are diverse (121).  
Numerous plant and animal pathogens employ T3SS to target their respective hosts.  Many 
T3SS effectors from plant pathogens such as Pseudomonas, Xanthomonas, and Erwinia 
species influence host cell defense mechanisms and are involved in the transcriptional 
cascades that control programmed cell death, hormone signaling through jasmonic acid 
pathways, or morphological changes in response to an invading pathogen.  Other T3SS 
effectors deployed against plant hosts have protease or phosphatase activities that directly 
degrade or alter host proteins (125, 126).  Many T3SS effectors from animal pathogens 
interact with host GTP-binding proteins involved in regulation of cytoskeletal movement, 
trafficking, cell growth, and apoptosis (122).  For example, the well-studied Salmonella 
effector SopE activates the Rho GTPases Cdc42 and Rac1, thus promoting invasion into host 
cells through cytoskeletal rearrangements.  T3SS effectors from Yersinia have a 
complimentary effect and work by inactivating GTPases to prevent phagocytosis and 
inflammatory responses (122).  Other T3SS effectors deployed against animal hosts act as 
proteases, phosphatases, or kinases that directly inactivate target molecules or modulate 
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transcriptional cascades involved in the host immune response (122).  Numerous plant and 
animal pathogens require a functional T3SS for virulence. 
Like T3SS assemblages, T4SSs resemble another bacterial macrostructure in that their 
extracellular filament is related to pili.  T4SSs are found in Gram-positive and Gram-negative 
organisms and are used to transfer both DNA and protein effectors (127, 128).  They carry 
out plasmid conjugation, transfer of conjugative elements to other bacteria, and delivery of 
proteins to eukaryotic cells.  The well-studied conjugative T4SS encoded by the vir locus in 
Agrobacterium tumefaciens delivers a nucleoprotein complex into plant cells, resulting in 
integration of bacteria DNA into the host genome and tumor formation (128, 129).  
Conjugative T4SSs in Gram-negative bacteria, such as the VirB/Vir4 T4SS in A. tumefaciens  
and the well-studied F-pilus, are typically encoded on plasmids (129).  T4SS structures in 
Neisseria and Helicobacter pylori transport DNA to and from the extracellular space instead 
of directly to or from a target cell.  Most protein-transferring T4SS complexes are found in 
pathogens such as Bordetella, Legionella, and Bartonella (129).  Both contact-dependent and 
contact-independent mechanisms of T4SS effector secretion and delivery have been 
characterized. 
In Gram-negative bacteria, T4SSs are anchored to the cell by a large core complex 
composed of distinct inner membrane and outer membrane regions and more than a dozen 
Vir proteins (130).  At its widest point, the diameter of this structure is 80 Å wide and can 
presumably accommodate large substrates.  At the outer membrane face, the pore constricts 
to 10 Å, and conformational changes of the membrane-spanning protein VirB10 gate the 
release of substrates (131).  Conserved pili-like structures extend outward from the surface of 
the cell and mediate substrate delivery to the extracellular space or target cells.  F-type pili 
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are dynamic and can undergo cycles of extension and retraction.  Conversely, P pili are not 
thought to retract and instead are static structures that are deposited on the target cell surface 
after conjugation (129, 132).  F pili have an inner pore diameter of 30 Å, which can 
accommodate unfolded protein substrates or single-stranded DNA (131).  The T4SS from H. 
pylori and L. pneumophila contain non-canonical surface structures that are larger than F- 
and P-type pili (133).  Cytoplasmic coupling proteins related to VirD4 interact with 
substrates in the cytoplasm, and many contain ATP-binding motifs (130).  Export of T4SS 
effectors, as with other secretion systems, depends on ATPase activity (129, 134).   
Conjugative T4SSs have been identified in a number of Gram-positive organisms, 
including Enterococcus faecalis, Streptococcus species, and Bacillus subtilis, and are found 
on both plasmids and genomic integrative and conjugative elements (ICEs) (133, 135).  Vir 
homologs in Gram-positive T4SSs resemble the components needed for effector 
translocation across the inner membrane of Gram-negative cells, and these Vir components 
are thought to form the core complex of Gram-positive T4SSs (133, 136).  Gram-positive 
T4SS surface structures are similar to adhesin proteins, not the pili-like structures that extend 
from Gram-negative T4SSs (137).  The transfer of plasmid elements via T4SS complexes in 
Enterococcus species is tightly regulated by pheromone signaling and is required for 
virulence (136, 138). 
2. Two-step transport systems (T2SS and T5SS) 
Unlike the one-step transport processes that export unfolded substrates through narrow 
tubes, T2SSs can secrete folded proteins (134).  T2SS substrates are first transported from the 
cytoplasm to the periplasm via the Sec (unfolded precursors) or Tat (folded precursors) 
pathways and then exported across the outer membrane by the T2SS apparatus.  As with 
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other secretion systems, T2SS machinery contains outer membrane, periplasmic, inner 
membrane, and cytoplasmic components, but role of these must be bridged by secretion from 
the cytoplasm into the periplasm by a different system before T2SS-mediated export can take 
place.  While T2SSs do not elaborate a true extracellular pilus, they contain a pseudopilus 
that is anchored to the inner membrane and spans the perisplasm (134, 139).  This is related 
to the T4SS pilus that extends outside the cell and used for transfer of protein and DNA 
substrates.  The GspD monomer that makes up the T2SS outer membrane structure is 
homologous to other secretion systems and filamentous phage (139).  Like other secretion 
systems, the inner membrane baseplate anchors the apparatus and connects to a cytoplasm 
ATPase, GspE, which is required for activity; the proton motive force is also required for 
substrate export (140). 
T2SS effector molecules are diverse and include a variety of toxins, enzymes, and 
cytochromes (139-141).  However, these substrates are specific not only for T2SS-mediated 
export, but the specific T2SS complexes from the organisms in which they are produced 
(140).  Several studies support the idea of T2SS-specific motifs required for export of 
substrates, though these are not yet well-defined (142).  The literature on T2SS export signals 
suggest that the residues in these domains are not co-localized in primary sequence, and that 
any required structural motifs may be formed by protein folding and disulfide bond 
formation in the periplasm prior to export across the outer membrane (140, 142). 
Type V secretion systems are composed of either one or two polypeptides that enable the 
surface display of a large filamentous exoprotein.  These surface proteins are common 
virulence factors and can be used for adhesion to other cells, in biofilm formation, and for the 
delivery of toxic effectors to neighboring bacteria (143).  There are currently 5 known 
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subfamilies of T5SSs (Va – Ve), with the best studied being the class Va autotransporters, 
which consist of a single polypeptide that forms the substrate pore as well as the exported 
substrate, and the class Vb two-partner secretion systems, which utilize separate proteins for 
pore formation and substrate secretion (144).  Two-partner secretion (TPS) systems utilize 
separate proteins for pore formation and substrate secretion.  Both autotransporters and TPS 
systems require the Sec machinery for translocation across the inner membrane of cells, and 
they catalyze their own export across the outer membrane.  Contact-dependent growth 
inhibition systems, which are the focus of this thesis, are two-partner secretion systems and 
will be described in detail in the following sections.  Autotransporters are secreted into the 
periplasm in an unfolded state by the Sec machinery, where the periplasmic chaperones keep 
them in this conformation until they are assembled on the cell surface.  Interestingly, the N-
terminal signal peptide domains of autotransporters are longer than canonical Sec-dependent 
signal peptide sequences, and this extra sequence space seems to slow down translocation 
(145).  The translocation domain of these systems is recognized by the Bam complex of 
essential proteins (BamABCDE) that is required for the biogenesis of outer membrane 
proteins.  The C-terminal region of autotransporter polypeptides is then exported to the 
surface of the outer membrane.  Recent evidence suggests that the final secretion steps of 
autotransporter proteins require the Bam complex as well as other cellular machinery.  After 
secretion, many autotransporter proteins undergo autoproteolysis and are released from the 
cell surface, although some remain anchored to the outer membrane (146, 147). 
TPS systems encode a β-barrel transport protein (generically called TpsB), which is 
responsible for the surface display of the filamentous protein TpsA (143).  Most TpsB 
proteins are substrate-specific and only export one TpsA protein.  TpsB is structurally 
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homologous to BamA and forms a 16-strand β-barrel in the outer membrane with two 
periplasmic POTRA domains.  TpsA proteins interact with their cognate TpsB via a highly-
conserved TPS domain near the N-terminus; this region interacts with the POTRA domains 
of TpsB.  The N-terminal region of TpsA proteins also contains an extended signal peptide 
that is required for secretion into the periplasm.  Once translocated to this compartment, 
periplasmic chaperones help keep these peptides unfolded until secretion across the outer 
membrane.  Two models exist for the orientation of TpsA during outer membrane 
translocation.  The first, put forth by Mazar and Cotter when studying FHA systems in 
Bortadella pertussis, posits that the N-terminus remains anchored in the periplasm, while the 
C-terminus loops around in a hairpin and is displayed on the cell surface, where it is 
processed and released (148).  Conversely, the HMW1 adhesin from Haemophilus influenzae 
is oriented such that the C-terminus stays in the periplasm, where a peptide loop prevents 
release from HMW1B (the TpsB homolog for this system) (149).  The orientation of contact-
dependent growth inhibition proteins during biogenesis is unknown and will be speculated 
upon in the conclusion chapter. 
In addition to autotransporters and two-partner secretion systems, three additional 
subclasses of T5SSs have been described:  trimeric autotransporters (Vc), fused two-partner 
secretion systems (Vd), and inverted autotransporters (Ve) (143, 150).  Unlike monomeric 
transporters, trimeric autotransporters are not cleaved at the cell surface and instead remain 
attached to the outer membrane.  They are widespread in pathogenic bacteria and are often 
used to bind eukaryotic host cells, as is the case for YadA in Yersinia enterocolitica (151).  
Trimeric autotransporters are secreted across the inner membrane into the periplasm, where a 
combination of chaperones and internal peptide motifs keep them in an unfolded state until 
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secreted by their trimeric outer membrane β-barrel proteins.  Members of the Vd family of 
fused two-partner secretion systems are autolytically processed like autotransporters but are 
found as a single peptide that also contains a β-barrel outer membrane protein with an 
associated POTRA domain (143).  The intimin and invasin proteins that make up the Ve 
subfamily of inverted autotransporters also make contact with host cells and are important for 
pathogenesis, but the orientation of export is opposite that in the Va subfamily in that the N-
terminus is looped outside the cells, and the C-terminal end is then transported to the surface, 
where it makes contact with target cells (143, 150, 152, 153). 
3. The type 7 secretion systems of Gram-positive bacteria 
In contrast to secretion systems in Gram-negative bacteria, Gram-positive cells must 
export extracellular substrates across a single membrane and a thick cell wall that undergoes 
constant turnover.  This necessitates structural differences in comparison to the protein 
complexes that anchor Gram-negative secretion systems to the cell wall.  Type 7 secretion 
systems (T7SS) are composed of a conserved protein complex that spans the plasma 
membrane, and they lack the pseudopili or pili-like filaments that project away from the cell 
surface in many Gram-negative secretion systems (134).  As with other secretion systems, 
T7SSs contain a conserved AAA+ ATPase essential for activity.  T7SS loci have been 
characterized in a variety of Gram-positive organisms, including Bacillus subtilis, 
Staphylococcus aureus, and Listeria species, as well as in mycobacteria (154).  T7SS 
substrates belong to the ESAT-6/WXG100 family, named as such because these proteins are 
approximately 100 amino acids in size and contain a conserved WXG motif.  A related 
family of secreted toxins, the PF04740 proteins from Bacillus subtilis, are related to ESAT-
6/WXG100 proteins and have been characterized as toxic RNases (155). 
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C. Contact-dependent growth inhibition (CDI) systems 
1. Discovery of contact-dependent growth inhibition 
Contact-dependent growth inhibition (CDI) was first described in 2005 in E. coli strain 
EC93, an intestinal isolate from a rat colony (156).  Like many natural isolates, EC93 has a 
significant growth advantage over domesticated E. coli K-12 lab strains; in co-culture, EC93 
reduces the number of viable K-12 cells several thousand-fold after only a few hours (156-
159).  Unlike many previously-characterized natural isolates, EC93 does not inhibit bacteria 
solely using diffusible toxins like colicins, but instead requires direct physical contact with 
target cells (156, 157).  Thus, this new form of bacterial competition was termed contact-
dependent growth inhibition (CDI) (156).  The locus responsible for CDI was identified 
using a genomic library from E. coli EC93, and the gene cluster cdiBAI was found to be 
sufficient to confer the CDI
+
 phenotype to laboratory strains of E. coli (156). 
The first two gene products from the CDI operon, CdiB and CdiA, comprise a two-
partner secretion (TPS) system in which CdiB facilitates the display of CdiA on the cell 
surface.  TPS systems are a sub-family of type V secretion systems and include a number of 
adhesins that are important for bacterial virulence in eukaryotic hosts (160-164).  As the 
name indicates, TPS systems are composed of two proteins (generically known as TpsB and 
TpsA) that are secreted across the Gram-negative cell envelope.  TpsB proteins are outer 
membrane β-barrels of the Omp85 family, which are responsible for secretion of the TpsA 
cargo across the outer membrane.  TpsA proteins are often very large and are predicted to 
form long α-helical filaments (165, 166).  CdiB corresponds to the TpsB transporter, and 
CdiA represents the large filamentous TpsA cargo protein.  CdiA is a large exoprotein (up to 
600 kDa) that is predicted to project away from the cell membrane.  As discussed below, 
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CdiA also contains a C-terminal toxic effector domain and is responsible for the inhibition of 
target bacteria (156, 167, 168).  The third gene of the cluster, cdiI, encodes an immunity 
protein (CdiI) that is required to protect cells from inhibition by its neighboring sibling 
(CDI
+
) cells (167, 169).  
Though CdiA proteins vary in size (180 – 640 kDa), they contain a series of conserved 
domains that most closely resemble the filamentous hemagglutinin adhesins from Bordetella 
(148, 160).  As with many T5SS substrates, CdiA contains an N-terminal signal sequence 
that directs it to the Sec machinery for secretion into the periplasm.  The N-terminal region of 
CdiA also contains a TPS domain that is recognized by CdiB when it reaches the periplasm; 
the TPS domain is required for surface display on the outer membrane (156, 167, 170).  Data 
from the well-characterized TPS system from Bordetella pertussis shows that the TpsB outer 
membrane component (FhaC in B. pertussis, CdiB in CDI systems) threads the unfolded 
TpsA substrate (FhaB in B. pertussis, CdiA in CDI systems) through a central pore upon 
recognition of the TPS domain (166, 171).  Dual FHA repeat domains in CdiA suggest that 
this exoprotein could extend up to 140 nm from the cell surface (170). 
2. Genetic structure of CDI systems in gammaproteobacteria 
A majority of the length of CdiA is highly conserved, but sequence homology drops off 
significantly towards the C-terminus.  In E. coli, this hypervariable region is demarcated by a 
conserved tetrapeptide motif (VENN) located a few hundred residues from the C-terminal 
end of the protein (167).  These C-terminal residues encode the toxin domains of CDI 
systems (abbreviated CdiA-CTs).  CdiA-CT toxins can themselves be subdivided into 
distinct regions.  Bioinformatic analysis of many toxins reveals the presence of two discrete 
domains, which we have termed the N-terminal domain and C-terminal domain (NT and CT, 
22 
 
respectively) (172, 173).  This architecture is reminiscent of colicins, which contain three 
domains that carry out unique functions during the process of cell killing (23).  These CdiA-
CT domains function independently and can be rearranged with other CdiA-CTs or colicin 
domains to produce functional chimeras that are capable of inhibiting cell growth (173, 174).  
Work demonstrating the purpose of the N-terminal domain of CdiA-CTs will be discussed in 
Chapter II.  Remarkably, this modularity extends across species, and CdiA-CT cytotoxic 
domains from Yersinia, Dickeya dadantii, and Enterobacter cloacae have been successfully 
fused to E. coli CdiA at the VENN motif and delivered into E. coli target cells (167, 175).   
The discrete domain structures observed in CdiA-CT toxins may have arisen from 
genomic rearrangement and recombination events that could increase diversity of CDI 
systems.  A number of CDI loci have “orphan” toxin/immunity pairs downstream of the main 
cdiAI genes (176).  Orphan immunity genes are often expressed, but the associated toxins are 
not fused to the structural CdiA core and do not function as delivered effector molecules 
under normal conditions (167, 176).  However, they encode functional toxins and are active 
when expressed intracellularly or when fused to CdiA and delivered to target cells (167, 173, 
177).  Many orphan cdiA-CT/cdiI genes are flanked by integrases or transposable elements, 
suggesting that they have undergone or are capable of undergoing genetic rearrangements 
(176).  CDI loci are often found on pathogenicity islands, indicating that they can be 
exchanged via horizontal gene transfer (176, 178-180).  Further evidence for horizontal 
transfer of CDI systems can be found by examining closely-related toxin/immunity modules 
across species.  Recombination events that swap orphan toxin/immunity pairs may provide 
cells with a means to effectively load another toxin onto CdiA for deployment.  These orphan 
loci may represent a reservoir of toxin/immunity pairs that could expand the CDI weaponry 
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of a given strain. 
3. Genetic structure of CDI systems in other Gram-negative bacteria 
All cdi genes in gammaproteobacteria are ordered the same way (cdiBAI), but this gene 
arrangement is not conserved in distantly-related betaproteobacteria.  In Burkholderia, the 
CDI genes are ordered cdiAIB (170, 176).  The best-studied betaproteobacteria CDI systems 
are from B. thailandensis and B. pseudomallei, the latter of which contains 10 distinct CDI 
loci (169).  As in E. coli, CDI systems in Burkholderia are typically found on genomic 
islands (180, 181).  While Burkholderia CDI systems do not contain typical orphan 
toxin/immunity modules, many contain extra genes outside of the cdiAIB core set (169, 170, 
176).  Some Burkholderia loci contain multiple immunity genes, and 4 of the 10 types are 
associated with a gene termed bcpO that resides between cdiI and cdiB (170, 176, 182).  
While the precise function of BcpO is unknown, studies from the Cotter laboratory indicate 
that this gene product is a lipoprotein that is required for CDI in Burkholderia thailandensis 
(182).  However, our preliminary evidence suggests that the CDI systems in B. thailandensis 
E264 bcpO deletion strains are fully-functional (Fernando Garza-Sanchez and Christopher 
Hayes, unpublished work).  Further work will be required to characterize the contribution of 
this gene product to CDI. 
4. Outer membrane recognition and receptor binding 
CDI requires physical contact between inhibitor and target cells (156), suggesting that a 
cell-surface receptor may be required to engage CdiA on the surface of target bacteria.  Aoki 
et al. used a genetic approach to identify CDI-resistant mutants and isolated a strain with a 
transposon insertion upstream of bamA that was resistant to the CDI system from E. coli 
EC93 (157).  This transposon insertion disrupted the promoter region of bamA, and this 
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mutant expressed approximately 5-fold less BamA than wild-type cells.  BamA is an 
essential β-barrel outer membrane protein that is part of the Bam (β-barrel assembly 
machine) complex in Gram-negative bacteria, which also includes the proteins BamBCDE 
and is required for proper folding and insertion of proteins into the outer membrane (183-
190).  CDI does not require other components of the Bam complex or the POTRA-3 domain 
that is required for protein biogenesis (157, 188).  Cell-cell binding between inhibitors and 
targets is influenced by BamA levels on the surface, and anti-BamA antibodies block the 
interaction between these cell populations (157).  Furthermore, replacing the highly-
conserved extracellular loops of E. coli BamA with the corresponding region from other 
bacteria such as Salmonella or Enterobacter cloacae prevents CDI inhibitory activity and 
disrupts interactions between cells (159).  Together, this evidence indicates that BamA is a 
bonafide outer membrane receptor required for target cell recognition by CdiA.  
Interestingly, the region of CdiA that interacts with BamA varies across CDI classes, 
suggesting that a variety of outer membrane receptors may be required by different CDI 
families (Zach Ruhe, Christina Beck, David Low, and Chris Hayes, unpublished data). 
With the exception of three extracellular loops, BamA is highly conserved across 
enterobacteria (159, 191).  Given the physical interaction that must occur between BamA and 
CdiA in order for delivery of CDI toxins to occur, an attractive hypothesis is that the 
extracellular loops in BamA mediate binding, and polymorphisms in this region may restrict 
CDI efficacy across species.  This hypothesis is supported by experiments showing that the 
CDI system from EC93 does not inhibit closely-related bacteria such as Citrobacter freundii, 
Salmonella Typhimurium LT2, Proteus mirabilis, or Enterobacter species, but some of these 
bacteria become CDI-sensitive when they express plasmid-borne bamA
E. coli 
(159).  
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Furthermore, BamA from Enterobacter cloacae can be converted into a receptor for 
CdiA
EC93
 by swapping extracellular loops 6 and 7 with the corresponding sequence from E. 
coli (159).  This specificity profile dictates potential CDI interactions and restricts the 
inhibitory potential of the E. coli EC93 CDI system to other E. coli strains, thereby 
constraining the range of target bacteria that are susceptible to attack by E. coli CDI systems.  
This raises the question of what benefit is derived from only targeting sibling cells instead of 
different species that may be competing for space and nutrients in the same niche.   
Genetic selections for Burkholderia thailandensis mutants resistant to the CDI system 
from Burkholderia pseudomallei 1026b produced clones with transposon insertions in 
BTH_I0986, a predicted lipooligosaccharide glycosyl-transferase (192).  Cells lacking 
BTH_I0986 have altered LPS structures and show decreased binding to CDI
+
 Burkholderia 
inhibitor strains, indicating that this cell surface alteration affects the ability of CDI inhibitor 
cells to interact with their targets (192).  BamA was not identified as a binding determinant 
or cell-surface receptor in this study, suggesting that E. coli and Burkholderia CDI systems 
utilize distinct mechanisms to recognize their targets. 
5. The proton motive force is required for translocation across the inner membrane 
Many CDI toxins are nucleases that target intracellular substrates such as DNA or RNA 
(167, 169, 172, 175, 177, 193).  Given the location of these substrates, CdiA-CTs must 
presumably be delivered into the cytoplasm of target cells in order to exert their toxic 
effects.  We have previously showed that CdiA-CT fragments are transferred into target cells 
during CDI (194) and that delivery into target cells does not require active protein synthesis 
by CDI inhibitor cells (172).  E. coli utilizes the proton motive force (pmf) for a variety of 
processes, including generating ATP, transporting macromolecules and nutrients, turning 
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flagella (195), and transporting colicins into the cell (23, 196).  CDI toxin delivery also 
requires an active pmf, and target cells in which the pmf has been disrupted (by chemical 
uncoupling agents such as CCCP and DNP or by pore-forming CDI toxins) are resistant to 
inhibition and show no signs of toxin delivery as measured by activity assays (172).  This is 
true for CdiA-CTs with a variety of activities, indicating that the pmf requirement is a 
general feature of translocation and not a toxin-specific phenomenon.   
Membrane-spanning systems such as TonB-ExbB-ExbD transduce the energy of the pmf 
from the inner membrane to the outer membrane (197, 198), so it is possible that the pmf is 
required at either one of these barriers.  However, cell-cell binding between CDI
+
 inhibitors 
and target cells was not significantly altered when the target cell pmf was disrupted (172).  
Additionally, pmf-disrupted target cells that were mixed with CDI
+
 inhibitors and treated 
with proteinase K to remove extracellular CdiA retained the ability to import cytotoxic CdiA 
fragments when the pmf was restored by removal of chemical uncouplers (172).  Together, 
these data suggest that multiple independent steps occur during CDI, and that the pmf-
dependent step that occurs during CdiA-CT delivery is downstream of the binding event that 
occurs at the outer membrane.  This also suggests that the initial steps in CDI deliver a CdiA 
fragment to the periplasm of target cells which remains stable for several minutes and retains 
the ability to be translocated into the cytoplasm (172). 
6. CdiA-CTs do not require Tol and Ton pathways to enter target cells 
Of great interest in the CDI field is to determine the relationship between CdiA-CT 
domains and colicins.  Both are, at their core, proteinaceous toxin systems that deliver folded 
peptides across two membranes into the cytoplasm of target cells.  Colicin delivery requires 
either the Tol system (A group colicins) or the Ton system (B Group colicins) for 
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translocation (23).  CDI systems face the same challenge of moving a cytotoxic protein 
across cellular membranes, but they accomplish this in a Tol/Ton-independent manner (172).  
Neither TolA nor TonB are required for inhibition by CDI systems delivering ionophore 
toxins, DNases, or RNases (172), indicating that this is a general feature of CdiA-CT 
translocation that is not specific to any one class of toxins.  This may be indicative of another 
energy-transducing step involving CdiA.  Much of the structural region upstream of CdiA-
CT is uncharacterized, and it is possible that these regions are involved in harnessing the 
target cell pmf during delivery into cells.  With limited exceptions, exogenous addition of 
purified CdiA-CTs does not result in inhibition (174).  Conversely, colicins are small, 
diffusible toxins that do not need to be physically delivered to target cells in the same way as 
CdiA-CTs and type 6 secretion system toxins.   
Although CDI toxins do not require the Tol or Ton systems to transduce energy during 
toxin delivery, they may share other commonalities with colicin translocation pathways.  
Much work has been done to determine the mechanism by which colicins are transported 
across the inner membrane of target cells.  Colicins E3 and E9 have been shown to interact 
with and be destabilized by membrane phospholipids (80-82, 85), and the inner membrane 
AAA+ ATPase FtsH has also been implicated in colicin processing during delivery (85, 91, 
105).  As discussed in Chapter II, we have genetic evidence suggesting that a subset of CDI 
toxins also require FtsH for toxicity (173).  A variety of inner membrane proteins, including 
ABC and PTS transporters, are required for delivery of other CdiA-CTs (173).  The toxins 
that utilize these inner membrane proteins have diverse activities (167, 169, 175, 193).  
Therefore, while a pmf-dependent step may be a common feature in the delivery of these 
toxins across the inner membrane, the mechanistic steps and translocation partners involved 
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may vary. 
7.  Crystal structures can inform biochemical activity of CdiA-CTs 
Activities for the first characterized CdiA-CTs were identified using a series of 
biochemical screens and sequence homology to known bacteriocins.  Just as colicins have 
diverse functions, CdiA-CTs that act as DNases, RNases, and pore-formers have been 
identified (156, 167, 169, 173, 175-177).  More than 20 unique families of CdiA-CTs have 
been identified in E. coli alone (170).  Although bioinformatics analyses predict the existence 
of CdiA-CT domains with peptidase and deaminase activities (199, 200), we have yet to 
experimentally identify any toxins that carry out these functions.  Interestingly, there are no 
known CdiA-CTs that have cell wall-degrading activities similar to that of colicin M (56), 
perhaps indicating fundamental differences in biogenesis and toxin delivery mechanisms 
between these toxin families.  Recently, we have taken a structural approach to understand 
the activity of CdiA-CTs which have no significant homology to characterized proteins.  The 
data acquired from these endeavors have provided a wealth of information about many facets 
of CDI biology, including biochemical activity, inactivation by immunity proteins, and 
potential sites for evolution and diversification of CdiA-CTs across bacteria. 
The first CDI toxins for which crystal structures were resolved were CdiA-
CT/CdiIII
Bp1026b
 from Burkholderia pseudomallei and CdiA-CT/CdiIo11
EC869 
from E. coli 
EC869 (177).  These CdiA-CTs share little sequence homology (approximately 15%), but 
alignment of their crystal structures revealed striking similarities.  Both toxins are composed 
of a mix of β-strands and α-helices forming a half-β-barrel and are structurally similar to 
known restriction endonucleases, including the nickase BspD6I and a XisH protein from 
Anabaena varabilis that controls DNA excision (177, 201).  Despite this structural 
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conservation, these CdiA-CTs possess distinct nuclease activities.  CdiA-CTII
Bp1026b
 is an 
Mg
2+
-dependent tRNase that cleaves alanine and arginine tRNAs in the aminoacyl acceptor 
stem (169).  Based on the nuclease homology revealed by the crystal structure, CdiA-
CTo11
EC869
 was found to be a Zn
2+
-dependent DNase that degrades chromosomal DNA during 
cell-cell competitions as well as purified DNA in vitro.  We expand on these results in 
Chapter V to show that a family of site of immunity interaction (202).   
Recently, we published a crystal structure of a CdiA-CT/CdiI pair from Enterobacter 
cloacae (175).  CdiA-CT
ECL
 has little sequence homology to known proteins, but the crystal 
structure revealed structural homology (Z-score of 4.8) to the nuclease domain of colicin E3, 
which cleaves 16S RNA.  CdiA-CT
ECL
 and colicin E3 have a similar core structure composed 
of a twisted β-sheet, and potential catalytic residues in CdiA-CTECL superimpose on the 
known active site residues of E3.  Based on this structural similarity, Beck et al. confirmed 
that CdiA-CT
ECL
 also cuts 16S RNA.  HecA, a related toxin from Erwinia chrysanthemi 
EC16, shares a catalytic motif with colicin E3 and also cuts 16S RNA (175, 203).  However, 
molecular modeling suggests that each toxin interacts with the ribosome in a different 
manner and has a distinct mechanism for RNA cleavage.  Together, this illustrates how 
structural analysis of CdiA-CT families can reveal mechanistic differences in activity despite 
common core structures.   
8. Mechanisms of immunity inactivation revealed by crystal structure analysis 
Despite the conservation between CdiA-CTII
Bp1026b
 and CdiA-CTo11
EC869
, the respective 
CdiI proteins share little sequence or structural homology, and the mechanisms of 
inactivation by CdiI are markedly different (177).  CdiIII
Bp1026b
 directly binds the active site 
of its cognate CdiA-CT, rendering this inaccessible to tRNA substrates.  CdiIo11
EC869
 binds an 
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exosite formed by a β-hairpin that protrudes from the core of CdiA-CTo11
EC869.  β-
complementation between these hairpins form a 6-stranded antiparallel β-sheet; this motif is 
the first β-augmentation interaction identified stable toxin/immunity complexes and 
resembles structural features of eukaryotic signaling pathways (204), viral capsid assembly 
(205), and nascent membrane protein contacts with the Bam complex during outer membrane 
protein biogenesis in prokaryotes (206).  Both CdiA-CTs strongly associate with their 
cognate immunity (Kd values approximately 18-20 nM), but the non-cognate immunity does 
not block activity in vitro or in vivo (177).   
Similiarly, CdiA-CT
ECL
 and colicin E3 share structural conservation in their nuclease 
domains, but the methods of inactivation by cognate CdiI proteins is distinct.  The CdiA-
CT/CdiI
ECL
 interface is a complicated network of hydrogen bonds between residues in both 
proteins, hydrophobic patches, electrostatic interactions, and water molecules (175).  CdiI
ECL
 
contains multiple β-sheets that form a compact β-sandwich and protect against cleavage of 
16S RNA by directly binding the active site of CdiA-CT
ECL
 (175).  In contrast, ImmE3, 
which inactivates colicin E3, binds an exosite on the toxin and does not directly occlude the 
active site (207).  The immunity proteins do not cross protect against activity of the non-
cognate toxin, and this is likely mediated by a structural difference between the orientation of 
loop 2 in these toxins, the positioning of which may sterically prevent non-cognate immunity 
interactions.  Colicin E3 also contains a C-terminal helix that CdiA-CT
ECL
 lacks, which 
would likely prevent CdiI
ECL
 from binding to colicin E3.  While no structural data is 
available for the HecA toxin or immunity proteins, the HecA immunity does not protect 
against CdiA-CT
ECL
 or colicin E3, and neither of these immunity proteins inactivate HecA.  
Interestingly, colicins E3, E7, and E9 all interact with their respective immunity proteins via 
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exosite interactions, and it is believed that exosite immunity binding results in electrostatic 
repulsions between colicins and substrate molecules (78). 
Another example of inactivation of CdiA-CTs by active site occlusion comes from 
CdiIo2
MC58-1
, an immunity protein from Neisseria meningiditis (208).  All sequenced N. 
meningiditis isolates contain at least one CDI system, and some strains have multiple CDI 
loci or complex CDI loci that contain orphan toxin/immunity pairs.  CdiIo2
MC58-1
 contains a 
helical bundle packed against a 4-strand antiparallel β-sheet and has structural homology to 
the eukaryotic proteins Why2, a plant ssDNA binding protein involved in DNA repair (209), 
and MRP1, a mitochondrial RNA binding and editing protein (210).  However, CdiIo2
MC58-1
 
lacks the structural regions Why2 and MRP1 use to bind nucleic acids.  The CdiA-CT 
associated with CdiIo2
MC58-1
 is a predicted Mn
2+
-dependent nuclease, and a related MafB 
toxin from Neisseria has RNase activity (211).  Modeling suggests that CdiIo2
MC58-1
 blocks 
the active site of the cognate CdiA-CT to prevent activity.  If this CdiA-CT is indeed a 
nuclease and immunity inactivation occurs by binding the active site, that may explain the 
structural homology between nucleic acid binding proteins and CdiIo2
MC58-1
 despite 
CdiIo2
MC58-1
 lacking the structural domains required to bind these substrates.  Like CdiIo2
MC58-
1
, CdiI
ECL
 is also structurally similar to Whirly proteins (175) and binds the active site of 
CdiA-CT
ECL
.   
Riley and other colicin biologists have proposed that diversification of bacteriocins 
occurs at the toxin/immunity interface, where mutations in the immunity that retain high-
affinity binding to the colicin are matched by mutations in the toxin (38, 39, 212).  Similar 
evolutionary forces likely contribute to the diversity of CdiA-CT/CdiI pairs, and CdiI 
sequences usually diverge more than their related CdiA-CT toxins (213).  Mechanistic and 
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evolutionary implications of immunity inactivation will be explored elsewhere in this thesis.  
Chapter V discusses a superfamily of toxins related to CdiA-CTo11
EC869
 that have highly 
conserved structures but divergent CdiA-CT/CdiI interfaces (202).   
9. Crystal structures contribute to delineation of distinct CdiA-CT domains 
Bioinformatic analysis of CDI toxins reveals that many CdiA-CTs are divided into N-
terminal and C-terminal domains that independently cluster (193).  These domains are 
functionally interchangeable to some extent (172, 173, 194), and genetic analysis shows that 
N- and C-terminal domains can “mix and match” in CDI loci, resulting in N-terminal 
domains fused to different C-terminal sequences (and vice versa).  This dual domain 
architecture is supported by crystal structure analysis of CDI toxins.  Interestingly, N-
terminal domains are often poorly resolved or completely missing in structures, suggesting 
that they are susceptible to proteolytic degradation to a greater degree than the compact C-
terminal catalytic cores.  Coupled with evidence that the C-terminal catalytic cores of many 
CdiA-CTs are sufficient for activity (169, 177, 193), this suggests that the N- and C-terminal 
domains are functionally distinct, and the structural features of each may have intrinsic 
importance for function.  Catalytic C-terminal domains must adopt tight, carefully-folded 
structures to ensure that active site residues are appropriately situated for activity.  Perhaps 
the flexible, disordered nature of N-terminal domains is also critical for their function.  
Colicins exploit disordered domains to facilitate translocation across membranes into target 
cells (49, 87).  Given the intracellular location of many CDI substrates such as RNA and 
DNA, CdiA-CTs that target these molecules must presumably cross the outer and inner 
membranes to exert activity.  Chapter II presents work defining the contribution of N-
terminal domains to CdiA-CT delivery into the cytoplasm of target cells (173).   
33 
 
10. Some CdiA-CTs require the presence of a cofactor for activity 
Many CdiA-CTs are active in vitro with only purified components and do not require the 
presence of other protein factors for activity (167, 169, 175-177, 193).  An exception to this 
is a CdiA-CT from uropathogenic E. coli strain 536 (CdiA-CT
Ec536
), which is a general 
tRNase that cuts in the anticodon loops of target tRNA (193).  Initial studies showed that 
purified CdiA-CT
Ec536
 does not cleave tRNA in vitro unless whole-cell E. coli lysate is added 
to the reaction, suggesting that a cellular cofactor may be needed to activate this toxin (193).  
This so-called “permissive factor” was identified as CysK, an O-acetylserine sulfhydralase 
that functions with its binding partner CysE to synthesize L-cysteine from L-serine (214, 
215).  The other O-acetylserine sulfhydralase in E. coli, CysM (216), does not interact with 
CdiA-CT
Ec536
 and does not play a role in activating the toxin (193).  Interestingly, the 
enzymatic activity of CysK is not required for its function as a permissive factor, as a K42A 
mutation that alters a critical pyridoxal 5’-phosphate-coordinating residue (217) still supports 
CdiA-CT
Ec536
 activity in vitro and during CDI in co-culture experiments (193). 
The CysK-CysE interaction is mediated by the C-terminal four residues of CysE 
(sequence GDGI), which bind the active site of CysK (218-220).  This motif is nearly 
identical to the C-terminal residues of CdiA-CT
Ec536
 (sequence GYGI), which are required 
for binding to CysK and for activation of nuclease activity (193).  Preliminary work indicates 
that CdiI
Ec536
 and CysK do not bind overlapping sites, as ternary complexes with CdiA-
CT
Ec536
, CdiI
Ec536
, and CysK can be formed from purified proteins (Robert Morse, Celia 
Goulding, Christina Beck, and Christopher Hayes, unpublished data).  CysK enzymes found 
in Gram-positive organisms can interact with CymR, a transcription factor that controls 
expression of cysteine biosynthesis genes (221).  If the CysK/CdiA-CT
Ec536
 complex has an 
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additional function such as transcriptional control, cellular communication, or signaling, it 
could potentially exert this activity even in immune cells that are not susceptible to CdiA-
CT
Ec536
-induced toxicity.  Toxicity of CdiA-CT
Ec536
 may also be influenced by 
environmental conditions that regulate the expression of cysK.  Expanding our knowledge of 
CDI systems will determine whether CdiA-CTs utilize additional permissive factors and 
whether these CdiA-CT/co-factor complexes have biological roles other than inhibition.  
Chapter VI presents work on the relationship between CdiA-CT domains from E. coli and 
Klebsiella pneumoniae and the translation factor EF-Tu, which may function as a co-factor 
for these toxins. 
D. Additional inhibition systems that require physical contact between cells 
1. Contact-dependent inhibition systems in Gram-positive bacteria 
Other bacterial killing systems that require physical contact between inhibitor and target 
cells can be broadly classified as contact-dependent inhibition systems.  Classical CDI 
systems are found in Gram-negative bacteria, and the functions of CdiB and CdiA are finely-
tuned to support display of an exoprotein on the Gram-negative cell surface.  Bridging the 
outer membrane is specifically achieved by CdiB, which resides in the outer membrane and 
is responsible for elaborating CdiA on the surface of CDI
+
 cells.  The mechanistic details of 
CDI systems are inherently different than protein-based inhibition systems in Gram-positive 
organisms because of the fundamental differences between Gram-negative and Gram-
positive bacterial membranes and cell walls.  Gram-negative bacteria are separated from 
extracellular space by an outer membrane, a periplasmic space containing peptidoglycan, and 
an inner membrane.  The outer leaflet of the outer membrane is composed of 
lipidpolysaccharide molecules.  Gram-positive organisms are surrounded by a single 
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membrane and a thick cell wall composed primarily of peptidoglycan and smaller amounts of 
techoic and lipotechoic acids.  Though bonafide CDI systems are not present in Gram-
positive bacteria, many contain a similar inhibition system composed of the abundant wall-
associated protein A (WapA), which is associated with the thick peptidoglycan layer 
surrounding the cell (222). 
WapA was first identified in Bacillus subtilis and shares certain characteristics with 
CdiA.  Both are large – CdiA proteins range from 180-640 kDa, and the Bacillus subtilis 
strain 168 WapA is predicted to be approximately 250 kDa – and are associated with the cell 
surface (168, 170, 213, 222, 223).  As with toxicity conferred by CdiA, delivery of WapA-
CT domains into target bacteria is contact-dependent.  The C-terminal domains of both 
proteins are highly variable and encode toxic peptides; several WapA-CT regions have been 
characterized as tRNases (167, 224).  WapA-CT
168
 removes the CCA acceptor tail plus an 
additional nucleotide from the 3´ of tRNA molecules, WapA-CT
natto
 cleaves the anticodon 
loop of tRNA
Glu
, and WapA-CT
T-UB-10
 cleaves the anticodon loops of tRNA
Ser
 (224).  wapA 
is also immediately followed by variable open reading frames that encode immunity proteins 
that bind to and inactive their cognate WapA-CT toxins.  wapAI loci are found in a variety of 
Gram-positive organisms including Bacillus, Geobacillus, Anoxybacillus, and Listeria 
species and may be involved in kin/non-kin discrimination in a manner analogous to Gram-
negative CDI systems (159, 224, 225). 
2. Rearrangement hotspot systems 
rhs genes were first identified as rearrangement hotspots in E. coli (226), but they do not 
mediate large-scale genome rearrangements in the same way as transposable elements or 
rRNA operons (227).  Six families of rhs genes have been identified throughout 
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Enterobacteriaceae (227), and the genetic structure of these loci resemble those that encode 
CDI systems (176).  Two domains consisting of a conserved core and a variable C-terminal 
tip were originally identified in Rhs proteins (228, 229).  Recent work has refined this 
genetic structure to include four distinct domains:  1) an N-terminal domain that is conserved 
across rhs families, 2) a core domain with conserved secondary structure and glycine 
residues, 3) a DPXG repeat motif, and 4) a variable C-terminal tip that is not conserved in 
families, loci, or species.  As in cdi loci, “orphan” regions are often found downstream of the 
main rhs gene.  Many rhs tip orphans contain homology to the core domain, suggesting that 
they can undergo recombination to displace the native C-terminal tip of a given rhs loci 
(227).  Sequence analysis reveals the existence of a large genomic reservoir of C-terminal 
tips in Enterobacteriaceae, suggesting that gene displacement is the primary force behind 
diversity of rhs systems as opposed to rapid evolution of new domains (227).  Long-term 
passaging of Salmonella yielded cells in which orphan rhs genes had undergone 
recombination with the main structural gene, resulting in expression and delivery of these 
domains (230).  Indeed, rhs elements in Salmonella are found on mobile regions, suggesting 
that they can be transferred between cells through gene transfer (227). 
Rhs systems were first linked to CDI bioinformatically, when a C-terminal tip domain 
and the downstream nucleotides from Waddlia chondrophila were found to have homology 
to a CdiA-CT CdiI module from Yersinia pestis (176).  As with the VENN tetrapeptide 
sequences that separate CdiA-CT domains from the rest of CdiA, Rhs-CT domains are 
demarcated by a conserved PxxxxDPxGL motif (227).  Rhs-CT domains from Dickeya 
dadantii, a plant pathogen, inhibit cells via DNA degradation when expressed intracellularly 
and when delivered into a target cell in a contact-dependent manner.  The RhsA-CT domain 
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from E. coli is thought to inhibit cell growth by preventing translation (231).  Analogous to 
CdiI proteins, a small open reading frame downstream of the main rhs genes encode an 
immunity protein that blocks the activity of the cognate Rhs-CT toxin (176, 224).  Taken 
together, these genetic and biochemical data indicate that Rhs proteins encode another 
contact-dependent bacterial competition system in which a small, variable C-terminal peptide 
is delivered into neighboring cells. 
The C proteins of ABC toxin systems in Yersinia entomophaga contain RHS repeats and 
are predicted to have polymorphic C-terminal toxin domains that are auto-proteolytically 
processed during delivery (232, 233).  Remarkably, these ABC toxin complexes form a cage-
like structure that encapsulates the C-terminal toxic region of the C-protein.  The RHS 
repeats in protein C form strand-turn-strand motifs and comprise part of the shell in this 
structure, and a plug domain orients the toxin towards the lumen of the complex (233).  The 
repeat RHS motifs in Yersinia ABC toxins are structurally related to the YD-repeat peptides 
found throughout bacteria, fungi, and eukaryotes (224, 234).  YD-repeat proteins are 
involved in a variety of signaling pathways in eukaryotes as well as interactions between 
pathogenic bacteria and host cells (224, 234).  Interestingly, the C-terminal ends of some 
eukaryotic YD-repeat proteins are processed and function as signaling domains.  It is 
therefore intriguing to postulate that Rhs proteins that function as bacterial competition 
systems and YD-repeat proteins that function in eukaryotic neural signaling pathways may 
form elaborate conserved cage structures and share processing mechanisms. 
Like other bacterial inhibition systems, the distribution of rhs genes varies across species.  
Rhs systems in Pseudomonas can also produce bacteriocins (235) or target eukaryotic cells 
and elicit an immune response (236).  These gene clusters are also widespread in clinically-
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relevant pathogens such as Rothia mucilaginosa, which can cause infections in patients with 
cystic fibrosis or suppressed immune systems (237).  Salmonella strains usually have only 
one full-length copy, but E. coli and Shigella contain multiple Rhs systems (227).  While lab 
strains of E. coli do not contain inhibition systems such as colicins or CDI, they contain up to 
5 rhs loci (238).  In many species, rhs genes are associated with the vgr genes that are 
hallmarks of type 6 secretion systems (T6SS, discussed below) (227).  The Rhs-CTs from 
Dickeya dadantii are deployed in a T6SS-dependent manner (224).  This feature 
distinguishes Rhs from CDI systems, which do not require additional components outside of 
the cdi locus for activity.  Rhs systems have also been implicated in social behaviors such as 
mobility in Myxococcus xanthus (239).  While rhs genes are widely distributed, it is still 
unknown how they are regulated and under what conditions they are expressed (228).  The 
role of Rhs in cellular communication and competition both as a stand-alone system and as 
intertwined with other inhibition mechanisms is invariably complex and remains to be 
elucidated.   
3. Type 6 secretion systems 
CDI is a relatively simple inhibition system in that the three core genes in cdi loci are 
sufficient to confer an inhibitory CDI
+
 phenotype to CDI
-
 cells.  Of greater complexity are 
the type 6 secretion systems (T6SS) found throughout Gram-negative bacteria that inhibit 
both prokaryotic and eukaryotic cells (240-242).  T6SS loci encompass more than a dozen 
genes required for activity, stretching across 20 kilobases in some organisms (243).  The 
number of T6SS loci in a given organism varies greatly; Enterobacter cloacae contains two 
T6SS loci (244), the well-studied T6SS model organism Pseudomonas aeruginosa has three 
(245, 246), and a whopping six distinct systems have been identified in Burkholderia 
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thailandensis (247).  The existence of so many independent T6SS loci in the same organism 
is especially interesting considering the size of these systems. 
These structures mimic inverted phage tail spikes, which may be indicative of their 
evolutionary history in the bacterial lineage (248-252).  The T6SS core apparatus contains 
two proteinaceous tubes.  The inner sheath is composed of Hcp homohexamer subunits, 
which can contain toxic effector molecules encompassed in its central pore (245, 253), and 
the outer sheath is made of VipA and VipB (also annotated as TssB/TssC) (252).  The inner 
Hcp tube is required for assembly of the entire sheath, suggesting that Hcp polymerization 
precedes formation of the outer tube and may be important for scaffolding its assembly 
(254).  These are attached to the cell envelope via a membrane complex containing TssL, 
TssM, and TssJ (252), which in turn is capped by a baseplate that resembles phage structures 
used to anchor viruses to the cell surface (248, 255).  The baseplate anchors the T6SS 
assembly to the inner membrane of cells and is composed of TssE, TssK, and VgrG proteins 
(256, 257).  Upon recognition and firing into target cells, the inner Hcp is destabilized, 
releasing Hcp into the extracellular milieu as well as Hcp, VgrG, and effector molecules into 
target cells (240, 244, 246, 253).  After firing, the apparatus is disassembled by ClpV, an 
ATPase that unfolds VipB and destabilizes the sheath (252, 258, 259).   
Though the general regulation of T6SS loci is poorly-characterized, some progress has 
been made towards understanding the cues that activate these systems.  Work on the P. 
aeruginosa T6SS shows that this system fires into target cells in response to attack from 
other species expressing active T6SS, constituting a “tit-for-tat” response that ensures T6SS 
firing and effector delivery happens under conditions of duress (260).  T6SS firing also 
occurs in response to detection of type 4 secretion system structures as well as membrane 
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disruptions by polymixin B (261).  This level of control is practical considering the resources 
required for construction and firing. 
Although many T6SS systems deploy effectors of unknown function, a variety of toxins 
from these systems have been characterized.  These effector molecules target both 
periplasmic and cytoplasmic components of bacteria as well as eukaryotic cells and carry out 
a diverse array of activities.  So far, phospholipases, NAD(P)
+
 hydrolases, DNases, 
peptidases, muramidases, and peptidoglycan amidases have been identified as T6SS effectors 
(240, 244, 246, 253, 262).  Therefore, T6SS effectors must necessarily localize to different 
compartments in target cells.  Current T6SS models posit that delivery of effector molecules 
is facilitated by the sheath puncturing the outer membrane of target cells and releasing Hcp 
and associated proteins into the periplasm.  Given the somewhat crude method of delivery, it 
is thought-provoking to consider T6SS effectors must necessarily localize to different 
cellular compartments.  A recent study shows that the elongation factor EF-Tu is required for 
the import of a cytoplasmic-acting effector from P. aeruginosa (262).  As discussed in 
Chapter VI, the requirement for this protein co-factor may be shared with other inhibition 
systems such as CDI.  However, the exact translocation pathways for T6SS effectors that 
must reach the cytoplasm are unknown, as is the regulation of membrane puncture into the 
periplasm during delivery.  As previously mentioned, a functional T6SS is required for 
delivery of Rhs toxins from D. dadantii, hinting at an even greater degree of complexity in 
the role of this system in bacterial physiology (224). 
E. Thesis overview 
Bacterial competition systems, including contact-dependent growth inhibition (CDI), are 
widespread throughout bacteria.  Much of the early work on CDI demonstrated the scope and 
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complexity of cdi loci throughout Enterobacteriaceae and unraveled preliminary mechanistic 
details of target cell recognition and toxin activities (127, 156, 167, 168, 176, 194).  In this 
thesis, we build upon this past work and also begin to address fundamental questions 
regarding the role of CDI in complex environments.  In Chapter II, we present a recently-
published study describing the translocation of CdiA-CT domains into target cells, 
demonstrating that different toxin families require unique delivery pathways across the inner 
membrane.  Chapter III contains unpublished work examining the role of a specific inner 
membrane required for the translocation of CdiA-CTo11
EC869
, a toxin from E. coli.  This inner 
membrane protein, called YciB, is uncharacterized in E. coli.  We provide evidence that this 
protein is required for metal tolerance, thus complementing its role in CDI with a role in 
normal E. coli physiology.  In Chapter IV, we investigate the target cell stress response to 
delivery of CdiA-CTo11
EC869
 and the resulting DNA damage.  This constitutes the first 
attempt to characterize an outcome other than immediate cell death that could be relevant in a 
natural bacterial community undergoing CDI.  Chapter V characterizes the superfamily of 
CdiA-CTo11
EC869
-related toxins and specifically examines the CdiA-CT/CdiI interface to 
better understand diversification of this family of toxins throughout evolution. 
In Chapter VI, we present data suggesting that the elongation factor EF-Tu interacts with 
multiple CdiA-CTs in different ways.  In theory, this complements the recent finding from 
the T6SS field that EF-Tu is required for import of an effector molecule (262).  Finally, we 
step outside of bacterial physiology in Chapter VII to adapt CDI systems for synthetic 
biology purposes.  The conclusion chapter contains speculation on uncharacterized aspects of 
CDI systems, especially the regulation of these loci in natural environments.  
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II. CDI toxins exploit multiple independent cell-entry pathways 
A majority of this work has been published in the Proceedings of the National Academy 
of Sciences (USA).  Permission to reprint was obtained prior to inclusion in this thesis. 
A. Introduction 
Bacteria are constantly in competition for environmental resources and have evolved a 
number of systems to suppress the growth of competing cells.  Research during the past 
decade has revealed that Gram-negative bacteria commonly use type V and type VI secretion 
systems to deliver protein toxins into neighboring cells (213, 243).  The type V mechanism 
was the first to be identified and has been termed contact-dependent growth inhibition (CDI) 
because inhibitor cells must make direct contact with target bacteria to transfer toxins (156, 
157).  CDI
+
 bacteria express CdiB/CdiA two-partner secretion (TPS) systems, which 
assemble as a complex on the cell surface. CdiB is an outer-membrane β-barrel protein 
required for the export and presentation of toxic CdiA effectors.  CdiA proteins are very large 
(180–630 kDa depending on bacterial species) and are presented as individual β-helical 
filaments that emanate several hundred angstroms from the inhibitor-cell surface (263).  
CdiA binds to specific outer-membrane receptors on susceptible bacteria and transfers its C-
terminal toxin domain (CdiA-CT) into the target cell (159, 167).  CDI
+
 bacteria also produce 
CdiI immunity proteins to protect themselves from toxin delivered by neighboring sibling 
cells. The immunity protein binds to the CdiA-CT and neutralizes its toxin activity (167, 
169).  Notably, CdiA-CT/CdiI sequences are highly variable between bacteria and even 
between different strains of the same species (167, 169).  For example, isolates of 
Escherichia coli contain at least 20 CDI toxin/immunity sequence types.  These 
toxin/immunity protein families are distinct from one another and form specific CdiA-
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CT/CdiI cognate pairs.  Because CdiI immunity proteins do not protect against noncognate 
toxins, CDI provides a mechanism for self/nonself recognition between bacteria. 
A remarkable feature of CDI is the modularity of CdiA-CT toxins, which can be 
exchanged between different CdiA proteins to generate functional chimeras.  All CdiA 
proteins have a similar architecture consisting of an N-terminal TPS transport domain, an 
extended central region of filamentous hemagglutinin peptide repeats, and the CdiA-CT toxin 
region (Figure 1A).   In many bacteria, the variable CdiA-CT region is demarcated by the 
VENN peptide motif, which forms the C-terminal boundary of the pretoxin-VENN domain 
(Figure 1A) (167, 200).  Heterologous CdiA-CTs can be delivered into E. coli target cells 
when fused to the VENN sequence of CdiA
EC93
 from E. coli EC93 (167, 172, 175, 177, 194).  
Closer examination of the CdiA-CT region reveals that it is often composed of two variable 
domains that assort independently to form CdiA-CT composites (Figure 1B).  For example, 
the CdiA-CT
EC536
 from uropathogenic E. coli 536 and CdiA-CT
ECL
 from Enterobacter 
cloacae American Type Culture Collection 13047 (ECL) share nearly identical N-terminal 
domains but carry different C-terminal nucleases (175, 193).  The function of the CdiA-CT 
N-terminal domain has not been examined, but biochemical studies show this region is not 
required for nuclease activities in vitro (169, 177, 193).  Here, we provide evidence that the 
N-terminal domain of the CdiA-CT region plays a critical role in toxin translocation during 
CDI.  Using a genetic approach, we identified a collection of CDI-resistance (CDI
R
) 
mutations that protect E. coli target cells from specific CDI toxins.  Each CDI
R
 mutation 
disrupts expression of an inner-membrane protein (IMP) and confers resistance to CdiA-CTs 
that share homologous N-terminal domains.  We also demonstrate that the N- and C-terminal 
domains of CdiA-CT regions can be recombined to produce novel hybrids that are functional 
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in cell-mediated CDI.  We propose that the N-terminal domain of the CdiA-CT region binds 
to specific IMP receptors and mediates toxin transport across the inner membrane. 
B. Results 
1. Resistance to CdiA-CTs is conferred by mutations in genes encoding inner 
membrane proteins 
We performed a series of selections for CDI-resistant (CDI
R
) E. coli mutants, reasoning 
that protective mutations would disrupt genes required for toxin import and/or activation.  
Plasmid-borne chimeric CDI systems were constructed in which heterologous cdiA-CT/cdiI 
coding sequences were fused at the VENN encoding region of cdiA
EC93
 (Figure 1A).  Each 
chimeric fusion was functional in CDI, reducing target-cell viability between 10
3
- and 10
6
-
fold during co-culture (Figure 1C).  Moreover, target bacteria were protected when provided 
with the appropriate cognate cdiI immunity gene (Figure 1C), indicating that the grafted 
CdiA-CTs are responsible for growth inhibition. Inhibitor strains were then used to enrich 
CDI
R
 target cells from a pool of mariner transposon-insertion mutants.  CDI
R
 mutants were 
selected with iterative cycles of competition co-culture until the target-cell population was 
fully resistant.  We isolated individual target-cell clones from independent experiments and 
tested CDI
R
 phenotypes in competitions.  Linkage of CDI
R
 to each transposon insertion was 
confirmed by transduction. Identification of the transposon-insertion sites revealed that 
resistance to a given CdiA-CT toxin was due to disruption of one or two genes.  For example, 
CDI
MHI813
-resistant mutants contained independent insertions in metI, whereas the nine 
CDI1
Dd3937
-resistant mutants had multiple insertions within rbsC (Figure 2A).  CDI
TTO1
-
resistant mutants were disrupted in gltK or gltJ, and CDIo11
EC869
-resistant mutants carried 
insertions in yciC or yciB (Figure 2A).  Interestingly, ptsG mutations were isolated from 
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selections for resistance to CDI
NC101
 and CDI
EC3006
 (Figure 2A).  Notably, each disrupted 
gene encodes an integral membrane protein. MetI, RbsC, and GltJ/GltK are ABC transporter 
membrane permeases for D/L-methionine, D-ribose, and L-glutamate/L-aspartate, 
respectively (264-266).  PtsG is the main phosphotransferase system permease for D-glucose 
(267).  The functions of YciC and YciB are unknown, but both are predicted integral IMPs.  
In-frame deletions were constructed for each gene to confirm its role in CDI
R
 (Figure 2B).  
This analysis showed that ∆yciC mutants are not resistant to CDIo11
EC869
 (Figure 3), 
indicating that the original yciC insertion exerts a polar effect on yciB (Figure 2A).  
Complementation analysis confirmed the role of yciB in the CDIo11
EC869
 pathway, and 
showed the metI, rbsC, gltK, and ptsG are required for their respective CDI pathways (Figure 
3).  We also tested each in-frame deletion strain in competitions against other inhibitor 
strains and found that resistance was specific, such that ∆metI cells were resistant to 
CDI
MHI813
 but susceptible to other CDI systems (Figure 2B).  Thus, each CDI system requires 
a specific IMP to inhibit target cells. 
2. CdiA-CTs are not delivered to the cytoplasm of target cells in the absence of inner 
membrane proteins required for translocation 
Given that CDI
R
 was invariably associated with disruption of IMPs, we hypothesized that 
CDI toxins exploit these proteins to enter target bacteria.  We tested whether CDI toxins are 
delivered into CDI
R
 target cells by monitoring nuclease activities in competition co-cultures.  
CdiA-CTo11
EC869
 toxin has a potent DNase activity that produces anucleate target cells 
(Figure 4A) (177).  However, ∆yciB mutants retained normal nucleoid morphology during 
co-culture with CDIo11
EC869
 inhibitors and appeared similar to immune target cells that 
express the CdiIo11
EC869
 immunity protein (Figure 4A).  We also examined the tRNase 
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activity of CdiA-CT
EC3006
, which specifically cleaves tRNA1
Ile
.  Cleaved tRNA was detected 
in ptsG+ cells after 1 h incubation with CDI
EC3006
 inhibitors, but no tRNase activity was 
observed in co-cultures with ∆ptsG targets (Figure 4B).  These results suggest that toxin is 
excluded from the cytoplasm of CDI
R
 target cells.  Alternatively, the IMPs could function as 
so-called permissive factors, which activate CDI toxins after entry into target bacteria (193).  
This latter model predicts that CDI
R
 mutants should also be resistant to toxin produced 
internally.  To test this model, we used controllable proteolysis to degrade ssrA(DAS)-tagged 
immunity proteins and thereby activate toxins inside the cell (169, 176, 268).  CdiA-
CTo11
EC869
 activation was slow in yciB+ cells, with growth inhibition and in vivo DNase 
activity observed after 3 h (Figure 5A).  In contrast, ∆yciB cell growth was inhibited 
immediately upon toxin activation, and DNase activity was apparent within 1 h (Figure 5A).  
Similar results were obtained when CdiA-CT
EC3006
 was activated in ptsG+ and ∆ptsG cells, 
in which growth inhibition was immediate and tRNase activity was identical in both 
backgrounds (Figure 5B).  These results show that CdiA-CTo11
EC869
 and CdiA-CT
EC3006
 retain 
full toxicity when expressed inside CDI
R
 mutant strains, excluding the toxin-activation 
model.  Together, these data support a role for IMPs in the delivery of CDI toxins into the 
target-cell cytoplasm. 
3. The N-terminal domain of CdiA-CTs specifies translocation across the inner 
membrane of target cells, which does not require canonical transport function of 
inner membrane protein complexes 
Most of the CDI
R
 mutations disrupt metabolite permeases, raising the possibility that 
transport activity could play a general role in CDI toxin import.  We tested mutants lacking 
the cytoplasmic ATP-binding components of the Met (∆metN), Rbs (∆rbsA), and Glt (∆gltL) 
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ABC transporters and found that each strain was still sensitive to CDI (Figure 6).  We also 
tested PtsG proteins that carry the Cys421Ser mutation and lack the entire cytoplasmic IIB 
domain, both of which are unable to transport D-glucose (267, 269).  Each transport-
defective PtsG protein rendered ∆ptsG cells sensitive to CDIEC3006 (Figure 6).  Therefore, the 
membrane permeases are required for CDI-mediated growth inhibition, but their metabolite 
transport activities are not. 
ptsG mutants were isolated in selections for resistance to CDI
NC101
 and CDI
EC3006
 (Figure 
2A).  These CdiA-CT sequences are 73.7% identical over the first 167 residues, but the C-
terminal nuclease domains are unrelated (Figure 7A).  The CdiI immunity proteins also share 
no significant homology (Figure 7B).  In accord with this divergence, neither immunity 
protein protects against inhibition by the heterologous system (Figure 7C).  Together with 
previous analyses of CDI toxins (169, 177, 193), these observations indicate that CdiA-CT 
regions are often composed of two domains, with the extreme C-terminal domain containing 
the actual growth inhibition activity.  Moreover, the genetic interaction between PtsG and the 
N-terminal sequences of CdiA-CT
NC101
 and CdiA-CT
EC3006
 suggests that the shared domain 
specifies the cell-entry pathway.  The CdiA-CTs from uropathogenic E. coli 536 (EC536) 
and ECL also share N-terminal domains, but carry different C-terminal RNase domains and 
have distinct immunity proteins (Figure 8A and B) (175, 193).  Based on reports that E. coli 
∆ftsH mutants are resistant to multiple colicin nucleases (85, 91, 105), we screened ∆ftsH 
cells in CDI competitions and discovered that they are resistant to CDI
EC536
 and CDI
ECL
, but 
sensitive to inhibition by CDI
EC93
 (Figure 8C).  FtsH is a hexameric AAA+ 
unfoldase/protease that is tethered to the inner membrane through two transmembrane 
helices, again suggesting that each CDI system exploits a specific IMP.  ∆ftsH mutants are 
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also resistant to the CdiA-CT
PestA
 toxin from Yersinia pestis Pestoides A, which shares the N-
terminal domain with CdiA-CT
EC536
 and CdiA-CT
ECL
 (Figure 8A and B).  Together, these 
data show that CdiA-CT regions are commonly composed of two variable domains and 
suggest that the N-terminal domain may dictate the cell-entry pathway. 
Analyses of naturally occurring CdiA-CTs suggest that the N- and C-terminal domains 
can be rearranged to deliver nucleases through different pathways.  We tested this prediction 
with novel CdiA-CT hybrid constructs.  We fused the N-terminal domain of CdiA-CT
EC3006
 
(Val1–Leu167, numbered from Val1 of the VENN motif; Figure S3A) to the DNase domain 
of CdiA-CTo11
EC869
 (Ala154–Lys297) (177) (Figure 6), and then grafted the hybrid onto 
CdiA
EC93
 to generate a chimeric CDI system.  The resulting triple chimera reduced target-cell 
viability ∼100-fold in co-culture, and target cells were protected when they expressed 
cdiIo11
EC869
 but not the cdiI
EC3006
 immunity gene (Figure 9).  We then tested the 
EC3006/EC869o11 hybrid against ∆yciB and ∆ptsG target cells and found that only ∆ptsG 
mutants were resistant (Figure 9).  We used the same approach to deliver the CdiA-CT
EC536
 
tRNase domain (Lys127–Ile227) into target cells with the CdiA-CTEC3006 N-terminal domain 
(Figure 10).  As expected, CdiI
EC536
 protein protected target cells from the EC3006/EC536 
hybrid, and growth inhibition required PtsG (Figure 10).  These results show that the two 
CdiA-CT domains are modular, and nucleases can be delivered through different pathways 
specified by the N-terminal domain. 
4. FtsH activity is required for delivery of a class of CdiA-CTs but may be via an 
indirect mechanism as opposed to a direct interaction 
FtsH is a hexameric zinc-dependent protease that belongs to the AAA+ family of ATP-
dependent proteases.  It is tethered to the inner membrane by two transmembrane domains 
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connected by a 72-residue periplasmic loop (Figure 11) and contains cytoplasmic ATPase 
and protease domains (270, 271).  Because ∆ftsH cells were resistant to inhibition by CdiA-
CT
EC536
, CdiA-CT
ECL
, and CdiA-CT
PestA
, we wished to determine whether the activity of 
FtsH is required for translocation of these toxins or whether CdiA-CTs use FtsH in a 
different manner. 
We first asked whether the full-length FtsH protein is required for inhibition.  Our 
previous results demonstrate that transport-deficient PtsG mutants carrying either the 
Cys421Ser mutation or lacking the cytoplasmic IIB domain still support CDI.  Therefore, we 
wished to determine whether ATPase or protease function of FtsH is required for 
translocation of CdiA-CT domains.  To test this, we constructed truncations at residues K129 
(which maintains the membrane-spanning domains but removes the ATPase and protease 
domains) and S400 (which removes only the protease domain) and transformed these into 
∆ftsH cells.  We then mixed these with cells delivering CdiA-CTo1
EC93
, an orphan toxin 
found in the cdi locus first identified in E. coli EC93.  This toxin is 76% identical to CdiA-
CT
EC536
 (Figure 12A) and belongs to the same N-terminal domain family as CdiA-CT
ECL
 and 
CdiA-CT
PestA
.  As predicted, CdiA-CTo1
EC93
 is also FtsH-dependent (Figure 12A).  Cells 
expressing the K129 or S400 truncations in place of full-length FtsH were not inhibited by 
CdiA-CTo1
EC93
, indicating that the entire protein is necessary for CDI (Figure 12B).  To 
determine whether the specific protease or ATPase function of FtsH is required for CDI as 
opposed to simply the physical presence of these domains, we constructed point mutants in 
these regions.  Phe228Ala changes a key phenylalanine inside the substrate pore, and 
His414Tyr mutation disrupts the first of two histidine residues found in the HEXXH zinc-
coordinating motif of the FtsH protease domain; both mutations disrupt activity, as evidenced 
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by the ablation of proteolysis of RpoH (σ32), a heat shock transcription factor (85, 272-274).  
Neither mutant complemented CDI resistance of ∆ftsH targets during co-culture with 
CDIo1
EC93
 inhibitor cells (Figure 12B). 
During translocation into target cells, CDI nuclease toxins presumably traverse the 
periplasmic space as they cross from outer to inner membrane.  Therefore, we reasoned that 
if FtsH makes direct contact with CdiA-CTs, this may be facilitated by the 72-residue 
periplasmic loop that spans the two transmembrane domains anchoring FtsH to the inner 
membrane (271).  This region mediates the interaction between FtsH and the membrane-
anchored proteins HflKC and is also involved in substrate recognition and specificity (270).  
The loop is highly conserved in E coli and closely-related species but varies in other Gram-
negative bacteria (Figure 11B).  A comparison of the FtsH periplasmic domains from E. coli 
and Proteus mirabilis reveals that the loops are only 56% conserved, as opposed to 
approximately 90% homology across the rest of the protein (Figure 13A).  Therefore, we 
constructed an FtsH chimera in which the first 196 residues from E. coli were replaced with 
the corresponding region from Proteus mirabilis, resulting in a protein with the P. mirabilis 
periplasmic loop.  We then transformed this construct into ∆ftsH cells and measured survival 
during co-culture assays against CDIo1
EC93
 and CDI
ECL
 inhibitor cells.  Cells expressing 
FtsH
EC-Proteus
 were inhibited to wild-type levels, indicating that this construct supports CDI 
(Figure 13B).  Furthermore, we note that FtsH
EC-Proteus
 rescues the severe growth defect 
observed with ∆ftsH cells (data not shown), indicating that this protein is functional. 
Using CdiA-CTo11
EC869
 and CdiA-CT
3006
, we demonstrated that the IMPs required for 
delivery of these domains is not involved in activation of intracellular toxin (Figure 5).  
Because FtsH is a protease, we wondered whether this IMP is necessary for the function 
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FtsH-dependent toxins, or whether its role (direct or indirect) is solely part of the 
translocation process.  To test this, we fused the CdiA-CT/CdiI
Ec536
 module (starting at the 
VENN tetrapeptide motif of CdiA-CT) to an ssrA(DAS) tag.  This construct results in 
degradation of the immunity protein and release of intracellular toxin.  We then performed a 
transformation assay using this construct or an empty vector plasmid control into wild-type 
and ΔftsH cells and observed the growth of colonies on LB-agar plates supplemented with 
150 µg/mL ampicillin.  Both cell backgrounds grow when the empty pTrc99a plasmid is 
transformed, although we note that the ΔftsH strain has a severe growth defect that manifests 
as smaller colonies (Figure 15, left panel).  When the CdiA-CT/CdiI
Ec536
-ssrA(DAS) 
construct is expressed, both strain fail to form colonies.  A ΔcysK control grows under both 
conditions; CysK is a cysteine biosynthesis enzyme required for activation of CdiA-CT
Ec536
 
(193).  Because ΔftsH cells fail to grow when intracellular toxin is produced, this suggests 
that this IMP is not required for activity of CdiA-CT
Ec536
 and instead functions solely in the 
translocation step of CDI. 
5. Expression of inner membrane proteins required for inhibition permits delivery of 
CdiA-CTs across species 
CDI systems are generally conserved between bacteria, but Burkholderia systems have an 
alternative gene order, and the CdiA-CT region is demarcated by a distinct ELYN peptide 
motif(169, 182).  We found that fusion of CdiA-CTII
Bp1026b
 (Glu1–Asn297, numbered from 
Glu1 of ELYN) from Burkholderia pseudomallei 1026b to CdiA
EC93
 produces a 
nonfunctional chimera (Figure 14A).  However, the C-terminal tRNase domain from CdiA-
CTII
Bp1026b
 (Thr162–Asn297) can be delivered efficiently when fused to the N-terminal 
domain of CdiA-CTo11
EC869
 (Figure 14A).  Moreover, as predicted from the delivery domain 
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model, E. coli ∆yciB mutants are resistant to the EC869o11/Bp1026b hybrid CdiA-CT 
(Figure 14A).  This latter result shows that the Burkholderia tRNase domain can be delivered 
into E. coli target cells, raising the possibility that E. coli lacks the pathway required for 
native CdiA-CTII
Bp1026b
 import.  We recently discovered that Burkholderia thailandensis 
∆BTH_II0599 mutants are resistant to the CDIII
Bp1026b
 system (192).  BTH_II0599 encodes a 
member of the major facilitator superfamily (MFS), which are integral membrane 
transporters of small metabolites and antibiotics (275).  BTH_II0599 is highly conserved 
among Burkholderia species, but homologs are absent from enterobacteria. Therefore, we 
provided E. coli cells with plasmid-borne BTH_II0599 and tested them as targets in 
competitions against inhibitors that deploy the native CdiA-CTII
Bp1026b
.  Remarkably, cells 
that express BTH_II0599 became sensitized to growth inhibition, and showed a ∼15-fold 
decrease in viable cell counts after 3 h (Figure 14B).  Moreover, sensitized target cells were 
protected when they expressed the cognate cdiIII
Bp1026b
 immunity gene (Figure 14B), 
indicating that the CdiA-CTII
Bp1026b
 tRNase domain mediated growth inhibition.  
Collectively, these data reveal a genetic interaction between the N-terminal domain of CdiA-
CTII
Bp1026b
 and BTH_II0599 and suggest that this MFS protein is required for toxin 
translocation into target bacteria. 
C. Discussion 
We previously reported that variable CdiA-CT regions are often composed of two 
domains (169, 175, 177, 193).  The extreme C-terminal domain typically has nuclease 
activity and is sufficient to inhibit growth when expressed inside E. coli cells (175, 177, 193).  
In contrast, the N-terminal domain of the CdiA-CT has no inhibition activity, and its function 
has not been explored.  The findings presented here suggest that the N-terminal domain is 
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critical for nuclease toxin translocation during CDI.  This model is based on the identification 
of multiple CDI
R
 mutations that disrupt integral membrane proteins and concomitantly 
protect target bacteria from specific CdiA-CT toxins.  In principle, these membrane proteins 
could function as permissive factors that bind and activate CdiA-CT toxins after delivery 
(193).  However, CdiA-CTo11
EC869
 and CdiA-CT
EC3006
 nuclease domains have full activity 
when expressed inside CDI
R
 mutants, excluding permissive factor function (Figure 4).  
Moreover, ptsG, yciB, and ftsH mutants are resistant to CdiA-CTs based on the identity of the 
nontoxic N-terminal domains.  These genetic interactions suggest that N-terminal domains 
use specific IMPs as receptors during CDI.  Although our data do not demonstrate direct 
toxin–IMP interactions, this model is supported by experiments showing that BTH_II0599 
expression sensitizes E. coli to the native CdiA-CTII
Bp1026b
 toxin.  Because BTH_II0599 is 
completely heterologous, with no homologs in γ-proteobacteria, the simplest explanation is 
that CdiA-CTII
Bp1026b
 binds directly to this IMP to translocate into the cytoplasm.  Moreover, 
the N-terminal domain of CdiA-CTII
Bp1026b
 is limited to B. pseudomallei systems, arguing 
that these effectors target only other Burkholderia that contain BTH_II0599 homologs. 
Crystal structures are available for three CDI toxin/immunity protein complexes, but the 
N-terminal domain is resolved in only one model (175, 177).  Residues Met86–Thr153 of 
CdiA-CTo11
EC869
 form a small helical bundle that packs against the C-terminal DNase domain 
(177).  The tertiary contacts with the nuclease domain probably facilitated the resolution of 
this domain.  For many other CdiA-CT regions, the N- and C-terminal domains are 
connected by flexible peptide linkers, suggesting the domains have few or no tertiary 
contacts and move independently of one another.  Additionally, the N-terminal domains do 
not make direct contacts with CdiI immunity proteins (175, 177, 193).  Together, these 
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observations suggest that the N- and C-terminal domains are autonomous units that can be 
recombined in virtually any combination.  Although this hypothesis is supported by the 
functional hybrid CdiA-CTs constructed in this work, we note that the reengineered toxins 
are less effective than their naturally occurring counterparts.  Thus, a given nuclease domain 
may have a preferred translocation pathway that is more efficient than others. 
It is apparent that CdiA-CT nuclease domains are delivered into the target-cell cytoplasm 
(172, 175, 177, 194), but the molecular details of CDI toxin translocation remain obscure.  
Most of the IMPs identified here are metabolite transporters, but our data indicate that 
transporter activity is not required for toxin import.  Moreover, it seems unlikely that protein 
toxin domains could be transported in the same manner as small molecules due to size 
constraints of the pores used for transporting metabolites.  An interesting caveat to this model 
is the translocation of FtsH-dependent CdiA-CT domains.  Data obtained from co-culture 
assays shows that FtsH proteins lacking either the protease domain or both the protease and 
ATPase domains (truncations at residues Ser400 or Lys129, respectively) do not support 
CDI, suggesting that the function of at least one of these domains is required for the role of 
FtsH in CdiA-CT translocation.  However, it is unknown whether these truncated proteins 
correctly localize to the inner membrane, thereby complicating the interpretation of these 
results.  Targeted point mutations that alter the substrate pore or disrupt protease activity 
(Phe228Ala and His414Tyr, respectively) also prevent inhibition of target cells, which is 
unlike other IMP complexes tested in this study.  The simplest explanation would posit that 
the activity of FtsH is directly required for translocation of CdiA-CT domains, but careful 
consideration of FtsH activity complicates this model.  Cytoplasmic and membrane-
associated FtsH substrates are threaded into the substrate pore in the cytoplasm, not the 
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periplasm; delivered CdiA-CT fragments reside in the periplasm before the final 
translocation step across the inner membrane into the cytoplasm (111, 172, 276-279).  
Furthermore, FtsH degrades proteins in a processive manner that produces short peptides 
(280).  The processivity of this activity would most likely not cleave CdiA-CT proteins at a 
single location, and would instead produce multiple small peptides.  Given the minimum size 
of cytotoxic CT domains (167, 169, 177, 193, 202), it is unlikely that the small byproducts of 
FtsH degradation would be of sufficient size to carry out toxic activity.   
Instead of cleaving CdiA-CT molecules during delivery, FtsH may have an indirect 
influence on CDI.  FtsH regulates the E. coli heat shock response by rapidly degrading the 
transcription factor RpoH (with the help of DnaKJ adaptor proteins) under normal 
physiological conditions (109, 276).  During heat stress, RpoH is no longer efficiently 
degraded by FtsH, and it interacts with RNA polymerase to upregulate expression of a suite 
of heat shock response genes.  Another FtsH regulatory network could control expression of 
additional inner membrane proteins that are required for inhibition by CdiA-CT
ECL
, CdiA-
CT
EC536
, CdiA-CTo1
EC93
, and CdiA-CT
PestA
.  Alternatively, FtsH may also continually 
degrade the binding partner of another inner membrane protein.  In the absence of the 
protease, this ligand could accumulate and interact with a given IMP, blocking translocation 
of an incoming CdiA-CT.  FtsH could also regulate another protease or protein responsible 
for processing CdiA-CTs during delivery.  In these models, the absence of FtsH could leave 
CDI proteins in limbo in the periplasm during delivery, unable to complete translocation into 
the cytoplasm.  We have previously demonstrated that delivery of CdiA-CTs across the inner 
membrane requires the proton motive force of target cells, and that a stable fragment of CdiA 
resides in the periplasm of de-energized cells.  Upon restoration of pmf, delivery resumes, 
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and CdiA-CT activity can be detected (172).  Perhaps future work will consider the total 
proteome of FtsH targets in wild-type and ∆ftsH cells in an effort to determine whether 
another protein is required for translocation of this family of CdiA-CTs across the inner 
membrane of target cells.   
Another mechanism by which FtsH may influence CdiA-CT delivery is through an 
interaction with the membrane-associated periplasmic proteins HflKC.  Heterodimers of 
these proteins decorate the periplasmic face of FtsH and regulate activity against some 
substrates, including SecY (270, 278, 281, 282).  The HflKC interaction is mediated by the 
FtsH 72-residue periplasmic loop connecting the transmembrane domains (270).  If delivery 
of CdiA-CTs is mediated by HflK or HflC, one might predict that a non-canonical 
periplasmic loop would affect sensitivity of target cells.  However, the FtsH
Ec-Proteus 
chimera 
was inhibited to wild-type levels.  While it remains to be determined whether HflK and HflC 
interact with the P. mirabilis periplasmic loop, the sensitivity of target cells carrying this 
construct diminishes the probability that CDI delivery is mediated by a sequence-specific 
feature or interaction involving the periplasmic loop.  It would be interesting to perform the 
same experiment with a construct containing a drastically-different periplasmic loop region, 
such as that from Bacillus subtilis
1
. 
Substrate processing by FtsH can be initiated in a variety of ways.  Direct interaction 
between substrate and FtsH can be occur via N- and C-terminal recognition motifs, and more 
complex processing networks (such as the DnaKJ-mediated degradation of RpoH) require 
internal substrate sequences (109, 110, 276, 283).  This latter data is consistent with other 
                                                 
1
 We note that an FtsH
Ec-Bacillus
 construct was made but does not rescue the growth defect 
observed with ftsH knockouts, and that this complicates the interpretation of any inhibition 
experiments performed with these strains.  Interestingly, ftsH is not essential in Bacillus 
subtilis.  
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protease/substrate interactions, including the degradation of RepA by ClpAP and of MuA by 
ClpXP (284).  Hoskins and colleagues found that unfolding and degradation of an N-terminal 
GFP-RepA fusion protein by ClpAP was dependent on the N-terminal 15 residues of RepA, 
even when that motif was located in the middle of the fusion protein sequence.  A similar, 
albeit less efficient, phenomenon was observed with the ClpXP protease and the C-terminal 
recognition motif of MuA in a MuA-GFP chimera (284).  Therefore, it is plausible that an 
internal motif in CdiA-CT is processed, liberating this domain from a larger CdiA fragment 
and allowing for translocation of only the cytotoxic CdiA-CT.  Although preliminary 
sequence analysis has not revealed any strong or canonical FtsH recognition sequences, it 
remains to be determined whether CdiA-CTs contain cryptic motifs or processing sites.  
LpxC, which is contains a C-terminal FtsH recognition sequence (LAFKAPSAVLA, where 
bolded residues are required) (276).  Other recognition motifs are characterized by the 
presence of small hydrophobic residues that are required for recognition by FtsH (108, 111, 
276, 278).  FtsH-dependent CdiA-CTs share a conserved N-terminal domain after the VENN 
tetrapeptide, and this region is not conserved with other CdiA-CTs that utilize another IMP 
for translocation.  Therefore, if an FtsH recognition domain exists, it is plausible that it will 
be localized to this region.  Shortly after VENN, a conserved sequence consisting mostly of 
hydrophobic residues (S/ALV/IARGAVAA, where bold residues are identical between all 
tested CdiA-CTs that require FtsH) is present in FtsH-dependent CdiA-CTs.  An attractive 
model in the CDI field is that the VENN tetrapeptide motif is involved in processing and 
release of CdiA-CT into the cytoplasm during delivery.  Preliminary evidence suggests that 
mutating these asparagines residues prevents inhibition (Julia Shimizu Webb and Grant 
Gucinski, unpublished data), suggesting that they may play a catalytic role in the processing 
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of CdiA-CT.  Cleavage at this site would place the LXARGAVAA sequence near the N-
terminus of the resulting peptide and may position it in a manner that would be amenable to 
FtsH-mediated degradation or translocation into the cytoplasm.  However, this is a highly 
speculative model, and future studies will elucidate this translocation pathway by identifying 
delivered fragments in both the periplasm and cytoplasm to determine how processing 
events, including any mediated by FtsH, contribute to delivery of these toxins. 
Our alternative hypothesis is that CDI toxins exploit IMPs as receptors to bring nuclease 
domains into close proximity with the membrane, thereby allowing the toxin to enter and 
penetrate the lipid bilayer. Further, because the target-cell proton motive force is required for 
CDI (172), we postulate that this electrochemical gradient provides the driving force to 
transport toxins into the cytosol. This mechanism is similar to that proposed for colicin E3 
and E9 nuclease toxins, which spontaneously enter lipid micelles and mediate their own 
transport across membranes (80, 82). However, colicins do not appear to require IMP 
receptors, and nearly all CDI
R
 mutations provide no protection against colicins (285). The 
one exception is ftsH, which was originally identified as the tolZ mutation and confers 
resistance to nuclease toxins of group A and B colicins (105, 107).  FtsH is a membrane-
associated AAA+ superfamily member with ATP-dependent metalloprotease activity.  Two 
models have been proposed for the role of FtsH in colicin import. De Zamaroczy and 
coworkers have shown that FtsH is required for the release of colicin nucleases into the cell, 
and they hypothesize that the protease directly cleaves the domain (91, 92). Kleanthous and 
coworkers have proposed that the ATP-dependent unfoldase activity of FtsH is used to pull 
the nuclease domain into the cell (85). AAA+ proteases are processive enzymes that actively 
unfold and cleave proteins into small peptides, so, in these models, the colicin nuclease 
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domain must resist complete degradation during transport. Intriguingly, bacteriophages are 
also known to exploit IMPs to transfer their genomes into host cells. Phage λ requires the 
ManY component of the mannose phosphotransferase system to infect E. coli cells (286), and 
it was recently reported that PtsG is required for infection by E. coli phage HK97 (287). 
Thus, CDI and phages may use similar strategies to transport macromolecules into bacterial 
targets. 
Other toxin-delivery systems, including Neisseria MafB proteins (211), type VI 
secretion-associated Rhs proteins (176, 200, 224), and predicted type VII secretion toxins 
from Bacillus and Mycobacteria (155), carry C-terminal nuclease domains that are related to 
those in CdiA proteins. Like CDI, the genetic organization of these other toxin-delivery 
systems is modular, allowing toxin interchange at the C terminus of conserved delivery 
proteins (126). These observations imply that toxin/immunity coding sequences are subject to 
frequent horizontal gene transfer between systems. Therefore, widely distributed toxin 
domains must be active against multiple clades of bacteria. Perhaps this explains why so 
many of these toxins are nucleases, which should be effective against any bacterium provided 
the domain can be delivered into the cytoplasm. It seems likely that each competition system 
uses a different mechanism to deliver toxins into target bacteria. For example, type VI 
secretion is thought to mechanically penetrate the target cell envelope, which could explain 
why analogous translocation domains are not found adjacent to the C-terminal toxin domains 
of Rhs effectors. The physical basis for CDI toxin translocation is unknown, but the 
mechanism appears to be quite versatile, allowing a nuclease domain to be transported 
through multiple independent pathways.  Further, CDI exploits several membrane protein 
families, suggesting that, in principle, any IMP could be hijacked as a translocation receptor. 
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Given this plasticity, we speculate that the mechanism could be harnessed to transport other 
cargos into Gram-negative bacteria and perhaps form the basis of novel antibacterial 
therapies.  
D. Materials and Methods 
1.  General methods 
Bacterial strains are listed in Table S1. E. coli EPI100 cells carrying plasmid-borne cdi 
gene clusters were used as inhibitors, and E. coli MC4100 and MG1655 derivatives were 
used as target cells. E. coli MC4100 was subjected to mariner-mediated mutagenesis by 
using plasmid pSC189(288). Gene disruptions were from the Keio collection(289) and were 
transferred into E. coli MC4100 by using phage P1-mediated general transduction. Plasmids 
and oligonucleotides are listed in Tables S2 and S3, respectively. The details of all plasmid 
constructions are provided in SI Materials and Methods. Competition co-cultures were 
performed at a 1:1 inhibitor to target cell ratio in shaking lysogeny broth medium at 37 °C as 
described in SI Materials and Methods. Competitions with ∆ftsH target cells were performed 
at 30 °C, and chimeric EC93-Bp1026b inhibitors were used in 10-fold excess over target 
bacteria. Viable target cells were enumerated as cfu counts per milliliter and expressed as the 
average ± SEM for three independent experiments. RNA was isolated by guanidinium 
isothiocyanate-phenol extraction(290). Northern blots were performed with 10 µg of total 
RNA using a probe for E. coli tRNA1
Ile
. In vivo DNase activity was assessed by fluorescence 
microscopy of DAPI-stained bacteria as described in SI Materials and Methods. 
2.  Plasmid construction 
Plasmid-borne chimeric CDI systems were constructed by allelic exchange of the counter 
selectable pheS* marker from plasmid pCH10163 as described previously (177).  The 
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various cdiA-CT/cdiI sequences were amplified by PCR by using the following primer pairs: 
Escherichia coli NC101 (ECNC101_09164/09169), CH3176/CH3177; E. coli 3006 
(EC3006_4140/4139), CH3172/CH3173; E. coli MHI813 (ECSTECMHI813_1064/1065), 
CH3174/CH175; P. luminescens TTO1 (plu0548/plu0547), CH3519/CH3520; D. dadantii 
3937 (Dda3937_04704/02929), CH3513/CH3514; Yersinia pestis Pestoides A 
(YPS_3004/YPS_3003), CH3530/CH3531; and Burkholderia pseudomallei 1026b 
(BP1026B_II2207/cdiI is unannotated), CH2501/CH2504. Each cdiA-CT/cdiI fragment was 
fused to upstream and downstream homology regions amplified from the cdiA
EC93
 gene. The 
cdiA
EC93
 upstream homology fragment was amplified by using primers DL1527/DL2470, and 
the downstream fragment was amplified with primers DL1663/DL2368.  The three products 
(cdiA-CT/cdiI, upstream cdiA
EC93
, and downstream cdiA
EC93
) were then fused to each other 
through overlapping-end PCR (OE-PCR) by using primers DL1527/DL2368. The final DNA 
product (100 ng) was electroporated together with plasmid pCH10163 (300 ng) into E. coli 
strain DY378 cells as described previously(177). Clones with recombinant plasmids were 
selected on yeast extract glucose-agar supplemented with 33 µg/mL chloramphenicol and 10 
mM d/l-p-chlorophenylalanine.  The CdiA-CT/CdiIo1
EC93
 chimera plasmid was a gift from 
Stephanie Aoki and David Low (University of California, Santa Barbara). 
The EC3006/EC536 hybrid cdiA-CT/cdiI sequence was generated by OE-PCR. A 
fragment encoding the N-terminal domain of CdiA-CT
EC3006
 was amplified from plasmid 
pCH11483 by using primers DL1527/CH3683, and a fragment encoding the C-terminal 
tRNase domain of CdiA-CT
EC536
 and its immunity protein was amplified from plasmid 
pCH10673 by using primers CH3682/DL2368. The two PCR products were combined into 
one fragment through OE-PCR by using primers DL1527/DL2368, and the resulting product 
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was recombined into plasmid pCH10163 as described earlier. The EC3006/EC869o11 hybrid 
construct was generated in the same manner. A fragment encoding the N-terminal domain of 
CdiA-CT
EC3006
 was amplified from plasmid pCH11483 by using primers DL1527/CH3724, 
and a fragment encoding the C-terminal DNase domain of CdiA-CTo11
EC869
 and its immunity 
protein was amplified from plasmid pCH9305 by using primers CH3723/DL2368. 
The cdiI immunity genes were amplified by PCR by using the following primer pairs: E. 
coli NC101, CH3238/CH3239; E. coli 3006, CH3244/CH3245; E. coli MHI813, 
CH3240/CH3241; P. luminescens TTO1, CH3676/CH3677; D. dadantii 3937, 
CH3674/CH3675; and Y. pestis Pestoides A, CH3572/CH3571. All PCR products were 
digested with KpnI/XhoI and ligated to plasmid pTrc99KX (10). Genes encoding CDI
R
 
membrane proteins were amplified with the following primer pairs: yciB, CH2139/CH2140; 
BTH_II0599, CH2525/CH2526; ftsH, CH2636/CH2637; metI, CH3477/CH3478; ptsG, 
CH3612/CH3613; gltK, CH3629/3630; rbsC, CH3631/CH3632; and gltJ, CH3633/CH3634. 
The yciB, BTH_II0599, metI, gltK, gltJ, and rbsC PCR products were digested with 
KpnI/XhoI and ligated to plasmid pTrc99KX. The ftsH and ptsG products were digested with 
EcoRI/HindIII and EcoRI/PstI (respectively) and ligated to plasmid pTrc99A digested with 
the appropriate restriction endonucleases. The Cys421Ser mutation was introduced into ptsG 
by using megaprimer PCR. The 3′ region of ptsG was amplified with primers 
CH3481/CH3613, and the resulting product was used as a megaprimer in a second reaction 
with primer CH3612. The ptsG(E387Oc) ochre mutation that deletes the C-terminal IIB 
domain was made by PCR by using primers CH3612/CH3722. The CdiA-CT/CdiI
EC3006
-
DAS controllable proteolysis construct was made by amplifying the cdiA-CT/cdiI
EC3006
 gene 
pair with primers CH3269/CH3425 and ligating the product into NcoI/SpeI-digested plasmid 
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pCH9460. 
Additional ftsH constructs were made using the pTrc99a::ftsH construct created in this 
study.  Truncations were made using primer pairs CH2636/CH2638 (K129) or 
CH2636/CH2662 (S400) to amplify the appropriate section of DNA.  Point mutations were 
created using megaprimer PCR in which the first fragments were amplified using primer 
pairs CH2636/CH2660 (F228A) or CH2663/CH2637 (H414Y) and extended to full-length 
using the first PCR and primer CH2637 or CH2636 in a second reaction.  All truncation and 
point mutation PCR products were cloned into pTrc99a using EcoRI and HindIII enzymes.  
The E. coli/Proteus mirabilis FtsH chimera was constructed by amplifying the 5’ end of ftsH 
from Proteus mirabilis genomic DNA using primers CH2685/2686.  This region was then 
cloned into the existing pTrc99a::ftsH(coli) plasmid using EcoRI and an internal KpnI 
restriction site. 
YFP-labeled E. coli cells were generated by integrating the yfp coding sequence at the gal 
locus. First, a genomic integration construct was made by amplifying the kanamycin-
resistance cassette from plasmid pKAN(175) with primers CH106/CH107, followed by 
blunt-end ligation to SmaI-digested plasmid pBluescript. A clone was identified that had the 
kanamycin-resistance cassette in the opposite orientation as pKAN, and this plasmid was 
termed pNAK. A fragment of galM was then amplified by using primers CH3789/CH3790, 
and the product was ligated to SacI/BamHI-digested plasmid pNAK to produce plasmid 
pCH2500. A yfp-galT fragment was amplified from E. coli DA28100 (gift from Sanna 
Koskiniemi, Uppsala University, Uppsala, Sweden) by using primers CH3787/CH3788, and 
the product was digested with KpnI/EcoRI and then ligated into pCH2500 to yield plasmid 
pCH2503. The large KpnI/SacI fragment from pCH2503 was recombined into E. coli EPI100 
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and X90 cells that harbor plasmid pSIM6 as described previously(291). Target bacteria were 
labeled with mRaspberry by using plasmid pEL3C17 (pJ23110-mRFP-cat). 
3.  Transposon library construction and selection for CDIR mutants 
The mariner transposon was introduced into E. coli CH10229 cells through conjugation 
with E. coli MFDpir donor cells carrying plasmid pSC189. Donor and recipient cells were 
grown to mid-log phase in lysogeny broth (LB) medium supplemented with 150 µg/mL 
ampicillin and 30 µM diaminopimelic acid (donors) or 33 µg/mL chloramphenicol 
(recipients). Donors (∼6.0 × 108 cfu) and recipients (∼3 × 108 cfu) were mixed and collected 
by centrifugation for 2 min at 6,000 × g in a microcentrifuge. The supernatant was removed 
by aspiration and the cell pellet resuspended in 100 µL of 1× M9 salts. Cell mixtures were 
spotted onto 0.45-µm nitrocellulose membranes, and the filters were then incubated on LB 
agar (without inversion) for 4 h at 37 °C. The cells were then harvested from the filters by 
using 2 mL of 1× M9 salts. Transposon insertion mutants were selected by plating 10-fold 
serial dilution on LB-agar supplemented with 50 µg/mL of kanamycin. 
More than 20,000 colonies from each transposon library were collected from the agar 
plates in 1× M9 salts and inoculated into 50 mL of LB medium in a 250-mL baffled flask. 
CDI
+
 inhibitor strains were grown in a parallel 50 mL LB medium culture. Both cultures 
were grown at 37 °C until mid-log phase, then mixed at approximately a 1:1 ratio and 
cultured for 3 h with shaking at 37 °C. Viable target cells from the transposon mutant library 
were enumerated as cfu counts per milliliter on LB agar supplemented with 50 µg/mL of 
kanamycin. The survivors of the first round of CDI competition were harvested from the 
plates with 1× M9 salts and used to inoculate 50 mL LB medium culture for a second round 
of CDI selection. After the third round of selection, the target cell population was usually 
65 
 
completely resistant to the CDI inhibitor cells. Individual clones were then isolated and the 
CDI
R
 phenotype confirmed in competition co-cultures. The transposon mutations were then 
transferred into CDI-sensitive cells by bacteriophage P1-mediated transduction, and the 
resulting transductants were tested for the CDI
R
 phenotype. 
Transposon insertions that were linked to CDI
R
 were identified by rescue cloning. 
Chromosomal DNA was prepared from each CDI
R
 mutant by using phenol/chloroform 
extraction and ethanol precipitation. Genomic DNA (1 µg) was digested with AgeI and XmaI 
restriction endonucleases for 2 h at 37 °C and then the enzymes were inactivated at 65 °C for 
10 min. ATP and T4 DNA ligase were added and the reaction was incubated for 2 h at room 
temperature. The ligated DNA was precipitated with 95% (vol/vol) ethanol, washed once 
with 75% (vol/vol) ethanol, and dissolved in 50 µL water. The ligated DNA was 
electroporated into E. coli DH5α pir+ cells, and transformants were selected on LB agar 
supplemented with 50 µg/mL kanamycin. Plasmid DNA was isolated from selected 
transformants, and the transposon insertion junctions were identified by DNA sequencing by 
using primer CH2260. 
4. Competition co-cultures 
Competition co-culture assays were carried out as previously described (175, 177). 
Briefly, inhibitor cells (E. coli EPI100 carrying CDI expression constructs) and target cells 
(E. coli MC4100 or MG1655 carrying pTrc99a derivatives) were grown in LB medium 
supplemented with appropriate antibiotics overnight at 37 °C. The next day, cells were 
inoculated into fresh LB medium without antibiotics in baffled flasks. Individual cultures 
were grown with shaking until early log phase, and then the populations were mixed at a 1:1 
ratio in fresh prewarmed LB in baffled flasks. The competitions between EC93-Bp1026b 
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inhibitors and targets that express BTH_II0599 were conducted at a 10:1 inhibitor-to-target 
cell ratio. A sample of each co-culture was taken at initial mixing to enumerate viable target 
cells as cfu counts per milliliter. The co-cultures were incubated with shaking for 3 h at 37 
°C. Viable target cell counts are presented as the average ± SEM of three independent 
competition experiments. 
5. Activation of CdiA-CT toxins inside E. coli cells 
E. coli X90 cells (WT and ∆yciB and ∆ptsG mutants) were co-transformed with pTrc99a 
constructs that express CdiIo11
EC869
 or CdiI
EC3006
 and pCH450 derivatives that express CdiA-
CT/CdiIo11
EC869
-DAS or CdiA-CT/CdiI
EC3006
-DAS protein pairs. Transformants were selected 
overnight on LB agar supplemented with 150 µg/mL Amp, 15 µg/mL Tet, and 0.4% d-
glucose. The following day, transformants were inoculated into 25 mL of LB medium 
supplemented with Amp, Tet, and glucose. Cells were grown to mid-log phase, then diluted 
to an OD600 of 0.05 in fresh LB supplemented with Amp, Tet, 0.2% arabinose, and 0.15 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) to induce expression from both plasmids. Cell 
growth was monitored by measuring the OD600 of the culture every 30 min for 5 h. The 
presented growth curves show the average ± SEM for three independently performed 
experiments. Culture samples were removed at 0, 1, 3, and 5 h for microscopy or RNA 
isolation. 
6. RNA isolation and analysis 
Cells from internal expression experiments and CDI competition co-cultures were poured 
into an equal volume of ice-cold methanol, and cells were collected by centrifugation in a 
Sorvall RC 5B centrifuge at 15,000 × g for 15 min at 4 °C. Cell pellets were frozen at −80 °C 
and RNA was isolated by using guanidine isothiocyanate-phenol as described previously 
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(40). RNA (10 µg) was resolved on denaturing 8 M urea/10% (wt/vol) polyacrylamide gels 
and then electrotransferred onto nylon membrane (Nytran Supercharge). tRNA1
Ile
 was 
detected by Northern blot hybridization by using radiolabeled oligonucleotide CH577 as a 
probe. Blots were visualized on a Bio-Rad PhosphorImager by using Quantity One software. 
7. Microscopy 
Cells (equivalent to an OD600 of 0.2) were collected by centrifugation in a 
microcentrifuge for 2 min at 6,000 × g. Cells were fixed in freshly prepared 4% (vol/vol) 
formaldehyde in 1× PBS solution for 15 min, and the reaction was quenched with 125 mM 
glycine (pH 7.5).  Cells were washed three times with 1× PBS solution, resuspended in 100 
μL 1× PBS solution, and spotted onto poly-d-lysine–treated slides. Excess liquid was 
removed with a Kimwipe, and slides were dried and gently rinsed with Nanopure water to 
remove nonadherent bacteria.  Slides were sealed with Fluorogel II with DAPI (Fisher 
Scientific/EMS) and a glass coverslip. Images were acquired on an Olympus fluorescent 
microscope with a 100× oil objective by using an Optronics MacroFire digital microscope 
camera. Light-field images were taken with a 12-ms exposure (gain 2).  DAPI-stained images 
were acquired with a 48-ms exposure (gain 2).  Fluorescent images were recorded in 
grayscale by using a 502-ms exposure (gain 5).  Images were false-colored, overlaid by using 
FIJI (292), and cropped to 200 × 200 pixels using GIMP. 
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Figure 1.  Activity of CdiA chimeras.  (A) CdiA proteins contain an N-terminal TPS transport domain and two 
filamentous hemagglutinin (FHA)-peptide repeat regions. The pretoxin-VENN domain is adjacent to and 
demarcates the variable CdiA-CT region. (B) Predicted CdiA-CT domain structures. Toxins from E. coli 
MHI813 and Photorhabdus luminescens TTO1 carry predicted C-terminal Nuclease_NS2 (Pfam database ID: 
PF13930) and Endonuclease_VII (PF14411) domains, respectively.  The C-terminal nuclease domains from E. 
coli NC101 and 3006 cleave tRNA
Asp
/tRNA
Glu
 and tRNA
Ile
, respectively.  The nuclease domain from E. coli 
EC869 is a Zn
2+
-dependent DNase, and the activity of the Dickeya dadantii 3937 toxin is unknown. N-terminal 
domains are labeled according to their putative membrane receptors.  The pretoxin-VENN domain and the 
conserved VENN motif are also depicted. (C) CDI competitions.  E. coli target cells were cocultured with the 
indicated CDI inhibitors.  Average target-cell counts (±SEM) are presented for three independent experiments. 
Where indicated, target cells were provided with the cognate cdiI immunity gene.  
69 
 
 
Figure 2.  Specificity of CDI
R
 mutations.  (A) Transposon-insertion sites are shown for each toxin.  No other 
verified CDI
R
 mutations were identified during the selections. (B) CDI
R
 mutations are toxin-specific.  The 
indicated target cell strains were cocultured with inhibitors that deploy CdiA-CT
EC3006
, CdiA-CT
MHI813
, CdiA-
CT
TTO1
, CdiA-CT1
Dd3937
, or CdiA-CTo11
EC869
 toxins.  Average target-cell counts (±SEM) per mL are presented 
for three independent experiments. 
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Figure 3.  Complementation of CDI
R
 mutations. E. coli target cells of the indicated genotypes were 
cocultured for 3 h at a 1:1 ratio with inhibitor strains that deploy the indicated CdiA-CT toxins.  For each CDI
R
 
mutation, expression of the WT gene from a plasmid (e.g., pYciB) restores sensitivity to growth inhibition. 
Average target-cell counts (±SEM) are presented for three independent experiments. 
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Figure 4.  Toxin nuclease activities inside target bacteria. (A) Fluorescence microscopy of CDIo11
EC869
 
competition cocultures.  Inhibitor cells (YFP-labeled) were incubated with the indicated yciB
+
 or ∆yciB target 
cells (mRFP-labeled), and nucleoids were visualized with DAPI staining.  (B) Northern blot analysis of 
CDI
EC3006
 competition cocultures. Target cells (ptsG
+
 or ∆ptsG) were incubated with CDIEC3006 inhibitor cells 
and RNA isolated for Northern blot analysis of tRNA1
Ile
.  The migration position of uncleaved tRNA1
Ile
 is 
indicated. 
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Figure 5.  Toxin expression inside CDI
R
 mutants.  (A) CdiA-CTo11
EC869
 was induced at 0 h from a pBAD 
vector in yciB
+
 and ∆yciB cells as described previously (176).  Cell growth was monitored by measuring the OD 
at 600 nm of the culture.  CdiIo11
EC869
 immunity protein was coexpressed from a pTrc vector where indicated. 
(Right) DAPI-stained cells sampled at 0, 1, 3, and 5 h of culture.  (B) CdiA-CT
EC3006
 was induced at 0 h from a 
pBAD vector in ptsG
+
 and ∆ptsG cells, and growth was monitored by measuring the OD600 of the culture.  
CdiI
EC3006
 immunity protein was coexpressed from a pTrc vector where indicated. (Right) Northern blot analysis 
of RNA isolated at 0, 1, 3, and 5 h. The arrows indicate the migration position of full-length tRNA1
Ile
. 
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Figure 6.  Metabolite transport activity is not required for CDI.  E. coli target cells of the indicated 
genotypes were cocultured for 3 h at a 1:1 ratio with inhibitor strains that deploy the indicated CdiA-CT toxins.  
Average target-cell counts (±SEM) are presented for three independent experiments. 
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Figure 7.  The N-terminal domain of the CdiA-CT region dictates the specificity of resistance.  (A) 
Alignment of CdiA-CT sequences from E. coli strains 3006 (EC3006_4140), NC101 (ECNC101_09164), 
STEC_O31 (ECSTECO31_4009), and Dickeya zeae Ech1591 (Dd1591_2008).  The conserved VENN peptide 
motif is presented in red type. Sequences were aligned by using Clustal Omega on the Uniprot server 
(www.uniprot.org/align/), and the results rendered at 30% sequence identity by using Jalview 
(www.jalview.org). (B) Alignment of CdiI immunity protein sequences from E. coli strains 3006 
(EC3006_4139), NC101 (ECNC101_09169), and STEC_O31 (ECSTECO31_4008), and D. zeae Ech1591 
(Dd1591_2009).  (C) E. coli target cells expressing the indicated cdiI immunity genes were cocultured for 3 h at 
a 1:1 ratio with inhibitor strains that deploy CdiA-CT
NC101
 or CdiA-CT
EC3006
.  Average target-cell counts 
(±SEM) are presented for three independent experiments.  
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Figure 8.  Analyses of FtsH-dependent CDI toxins.  (A) Alignment of CdiA-CT sequences from E. coli 
EC536 (ECP_4580), ECL (ECL_04451), and Y. pestis Pestoides A (YPS_3004).  The conserved VENN peptide 
motif is presented in red type. Sequences were aligned by using Clustal Omega on the Uniprot server 
(www.uniprot.org/align/), and the results rendered at 30% sequence identity by using Jalview 
(www.jalview.org). (B) Alignment of CdiI immunity protein sequences from E. coli EC536 (ECP_4579), ECL 
(unannotated), and Y. pestis Pestoides A (YPS_3003).  (C) Inhibitor strains that deploy indicated CdiA-CT 
toxins were cocultured for 3 h at a 1:1 ratio with target cells of the indicated genotypes.  Plasmid-borne ftsH 
(pFtsH) complements the ∆ftsH mutation and restores sensitivity to FtsH-dependent CDI toxins.  Average 
target-cell counts (±SEM) are presented for three independent experiments. 
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Figure 9.  CdiA-CT constituent domains are modular.  The N-terminal domain of CdiA-CT
EC3006
 was fused 
to the C-terminal DNase domain of CdiA-CTo11
EC869
.  EC3006-EC869o11 hybrid inhibitors were cocultured with 
the indicated target strains. Average target-cell counts (±SEM) are presented for three independent experiments. 
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Figure 10.  CdiA-CT constituent domains are modular.  The N-terminal domain of CdiA-CT
EC3006
 was fused 
to the C-terminal tRNase domain of CdiA-CT
EC536
.  EC3006-EC536 hybrid inhibitors were cocultured with the 
indicated target strains. Average target-cell counts (±SEM) are presented for three independent experiments. 
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Figure 11.  FtsH is a highly-conserved AAA+ protease anchored to the inner membrane.  (A) FtsH 
sequences are conserved across Gram-negative species.  Proteins from Enterobacter aerogenes (EAE); 
Enterobacter cloacae (ECL); E. coli strains 536 (Ec536), F11 (EcF11), and K12 (EcK12), Proteus mirabilis 
(Pmira); Shigella flexerni (Shigella); and Klebsiella pneumoniae (Klebsiella) were identified using the NCBI 
BLAST database and were aligned using Clustal Omega.  The alignment was rendered using Jalview, and 
79 
 
purple highlighting indicates percent conservation.  The orange line above the top sequence marks the residues 
that make up the periplasmic loop.  (B) A cartoon schematic showing the orientation of FtsH in the cell.  Two 
transmembrane domains spanned by a short loop anchor the protein to the inner membrane.  The AAA+ 
ATPase domain is signified by the brick red bubble.  The protease domain is represented by the turquoise 
trapezoid, and the zinc ion is shown as a purple circle. 
 
 
 
 
 
 
 
Figure 12.  FtsH activity is required for CDI.  (A) Alignment of the CdiA-CT sequences from Ec536 and 
Ec93o1.  Sequences were aligned using Clustal Omega.  The image was rendered in Jalview.  Purple 
highlighting signifies identical residues. (B) Mutations that remove or disrupt the ATPase or protease domains 
block CDI.  Target cells carrying the indicated ftsH alleles were incubated with mock inhibitors or inhibitor 
cells delivering the CDIo1
EC93
 system.  Viable target bacteria were quantified at 0 and 3 h.  
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Figure 13.  The FtsH periplasmic loop from Proteus mirabilis permits delivery of CdiA-CT toxins into E. 
coli target cells.  (A) The 72-residue region constituting the periplasmic loops of FtsH from E. coli and Proteus 
mirabilis were aligned using Clustal Omega and rendered using Jalview.  Purple highlighting signifies identical 
residues. (B) Inhibitor cells delivering a mock CDI system, the orphan CdiA-CT from EC93, or a CdiA-CT 
from E. cloacae were mixed with target cells expressing the indicated ftsH allele.  Viable target cell bacteria 
were quantified at 0 and 3 h. 
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Figure 14.  BTH_II0599 allows CdiA-CTII
Bp1026b
 delivery into E. coli cells. (A) Inhibitor strains (mock CDI
−
, 
Bp1026b, and hybrid EC869o11-Bp1026b) were co-cultured with target bacteria of the indicated cdiI and yciB 
genotypes. Viable target bacteria were quantified at 0 and 3 h. (B) Inhibitor strains (mock CDI
−
 and Bp1026b) 
were cocultured with target cells that express BTH_II0599 and cdiIII
Bp1026b
 where indicated. Average target-cell 
counts (±SEM) are presented for three independent experiments. 
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Figure 15.  FtsH is not required for intracellular activation of CdiA-CT
Ec536
.  An empty plasmid vector (left 
panel) or a plasmid expressing CdiA-CT
Ec536
 (right panel), which requires FtsH for inhibition in co-culture, 
were transformed into wild-type, ΔcysK, or ΔftsH cells.  All cells grow with the empty vector, but CdiA-CTEc536 
inhibits growth of wild-type and ΔftsH cells when intracellularly expressed.  ΔcysK cells grow in the presence 
of this toxin, as CysK is a cofactor required for toxicity. 
 
 
  
83 
 
Table 1.  Bacterial strains used in this study. 
 
Strain  Description
a
 Reference 
X90 
F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) rifr thi-
1, Rif
R
  
 
MG1655 wild-type strain  
DA28100 galK::sYFP2opt-cat, Cm
R
 Sanna Koskiniemi 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, 
leu)7697 galU galK λ– rpsL nupG, StrR 
Epicentre 
DY378 W3110 λcI857 ∆(cro-bioA) (291) 
MFDpir 
MG1655 RP4-2-Tc::[∆Mu1::aac(3)IV-∆aphA-∆nic35-
∆Mu2::zeo] dapA::(erm-pir) ∆recA, AprR ZeoR ErmR 
(293) 
CH43 MG1655 ∆ftsH3::kan lpxC (294) 
CH2505 X90 galK::sYFP2opt-kan, Rif
R
 Kan
R
 This study 
CH2550 EPI100 galK::sYFP2opt-kan, Kan
R
 This study 
CH7157 X90 ∆clpX ∆clpA::kan, RifR KanR (169) 
CH8119 DH5α λpir+ Biomedal 
CH8251 MC4100 rif
r
, Rif
R
 This study 
CH9404 CH8251 ∆yciB::kan, RifR KanR This study 
CH9405 X90 ∆yciB::kan, RifR KanR This study 
CH10013 JCM158 rif
r
, Rif
R
 (167) 
CH10229 JCM158 rif
r
 ∆wzb::cat, RifR CmR (167) 
CH11843 CH8251 ∆metI::kan, RifR KanR This study 
CH11844 CH8251 ∆metN::kan, RifR KanR This study 
CH11845 CH8251 ∆ptsG::kan, RifR KanR This study 
CH12000 CH8251 ∆rbsA::kan, RifR KanR This study 
CH12002 CH8251 ∆rbsC::kan, RifR KanR This study 
CH12008 CH8251 ∆gltJ::kan, RifR KanR This study 
CH12009 CH8251 ∆gltK::kan, RifR KanR This study 
CH12010 CH8251 ∆gltL::kan, RifR KanR This study 
CH12741 X90 ∆ptsG::kan, RifR KanR This study 
a
Abbreviations: Amp
R
, ampicillin-resistant; Apr
R
, aprimycin-resistant; Cm
R
, chloramphenicol-resistant; Erm
R
, 
erythromycin-resistant; Kan
R
, kanamycin-resistance; Rif
R
, rifampicin-resistant; Tet
R
, tetracycline-resistant; 
Zeo
R
, zeocin-resistant 
 
Table 2.  Plasmids used in this study. 
 
Plasmid Description
a
 Reference 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 GE Healthcare 
pTrc99KX 
Derivative of pTrc99a that contains a 5´-KpnI 
restriction site and 3´-SpeI and XhoI sites, Amp
R
 
(175) 
pCH450 
pACYC184 derivative with E. coli araBAD promoter 
for arabinose-inducible expression, Tet
R
 
(172) 
pNAK 
pBluescript derivative with FRT-flanked kanamycin-
resistance cassette, Amp
R
 Kan
R
 
This study 
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pSC189 
Mobilizable plasmid with R6Kγ replication origin. 
Carries the mariner transposon containing 
kanamycin-resistance cassette, Amp
R
 Kan
R
 
(288) 
pSIM6 
Heat-inducible expression of the phage l Red 
recombinase proteins, Amp
R
 
(291) 
pDAL879::cat 
Constitutive expression of chimeric cdiA
EC93
-CTo1
EC93
 
and cdiIo1
EC93
 genes, Cm
R
 
Stephanie Aoki 
pCH172 pEL3C17-pJ23110-mRFP-cat, Cm
R
 Sanna Koskiniemi 
pCH360 pTrc99a::ftsH, Amp
R
 This study 
pCH361 pTrc(CM)::BTH_II0599, Cm
R
 This study 
pCH406 
pTrc99a::ftsH K129, IPTG-inducible expression of 
ftsH K129 truncation, Amp
R
 
This study 
pCH407 
pTrc99a::ftsH S400, IPTG-inducible expression of 
ftsH S400 truncation, Amp
R
 
This study 
pCH569 
pTrc99a::ftsH(E. coli-Proteus mirabilis), IPTG-
inducible expression of ftsH with P. mirabilis 
transmembrane domains and periplasmic loop, Amp
R
 
This study 
pCH581 
pTrc99a::ftsH F228A, IPTG-inducible expression of 
ftsH F228A point mutation, Amp
R
 
This study 
pCH583 
pTrc99a::ftsH H414Y, IPTG-inducible expression of 
ftsH H414Y point mutation, Amp
R
 
This study 
pCH1417 
Constitutive expression of chimeric cdiA
EC93
-CT
PestA
 
and cdiI
PestA
 genes, Cm
R
 
This study 
pCH2156 
pTrc99KX::cdiI
PestA
, IPTG-inducible expression of 
cdiI
PestA
 immunity gene, Amp
R
 
This study 
pCH2500 pNAK::galM´, Amp
R
 Kan
R
 This study 
pCH2503 pNAK::galT´-yfp-galM´, Amp
R
 Kan
R
 This study 
pCH7959 
pCH450::cdiA-CT/cdiIo11
EC869
-DAS, produces 
CdiIo11
EC869
 with C-terminal ssrA(DAS) epitope for 
controllable proteolysis, Tet
R
 
(176) 
pCH9305 
Constitutive expression of chimeric cdiA
EC93
-
CTo11
EC869
 and cdiIo11
EC869
 genes, Cm
R
 
(177) 
pCH9315 
pTrc99a::cdiIo11
EC869
, IPTG-inducible expression of 
cdiIo11
EC869
 immunity gene, Amp
R
 
(177) 
pCH9433 
Constitutive expression of chimeric cdiA
EC93
-
CTII
Bp1026b
 and cdiIII
Bp1026b
 genes, Cm
R
 
This study 
pCH9577 
pTrc99a::cdiIII
Bp1026b
, IPTG-inducible expression of 
cdiIII
Bp1026b
 immunity gene, Amp
R
 
(169) 
pCH9922 
pTrc99KX::yciB, IPTG-inducible expression of yciB, 
Amp
R This study 
pCH10163 
Cosmid pCdiA-CT/pheS* that carries a kan-pheS* 
cassette in place of the E. coli EC93 cdiA-CT/cdiI 
coding sequence. Used for allelic exchange and 
counter-selection. Cm
R
 Kan
R
 
(177) 
pCH10415 
Constitutive expression of chimeric cdiA
EC93
-
NTo11
EC869
-CTII
Bp1026b
 and cdiIII
Bp1026b
 genes, Cm
R
 
(172) 
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pCH10445 
Constitutive expression of chimeric cdiA
EC93
-CT
ECL
 
and cdiI
ECL
 genes, Cm
R (175) 
pCH10673 
Constitutive expression of chimeric cdiA
EC93
-CT
EC536
 
and cdiI
EC536
 genes, Cm
R
 
(172) 
pCH11434 
Constitutive expression of chimeric cdiA
EC93
-CT
NC101
 
and cdiI
NC101
 genes, Cm
R
 
This study 
pCH11446 
Constitutive expression of chimeric cdiA
EC93
-CT
MHI813
 
and cdiI
MHI813
 genes, Cm
R
 
This study 
pCH11483 
Constitutive expression of chimeric cdiA
EC93
-CT
EC3006
 
and cdiI
3006
 genes, Cm
R
 
This study 
pCH11840 
pTrc99a::ptsG, IPTG-inducible expression of ptsG, 
Amp
R
 
This study 
pCH11949 
Constitutive expression of chimeric cdiA
EC93
-CT
TTO1
 
and cdiI
TTO1
 genes, Cm
R
 
This study 
pCH11950 
Constitutive expression of chimeric cdiA
EC93
-
CT1
Dd3937
 and cdiI1
Dd3937
 genes, Cm
R
 
This study 
pCH12021 
pTrc99KX::ptsG(C421S), IPTG-inducible expression 
of ptsG(C421S), Amp
R
 
This study 
pCH12022 
pTrc99KX::metI, IPTG-inducible expression of metI, 
Amp
R
 
This study 
pCH12024 
pTrc99KX::rbsC, IPTG-inducible expression of rbsC, 
Amp
R
 
This study 
pCH12025 
pTrc99KX::gltK, IPTG-inducible expression of gltK, 
Amp
R
 
This study 
pCH12042 
pTrc99KX::cdiI
NC101
, IPTG-inducible expression of 
cdiI
NC101
 immunity gene, Amp
R
 
This study 
pCH12043 
pTrc99KX::cdiI
MHI813
, IPTG-inducible expression of 
cdiI
MHI813
 immunity gene, Amp
R
 
This study 
pCH12045 
pTrc99KX::cdiI
EC3006
, IPTG-inducible expression of 
cdiI
EC3006
 immunity gene, Amp
R
 
This study 
pCH12077 
Constitutive expression of chimeric cdiA
EC93
-
NT
EC3006
-CT
EC536
 and cdiI
EC536
 genes, Cm
R
 
This study 
pCH12082 
pTrc99KX::cdiI1
3937
, IPTG-inducible expression of 
cdiI1
3937
 immunity gene, Amp
R
 
This study 
pCH12202 
pTrc99a::ptsG(E387Oc), IPTG-inducible expression 
of PtsG lacking the C-terminal IIB domain, Amp
R
 
This study 
pCH12205 
pTrc99KX::cdiI
TTO1
, IPTG-inducible expression of 
cdiI
TTO1
 immunity gene, Amp
R
 
This study 
pCH12237 
Constitutive expression of chimeric cdiA
EC93
-
NT
EC3006
-CTo11
EC869
 and cdiIo11
EC869
 genes, Cm
R
 
This study 
pCH12599 
pCH450::cdiA-CT/cdiI
EC3006
-DAS, produces 
CdiI
EC3006
 with C-terminal ssrA(DAS) epitope for 
controllable proteolysis, Tet
R
 
This study 
a
Abbreviations: Amp
R
, ampicillin-resistant; Cm
R
, chloramphenicol-resistant; Kan
R
, kanamycin-resistance; Rif
R
, 
rifampicin-resistant; Tet
R
, tetracycline-resistant 
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Table 3.  Oligonucleotides used in this study. 
 
Oligonucleotide Sequence
a
 Reference 
DL1527 5´ - GAA CAT CCT GGC ATG AGC G  (177) 
DL1663 5´ - CCC AAA GGT TAG ACA CCA GAC C (177) 
DL2368 5´ - GTT GGT AGT GGT GGT GCT G (177) 
DL2470 5´ - ATT ATT CTC AAC CGA GTT CCT ACC TG (177) 
CH106 (Kan-1) 5´ -  TGT GTA GGC TGG AGC TGC TTC This study 
CH107 (Kan-2) 5´ - CAT ATG AAT ATC CTC CTT AGT TCC This study 
CH577 (Ile 1 probe) 5´ - ACC GAC CTC ACC CTT ATC AG This study 
CH2139 (yciB-Kpn-
for) 
5´ - AAT GGT ACC ATG AAG CAG TTT CTT GAT 
TTT TTA C 
This study 
CH2140 (yciB-Xho-
rev) 
5´ - GCA CTC GAG TTA GGA TTT ATC TTC CTG 
CGG 
This study 
CH2260 (mariner rev 
seq) 
5´ - CAA GCT TGT CAT CGT CAT CC This study 
CH2501 (EC93-
1026b) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATG CAC TGG GCA ACG ACC CCC AAA AAA 
CG 
This study 
CH2504 (EC93-
1026b) 
5´ -  GGT CTG GTG TCT AAC CTT TGG GTT ACC 
TCC GGT ATT CGT TAT CTT GC 
This study 
CH2525 (BTH0599-
Kpn-for) 
5´ - AAT GGT ACC ATG CAA CTG ATC GAA 
GTC TCC 
This study 
CH2526 (BTH0599-
Xho-rev) 
5´ - ATA CTC GAG TCA TCG ATC GGA GGT GTT 
CGG 
This study 
CH2636 (ftsH-Eco-
for) 
5´ - GTT TTG AAT TCA GTT GTA ATA AGA GG  This study 
CH2637 (ftsH-Hind-
rev) 
5´ - AAA AAG CTT CAT GAT GTT ATC CCT GG This study 
CH2638 (ftsH(K129)-
Hind-rev) 
5' - ACA AAG CTT ATT TGC CAC CGC CGC C - 3' This study 
CH2660 (ftsH-
F228A) 
5' - GCA CCC ACA CCG ACG GCC ATT TCT ACG 
- 3' 
This study 
CH2662 (ftsH-S400-
Hind-rev) 
5' - TTA AGC TTA GGA GCG ACG TTC C - 3' This study 
CH2663 (ftsH-
H414Y) 
5' - CGA CGG CTT ACT ACG AAG CGG GTC ATG 
- 3' 
This study 
CH2685 (Pmir-ftsH-
Eco-for) 
5' - AAG GAA TTC GTT AAC ACA GTT GTA ATA 
TG - 3' 
This study 
CH2686 (Pmir-ftsH-
Kpn-rev) 
5' - ACC GGT ACC CGG AGG ACC AAC CAT 
TAG G - 3' 
This study 
CH3172 (3006) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATT ATC TTA GCG TGT CTG AAA AGA CAG 
AGC 
This study 
CH3173 (3006) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT AAT 
TAT TCA GAG GAT AAG CTT TTG AAA AAT 
This study 
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CAT CG 
CH3174 (MHI813) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATT TTT TGA CCG CAG ATC AGA TCG ATA GC 
This study 
CH3175 (MHI813) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT ATA 
GTT CAT CAT CAT ATT GAA AGT TTA TGC 
TAA 
This study 
CH3176 (NC101) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATT ACC TGA GCG TGT CTG AAA AGA CAG 
This study 
CH3177 (NC101) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT ATT 
CAG GCC ATG CCA ATC CAT C 
This study 
CH3238 (NC101-
cdiI-for) 
5´ - CTG GTA CCA TGG ATA TTT GGC CTG This study 
CH3239 (NC101-
cdiI-rev) 
5´ - GAC TCG AGT TAT TCA GGC CAT GCC AAT 
C 
This study 
CH3240 (MHI-cdiI-
for) 
5´ - CTG GTA CCA TGA ACG AAT TAG ATG This study 
CH3241 (MHI-cdiI-
rev) 
5´ - GAC TCG AGT TAT AGT TCA TCA TCA TAT 
TG 
This study 
CH3244 (3006-cdiI-
for) 
5´ - CTG GTA CCA TGA TAA ATG TGA ATA G This study 
CH3245 (3006-cdiI-
rev) 
5´ - GAC TCG AGT TAA TTA TTC AGA GGA 
TAA GC 
This study 
CH3269 (PSI-univ-
Nco-for) 
5´ - TTT AAG AAG GAG TCT CTC CCA TGG - 3' This study 
CH3422 (NC101-
cdiI-Spe-rev) 
5´ - GAA CTA GTT TCA GGC CAT GCC AAT C This study 
CH3425 (3006-cdiI-
Spe-rev) 
5´ - GAA CTA GTA TTA TTC AGA GGA TAA 
GCT TTT G 
This study 
CH3477 (metI-for) 
5´ - CTG GTA CCA TGT CTG AGC CGA TGA TGT 
G 
This study 
CH3478 (metI-rev) 
5´ - GAC TCG AGT TAC TTG CGA GTG ACA 
GCC 
This study 
CH3481 (ptsG-
C421S-for) 
5´ - CAT TAC TAA CCT CGA CGC AAG TAT TAC 
CCG TCT GC 
This study 
CH3513 (Dd3937-1) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATT TCC TGA ACA AAG GAA GAC CG 
This study 
CH3514 (Dd3937-1) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT AAC 
TCC ACT TCC ATT TTA TGA TCA AAT 
This study 
CH3519 (PlumTTO1) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATG CGC TGG CCT CGC GAA ATC 
This study 
CH3520 (PlumTTO1) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT AAT 
TAC CTT CTA TCC ATA CTT GC 
This study 
CH3530 (Pestoides 
A) 
5´ - CAG GTA GGA ACT CGG TTG AGA ATA 
ATG CGC TGG GTC TGG CTC TGA AG 
This study 
CH3531 (Pestoides 
A) 
5´ - GGT CTG GTG TCT AAC CTT TGG TTA ATA 
CCA TTT TAC ATT AAA ATC AGC  
This study 
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CH3570 (pUC rev 
Xho)  
5´ - AAA CTC GAG GCC TCT GCA GTC G This study 
CH3571 (pUC for 
Xho) 
5´ - AAA CTC GAG TCG CGA ATG CAT C This study 
CH3572 (Pest cdiI 
for)  
5´ - GGA GGT ACC ATG ATC TTG AAA AAA G This study 
CH3612 (ptsG-Eco-
for) 
5´ - GTT CCG AAT TCA AGA ATG CAT TTG CTA 
ACC TG 
This study 
CH3613 (ptsG-Pst-
rev) 
5´ - GAC TGC AGT TAG TGG TTA CGG ATG TAC 
TC 
This study 
CH3629 (gltK-for) 
5´ - CTG GTA CCA TGT ACG AGT TTG ACT GGA 
G 
This study 
CH3630 (gltK-rev) 
5´ - GAC TCG AGT TAT GCT GTC CTT CTT TTC 
AAG 
This study 
CH3631 (rbsC-for) 
5´ - CTG GTA CCA TGA CAA CCC AGA CTG TCT 
C 
This study 
CH3632 (rbsC-rev) 
5´ - GAC TCG AGT TAC TGC TTT TTG TTG TCT 
ACC 
This study 
CH3633 (gltJ-for) 
5´ - CTG GTA CCA TGT CTA TAG ACT GGA ACT 
GG 
This study 
CH3634 (gltJ-rev) 5´ - GAC TCG AGT TAT TTG CCC CCC ATG TTG This study 
CH3674 (3937-cdiI2-
Kpn-for) 
5´ - GAA GGT ACC ATG AAA TGT AAT GAT TTT This study 
CH3675 (3937-cdiI2-
Xho-rev) 
5´ - TTT CTC GAG CTA ACT CCA CTT CCA TT This study 
CH3676 (TTO1-cdiI-
Kpn-for) 
5´ - TTT GGT ACC ATG AAT ACT AAA CTT AAT 
G 
This study 
CH3677 (TTO1-cdiI-
Xho-rev) 
5´ - TTT CTC GAG CTA ATT ACC TTC TAT CC This study 
CH3682 (536-K127-
for) 
5´ - AAA ACT GTA GAT AAG CTT AAT CAG 
AAG 
This study 
CH3683 (3006-L167-
OE-rev) 
5´ - CTT CTG ATT AAG CTT ATC TAC AGT TTT 
CAG AAC TTC TAT CTT ACT GGC C 
This study 
CH3722 (ptsG-R386-
Xho-rev)  
5´ - GAC TCG AGT TAA CGA CCC GGC GTT TTC This study 
CH3723 (o11CT-
T151-for) 
5´ - ACA GCG ACA GCG ACG This study 
CH3724 (3006NT-
L167-o11CT-T151-
rev) 
5´ - CGT CGC TGT CGC TGT CAG AAC TTC TAT 
CTT ACT GGC C 
This study 
CH3787 (galT-Kpn-
for) 
5´ - CAC GGT ACC ATT TGG GCA AAT AGC TTC 
C 
This study 
CH3788 (yfp-Eco-
rev) 
5´ - CT GAA TTC GCG GCC GCT TCT AGA This study 
CH3789 (galM-Bam-
for) 
5´ - CGC GGA TCC CGG AAG AGC TGG This study 
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Restriction endonuclease sites are underlined. 
  
CH3790 (galM-Sac-
rev) 
5´ - TCT GAG CTC AGG GCA AAC AGC ACC This study 
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III. YciB is required for metal tolerance in Escherichia coli  
This work is part of a manuscript in preparation and has not yet been published.  
A. Introduction 
A number of E. coli proteins are required for the binding, delivery, and activity of CdiA-
CTs during CDI.  These proteins have other known physiological functions (157, 173, 192, 
193), and there are no examples of E. coli genes outside of the cdi locus that produce proteins 
specifically required for CDI and no other cellular role.  Parsing apart the physiological role 
of metabolic proteins required for CDI and their contribution to toxin delivery is of great 
interest, as unraveling these complexities will allow us to better understand the evolution and 
function of CDI families.  We have previously identified inner membrane proteins required 
for the translocation of nuclease CdiA-CTs, including some (such as MetI and PtsG) that are 
part of multiunit membrane complexes that function as metabolite and small molecule 
transporters (173).  The physiological function of these proteins and protein complexes is not 
required for CDI.  PtsG mutants unable to transport or phosphorylate glucose still permit the 
delivery of specific CdiA-CT molecules, and other parts of the MetI protein complex can be 
deleted from target cells without disrupting CDI (173). 
During our search for inner membrane proteins required for the delivery of CdiA-CTs, 
we identified yciB as a gene necessary for the translocation of CdiA-CTo11
EC869
 from E. coli 
into target cells (173).  YciB is encoded by a small open reading frame and is predicted to 
localize to the inner membrane in E. coli (295, 296).  As with other “y” genes in E. coli, the 
exact function of the yciB gene product is unknown (297, 298).  Therefore, we were 
interested in characterizing YciB to better understand not only its role in normal E. coli 
physiology, but also the function of this protein in CdiA-CT transport during contact-
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dependent inhibition.  Here we present results implicating YciB as a component required for 
metal tolerance in E. coli. 
B. Results 
1. yciB encodes a non-essential putative inner membrane protein in E. coli that  is 
highly conserved in gammaproteobacteria 
The yciB gene is located on the minus strand of the E. coli chromosome near the φ80 
phage att site (295, 299).  It is flanked by the opp operon, which encodes an oligopeptide 
permease (300), and the trp operon, which regulates tryptophan biosynthesis (301) (Figure 
1A).  yciB is 540 nucleotides in length and is predicted to encode a 179-residue inner 
membrane protein (296).  Experimental analysis of ispA, the yciB homolog in Shigella 
flexneri, revealed that ispA mutants have a division defect during intracellular infection of 
epithelial cells (302, 303).  While no detailed mechanistic function has been ascribed to YciB 
in E. coli, recent reports suggest that YciB interacts with ZipA, RodZ, and MurG, which are 
involved in peptidoglycan synthesis and cell division (304, 305). 
YciB is predicted to form a 5-pass transmembrane protein with a periplasmic N-terminal 
tail and a cytoplasmic C-terminus (306, 307) (Figure 1B).  The E. coli YciB and Shigella 
IspA proteins are virtually identical (99.4% conservation, or 178/179 residues identical) (302, 
303), so we asked whether this conservation extended throughout gammaproteobacteria.  We 
identified closely-related homologs using the protein BLAST database (308) and created a 
sequence logo from the top 100 matches (including Shigella, Citrobacter, Salmonella, 
Enterobacter, Klebsiella, Yokenella, Kluyvera, Raoultella, Trabulsiella, Leclercia, and 
Escherichia species) using WebLogo (309) to easily identify completely conserved residues 
(Figure 1C).  This protein is highly conserved across all examined species.  The sequence 
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variations that do exist occur at the residues predicted to be localized inside transmembrane 
domains (Figure 1C, black lines), in the cytoplasmic loop between transmembrane passes 3 
and 4, and in the cytoplasmic tail.  The N-terminal sequence (up to transmembrane domain 1) 
is almost completely conserved across all 100 input sequences. 
We next investigated the role of YciB in E. coli physiology under standard laboratory 
conditions.  We performed growth curves with wild-type and ΔyciB E. coli MC4100 cells 
(Figure 2A) and found that they have almost identical growth rates.  Microscopy images 
were captured at various timepoints during growth representing early log phase (1 hr), mid-
log phase (3 hr), and stationary phase (5 hr) and were used to examine the morphology of 
wild-type and ΔyciB strains.  The cells are phenotypically similar over different growth 
phases (Figure 2B), although we note that the ΔyciB cells appear less opaque in stationary 
phase (Figure 2B, 5 hr).  Using the same microscopy images represented in Figure 2B, the 
length of wild-type and ΔyciB cells were measured at each timepoint (N between 160 and 
192 cells for all samples).  There is a statistically-significant difference between the length of 
wild-type cells and ΔyciB cells after 1 and 3 hours of growth (Figure 1C), but we note that 
this size difference is extremely small (Table 1) and does not match the cell-length 
differences observed by Badaluddin and Kitakawa (304). 
2. YciB is required for tolerance to select metals under aerobic conditions 
In 2012, Nichols and coworkers in the Gross lab at UC San Francisco published a 
comprehensive phenotypic screen of the entire Keio collection of single-gene knockouts in E. 
coli (289, 310).  Their dataset, which can be accessed at http://ecoliwiki.net/tools/chemgen/, 
indicated that yciB knockouts were highly susceptible to a variety of compounds, including 
metals (copper and nickel), detergents (SDS and deoxycholate), chelators (EGTA and 
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EDTA), and antibiotics (including gentamicin, tobramycin, puromycin, bleomycin, and 
amikacin).  To verify these results, we tested the growth of wild-type and ΔyciB cells on LB-
agar plates supplemented with metals, EGTA, and deoxycholate (Figure 3A).  ΔyciB cells 
have a severe growth defect when grown on media containing 4 mM CuCl2, but we did not 
observe a growth defect when grown on media containing 1 mM NiSO4.  Interestingly, we 
found that ΔyciB cells grew better than wild-type on LB-agar supplemented with 2% 
deoxycholate.  All growth differences were complemented to wild-type levels by providing 
cells a plasmid-borne copy of yciB. 
Because the most severe growth phenotype was observed in the presence of copper, we 
tracked the growth rate of cells in LB media supplemented with 4 mM CuCl2 to determine 
how growth is affected over time in these conditions.  Wild-type cells continue to grow when 
treated with copper, albeit at a much slower rate than untreated cells (Figure 3B, compare 
maroon and dark purple lines).  However, yciB knockout cells were completely unable to 
grow over the course of 6 hours when treated with copper (Figure 3B, light purple line).  To 
test whether the growth deficiency observed in the presence of copper could be phenocopied 
in additional metal-rich envionments not tested by Nichols et al., we grew wild-type, ΔyciB, 
and ΔyciB cells complemented with plasmid-borne yciB in LB media supplemented with 
varying concentrations of silver (AgNO3) and zinc (ZnCl2) in 96-well plates and measured 
the OD600 to track cell growth.  ΔyciB cells became susceptible to both metals at a 
concentration 10-fold lower than the level at which growth of wild-type cells was fully 
inhibited (10 µM vs 100 µM AgNO3 and 1 mM vs 10 mM ZnCl2) (Figure 3C, D).   
Two chromosomally-encoded systems are utilized by E. coli for handling high 
concentrations of copper inside the cell.  Under aerobic conditions, CueR regulates the 
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expression of the ATPase efflux pump CopA and the periplasmic multicopper oxidase CueO 
(311-314).  Under anaerobic conditions, the two-component signal transduction system 
CusRS regulates the expression of the CusABC multidrug efflux system and CusF, a 
periplasmic copper/silver-binding protein (312, 315, 316).  To compare the toxicity of yciB 
knockouts in high copper environments with the well-characterized Cue and Cus systems, we 
constructed single-gene knockouts of all cue and cus genes (copA, cueEO, and cusABCFRS) 
by transducing these alleles from the Keio collection (289) into a fresh background.  We 
grew these strains on LB-agar plates supplemented with 2 mM CuCl2 and compared their 
growth to wild-type or ΔyciB cells (Figure 4).  The most severe growth defect on copper 
plates occurred in the ΔcopA strain, and the cueO deletion mutant also had a noticeable 
colony phenotype compared to wild-type cells (Figure 4, top panels).  ΔyciB cells exhibited a 
growth phenotype similar to that observed with the ΔcueO strain.  Providing plasmid-borne 
yciB complemented the growth phenotype and restored colony growth and morphology to 
wild-type levels.  Colony morphology of the cus system knockouts did not change in 
response to copper (Figure 4, bottom panels), which is in agreement with previous studies 
showing that this system is important for anaerobic, not aerobic, copper tolerance (312, 315, 
316). 
We next wanted to determine which domains or regions in YciB are important for 
conferring tolerance to copper stress.  As YciB is predicted to localize to the inner 
membrane, it is possible that this protein interacts with partners on either the periplasmic or 
cytoplasmic face.  To test this, we constructed in-frame insertions in which the periplasmic 
and cytoplasmic loops connecting the transmembrane domains were individually disrupted 
by a 9-residue HA epitope (sequence YPYDVPDYA).  The residues replaced by the HA tag 
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are indicated by the black brackets in Figure 5A.  We then transformed these plasmids into 
ΔyciB cells and tested their ability to grown on LB-agar plates supplemented with 2 mM 
CuCl2.  All HA insertions complemented growth (Figure 5B). 
We next constructed a set of point mutations in the N-terminal periplasmic domain and in 
loop 3, which resides in the cytoplasm.  The N-terminus of YciB is highly conserved, so we 
reasoned that some of the most conserved residues here may contribute to function.  We also 
made constructs containing individual polymorphisms in loop 3 that have been found in 
sequenced E. coli isolates from the ECOR database (317) (Pro99Gln, Thr110Met, 
Leu111Val, Pro114Ser, and Ser117Leu).  We provided plasmid-borne copies of these 
mutated yciB alleles to ΔyciB cells and grew them on copper LB-agar plates to observe 
growth defects.  All HA tag insertions fully complemented the growth phenotype (Figure 
5B), and ΔyciB cells carrying all individual point mutation constructs grew as well as wild-
type (Figure 5C). 
3. yciB alleles from different species are functionally equivalent 
Because none of the loop insertions or individual point mutations we constructed affected 
the function of YciB, we asked whether alleles from different species were functionally 
equivalent in E. coli.  Although the sequence of YciB is generally conserved (Figure 1C), the 
genetic neighborhood surrounding this gene can vary due to its proximity to the φ80 att site 
(Figure 1A).  Something about prophages, other islands present.  Additionally, other species 
might inhabit other environments that influence the need for and expression of yciB, the 
polymorphisms in these alleles could affect function.  We cloned yciB from the 
gammaproteobacteria species Enterobacter cloacae (ECL), Enterobacter aerogenes (EAE), 
and Yersinia pseudotuberculosis YPIII (YPIII), all of which are closely related to E. coli 
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(Figure 6A).  We also cloned yciB from Burkholderia thailandensis, which is a 
betaproteobacteria and therefore more distantly-related to E. coli than the other organisms 
(Figure 6B).  When provided on a plasmid to ΔyciB cells, these alleles all complement the 
copper sensitivity observed with the empty vector control (Figure 6C). 
Though the normal physiological role of YciB appears to be providing resistance to metal 
toxicity, we are also interested in this protein because of its role in the delivery of CdiA-
CTo11
EC869
 during CDI, a process mediated by the N-terminal domain of this toxin (173).  
Because this toxin must translocate across the inner membrane of target cells, it may require 
direct contact with YciB on either the periplasmic or cytoplasmic face.  We therefore utilized 
the point mutations and HA tag insertions in periplasmic and cytoplasmic domains of YciB 
to determine whether these regions were required for interaction with CdiA-CTo11
EC869
.  
ΔyciB cells are resistant to inhibition by CdiA-CTo11
EC869
, and this phenotype is easily 
quantifiable using co-culture assays to enumerate viable target cells of a given genotype.  
Therefore, we individually transformed all point mutations, HA tag insertion, and 
heterologous allele plasmids into a ΔyciB background and competed these against 
CDIo11
EC869
.  As shown in Figure 7, all mutations complemented the CDI-resistant phenotype 
of ΔyciB cells, indicating that none of these regions are essential for CDI.  We also tested the 
heterologous alleles from E. cloacae, E. aerogenes, Yersinia pseudotuberculosis YPIII, and 
B. thailandensis and found that they all complemented CDI resistance.  Therefore, in the 
context of these experiments, providing a functional yciB gene to E. coli target cells is 
enough to confer sensitivity to CdiA-CTo11
EC869
. 
C. Discussion 
As with other trace metals, the physiological level of copper must be tightly regulated in 
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bacteria.  While trace amounts of copper must be present for use in enzymes such as copper- 
and zinc-containing superoxide dismutase (318), excess can be toxic (313, 319).  Copper can 
participate in the Fenton reaction, which produces free hydroxyl radicals and contributes to 
membrane oxidation in cells, although the in vivo relevance of this reaction in the presence of 
copper is under debate.  Because of the affinity between thiol groups and copper ions, 
another mechanism by which excess copper can exert toxicity is by the displacement of iron 
from iron-sulfur clusters in dehydratases (320, 321).  This delicate balance is further 
complicated by host-pathogen interactions; during infection, eukaryotic hosts increase serum 
levels of copper as well as the concentration of copper at localized areas such as wounds or 
burns (322, 323).  The mammalian copper transporter ATP7A also transfers copper to 
phagolysosomes containing internalized bacteria (322, 324-326). 
Two chromosomally-encoded systems are used to detoxify excess copper in E. coli.  The 
Cue system is regulated by CueR, a MerR-type metal-activated transcription factor that binds 
cytoplasmic copper and activates the expression of copA and cueO (311-314, 327).  CopA is 
a P-type ATPase efflux pump that is active against Cu
+
 and other heavy metals (206, 311, 
319, 327).  CueO is a periplasmic multicopper oxidase that converts toxic Cu
+
 to the less 
toxic Cu
2+
 (311).  As this process requires oxygen, the Cue system is the predominant copper 
response system under aerobic growth conditions.  The Cus system is a two-component 
signal transduction copper response system mediated by CueRS, which activate the 
expression of the cusCFBA operon during copper and silver stress (311, 312, 316).  CusABC 
form a tripartite complex analogous to multidrug efflux pumps (315, 316), and CusF is a 
small periplasmic metal-binding protein that binds Cu
+
 and Ag
+
 (315).  While there is some 
functional redundancy between the Cue and Cus systems, Cue generally regulates the 
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response to copper under aerobic conditions while the Cus system functions anaerobically 
(312, 313, 315, 316, 328, 329).  In addition to the two chromosomal copper detoxification 
systems, some natural isolates of E. coli also carry plasmid-borne copper resistance system 
composed of the Pco proteins (319, 329, 330).  This is analogous to the aerobic Cue system, 
as PcoA is partially redundant with the periplasmic oxidase activity of CueO (330). 
Here, we show that YciB contributes to metal tolerance in E. coli.  Strains lacking yciB 
phenocopied a cueO deletion when grown on 2 mM CuCl2 (Figure 4).  Because there is 
overlap between silver and copper detoxification systems in E. coli (331-333), we tested 
whether yciB mutants also show an increased sensitivity to silver.  Interestingly, we observed 
a statistically-significant growth defect in a ΔyciB strain compared to wild-type when grown 
in the presence of not only silver, but also zinc (Figure 3C and D).  However, we note that 
yciB expression did not change in response to copper or zinc stress in previous transcriptional 
studies (334, 335).  We did not observe a colony morphology defect when grown on media 
supplemented with nickel (Figure 3A), suggesting that YciB is not required for tolerance to 
this metal under the conditions we tested.  The large-scale phenotypic screen carried out by 
Nichols et al. identified high nickel as a condition in which yciB mutants have a growth 
defect, but their experiments were performed using minimal media instead of rich LB media 
(310).  Perhaps the differences in nutrient and metal concentrations between these two media 
account for these contrasting results. 
The first hints at YciB function came from studies on the homolog IspA in Shigella 
flexneri, in which it was observed that ispA mutants exhibit cell division defects during 
intracellular infection (302, 303).  We did not observe any noticeable cell division effects or 
filamentation phenotypes during growth of ΔyciB strains in standard laboratory conditions 
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using rich media (Figure 2).  However, an article from Badaluddin and Kitakawa reports that 
yciB deletion strains are approximately half the length of wild-type E. coli cells (304).  Their 
experiments were performed using the BW25113 background, which was used for 
construction of the Keio collection of single-gene knockouts (289).  The genotypes of this 
strain and the strains used in this study (MC4100 and X90) vary significantly and may give 
rise to the conflicting results regarding cell length.  Furthermore, the reported length of their 
wild-type strain (3.0 ± 0.7 µm) is greater than our wild-type X90 strain (1.593 ± 0.02545 
µm).  We also did not observe the same growth rate defect in ΔyciB cells that was reported 
by this study, and note that the growth defect reported by Badaluddin and Kitakawa (304) is 
not immediately comparable to the results presented in their other study on YciB function in 
E. coli (305). 
The host environments in which Shigella IspA mutants were observed to have 
morphological defects differ greatly from the laboratory conditions in which these 
experiments were performed, and the contribution of copper to host immune responses is 
well-documented (322, 324-326, 336).  Perhaps in an environment mimicking intracellular or 
other host conditions, deletion of yciB would, in fact, lead to cell division defects in E. coli as 
with Shigella.  It would also be interesting to repeat the cell measurement experiments in 
conditions with sub-inhibitory concentrations of copper or other metals to determine whether 
yciB mutants have a cell division defect under these conditions. 
Although we constructed a number of point mutations and insertions in YciB, we were 
unable to find mutants that affected metal tolerance activity or function in the context of CDI 
(Figure 7).  These activities may be mediated by the cytoplasmic C-terminal tail, which we 
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did not mutate.
2
  Copper typically associates with the thiol side chain of cysteine residues, 
but histidine and methionine can also coordinate this metal.  CusF, the periplasmic 
component of the CusABCF system, coordinates both copper and silver via a unique His-
Met-Met coordination site (331-333).  YciB lacks the canonical Cys-X-X-Cys copper 
binding motif utilized by ATPases and copper chaperones (206).  Though the C-terminal tail 
contains residues that could be involved in metal coordination, this sequence varies among 
species and therefore may not contribute to a conserved function (Figure 1).  It is interesting 
to note that the C-terminal residues of YciB (HMPQEDKS) are found at the C-terminus of a 
P-type ATPase involved in copper transport in Coprothermobacter proteolyticus 
(HMPQEEK), but this motif has no specific ascribed function in this organism.  YciB may 
also interact with other proteins by dimerizing or oligomerizing via transmembrane domains.  
Perhaps YciB interacts with components of previously-described metal detoxification 
systems in an unknown way.  Alternatively, YciB and any interacting partners could 
constitute another metal tolerance system with broad substrate specificity. 
The immediate genetic neighborhood surrounding yciB is highly conserved throughout 
species (Figure 8).  Using the Prokaryotic Sequence homology Analysis Tool (PSAT, 
available at http://www.nwrce.org/psat/index.html) (337), we examined the genes in a 25-
kilobase region surrounding yciB from 93 closely-related organisms to compare gene 
conservation.  A yciB homolog was present in all genomes (Figure 8, center orange rectangle 
labeled with red text).  yciC and yciA, the genes immediately upstream and downstream of 
yciB, were present in almost all genomes examined (Figure 8, pink and yellow rectangles 
flanking yciB).  Interestingly, insertions of other genes separate these in organisms like 
                                                 
2
 We note that attempts to construct a C-terminal GFP fusion protein were difficult and 
suggest that interfering with this region may lead to toxicity in E. coli. 
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Yersinia, Klebsiella, and Photorhabdus, but all three genes are located in the same region of 
the genome.  We note that the organisms in which either yciA or yciC are not present, the 
large intergenic regions in this area may not have been properly annotated.  The location of 
tonB and ompW genes are conserved throughout nearly all of these organisms (88/93 for tonB 
and 90/93 for ompW).  An interesting set of exceptions are the Klebsiella genomes examined 
here; many of them lack an annotated tonB gene in this area.  The presence of other 
uncharacterized yci genes in this region (including yciEFG) is not widely-conserved 
throughout Gram-negative bacteria. 
Although the location of yciB and the adjacent genes is well-conserved, the genomic 
region surrounding them is remarkably fluid (Figure 8, observe insertions upstream and 
downstream of the central yciABC region).  The φ80 att site is located immediately upstream 
of yciB, and many sequenced isolates contain prophages or other insertions (like the type 3 
secretion system in E. coli strain O111:H11128) that separate the opp locus from tonB, 
yciABC, and ompW.
3
  Other isolates contain prophages or genomic islands downstream of 
ompW (such as the prophage CP933O/genomic island OI-57 in many enteropathogenic and 
Shiga toxin-producing E. coli isolates (338, 339)) although there is no annotated integration 
site here.  Perhaps the conservation of genes in this area is indicative of co-expression or 
interaction patterns involved in the function of YciB. 
In addition to metal tolerance, YciB may play a role in the maintenance of membrane 
integrity.  Nichols et al. (cite) reported that yciB mutants showed growth deficiencies in a 
number of conditions, including high EGTA, high EDTA, and 4% SDS, which would 
promote destabilization or disruption of membranes.  The presence of EGTA and EDTA 
                                                 
3
 E. coli DH10B contains a φ80 derivative, but this is a result of direct laboratory genetic 
manipulation to facilitate α-complementation, not natural variation in this region. 
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results in chelation of the magnesium and calcium ions that contribute to the integrity of the 
outer membrane of Gram-negative cells by bridging LPS chains, and SDS is a anionic 
detergent that solubilizes membrane proteins and lipids.  Our own preliminary results 
confirm these data and show that yciB deletion strains have a growth defect in the presence of 
EGTA, EDTA, and SDS, but not the membrane-disrupting antibiotic polymixin B (data not 
shown).  We also do not detect any defects in the levels of outer membrane proteins such as 
LamB and OmpA (data not shown).  Additional experiments will be required to fully 
understand the role of YciB in E. coli physiology and whether this involves any other 
interacting partners in the cytoplasm, periplasm, or membrane.  A more in-depth 
understanding of the motifs and domains required for YciB activity can also help elucidate 
the role of this protein in CdiA-CT translocation during CDI.   Based on other inner 
membrane proteins required for delivery of CdiA-CT domains, we predict that the yet-
unknown metal tolerance activity of YciB will be distinct from its contribution to CDI. 
D. Materials and methods 
1. Plasmid construction 
All E. coli yciB mutations were constructed using pCH9922 as a template.  The HA tag 
insertions were constructed via megaprimer PCR as follows.  The HA tag sequence was 
fused to the coding region of yciB using primers CH2139/CH2616 (loop 1), 
CH2139/CH2617 (loop 2), CH2618/CH2140 (loop 3), or CH2619/CH2140 (loop 4).  The 
resulting PCR product was purified and used in a second PCR reaction with either primer 
CH2140 (loops 1 and 2) or CH2139 (loops 3 and 4) and pCH9922 as template.  The N-
terminal P9A and V12P mutations were amplified using primers CH2804/CH2140 and 
CH2805/CH2140, respectively. The point mutations in loop 3 were constructed using 
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megaprimer PCR as follows.  First, yciB was amplified with the appropriate codon 
substitutions using forward primers CH2634 (P99Q), CH2635 (T110M), CH2636 (L111V), 
CH2637 (P114S), and CH2638 (S117L) with reverse primer CH2140.  The resulting PCR 
products were purified and used in a second reaction with template pCH9922 and primer 
CH2139.  All final PCR products were purified, digested with KpnI and XhoI restriction 
enzymes, and ligated to a pTrc99KX vector treated with the same enzymes.  Mutations and 
insertions were confirmed by DNA sequencing (University of California, Berkeley). 
Heterologous alleles were amplified from genomic DNA or bacterial colonies using 
primers CH2460/CH2461 (Yersinia pseudotuberculosis YPIII YPK_2053), CH2139/CH2462 
(Enterobacter aerogenes EAE21485), CH2139/CH2463 (Enterobacter cloacae ECL01649), 
or CH2683/CH2684 (Burkholderia thailandensis).  B. thailandensis and Yersnia 
pseudotuberculosis YPIII genomic DNA was graciously provided by David Low and 
Natasha Edman. 
2. In silico analysis 
Genetic analysis of the yciB gene location was primarily done with the PEColi and 
EcoCyc databases (295, 296).  The Prokaryotic Sequence homology Analysis Tool (PSAT) 
was used for the large genetic neighborhood analysis (337).  The E. coli MG1655 yciB gene 
was used as an input, and output alignments were constrained only by the available genome 
sequences in the PSAT database.  Predictions of the YciB membrane orientation were 
performed using the TMHMM server to predict transmembrane helices (306).  The top 
predictions were put through additional transmembrane prediction software to confirm their 
validity.  Transmembrane maps were created by using the domains predicted by TMHMM as 
input parameters for Topo2 (307).  Sequence logos were created by using the NCBI protein 
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BLAST database to identify highly-conserved non-E. coli YciB sequences (308).  These 
were aligned using Clustal Omega, and the FASTA output was loaded onto the WebLogo 
server (available at http://weblogo.berkeley.edu/logo.cgi, University of California, Berkeley). 
3. Growth conditions 
Media ingredients and chemicals were purchased from Sigma-Aldrich unless otherwise 
indicated.  Cells were routinely grown in lysogeny broth (LB) with antibiotics as indicated.  
For growth curve analysis of growth rate, wild-type E. coli MC4100 as well as a yciB 
knockout strain were grown overnight in LB media with antibiotics (200 µg/mL rifampicin 
or 50 µg/mL kanamycin) and were diluted into fresh LB media without antibiotics the next 
day.  These cells were grown to mid-log phase at 37 °C with shaking, at which point they 
were diluted to an OD600 of 0.05 in fresh pre-warmed LB media without antibiotics.  OD600 
values were measured every 30 m to track growth.  4 mM CuCl2 was added after 30 minutes 
where indicated.  Data is presented as the average of two independent experiments. 
To observe colony morphology under different stress conditions, strains were grown 
overnight in LB media supplemented with antibiotics.  The next day, cells were diluted into 2 
mL LB media without antibiotics and grown at 37 °C with shaking until they reached mid-
log phase.  Each culture was adjusted to the same cell number per volume based on OD600 
values, and 10-fold serial dilutions were performed in 1xM9 salts.  1 µL of each dilution was 
spotted onto LB-agar plates (plain or supplemented with chemicals, as indicated).  Plates 
were incubated upright at 37 °C to allow the cultures to soak in, after which point they were 
turned upside down and incubated for 12-18 hours at 37 °C. 
Growth assays in varying concentrations of ZnCl2 and AgNO3 were performed in flat-
bottom 96 well plates (Nunc).  Overnight cultures of the indicated strains were grown in LB 
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supplemented with antibiotics and were diluted into fresh LB media without antibiotics the 
next day.  Cultures were grown to mid-log phase, at which point 1 µL of culture was seeded 
into the appropriate wells.  OD600 values of each strain were measured to ensure equal cell 
per volume loading.  96 well plates were incubated at 37 °C with shaking on a Lab-Line 
4625 Titer plate shaker at speed 5 for the indicated time, at which point the OD600 values 
were read using a 96-well plate reader.  Data is represented as the mean of three independent 
replicates ±SEM. 
4. Competition co-culture 
Co-culture competitions with CDI inhibitor cells were carried out as previously described 
(177).  Briefly, E. coli EPI100 inhibitor cells carrying pCH9305 and CH8251 target cells 
(wild-type or ΔyciB::kan) carrying a pTrc99a vector or the indicated yciB derivatives were 
grown overnight at 37 °C in LB media with antibiotics (150 µg/mL ampicillin).  The next 
day, cells were diluted into separate 25 mL flasks in fresh LB without antibiotics and were 
grown until mid-log phase.  Inhibitors and targets were mixed together at a 10:1 
inhibitor:target ratio in fresh pre-warmed LB and were co-cultured for the indicated amount 
of time at 37 °C with shaking.  At 0 and 3 hours, an aliquot of each was removed, diluted in 
1xM9 salts, and plated onto LB-agar supplemented with 200 µg/mL rifampicin and 150 
µg/mL ampicillin to select for viable target cells.  Data presented is the average of three 
independent experiments ±SEM (where error bars are shown). 
5. Microscopy and cell length analysis 
Cells used for microscopy were wild-type or ΔyciB E. coli X90 derivatives.  These 
cultures were grown overnight in LB supplemented with antibiotics and were diluted into 
fresh LB at 37 °C with shaking the next day.  In mid-log phase, cells were diluted to an 
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OD600 of 0.05 in fresh pre-warmed media.  At the indicated timepoints, samples were 
removed and spotted onto agarose pads for visualization.  Agarose pads were made by 
mixing 1xM9 salts with 1% molecular biology grade agarose (Fisher Scientific) and pouring 
the solution between two plain microscopy slides.  After solidifying, agarose pads were cut 
into strips and placed onto a glass microscopy slide.  5 µL of cell culture was pipetted onto 
the center of the agarose strip and covered by a glass coverslip.  Slides were incubated face-
up for 10 minutes at room temperature to allow the cells to adhere to the agarose and were 
imaged with an Olympus fluorescent microscope using a 100x oil objective and an Optronics 
MacroFire digital microscope camera.  For length analysis, images were imported into FIJI 
(292), and cell lengths were measured using the line tool and ROI manager as previously 
described (202).  Fields of view were cropped to 200x200 pixels using the GIMP software 
suite, and representative images are shown. 
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Figure 1.  yciB encodes a putative inner membrane protein in E. coli that is highly conserved throughout 
gammaproteobacteria. (A) Genetic location of yciB.  Genes in the opp operon are shaded light purple.  Genes 
in the trp operon are shaded green.  Other yci genes are colored salmon.  yciB is shown in the center and is 
colored red.  The φ80att site between yciI and tonB is indicated by the dashed line.  (B) Transmembrane 
prediction of YciB as predicted by TMHMM and rendered by Topo2.  (C) YciB proteins are highly conserved.  
A sequence logo was generated from the top 100 BLAST results (with E. coli sequences excluded).  Letters 
spanning the entire y-axis are invariant among input sequences.  Residues included in transmembrane domains 
are indicated, and the numbers correspond to the labels in (B). 
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Figure 2.  yciB is a nonessential gene under laboratory conditions.  (A) Wild-type and yciB cells have 
similar growth rates when grown with aeration in LB media.  Values reported are the mean of three independent 
replicates.  Wild-type and yciB cells have (B) similar morphologies and (C) similar cell lengths over a 5 hour 
growth period (1 hour = early log phase, 3 hours = mid-log phase, 5 hours = stationary phase).  Representative 
microscopy fields are shown in (B).  In (C), each point represents a single measured cell.  Unpaired two-tailed t-
tests were used to determine significant length differences.  *, P = 0.0175; ***, P = 0.0002.  
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Figure 3.  yciB is required for metal tolerance in E. coli.  (A) Wild-type, ΔyciB, and ΔyciB pYciB derivatives 
of E. coli MC4100 were grown to mid-log phase and spotted onto LB-agar plates supplemented with a variety 
of compounds to assess growth.  ΔyciB cells exhibit a severe growth defect compared to a wild-type control 
when grown with 4 mM CuCl2 and have a growth advantage when grown with 2% deoxycholate.  (B) ΔyciB 
cells (light purple line) have a severe growth defect compared to wild-type cells (dark purple line) when treated 
with 4 mM CuCl2.  ΔyciB cells also exhibit a growth defect when grown with (C) AgNO3 and (D) ZnCl2. 
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Figure 4.  Deleting yciB phenocopies the loss of the aerobic copper response regulator CueO.  All cells 
were grown to mid-log phase, diluted, and spotted onto LB-agar or LB-agar/CuCl2 plates as indicated.  Plates 
were imaged after overnight growth at 30 
o
C.   
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Figure 5.  Individual loop domains in the periplasm and cytoplasm are not required for function of YciB.  
(A) The locations of all single point mutations constructed in this study were mapped onto the predicted 
transmembrane orientation of YciB.  Mutated residues are shown in orange squares.  The four loops in which 
HA epitope insertions were constructed are labeled and numbered accordingly.  (B) Plasmids expressing yciB 
with single HA epitope insertions were transformed into  yciB deletion strain and grown on LB-agar and LB-
agar supplemented with 2 mM CuCl2 to qualitatively analyze growth deficiencies.  (C) pYciB constructs with 
the individual point mutations highlighted in (A) were transformed into ΔyciB cells and grown on LB-agar or 
LB-agar supplemented with 2 mM CuCl2.  
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Figure 6.  Heterologous yciB alleles are functionally equivalent .  (A) YciB proteins from E. coli MG1655, 
Yersinia pseudotuberculosis YPIII, Enterobacter cloacae (ECL), and Enterobacter aerogenes (EAE) were 
aligned using the Clustal Omega server (http://www.ebi.ac.uk/Tools/msa/clustalo/).  The image was rendered 
using Jalview (available at http://www.jalview.org/).  Purple shading indicates residue conservation.  (B) YciB 
sequences from E. coli and Burkholderia thailandensis (B.t.) were aligned to show the lack of conservation 
between these proteins.  (C) Plasmids carrying the yciB alleles from the indicated species were transformed into 
E. coli ΔyciB cells and grown on LB-agar and LB-agar supplemented with 2 mM CuCl2. 
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Figure 7.  Mutations in yciB complement CDI resistance.  (A) Point mutations were constructed at well-
conserved residues in the N-terminal periplasmic tail (green bars) or in loop 3 as identified in the ECOR 
database (purple bars).  These were transformed into ΔyciB cells and co-cultured with inhibitor cells at a 1:10 
target:inhibitor ratio.  Viable target cell numbers were measured at 0 and 3 h timepoints.  (B) Individual HA tag 
constructs and (C) heterologous yciB alleles were transformed into ΔyciB cells and mixed with inhibitor cells 
under the same conditions as in (A).  Viable target cells were scored at 0 and 3 h.  Data presented is the mean of 
3 independent experiments ±SEM.  
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Figure 8.  Genetic neighborhood analysis of yciB.  Conserved genomic regions near yciB from 93 organisms 
were aligned using the PSAT website (available at http://www.nwrce.org/psat/index.html).  yciB or the relevant 
homolog gene is depicted as the orange rectangle with red text in the center of each frame.  Conserved genes 
across species are annotated with the same color scheme as the E. coli MG1655 reference genome (top). 
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Table 1.  Measurements of wild-type and ΔyciB cells. 
 
 Wild-type ΔyciB 
Timepoint N (cells) Measurement (µm) N (cells) Measurement (µm) 
1 hr 160 1.593 ± 0.02545 178 1.494 ± 0.03187 
3 hr 167 1.355 ± 0.02613 192 1.229 ± 0.02145 
5 hr 177 1.190 ± 0.01698 183 1.219 ± 0.02330 
 
Table 2.  YciB variations present in the E. coli Reference (ECOR) Collection (317). 
 
ECOR Strain YciB variant Serotype Host 
28 T110M O104:HNM 
Group B1 strain 
from a healthy 
human child 
28 S117L O104:HNM 
Group B1 strain 
from a healthy 
human child 
31 P99Q O79:H43 
Group E strain 
from a healthy 
leopard in captivity 
52 P114S O25:H1 
Group B2 strain 
from a healthy 
orangutan 
60 L111V O4:HN 
Group B2 strain 
from a human host 
with a UTI and 
acute cystitis 
 
Table 3.  Bacterial strains and plasmids used in this study. 
 
Strain  Description
a
 Reference 
X90 
F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) rifr thi-1, 
Rif
R
  
 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, leu)7697 
galU galK λ– rpsL nupG pir+(DHFR), StrR TpR 
Epicentre 
CH1426 X90 ΔcopA::kan, RifR KanR This study 
CH1427 X90 ΔcueO::kan, RifR KanR This study 
CH1428 X90 ΔcueR::kan, RifR KanR This study 
CH1429 X90 ΔcusA::kan, RifR KanR This study 
CH1430 X90 ΔcusB::kan, RifR KanR This study 
CH1431 X90 ΔcusC::kan, RifR KanR This study 
CH1432 X90 ΔcusF::kan, RifR KanR This study 
CH1433 X90 ΔcusR::kan, RifR KanR This study 
CH1434 X90 ΔcusS::kan, RifR KanR This study 
CH7838 Enterobacter aerogenes ATCC 13048 American Type 
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Culture 
Collection 
CH7839 Enterobacter cloacae ATCC 13047 
American Type 
Culture 
Collection 
CH8251 MC4100 rif
r
, Rif
R
 (173) 
CH9404 CH8251 ∆yciB::kan, RifR KanR (173) 
CH9405 X90 ∆yciB::kan, RifR KanR (173) 
Plasmid Description
a
 Reference 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 GE Healthcare 
pTrc99KX 
Derivative of pTrc99a that contains a 5´-KpnI restriction site 
and 3´-SpeI and XhoI sites, Amp
R
 
(175) 
pCH351 
pTrc99KX::yciB-HA1, IPTG-inducible expression of yciB in 
which the first loop has been replaced by an HA tag, Amp
R
 
This study 
pCH353 
pTrc99KX::yciB-HA2, IPTG-inducible expression of yciB in 
which the second loop has been replaced by an HA tag, Amp
R
 
This study 
pCH355 
pTrc99KX::yciB-HA3, IPTG-inducible expression of yciB in 
which the third loop has been modified to include an HA tag, 
Amp
R
 
This study 
pCH357 
pTrc99KX::yciB-HA4, IPTG-inducible expression of yciB in 
which the fourth loop has been replaced by an HA tag, Amp
R
 
This study 
pCH839 
pTrc99KX::yciB (B. thailandensis), IPTG-inducible 
expression of the yciB allele from Burkholderia thailandensis 
E264, Amp
R
 
This study 
pCH1084 
pTrc99KX::yciB P9A, IPTG-inducible expression of yciB 
with a Pro9Ala point mutation, Amp
R
 
This study 
pCH1086 
pTrc99KX::yciB V12P, IPTG-inducible expression of yciB 
with a Val12Pro point mutation, Amp
R
 
This study 
pCH2145 
pTrc99KX::yciB P99Q, IPTG-inducible expression of yciB 
with a Pro99Gln point mutation, Amp
R
 
This study 
pCH2147 
pTrc99KX::yciB T110M, IPTG-inducible expression of yciB 
with a Tyr110Met point mutation, Amp
R
 
This study 
pCH2149 
pTrc99KX::yciB L111V, IPTG-inducible expression of yciB 
with a Leu111Val point mutation, Amp
R
 
This study 
pCH2151 
pTrc99KX::yciB P114S, IPTG-inducible expression of yciB 
with a Pro114Ser point mutation, Amp
R
 
This study 
pCH2153 
pTrc99KX::yciB S117L, IPTG-inducible expression of yciB 
with a Ser117Leu point mutation, Amp
R
 
This study 
pCH9922 pTrc99KX::yciB, IPTG-inducible expression of yciB, Amp
R 
(173) 
pCH9305 
Constitutive expression of chimeric cdiA
EC93
-CTo11
EC869
 and 
cdiIo11
EC869
 genes, Amp
R
 
(177) 
pCH10416 
pTrc99KX::yciB (E. cloacae), IPTG-inducible expression of 
the yciB allele from Enterobacter cloacae ATCC 13047, 
Amp
R
 
This study 
pCH10417 
pTrc99KX::yciB (E. aerogenes), IPTG-inducible expression 
of the yciB allele from Enterobacter aerogenesATCC 13048, 
This study 
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Amp
R
 
pCH10418 
pTrc99KX::yciB (YPIII), IPTG-inducible expression of the 
yciB allele from Yersinia pseudotuberculosis YPIII, Amp
R
 
This study 
a
Abbreviations: Amp
R
, ampicillin-resistant; Apr
R
, aprimycin-resistant; Cm
R
, chloramphenicol-resistant; Erm
R
, 
erythromycin-resistant; Kan
R
, kanamycin-resistance; Rif
R
, rifampicin-resistant; Tet
R
, tetracycline-resistant; 
Zeo
R
, zeocin-resistant. 
 
Table 4.  Oligonucleotides used in this study. 
 
Oligonucleotide Sequence
a
 Reference 
CH2139 (yciB-Kpn-for) 
5' – AAT GGT ACC ATG AAG CAG 
TTT CTT GAT TTT TTA C – 3' 
(173) 
CH2140 (yciB-Xho-rev) 
5' – GCA CTC GAG TTA GGA TTT 
ATC TTC CTG CGG – 3' 
(173) 
CH2634 (yciB-P99Q) 
5' – GAA AAA GCA GCT AAT TCA 
GCG G – 3' 
This study 
CH2635 (yciB-T110M) 
5' – AGA ACT CAT GCT GCC GCA 
ACC GG – 3' 
This study 
CH2636 (yciB-L111V) 
5' – AGA ACT CAC GGT GCC GCA 
ACC GG – 3' 
This study 
CH2637 (yciB-P114S) 
5' – CTC ACG CTG CCG CAA TCG 
GTA TGG – 3' 
This study 
CH2638 (yciB-S117L) 
5' – TAT GGT TGA AGC TGA ATC 
TGG – 3' 
This study 
CH2460 (YPK2053-Kpn-for) 
5' – AAT GGT ACC ATG AAG CAA 
CTT TTA G – 3' 
This study 
CH2461 (YPK2053-Xho-rev) 
5' – GCA CTC GAG TTA AGA CTT 
CTT CTG C – 3' 
This study 
CH2462 (EAE21485-Xho-rev) 
5' – GCA CTC GAG TTA GTG CTT 
ATC GTC C – 3' 
This study 
CH2463 (ECL01649-Xho-rev) 
5' – GCA CTC GAG TCA GTG TTT 
ATC ATC C – 3' 
This study 
CH2616 (yciB-HA-1) 
5' – GCC ATC TTA GCG TAA TCT 
GGA ACA TCG TAT GGG TAG CGA 
ACC C – 3' 
This study 
CH2617 (yciB-HA-2) 
5' – CTT CCA TTT AGC GTA ATC 
TGG AAC ATC GTA TGG GTA ATC 
ATT GTG G – 3' 
This study 
CH2618 (yciB-HA-3) 
5' – GAT GCT GTA CCC ATA CGA 
TGT TCC AGA TTA CGC TGT ATG 
GTC G – 3' 
This study 
CH2619 (yciB-HA-4) 
5' – GGC TGC CGT ACC CAT ACG 
ATG TTC CAG ATT ACG CTA ACT 
TTA AAG TC – 3'  
This study 
CH2683 (Bth-yciB-Kpn-for) 5' – GCG GGT ACC ATG AAA TTC This study 
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CTG TTC GAT C – 3' 
CH2684 (Bth-yciB-Xho-rev) 
5' – CGC TCG AGG TTA TTC TCC CTT 
CAG GTA TTT CG – 3' 
This study 
CH2804 (yciB-P9A-Kpn) 
5' – TTT GGT ACC ATG AAG CAG 
TTT CTT GAT TTT TTA GCG CTG 
GTT GTC – 3' 
This study 
CH2805 (yciB-V12P-Kpn) 
5' – TTT GGT ACC ATG AAG CAG 
TTT CTT GAT TTT TTA CCG CTG 
GTT CCC TTT TTC GCG – 3' 
This study 
a
Restriction enzyme recognition sites are underlined. 
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IV. Insertion element transposition provides transient resistance against 
contact-dependent inhibition toxins from E. coli 
This work is part of a manuscript in preparation and has not yet been published. 
A. Introduction 
Contact-dependent inhibition (CDI) systems that deploy nuclease toxins must ensure that 
these domains reach the cytoplasmic compartment of target cells, where their DNA and RNA 
substrates reside.  We recently demonstrated that nuclease CdiA-CTs require the presence of 
specific inner membrane proteins to accomplish this (Chapter II and (173)).  These proteins 
were primarily identified using transposon mutagenesis screens and the selective pressure of 
CDI toxin delivery to isolate resistant mutants from a large starting population.  The inner 
membrane proteins identified are required for the transport of a variety of sugars, amino 
acids, and small metabolites into the cell.  Interestingly, we have shown that for some of 
these proteins, such as the methionine transporter MetI and the glucose transporter PtsG, 
their metabolic function is not required for their role in CDI. 
Delivery of CdiA-CTo11
EC869
, a DNase toxin from E. coli EC869, requires the 
uncharacterized putative inner membrane protein YciB (173).  As we showed in Chapter III, 
yciB is required for tolerance to metals, including copper and zinc.  Though it is a non-
essential gene under standard laboratory growth conditions, a yciB deletion strain is unable to 
grow under copper stress and phenocopies the loss of the well-characterized aerobic copper 
response regulator CueO (see Chapter III and (312).  During CDI, YciB is required for the 
delivery of toxins with the same N-terminal domain as CdiA-CTo11
EC869
.  We previously 
showed that a chimera toxin containing the N-terminal domain from CdiA-CTo11
EC869
 fused 
to the C-terminal tRNase domain from CdiA-CTII
Bp1026b
 inhibits cells in a YciB-dependent 
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manner (Chapter II and (173)). 
While characterizing isolates resistant to CdiA-CTo11
EC869
, we isolated a subset of 
mutants with transposon insertions disrupting the coding sequence of yciB (Chapter II and 
(173)).  Subsequent experiments confirmed that YciB is required for the delivery of this toxin 
to the cytoplasm of target cells.  Here, we describe another set of mutants isolated in these 
experiments that do not contain transposon insertions in yciB.  The transposons in this second 
class of isolates are not genetically linked to resistance, and the CDI-resistant phenotype is 
mediated by secondary mutations in yciB.  A majority of these mutations are attributed to 
insertion sequence elements that appear to have transposed into the yciB open reading frame 
in response to stress induced by the delivery of CdiA-CTo11
EC869
.  We propose that genomic 
rearrangements such as these transposition events could be a transient resistance mechanism 
that allows cells to escape immediate inhibition by a neighboring CDI
+
 cell while ultimately 
retaining the ability to revert to the wild-type allele to regain physiological function in the 
absence of selective pressure from CDI. 
B. Results 
1. A subset of CDIR isolates have unlinked transposon insertions and secondary 
mutations in yciB 
We previously showed that the inner membrane protein YciB is required for the delivery 
of CdiA-CTo11
EC869
 (Chapter II and (173)).  Mutants with transposon insertions in yciB were 
isolated from co-culture enrichment experiments in which a transposon pool was iteratively 
mixed with cells expressing CDIo11
EC869
 (173).  As discussed in Chapter II, a number of CDI
R
 
strains had transposon hops in yciB or the upstream gene yciC, although single-gene 
knockout experiments suggested that insertions in yciC were likely polar mutations affecting 
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expression of yciB.  These insertions were all genetically linked to CDI resistance, and 
resistance to this toxin could be conferred to a CDI-sensitive strain of E. coli K-12 by 
transducing the antibiotic resistance marker associated with the transposon into a fresh cell 
background (Chapter II).  During the course of these experiments, we also isolated a number 
of clones with transposon insertions that were unlinked to the CDI resistance phenotype.  
When grown in co-culture assays with CDIo11
EC869
 cells, these strains were all resistant as 
measured by viable colony counts at 0 and 3 h post-mixing (Figure 1A).  However, these 
transposon insertions did not confer resistance to a CDI
S
 background when transferred into a 
fresh cell background via P1 phage transduction (Figure 1B).  We sequenced the 
transposon/genomic DNA junction in these isolates to identify the location of these insertions 
in an effort to determine whether the unlinked mutations were related to one another (Table 
1).  The genes in which transposon insertions were found in these strains belonged to a 
number of cellular pathways (295, 296), including those involved in cell division (340) and 
sugar metabolism (341, 342), but no common operons or biochemical themes that seemed 
like plausible CdiA-CT translocation pathways could be identified from this genetic data.   
Isolating CDI
R
 clones from a transposon pool entails iterative co-culture of transposon-
mutagenized target cells and inhibitor cells expressing a CDI system of interest.  CDIo11
EC869
 
is potent and can decrease the number of viable target cells in a given culture more than 
10,000-fold over the course of a few hours (177).  As such, these enrichment experiments put 
significant selective pressure onto a population of target cells.  Additionally, target cells 
undergo a round of transposon mutagenesis to generate the input library, representing another 
source of potential cellular stress.  We reasoned that some target cells may accumulate 
secondary mutations outside of the transposon during the three rounds of co-culture.  Given 
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the requirement of YciB for the delivery of CdiA-CTo11
EC869
, cells that gained secondary 
mutations in this gene could be selected for over the course of the enrichment procedure.  We 
therefore decided to examine yciB alleles from CDI
R
 mutants with unlinked transposon 
insertions in an effort to identify secondary mutations that could confer resistance to 
CDIo11
EC869
.  As described in Chapter III, YciB is a putative inner membrane protein with 
two periplasmic and two cytoplasmic loops that connect 5 transmembrane domains.  Because 
CdiA-CTo11
EC869
 must be translocated through the periplasm across the inner membrane to 
reach the cytoplasmic DNA substrate, we hypothesized that we might find mutations in the 
periplasmic loop regions that prevented or altered an interaction with CdiA-CTo11
EC869
 during 
delivery to the cytoplasm. 
To test this hypothesis, we transformed a plasmid construct expressing yciB into the 
mutants listed in Table 1 and repeated the co-culture assays with CDIo11
EC869
, reasoning that 
if secondary mutations were present in yciB, then a expression of wild-type allele may restore 
the pathway needed for import of this toxin and thus render these cells CDI-sensitive.  In all 
mutants tested, the plasmid-borne copy of yciB complemented the CDI
R
 phenotype of these 
isolates, and cells were as sensitive as a wild-type, unmutagenized control strain of E. coli 
(Figure 2A).  We then amplified the yciB open reading frame as well as several hundred base 
pairs upstream and downstream of the start and stop codons and analyzed these pieces of 
DNA via gel electrophoresis to determine whether these genes were still intact.  Surprisingly, 
4 of 5 mutant alleles we amplified were larger than the wild-type control (Figure 2B).  The 
yciB gene from one mutant, A3, ran at approximately the same distance as wild-type.  We 
sequenced these mutant alleles to find the source of the size differences and found that in the 
4 mutants with larger alleles, the yciB open reading frames were disrupted by insertion 
130 
 
sequence (IS) elements (Table 2).  Mutant A3, which had a wild-type yciB allele as assessed 
by PCR, contained a nonsense mutation created by an A to T transversion at nucleotide 
position 223, which created a premature stop codon and a protein product 74 residues in 
length (Table 2). 
IS elements are small, mobile pieces of DNA that catalyze their own transposition 
throughout the genomes of bacteria.  They commonly flank larger genomic islands and are 
involved in complex genome rearrangements, even in laboratory strains of E. coli (343).  
Approximately 30 distinct families of IS elements have been identified in prokaryotic 
organisms to date, with many families containing multiple sub-groups (ISFinder, see 
https://www-is.biotoul.fr/index.php and (344-346)).  We analyzed the IS elements disrupting 
yciB in these mutants and found examples of IS1 and IS10 transposition; these are from two 
distinct families of IS elements.  Each mutant contained an independent transposon hop as 
evidenced by unique insertion sites and the nucleotide location of the 9-base pair inverted 
repeat sequences that flank IS elements in the genome (347) (Table 2).   
2. Spontaneous resistance to CDIo11
EC869
 can be achieved by IS element transposition 
The IS elements detected in mutants A1, A4, A5, and B1 represent rare transposition 
events.  IS elements undergo spontaneous transposition at rates of 10
-3
 – 10-8 events per 
element per generation (347, 348).  The cells in which they were identified were first 
subjected to transposon mutagenesis before enrichment against CDIo11
EC869
.  Therefore, it is 
possible that secondary mutations in yciB accumulated during the initial mutagenesis and are 
an artifact of the experimental procedure.  We wished to test whether co-culturing 
CDIo11
EC869
 with unmutagenized cells would result in the same pattern of IS element-
mediated CDI resistance, which could suggest that the specific activity of CDIo11
EC869
 was 
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inducing IS element transposition in target cells.  To do this, we performed iterative co-
culture assays with an unmutagenized input pool of target cells.  This approach was designed 
to isolate spontaneous mutations leading to resistance to CDIo11
EC869
.  Both E. coli MC4100 
and EPI100 target cells were used to test cell responses to delivery of this toxin in multiple 
cell backgrounds.  Complete population resistance to CDIo11
EC869
 was achieved after three 
rounds of co-culture.  We then amplified yciB alleles (including regions upstream and 
downstream) from isolated clones from each enrichment pool and analyzed them with gel 
electrophoresis and DNA sequencing (Figure 3).  Both target populations produced 
spontaneous mutants in which yciB was larger than the wild-type gene (Figure 3).  
Sequencing confirmed that the change in allele size was attributed to the presence of IS 
elements, specifically IS1, IS5, and IS10 (Table 3).  Interestingly, a number of smaller yciB 
alleles were also observed, and sequencing revealed that these are due to deletions between 
small direct repeat sequences in the yciB coding region (Figure 3 and Table 3).  These 
deletion mutants create new open reading frames that would translate through to the native 
yciB stop codon, and they are predicted to contain transmembrane domains (data not shown). 
3. IS element transposition does not occur in response to delivery of a tRNase toxin 
CdiA-CTo11
EC869
 is a potent nuclease that cleaves DNA both in vitro and in vivo (177, 
202).  DNA damage response pathways in Gram-negative bacteria are well-characterized, 
and the canonical SOS response requires cleavage of the LexA repressor protein by the 
ssDNA-binding protease RecA (41).  This releases transcriptional repression of the suite of 
SOS-response genes, which include those required for nucleotide excision repair (41).  The 
late stages of SOS response stop cell division to ensure that DNA damage is fixed before the 
cell divides (41).  Because CdiA-CTo11
EC869
 is a DNase, we wished to determine whether the 
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transposition of IS elements observed in transposon-mutagenized and spontaneous CdiA-
CTo11
EC869
-resistant mutants was triggered by the activity of this toxin.  To test this, we took 
advantage of the fact that many CdiA-CTs are bipartite and modular (173, 176).  We 
previously demonstrated that the C-terminal catalytic DNase domain of CdiA-CTo11
EC869
 
could be replaced with the corresponding region from CdiA-CTII
Bp1026b
, a tRNase from 
Burkholderia pseudomallei (169, 173).  This results in a functional chimera that inhibits 
target cells in a YciB-dependent manner yet requires CdiIII
Bp1026b
 to protect against inhibition 
(173).  We reasoned that by delivering a different toxic effector through the same pathway as 
CdiA-CTo11
EC869
, we could determine whether spontaneous mutations in yciB accumulate, 
and whether the pattern of mutations matches those obtained from co-culture with 
CDIo11
EC869
.  Using the same procedure outlined previously, we isolated spontaneous mutants 
that were resistant to CdiA-CT
NT
(o11
EC869
)-
CT
(II
Bp1026b
) and amplified the yciB alleles from 
these strains to examine via gel electrophoresis.  All PCR products from mutants enriched 
against CDI
NT
(o11
EC869
)-
CT
(II
Bp1026b
) appeared to be the same size as wild-type yciB (Figure 4).  
We then sequenced these PCR products to determine whether they also contained mutations 
and found that all CDI
R
 strains had mutated yciB alleles, but that these were nonsense or 
frameshift mutations leading to a prematurely-truncated protein product (Table 4).  We did 
not observe the same pattern of alleles disrupted by IS element transposition in response to 
CDI
NT
(o11
EC869
)-
CT
(II
Bp1026b
) as with CDIo11
EC869
.  This suggests that the high percentage of IS 
elements mutations observed in CDIo11
EC869
-resistant cells may be attributed to delivery of a 
specific DNase toxin, not just the general process of CDI. 
4. IS element transposition in response to CdiA-CTo11
EC869
 does not require recA 
Because induction of the SOS response relies on the activation of RecA and subsequent 
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cleavage of the transcriptional repressor LexA, we hypothesized that DNA damage from 
delivery of CdiA-CTo11
EC869
 could induce SOS response, leading to an upregulation of IS 
element transposition.  The SOS response and DNA damage have also been linked to 
transposition of some families of IS elements and other transposable elements (349, 350).  
Although the EPI100 background that was used for the enrichments shown in Figure 3 has a 
defective recA1 allele that can bind single-stranded DNA but lacks ATPase activity and 
cannot stimulate SOS response, we created a clean recA knockout in MC4100 and EPI100 
backgrounds and repeated the enrichment process.  As shown in Figure 5, alleles both larger 
and smaller than wild-type yciB were observed in ΔrecA CDIR spontaneous mutants.  These 
mutations are attributed to both IS element transposition as well as small internal deletions.  
Therefore, induction of SOS response via the canonical RecA cleavage of LexA is not 
required for the IS transposition that takes place in response to CdiA-CTo11
EC869
. 
5. IS elements in yciB are unstable over time 
IS element transposition under wild-type conditions happens extremely infrequently (347, 
348).  This is advantageous for cells, because random transposition events have some 
probability of disrupting essential processes, ultimately leading to decreased cell fitness or 
cell death.  Because IS element transposition into yciB was observed in response to 
conditions of increased stress, we wondered whether it would be advantageous for cells to 
retain these IS elements in this new genomic location in the absence of selective pressure 
from CDIo11
EC869
.  To determine this, we isolated single colonies of yciB-IS mutants and 
grew them as monocultures in rich media under standard laboratory conditions, allowing the 
cultures to go through all stages of the bacterial growth cycle and enter stationary phase.  An 
aliquot of each culture was transferred to a new tube with fresh media every 7 generations.  
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Every 49 generations, we removed an aliquot of the population and competed it in a co-
culture experiment with CDIo11
EC869
 to assay the population level of resistance to this toxin 
over time.  We chose a variety of mutants to represent multiple IS element families.  A wild-
type, unmutagenized strain with wild-type yciB was included as a control.  As shown in 
Figure 6A, wild-type cells do not spontaneously become CDI-resistant with repeated 
passaging (up to 300 generations).  With extended passaging, the mutant cultures became 
less resistant to CDIo11
EC869
 as measured by viable cell counts (Figure 6B to D).  Mutants A1 
and A4 were inhibited as much as wild-type cells after 298 generations. 
This trend may be explained in part by data presented in Chapter III, which describes a 
physiological role for YciB.  Clearly yciB is required for metal tolerance and possibly 
membrane integrity in E. coli, but careful growth curve measurements show that these 
mutants have a growth pattern that is nearly identical to wild-type cells.  However, the 
timescale of this growth curve experiment does not capture what happens in extended 
cultures that are allowed to persist in stationary phase.  Therefore, it is possible that yciB 
mutants are less fit over long-term periods of growth during which cells must cycle in and 
out of logarithmic and stationary phase.  To determine whether yciB mutants have a general 
defect in long-term evolution experiments, we performed passaging series with a mixture of 
wild-type and ΔyciB cells and measured the viability of each by selective antibiotic markers.  
After several generations, wild-type bacteria are higher at present numbers than the ΔyciB 
strain (Figure 7).  This data suggests that deletion of yciB contributes to a defect in exiting 
stationary phase.  Because passaging experiments allow cells to grow to stationary phase 
before passage into fresh media, this growth defect could be the driving force behind IS 
element loss over time. 
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6. Spontaneous IS element transposition into genes required for CdiA-CT delivery is 
observed after co-culture with other CDI systems 
We did not observe substantial IS element-mediated CDI resistance in response to delivery of 
the tRNase domain from CdiA-CTII
Bp1026b
.  We therefore wondered whether yciB is a special 
target for IS element transposition, or whether this effect could be observed with other CDI 
toxins that have DNase activity.  We chose a CdiA-CT from E. coli MHI813, which degrades 
chromosomal DNA in target cells as measured by DAPI staining and epifluorescence 
microscopy (Figure 8).  This toxin requires the inner membrane protein MetI for delivery, 
which is normally used for transport of methionine into E. coli (173).  We isolated 
spontaneous mutants using iterative co-culture assays and examined the metI alleles for the 
presence of IS elements.  9 of the 14 metI alleles tested contained IS elements in the coding 
region (Table 5), consistent with the theory that DNA damage leads to increased IS element 
transposition.  These insertion elements were largely IS1, although an IS5 transposition event 
was also detected.  These IS1 insertions were unique events and were not duplicates of other 
mutants (Table 5).  The other 5 mutants that were sequenced contained 1 nucleotide 
frameshifts leading to a premature stop codon.  Again, these mutations were scattered 
throughout the coding sequence and were not localized to a single region. 
We performed the same experiment using CDI
Ec536
, which delivers a general tRNase that 
requires the non-essential permissive factor CysK for activity (193).  cysK was amplified 
from resistant clones, but surprisingly, 8 of 10 sequenced alleles contained an IS element in 
the coding sequence (Table 6).  All 8 IS elements were IS10, although multiple alleles could 
be detected based on sequence identity.  Furthermore, all IS10 insertions were located at the 
same position in cysK (nucleotide 187), even across 5 independent pools of mutants.  Upon 
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close examination of cysK, we discovered that the location at which IS10 had integrated in 
these mutants is nearly identical to a known Tn10 hotspot and an IS10 hotspot in hisD (351).  
Therefore, it is possible that an IS10 element in this location in cysK was present in the 
parent population, and that it was selected for due to its resistance to CDI
EC536
.  The pattern 
of IS elements distribution (or lack of distribution) does not match the spread of IS elements 
throughout the coding sequences of yciB and metI that are detected in response to DNA 
damage. 
C. Discussion 
In this study, we have demonstrated that transposition of insertion elements into a gene 
required for delivery of CdiA-CTo11
EC869 
can be detected after co-culture.  This is presumably 
a result of increased global IS element transposition, but the selection bias of our experiments 
results in detection in only yciB.  We have made several efforts to detect a general increase in 
IS element transposition above a basal level after competition of cells with CDIo11
EC869
, but 
have been unable to detect individual transposition events.  This may be the result of several 
phenomena.  Our experimental attempts utilized reporter systems that would indicate the 
presence of absence of an IS element by growth on an antibiotic or by development of a blue 
color in blue/white screening.  However, these tests rely on the presence or absence of 
protein products.  IS element transposition into a gene would disrupt future transcription and 
translation of these gene products, but would not disrupt translation from pre-existing mRNA 
and would not deplete the current levels of protein.  Therefore, it may take time to dilute out 
these proteins through cell division, complicating the interpretation of these results. 
An additional compounding factor may be the number of stress “events” a cell needs to 
undergo before upregulating IS element transposition.  Perhaps the accumulation of stress 
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events and DNA damage over the iterative cycles of enrichment culminates in the 
transposition of IS elements, but a single damage event is not enough to stimulate this.  This 
goes against the dogma of colicin inhibition, which posits that a “single hit” or delivery of a 
single toxin is enough to result in cell death.  The ability of CDI target cells to respond and 
accumulate IS element transposition events in favorable locations argues that more than one 
“event” must occur to ultimately kill the cell.  This makes sense in the context of cell 
division.  If a single CDI toxin is delivered to a target cell in a bacterial environment, and that 
cell is able to undergo division before cell death occurs, then one daughter cell would not 
contain toxin and would presumably be able to survive.  This may be indicative of the true 
role of CDI systems in bacterial physiology, which may be to induce signaling cascades or 
alter gene expression through microevents instead of inducing true cell death. 
If DNase toxins can induce IS element transposition, is there an analogous course of 
action in response to other toxins?  The obvious system to test in the presence of RNase 
toxins is stringent response, although preliminary evidence suggests that the stringent 
response is not activated by delivery of RNase toxins (Zach Ruhe, unpublished data).  
However, another translation stress pathway may be activated by the slow degradation of 
tRNA or ribosomal RNA substrates.  While a tRNase toxin tested here did lead to IS element 
accumulation in the gene encoding its cofactor, we do not believe that this occurs through the 
same process as the DNA damage-mediated transposition observed with CdiA-CTo11
EC869
 
and CdiA-CT
MHI813
.  First, the distribution patterns of the IS elements in yciB and metI show 
random spread throughout the coding region of these genes.  Additionally, multiple IS 
elements, including IS1, IS5, an IS10 were observed in these genes.  In cysK, only IS10 
elements were present, and they were all located at the same nucleotide position, even in 
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mutants derived from different starting pools of cells.  This suggests that this region is a 
hotspot for IS element transposition, and that this particular IS insertion may exist at some 
low frequency in a parental population of cells.  Enriching for resistant mutants would result 
in detection of this allele as well as true spontaneous mutants.  Finally, we note that previous 
transposon mutagenesis experiments using a related toxin produced more than 100 mutants 
with transposon hops in CysK, indicating that toxicity-mediated IS element transposition into 
cysK does not greatly contribute to resistance using a mutagenized pool of target cells.  This 
is in stark contrast to the results observed from transposon mutagenesis using the CDIo11
EC869
 
system, where IS element-mediated resistance was observed at an equal or greater frequency 
than resistance caused by insertion of the transposon element into yciB. 
Perhaps the most interesting observation made here is that IS element transposition into 
yciB is not a permanent event that remains fixed in the absence of selective pressure from 
CDIo11
EC869
.  Monocultures of IS mutants that were serially passaged eventually lost 
population resistance to this toxin, and PCR screens confirm that these alleles have reverted 
to wild-type yciB.  This supports the hypothesis that YciB has a “normal” role in E. coli 
physiology, and that some growth defect is attributed to yciB mutants.  This is supported by 
the general growth defect observed in yciB cells after co-culture with wild-type mutants 
strains.  Additionally, yciB is highly conserved across gammaproteobacteria, and we have 
found no examples of sequenced strains in which this allele is defective or shows evidence of 
degrading.  This is suggestive of an important physiological role for this gene product.  
Perhaps the flexibility in IS element transposition in response to DNA damage is 
representative of how cells respond to CDI systems in a natural environment.  One could 
imagine a model in which a population of cells undergoes stress when it encounters a CDI 
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system deploying CdiA-CTo11
EC869
.  Accumulation of DNA damage results in random IS 
element transposition throughout the genome, but only cells in which IS elements have 
transposed into yciB would be resistant to further insult from this toxin.  These cells could 
then propagate in the presence of this selective pressure.  When a shift in environment causes 
relief of this pressure in the absence of this CDI system, yciB mutants would be at a 
disadvantage over cells in the environment with a wild-type copy of this allele.  This would 
then contribute to the overall loss of IS elements from ycB and reversion of this allele to 
wild-type.  The cells would then regain the physiological function associated with yciB.  In 
this way, IS element transposition may act as a genetic switch that results in transient 
resistance to CDI systems but allows cells to regain wild-type function in the absence of this 
selective pressure.  This may be a method by which cells adapt to ever-changing conditions 
in dynamic microbial communities without affecting permanent changes that would become 
fixed in a population (Figure 9). 
A final note of interest is that CdiA-CTo11
EC869
 intoxication results in a dramatic 
phenotype in target cells.  Inhibited cells become extremely long and filamentous, indicated 
that some response is taking place.  Filamentation of bacterial cells can occur during the SOS 
response after DNA damage but has also been attributed to a variety of other pathways and 
factors.  Perhaps for CDIo11
EC869
, this morphological change associated with upregulation of 
IS element transposition.  Future work is needed to elucidate the damage response pathways 
associated with inhibition by this toxin and to determine whether this response is conserved 
across DNase toxins in CDI systems and in other bacterial inhibition systems.  We have 
preliminary evidence that at least two responses take place after attack by DNase toxins.  A 
CdiA-CT from Dickeya dadantii is also a DNase, but cells inhibited by this system do not 
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become elongated or filamentous like cells inhibited by CdiA-CTo11
EC869
 (194).  The inner 
membrane transporter for this toxin is unknown, but it would be interesting to repeat the 
spontaneous mutant enrichment procedure once a target gene has been identified to 
determine whether DNA damage from this toxin also induces IS element transposition. 
D. Materials and methods 
1. Transposon library construction and selection for mutants 
The mariner transposon was introduced into E. coli CH10229 cells through conjugation 
with E. coli MFDpir donor cells carrying plasmid pSC189. Donor and recipient cells were 
grown to mid-log phase in lysogeny broth (LB) medium supplemented with 150 µg/mL 
ampicillin and 30 µM diaminopimelic acid (donors) or 33 µg/mL chloramphenicol 
(recipients). Donors (∼6.0 × 108 cfu) and recipients (∼3 × 108 cfu) were mixed and collected 
by centrifugation for 2 min at 6,000 × g in a microcentrifuge. The supernatant was removed 
by aspiration and the cell pellet resuspended in 100 µL of 1× M9 salts. Cell mixtures were 
spotted onto 0.45-µm nitrocellulose membranes, and the filters were then incubated on LB 
agar (without inversion) for 4 h at 37 °C. The cells were then harvested from the filters by 
using 2 mL of 1× M9 salts. Transposon insertion mutants were selected by plating 10-fold 
serial dilution on LB-agar supplemented with 50 µg/mL of kanamycin. 
More than 20,000 colonies from each transposon library were collected from the agar 
plates in 1× M9 salts and inoculated into 50 mL of LB medium in a 250-mL baffled flask. 
CDI
+
 inhibitor strains were grown in a parallel 50 mL LB medium culture. Both cultures 
were grown at 37 °C until mid-log phase, then mixed at approximately a 1:1 ratio and 
cultured for 3 h with shaking at 37 °C. Viable target cells from the transposon mutant library 
were enumerated as cfu counts per milliliter on LB agar supplemented with 50 µg/mL of 
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kanamycin. The survivors of the first round of CDI competition were harvested from the 
plates with 1× M9 salts and used to inoculate 50 mL LB medium culture for a second round 
of CDI selection. After the third round of selection, the target cell population was usually 
completely resistant to the CDI inhibitor cells. Individual clones were then isolated and the 
CDI
R
 phenotype confirmed in competition co-cultures. The transposon mutations were then 
transferred into CDI-sensitive cells by bacteriophage P1-mediated transduction, and the 
resulting transductants were tested for the CDI
R
 phenotype. 
Transposon insertions linked to the CDI
R
 phenotype were identified by rescue cloning. 
Chromosomal DNA was prepared from each mutant by using phenol/chloroform extraction 
and ethanol precipitation. Genomic DNA (1 µg) was digested with AgeI and XmaI restriction 
endonucleases for 2 h at 37 °C, and the enzymes were inactivated at 65 °C for 10 min. ATP 
and T4 DNA ligase were added and the reaction was incubated for 2 h at room temperature. 
The ligated DNA was precipitated with 95% (vol/vol) ethanol, washed once with 75% 
(vol/vol) ethanol, and dissolved in 50 µL water. The ligated DNA was electroporated into E. 
coli DH5α pir+ cells, and transformants were selected on LB agar supplemented with 50 
µg/mL kanamycin. Plasmid DNA was isolated from selected transformants, and the 
transposon insertion junctions were identified by DNA sequencing by using primer CH2260. 
2. Competition co-culture 
Competition co-culture assays were carried out as previously described (175, 177). 
Briefly, inhibitor cells (E. coli EPI100 carrying CDI expression constructs) and target cells 
(E. coli MC4100 or MG1655 carrying pTrc99a derivatives) were grown in LB medium 
supplemented with appropriate antibiotics overnight at 37 °C. The next day, cells were 
inoculated into fresh LB medium without antibiotics in baffled flasks. Individual cultures 
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were grown with shaking until early log phase, and then the populations were mixed at a 1:1 
ratio in fresh prewarmed LB in baffled flasks. The competitions between EC93-Bp1026b 
inhibitors and targets that express BTH_II0599 were conducted at a 10:1 inhibitor-to-target 
cell ratio. A sample of each co-culture was taken at initial mixing to enumerate viable target 
cells as cfu counts per milliliter. The co-cultures were incubated with shaking for 3 h at 37 
°C. Viable target cell counts are presented as the average ± SEM of three independent 
competition experiments. 
3. Microscopy 
Cells (equivalent to an OD600 of 0.2) were collected by centrifugation in a 
microcentrifuge for 2 min at 6,000 × g. Cells were fixed in freshly prepared 4% (vol/vol) 
formaldehyde in 1× PBS solution for 15 min, and the reaction was quenched with 125 mM 
glycine (pH 7.5). Cells were washed three times with 1× PBS solution, resuspended in 100 
μL 1× PBS solution, and spotted onto poly-d-lysine–treated slides. Excess liquid was 
removed with a Kimwipe, and slides were dried and gently rinsed with Nanopure water to 
remove nonadherent bacteria. Slides were sealed with Fluorogel II with DAPI (Fisher 
Scientific/EMS) and a glass coverslip. Images were acquired on an Olympus fluorescent 
microscope with a 100× oil objective by using an Optronics MacroFire digital microscope 
camera. Light-field images were taken with a 12-ms exposure (gain 2). DAPI-stained images 
were acquired with a 48-ms exposure (gain 2). Fluorescent images were recorded in 
grayscale by using a 502-ms exposure (gain 5). Images were false-colored, overlaid by using 
FIJI (61), and cropped to 200 × 200 pixels using GIMP. 
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Figure 1.  A subset of transposon mutants are CDI
R
 and have secondary mutations in yciB.  (A) Initial 
mutants isolated from transposon mutagenesis are resistant to inhibition by CdiA-CTo11
EC869
.  (B) The 
transposon insertions from (A) were moved into a fresh background and tested for linked resistance.   
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Figure 2.  Unlinked transposon isolates have secondary mutations in yciB.  (A) Plasmids expressing wild-
type yciB were transformed into the original mutants and tested for sensitivity.  (B) yciB alleles were amplified 
from several different mutants and analyzed via gel electrophoresis.  4 of 5 strains tested had alleles that ran 
larger than the wild-type gene on an agarose gel. 
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Figure 3.  Isolation of unmutagenized, spontaneous CDI
R
 mutants reveals disruptions in yciB.  The 
indicated E. coli strains were competed in co-culture assays against cells expressing CDIo11
EC869
.  Resistant 
clones were isolated, and yciB was amplified and analyzed via gel electrophoresis. 
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Figure 4.  Insertion elements do not accumulate in yciB in response to delivery of a tRNase CdiA-CT.  
Unmutagenized E. coli target cells were co-cultured with CDIo11
EC869
 or CDI
EC93
-NTo11
EC869
-CTII
Bp1026b
.  After 
enrichment, yciB alleles from isolated clones were amplified and analyzed via gel electrophoresis and ethidium 
bromide staining.  A wild-type yciB PCR is run in the first lane for size comparison. 
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Figure 5.  Transposition of insertion elements does not depend on RecA.  Unmutagenized E. coli target cells 
lacking recA were co-cultured with CDIo11
EC869
.  After enrichment, yciB alleles from isolated clones were 
amplified and analyzed via gel electrophoresis and ethidium bromide staining. 
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Figure 6.  Insertion element transposition is reversible in the absence of selective pressure from 
CDIo11
EC869
.  Mutants from the original transposon mutagenesis screen that contained IS element insertions in 
yciB were grown in monocultures in the absence of CDIo11
EC869
.  Every 7 generations, the culture was diluted 
into fresh LB media and grown again.  Every 49 generations, an aliquot of the culture was removed and mixed 
with cells expressing CDIo11
EC869
 to estimate the overall CDI resistance of the population.  A wild-type, 
unmutagenized strain was passaged alongside the mutants as a control for spontaneous mutations in yciB that 
would result in CDI resistance.  
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Figure 7.  yciB deletion strains have a fitness defect over time in co-culture with wild-type cells.  Wild-type 
cells and cells lacking yciB were grown to mid-log phase and mixed together at a 1:1 ratio.  The culture was 
grown for 10 generations, at which point the cells were diluted into fresh LB media.  The culture was 
propagated for another 10 generations and diluted; this process was repeated once more.  At each indicated 
timepoint, a sample was removed and diluted in M9 salts before plating onto LB-agar plates.  Data presented is 
viable cells per mL culture. 
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Figure 8.  CdiA-CT
MHI813
 is a DNase.  Unlabeled inhibitor cells were mixed with dsRED-labeled target cells at 
a 1:1 ratio.  At 0 and 2 h timepoints, cells were removed and spotted onto an agarose pad for imaging.  Red cells 
stain with DAPI at 0 h but lose DAPI staining at 2 h, indicating loss of chromosomal DNA. 
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Figure 9.  Model for transient CDI resistance mediated by insertion element transposition. 
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Table 1.  Location of transposon insertions outside of yciB. 
Gene Predicted protein product 
uhpC Regulatory membrane protein 
gnd 6-phosphogluconate dehydrogenase 
yiiE/yiiF Uncharacterized protein 
yjcD Predicted permease 
amiB N-acetylmuramoyl-l-alanine amidase II 
ybaY outer membrane lipoprotein 
yigI/pldA 4HBT family of thioesterases 
16S rRNA  
 
Table 2.  Location and identity of insertion sequence elements in yciB from transposon-
mutagenized isolates. 
 
Identifier Mutation Duplication Nucleotide position 
A1 IS10 AGCTGAATC 360 
A3 Stop codon N/A 223 
A4 IS1 AATGGAAGG 232 
A5 IS1 ATGGAAGGT 233 
B1 IS1 GACCGCCCT 470 
 
Table 3.  Location and identity of yciB mutations detected in spontaneously-resistant 
clones. 
 
Identifier Mutation Location 
J1 Stop codon K90  stop 
J2 Deletion 30 AA deletion after L111 
J3 Deletion 62 AA deletion after P112 
J4 IS5 Insertion after nt 397 
J5 Deletion Sibling with J2 
J6 Deletion Sibling with J2 
J7 Stop codon L116  stop 
J8 IS1 Insertion after nt 84 
 
 
Table 4.  Nonsense and frameshift mutations are present in yciB alleles from 
spontaneous mutants generated against a tRNase toxin delivered through YciB. 
 
Identifier 
Mutation 
(nucleotide position) 
Outcome  
J1 G369A 
Premature stop 
codon, 123-residue 
product 
Siblings present in 
same pool 
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E1-1 
Insertion after 
position 291 
IS1 insertion  
E2-1 
Insertion of C after 
position 437 
Frameshift and 
premature stop 
codon, 150-residue 
product 
Siblings present in 
same pool 
E2-3 Deletion of G256 
Frameshift and 
premature stop 
codon, 90-residue 
product 
Siblings present in 
same pool 
NT1-2 G123A 
Nonsense mutation, 
41-residue product 
Siblings present in 
same pool 
NT3-5 Deletion of T29 
Frameshift and 
premature stop 
codon, 29-residue 
product 
 
NT4-1 T538G 
TAA  Glu, extends 
open reading frame 
approximately 15 
residues 
Siblings present in 
same pool 
NT4-3 A539C 
TAA  Ser, extends 
open reading frame 
approximately 15 
residues 
Siblings present in 
same pool 
NT1 G123A 
Nonsense mutation, 
41-residue product 
Independent of 
mutant NT1-2 
NT3 G510C 
Nonsense mutation, 
170-residue product 
 
NT5 
Insertion after 
position 246 
IS10 insertion  
 
 
Table 5.  Mutations present in metI after enrichment of spontaneous mutants resistant 
to CDI
MHI813
. 
 
Pool Mutant Mutation Details 
1 MHI3 1 nt insertion 
T inserted after nt 
T405, frameshift 
leads to stop 
 
MHI4 1 nt insertion 
G inserted after 
G539, frameshift 
leads to stop 
 
MHI5 IS5 
NT 146, forward 
orientation 
2 13 IS1 
NT 19, reverse 
orientation 
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3 21 1 nt deletion 
nt 384C, leads to 
frameshift/premature 
stop codon 
 
23 IS1 
NT167, forward 
orientation 
4 13 IS1 
NT 592, reverse 
orientation 
 
16 1 nt deletion 
T deleted after NT 
477 
5 21 1 nt insertion 
C inserted after NT 
634 
6 N=2 1S1 PCR confirmed 
7 N=2 1S1 PCR confirmed 
 
 
Table 6.  Mutations present in cysK alleles from spontaneous mutants resistant to 
CDI
EC536
. 
 
Pool Mutant Mutation Details 
1 13 IS10 
NT 187, forward 
orientation 
 
14 (sib 15) 1 nt deletion 
Frameshift leads to 
premature stop codon 
(also has 15 nt in-
frame deletion 
downstream) 
 
16 IS10 
NT 187, reverse 
orientation 
2 21 IS10 
NT 187, forward 
orientation 
 
23 (sib 24) 1 nt deletion 
Frameshift leads to 
premature stop codon 
(also has 15 nt in-
frame deletion 
downstream) 
3 31 IS10 
NT 187, forward 
orientation 
 
32 IS10 
NT 187, reverse 
orientation 
4 54-528 IS10 
NT 187, reverse 
orientation, different 
IS10 allele based on 
SNPs 
5 51 (sib 54, 55) IS10 
NT 187, reverse 
orientation 
 
52 (sib 53) IS10 NT 187, forward 
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orientation, different 
IS10 allele based on 
SNPs 
 
Table 7.  Strains used in this study. 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, 
leu)7697 galU galK λ– rpsL nupG, StrR 
Epicentre 
CH8251 MC4100 rif
r
, Rif
R
 (177) 
pCH9305 
Constitutive expression of chimeric cdiA
EC93
-CTo11
EC869
 
and cdiIo11
EC869
 genes, Cm
R
 
(177) 
pCH10415 
Constitutive expression of chimeric cdiA
EC93
-NTo11
EC869
-
CTII
Bp1026b
 and cdiIII
Bp1026b
 genes, Cm
R
 
(172) 
 
  
156 
 
V.  Diversification of β-augmentation interactions between CDI 
toxin/immunity proteins 
This research was conducted in collaboration with Robert Morse and Celia Goulding at 
the University of California, Irvine.  A majority of this work was published in October 2015 
in the Journal of Molecular Biology (doi: 10.1016/j.jmb.2015.09.020), and much of the text 
appears as published.  The Goulding laboratory performed all crystallography and binding 
affinity studies. 
A. Introduction 
Bacteria possess many strategies to compete and cooperate with other microorganisms in 
the environment.  Contact-dependent growth inhibition (CDI) is one competitive mechanism 
used by some Gram-negative species to inhibit the growth of neighboring bacteria (156, 
167).  CDI
+
 cells express CdiB/CdiA two-partner secretion systems, which deliver protein 
toxins into target bacteria through a receptor-mediated process.  CdiB is an Omp85 outer-
membrane protein that exports and assembles toxic CdiA effectors onto the surface of CDI
+
 
cells.  CdiA proteins range from 180 – 630 kDa depending on bacterial species and form β-
helical filaments that are predicted to extend several hundred Å from the inhibitor-cell 
surface.  CdiA binds to specific receptors on susceptible bacteria and subsequently delivers a 
toxin domain derived from its C-terminus (CdiA-CT) into the target cell (157, 159, 194). 
CDI
+
 bacteria deploy a variety of CdiA-CT toxins with distinct activities.  The CdiA-CT
EC93
 
from Escherichia coli EC93 dissipates ion gradients by forming membrane pores (158), but 
most other characterized CDI toxins have specific nuclease activities.  CDI toxins from E. 
coli EC869 and Dickeya dadantii 3937 are potent DNases capable of degrading target-cell 
chromosomes (177, 194), and CdiA-CT
ECL
 from Enterobacter cloacae ATCC 13047 cleaves 
157 
 
16S rRNA to block protein synthesis (175).  CDI
+
 bacteria protect themselves from auto-
inhibition by producing small CdiI immunity proteins that bind to the CdiA-CT and block its 
toxin activity.  Because CDI toxins are diverse, CdiA-CT/CdiI protein interactions are 
necessarily specific between cognate pairs.  Therefore, CdiI immunity proteins neutralize 
their cognate CdiA-CT, but provide no protection against the toxins deployed by other 
bacteria (176, 177).  This diverse network of toxin/immunity pairs suggests that CDI plays an 
important role in inter-cellular competition and self/non-self recognition. 
We recently surveyed the Uniprot database and identified at least 120 distinct CdiA-CT 
toxin families.  Only 26 of these toxins have Pfam designations (200) and the remaining 
domains are uncharacterized.  We initiated structural studies of these protein pairs to discover 
new toxin activities and toxin/immunity binding interactions.  The first CDI toxin/immunity 
protein complex structures to be determined were from Burkholderia pseudomallei 1026b 
and enterohemorrhagic E. coli strain EC869 (177).  The CdiA-CT toxin sequences from these 
bacteria are not related, yet the three-dimensional structures of the domains superimpose with 
an RMSD of 3.9 Å.  Structural homology searches revealed significant similarity to type IIS 
restriction endonucleases, suggesting that both toxins are DNases.  Indeed, the C-terminal 
domain of CdiA-CTo11
EC869
 has potent Zn
2+
-dependent DNase activity in vitro and in vivo 
(177). However, CdiA-CTII
Bp1026b
 has no detectable activity on DNA, and instead this toxin 
preferentially cleaves near the 3´-end of tRNA
Ala
 molecules (169).  Thus, the same toxin fold 
is used to target different nucleic acid substrates.  Though CdiA-CTo11
EC869
 and CdiA-
CTII
Bp1026b
 are similar in structure, other CDI toxins do not share the type IIS restriction 
endonuclease fold.  The crystal structure of CdiA-CT
ECL
 from E. cloacae ATCC 13047 
reveals similarity to the C-terminal nuclease domain of colicin E3 (79, 176, 207), and 
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sequence homology and activity studies strongly suggest that CdiA-CT
K96243
 from B.  
pseudomallei K96243 is related to the C-terminal nuclease domain of colicin E5 (167, 169).  
Moreover, Aravind and colleagues have predicted that CDI systems deploy two classes of 
RNA deaminase (Pfam: PF14424 and PF14437), as well as homologues of the EndoU 
poly(U)-specific endonuclease that processes eukaryotic snoRNAs (Pfam: PF14436)(200, 
352, 353).  Thus, CDI represents a versatile platform to deliver structurally diverse toxins 
into Gram-negative bacteria. 
Although toxin/immunity pairs within a given family are homologous, there is often 
considerable sequence diversity between members, suggesting that families continue to 
diverge and evolve.  When viewed in the context of available crystal structures, it is apparent 
that residues at the interface of the toxin/immunity protein complexes are diversifying most 
rapidly.  This phenomenon is exemplified by toxin/immunity proteins that are homologous to 
the orphan-11 (o11) CdiA-CT/CdiI pair from E. coli EC869 (176, 177).  CdiA-CTo11
EC869
 
interacts with CdiIo11
EC869
 through β-augmentation, in which the toxin domain extends a β-
hairpin to complete a six-stranded anti-parallel β-sheet within the immunity protein (Figure 
1A)(177).  The sequences encoding the β-hairpin (corresponding to β4 and β5) are the most 
variable between members of the CdiA-CTo11
EC869
 nuclease family (Figure 1B).  Moreover, 
CdiIo11
EC869
 residues that interact with the toxin are not conserved between related immunity 
proteins (Figure 1C), suggesting that each immunity protein is specific for its cognate toxin.  
Here, we use structure-function analyses to examine the β-augmentation interactions of two 
homologous CdiA-CT/CdiI complexes to study the diversification of CDI toxin/immunity 
protein interfaces.  We find that the CdiA-CT/CdiI
YPIII
 complex from Yersinia 
pseudotuberculosis YPIII also features a β-augmentation interaction; however, the precise 
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intermolecular contacts differ substantially between the complexes.  In accord with these 
differences, each CdiI immunity protein only protects against its cognate toxin, 
demonstrating that each pair is a distinct cognate toxin/immunity pair.  Finally, we 
synthesized a macrocyclic peptide mimic of the β-hairpin from CdiA-CTo11
EC869
 and solved 
its crystal structure in complex with the CdiIo11
EC869
 immunity protein.  This structure forms 
the basis to refine the β-hairpin mimic to increase affinity with the goal of producing 
compounds that activate DNase toxins through sequestration of immunity proteins. 
B.  Results 
1. Structure of the CdiA-CT/CdiIYPIII complex reveals conservation of the β-
augmentation interaction 
Alignment of CdiA-CTo11
EC869
 toxin homologues indicates that most secondary-structure 
elements have high sequence conservation with the exception of strands β4 and β5, which 
mediate the β-augmentation interaction with CdiIo11
EC869
 (Figure 1A and B).  To determine 
whether β-augmentation occurs in other homologous toxin/immunity pairs, we performed 
structural and functional analyses of the CdiA-CT/CdiI
YPIII
 complex encoded by the 
YPK_0575/YPK_0576 genes of Yersinia pseudotuberculosis YPIII.  The C-terminal 
nuclease domain of CdiA-CT
YPIII
 is 70.4% identical to CdiA-CTo11
EC869
 and shares all of the 
predicted active-site residues (Figure 1B).  Similarly, the CdiI
YPIII
 and CdiIo11
EC869
 immunity 
proteins share 49.1% identity, though CdiI
YPIII
 contains a 10-residue insertion between α1 
and α2 that is predicted to produce an elongated loop (Figure 1C).  We solved the crystal 
structure of the CdiA-CT/CdiI
YPIII
 complex to 2.1 Å resolution by molecular replacement 
using the structure of the CdiA-CT/ CdiIo11
EC869
 complex (PDB code: 4G6U) as a search 
model (Figure 2A).  As with other CdiA-CTs (175, 177), the N-terminal region (residues 
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Val1 – Gly173) was not resolved in the structure.  The final model included CdiA-CTYPIII 
residues 174 – 298 and 148 water molecules resulting in an Rwork/Rfree (%) of 20.5/25.6 
(Table 1).  The CdiA-CT/CdiIo11
EC869
 and CdiA-CT/CdiI
YPIII
 complexes have very similar 
structures.  The toxin domains superimpose with RMSD of 0.84 Å over 101 of 123 α-
carbons, and the immunity proteins superimpose with RMSD of 1.01 Å over 133 of 173 α-
carbons (Figure 2B).  The CdiA-CT/CdiI
YPIII
 complex also contains a β-augmentation 
interaction in which the toxin extends its β4/β5-hairpin into binding pocket within the 
immunity protein (Figure 2A and B).  However, in contrast to CdiA-CTo11
EC869
, which 
contains an ordered Zn
2+
 ion in the active site (177), no zinc was detected by metal K-edge 
absorption analysis of multiple CdiA-CT/CdiI
YPIII
 crystals.  Furthermore, the electron density 
spheres within the active site vicinity of CdiA-CT
YPIII
 were not within zinc coordinating 
distances with the catalytic residues and would not form a zinc tetra- or hexa-coordination 
sphere, and thus were modeled as water molecules (Figure 3).   
CdiA-CT
YPIII
 and CdiI
YPIII
 bind one another through a network of 14 direct H-bonds and 
ion-pairs (Table 2) combined with several hydrophobic interactions.  Only two CdiA-CT
YPIII
 
β-hairpin side-chains (Glu242 and Lys243) interact directly with CdiIYPIII, compared to the 
six direct side-chain interactions in the CdiA-CT/CdiIo11
EC869
 complex (Table 2 and Figure 
4).  The CdiA-CT/CdiI
YPIII
 β-hairpin pocket also contains a network of bridging water 
molecules and several more hydrophobic interactions than the CdiA-CT/CdiIo11
EC869
 complex 
(Figure 4).  Additionally, extensive interactions outside of the β-augmentation region 
contribute to CdiA-CT/CdiI
YPIII
 complex stability.  Loop L1 of CdiA-CT
YPIII
 forms several 
hydrophobic contacts with the elongated loop of CdiI
YPIII
.  Residue Lys195 within L1 forms 
a salt-bridge with CdiI
YPIII
 residue Glu137 within β6.  The loop connecting strands β2 and β3 
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also has several H-bond interactions, and Asp201 forms a prominent salt-bridge with Arg69 
in the elongated loop of CdiI
YPIII
 (Table 2 and Figure 2B).  In contrast, the CdiA-
CT/CdiIo11
EC869
 complex has a less extensive interaction network outside of the β-
augmentation region.  Loop L1 of CdiA-CTo11
EC869
 has fewer hydrophobic contacts and one 
ionic interaction between Asp183 and Arg71 of CdiIo11
EC869
 (Table 2).  Together, these 
structures reveal overall conservation between the toxin/immunity protein pairs, but reveal 
important differences in the network of bonds that stabilize each complex (Figure 5).   
2. CdiA-CTs in the EC869 superfamily have DNase activities in vitro 
The conservation of nuclease active-site residues strongly suggests that CdiA-CT
YPIII
 has 
DNase activity similar to that described for CdiA-CTo11
EC869 
(177).  We isolated the CdiA-
CT
YPIII
 domain from its immunity protein and tested for DNase activity in vitro using 
supercoiled plasmid as a substrate.  CdiA-CT
YPIII
 degraded the linear DNA template in the 
presence of both Mg
2+
 and Zn
2+
.  This differs from the characterized activity of the CdiA-
CTo11
EC869
 toxin, which has detectable DNase activity with Mg
2+
 and completely degrades 
plasmid DNA in the presence of Zn
2+
 ions (177).  CdiA-CT
Nlact
 also degrades linear DNA in 
the presence of both Mg
2+
 and Zn
2+
 (Figure 6B).  We next tested the CdiI
YPIII
, CdiIo11
EC869
, 
and other homolgoy immunity proteins for the ability to neutralize DNase activity in vitro.  
Each immunity protein was able to block the activity of its cognate toxin (Figure 6C and D), 
and CdiA-CT
YPIII
 was protected by all tested CdiI proteins.  However, we note that this cross-
protection may be an artifact of the protein concentrations used in this experiment, based on 
the calculated binding affinities between non-cognate CdiA-CT and CdiI domains (discussed 
below).   
Metal co-factors that support the activity of CdiA-CTo11
EC869
 in vitro are restricted to 
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Mg
2+
 and Zn
2+
 (177).  Given the strong structural conservation between this toxin and related 
homologs, we wondered whether these other toxins retained the tight metal utilization 
profile, or whether they were more promiscuous in their use of co-factors.  We isolated 
CdiA-CT
Nlact
 and incubated it with linearized DNA in the presence of CoCl2, CuCl2, and 
MnCl2, none of which support the DNase activity of CdiA-CTo11
EC869
 in vitro.  Surprisingly, 
we detected DNase activity in the presence of both Co
2+
 and Mn
2+
 (Figure 7).  None of the 
concentrations of Cu
2+
 tested supported activity.  However, this activity could not be blocked 
by the addition of the cognate CdiI at the highest metal concentrations tested. 
3. Binding affinities of non-cognate CdiA-CT/CdiI pairs 
We next measured the dissociation constants (Kd) for cognate and non-cognate 
complexes using biolayer interferometry.  CdiA-CT
YPIII
 and CdiI
YPIII
 form a high-affinity 
complex with Kd = 16 ± 1 nM, which is similar to the value (18 ± 7 nM) previously reported 
for the CdiA-CT/CdiIo11
EC869
 complex(177).  In contrast, CdiI
YPIII 
has ~ 1,000-fold lower 
affinity for non-cognate CdiA-CTo11
EC869
 with a Kd of 13 ± 2 μM.  This highly reduced 
affinity between CdiA-CTo11
EC869
 and CdiI
YPIII 
compared to cognate protein pairs is perhaps 
due, in part, to the shape and electrostatic incompatibility of the CdiA-CTo11
EC869
 β-hairpin 
with the binding pocket of CdiI
YPIII
 immunity protein (Figure 8).  Similarly, CdiA-CTo11
EC869
 
does not strongly interact with CdiI
Pasy
, CdiI
Ykris
, or CdiI
Nlact
 as observed by bait-prey binding 
assays (Figure 13). 
4. Immunity proteins only provide protection against their cognate toxins during 
cell-mediated CDI 
The CdiA-CT
YPIII
 toxin is encoded within a defective cdi locus that has been inactivated 
by complex gene rearrangements and deletions.  To ascertain whether the toxin is functional 
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in cell-mediated CDI, we fused the CdiA-CT
YPIII
 nuclease domain to the C-terminus of 
CdiA
EC93
 and tested the resulting chimera for inhibition activity against E. coli target cells.  
Inhibitor cells that express the CdiA
EC93
-CT
YPIII
 chimera reduced viable target-cell counts 
more than 500-fold after four hours of co-culture, but target cells that express the cognate 
CdiI
YPIII
 immunity protein were completely protected from inhibition (Figure 9A).  In 
contrast, target cells that express CdiIo11
EC869
 immunity protein were inhibited to the same 
extent as cells that lack any immunity gene (Figure 9A).  Similarly, the CdiI
YPIII
 immunity 
protein was unable to protect target cells from inhibitor cells that deploy the CdiA-CTo11
EC869
 
toxin (Figure 9A).  We also examined competition co-cultures by fluorescence microscopy to 
detect DNase activity in target bacteria.  We labeled inhibitor cells with YFP and target cells 
with mKate2 to differentiate the two populations and also stained the cells with DAPI to 
visualize nucleoids.  Immediately after cell mixing, both inhibitor and target cell populations 
had similar morphologies and nucleoid staining was uniform (Figure 9B).  After four hours 
of co-culture, target cells that lack the appropriate immunity protein became filamentous and 
lost DAPI staining (Figure 9B), indicating significant damage to the chromosome.  In 
contrast, target cells that express cognate CdiI immunity proteins retained normal 
morphology and DAPI staining (Figure 9B).  Together, these data demonstrate that these two 
toxin/immunity systems have diverged into distinct non-overlapping immunity groups. 
5. Intracellular expression of CdiA-CTs in the EC869 superfamily phenocopies 
inhibition by CdiA-CTo11
EC869
 
A hallmark of target cells inhibited by CdiA-CTo11
EC869
 is the formation of long, 
filamentous cells with severely-damaged chromosomal DNA (Figures 9 and 10).  Although 
the mechanism of filamentation is unknown, this phenotype is not observed during inhibition 
164 
 
by all DNases, suggesting that this target cell response is mounted with some specificity to 
the activity of the CdiA-CTo11
EC869
 toxin.  Given the structural similarity between CdiA-
CTo11
EC869
 and CdiA-CT
YPIII
 as well as the strong sequence conservation between these two 
toxins and CdiA-CT
Nlact
, we wondered whether other toxins in the EC869 superfamily 
induced morphological changes in target cells similar to those observed after inhibition by 
CdiA-CTo11
EC869
. 
First, we tested whether intracellular expression of CdiA-CT
YPIII
 and CdiA-CT
Nlact
 is 
toxic using a two-plasmid transformation assay.  E. coli X90 cells were co-transformed with 
pCH450 constructs carrying cdiA-CT genes and pTrc99A derivatives carrying the 
corresponding cdiI.  Induction of CdiA-CT
YPIII
 inside cells results in growth inhibition, as 
evidence by the lack of viable colonies on these plates (Figure 11A).  Expression of the 
cognate CdiI
YPIII
 rescues this growth defect.  CdiI
Nlact
 and CdiI
Pasy
 do not fully protect against 
growth inhibition.  Similarly, CdiA-CT
Nlact
 is toxic when intracellularly expressed, and 
CdiI
YPIII
 and CdiI
Pasy
 do not protect against growth inhibition (Figure 11B).  CdiIo11
EC869
 was 
not included in this assay, as overexpression of this immunity protein in the absence of any 
CdiA-CT domain is toxic to cells (data not shown).  Because the active site of these toxins is 
highly conserved, we mutated the residues corresponding to the aspartic acid at position 198 
that has been shown to be essential for activity of CdiA-CTo11
EC869
.  Mutating the 
corresponding aspartic acid residues in CdiA-CT
YPIII
 and CdiA-CT
Nlact
 resulted in attenuation 
of inhibitory activity when expressed intracellularly (Figure 11C and D), indicating that the 
structural conservation at the active site is important for the activity of these toxins. 
To determine whether intracellular expression of these homolog toxins results in the same 
filamentous phenotype associated with inhibition by CdiA-CTo11
EC869
, we transformed cells 
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with the pCH450::cdiA-CT
YPIII
 plasmid and the indicated pTrc99A cdiI constructs and grew 
the cells in liquid culture, removing an aliquot for microscopy at the indicated timepoints.  
With induction, cells filament and lose DAPI staining (Figure 12, left panels, 5 h).  This 
activity is blocked by co-expression of CdiI
YPIII
.  CdiI
Nlact
, CdiI
Pasy
, and CdiI
Ykris
 were unable 
to fully block the filamentation and DNase activity conferred by CdiA-CT
YPIII
 (Figure 12, 
middle 4 panels).  The Asp198Ala mutation that prevented in vitro DNA degradation also did 
not support intracellular activity (Figure 12, right panels).  Therefore, the filamentation 
observed with inhibition by CDIo11
EC869
 is a phenotypic response that is induced by other 
related toxins. 
6. β-augmentation is required for toxin/immunity protein complex formation 
The β-augmentation interactions observed in the two toxin/immunity protein complexes 
suggest that the proteins bind using a lock-and-key mechanism.  Therefore, we sought to 
crystallize and solve the structures of isolated toxins and immunity proteins to determine if 
the proteins undergo any conformational changes upon complex formation.  Neither of the 
isolated toxin domains formed crystals, but we were able to crystallize and solve the 1.8 Å 
structure of an isolated immunity protein (CdiI
Ykris
) encoded by the Ykris_10740 locus of 
Yersinia kristensenii ATCC 33638 (Table 1).  CdiI
Ykris
 shares 68.9% and 51.5% sequence 
identity with CdiIo11
EC869
 and CdiI
YPIII
 (respectively) (Figure 1C), and its structure 
superimposes onto CdiIo11
EC869
 and CdiI
YPIII
 with RMSD of 0.626 and 0.984 Å over all α-
carbons (respectively) (Figure 14).  In addition, structural homology searches identified yet 
another immunity protein homolog (CdiI
NMB
) encoded by the NMB0488 locus in Neisseria 
meningitidis MC58 (PDB: 2GKP).  CdiI
NMB
 superimposes onto each of the other immunity 
proteins with RMSD values < 0.7 Å over all α-carbons (Figure 14).  Collectively, these 
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structures indicate that CdiIo11
EC869
 homologues retain the same β-hairpin binding pocket 
architecture in the absence of bound toxin.  This finding suggests that β-hairpins are modular, 
raising the possibility that interaction specificity could be altered by exchanging β4/β5 (β-
hairpin) sequences between toxins. 
To test whether β-augmentation is required for stable complex formation, we replaced the 
CdiA-CTo11
EC869
 β-hairpin (residues Lys242 – Thr252) with a Gly-Ser-Gly peptide linker to 
generate CdiA-CTo11
EC869/Δβ4β5 (Figure 15A).  Wild-type CdiA-CTo11
EC869
 binds to its 
cognate immunity protein with nanomolar affinity and co-purifies with His6-tagged 
CdiIo11
EC869
 during Ni
2+
-affinity chromatography (Figure 15B).  In contrast, CdiA-
CTo11
EC869/Δβ4β5 did not co-purify with His6-tagged CdiIo11
EC869
 (Figure 15B), suggesting 
the mutant domain has lower affinity for the immunity protein.  We purified CdiA-
CTo11
EC869/Δβ4β5 to homogeneity by anion-exchange chromatography and measured its 
affinity for CdiIo11
EC869
-His6 using biolayer interferometry.  However, no binding interaction 
was detected, indicating that the dissociation constant is > 300 μM.  To test whether deletion 
of the β-hairpin disrupts toxin structure, we examined the CdiA-CTo11
EC869/Δβ4β5 domain 
using circular dichroism (CD) spectroscopy.  This analysis revealed that CdiA-
CTo11
EC869/Δβ4β5 has essentially the same secondary structure content as the wild-type 
domain (Figure 15C).  Taken together, these results demonstrate that the CdiA-CTo11
EC869
 β-
hairpin is critical for complex formation.  Moreover, despite the very low affinity of CdiI to 
CdiA-CTo11
EC869/Δβ4β5, a high level of expression of CdiA-CTo11
EC869/Δβ4β5 was observed 
(Figure 15B) together with healthy cell growth, suggesting that the β-hairpin is also required 
for toxic DNase activity.  This was confirmed by testing in vitro DNase activity in the 
presence of supercoiled plasmid DNA and Zn2 +, which showed that the CdiA-
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CTo11
EC869/Δβ4β5 domain had no observable DNase activity (data not shown). 
We next asked whether CdiI binding specificity can be altered by grafting heterologous 
β-hairpins onto the CdiA-CTo11
EC869
 toxin.  Using a catalytically inactive version of CdiA-
CTo11
EC869
 that contains an Asp198Ala mutation in the active site, we replaced residues 
Lys242 – Glu250 with the corresponding sequences from homologous toxins from Y. 
kristensenii ATCC 33638 (CdiA-CT
Ykris
 encoded by ykris0001_10730) and Neisseria 
lactamica ATCC 23970 (CdiA-CT
Nlact
 encoded by NEILACOT_05635) (Figure 16A).  We 
co-expressed CdiA-CTo11
EC869/Nlact
 and CdiA-CTo11
EC869/Ykris
 together with His6-tagged 
CdiIo11
EC869
 and purified the tagged immunity protein by Ni
2+
-affinity chromatography.  
Chimeric CdiA-CTo11
EC869/Nlact
 toxin co-purified with His6-tagged CdiIo11
EC869
, but CdiA-
CTo11
EC869/Ykris
 eluted in the void volume of the column (Figure 16B).  These results suggest 
that CdiA-CTo11
EC869/Nlact
 binds with relatively high affinity to CdiIo11
EC869
, whereas the 
CdiA-CTo11
EC869/Ykris
 toxin does not.  We first confirmed that each chimeric toxin was folded 
properly using CD spectroscopy (Figure 16C), then measured binding affinities for 
CdiIo11
EC869
 using biolayer interferometry.  CdiA-CTo11
EC869/Nlact
 and CdiA-CTo11
EC869/Ykris
 
bound to CdiIo11
EC869
 with dissociation constants of 180 ± 100 nM and 46 ± 36 μM, 
respectively (Table 3), consistent with the co-purification data.  The difference in affinities of 
the N. lactamica and Y. kristensenii chimeric toxins for the CdiIo11
EC869
 immunity protein is 
in part due to the differences in electrostatic and shape complementarity (Figure 17).  The N. 
lactamica and EC869 β-hairpins share similar electrostatics and shape (Figure 17A and B), 
allowing CdiA-CTo11
EC869/Nlact
 to retain nanomolar affinity for CdiIo11
EC869
 (Table 3).  In 
contrast, the Y. kristensenii β-hairpin has a different shape and altered electrostatics 
compared with CdiA-CTo11
EC869
, which results in low micromolar affinity of chimeric CdiA-
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CTo11
EC869/Ykris
 toxin for CdiIo11
EC869
 (Figures 14 and 17).  We then tested whether the grafted 
β-hairpins confer higher affinity for CdiINlact and CdiIYkris immunity proteins.  The CdiA-
CTo11
EC869/Ykris
 chimera bound to CdiI
Ykris
 with about the same affinity as CdiIo11
EC869
, but 
somewhat surprisingly this domain bound to CdiI
Nlact
 with ~10-fold higher affinity (Table 3).  
The CdiA-CTo11
EC869/Nlact
 domain bound to CdiI
Nlact
 with essentially the same affinity as for 
CdiIo11
EC869
 and interacted with CdiI
Ykris
 with approximately 10-fold lower affinity (Table 3). 
7. Structure of the MAC/CdiIo11
EC869
 complex 
In principle, molecules that disrupt CdiA-CT/CdiI complexes should liberate the toxin 
domain and induce CDI
+
 bacteria to undergo auto-inhibition.  Nowick and coworkers have 
previously developed macrocyclic peptides containing δ-linked ornithine turn units that adopt 
a β-hairpin conformation and should be suitable to disrupting the CdiA-CT/CdiI 
complex(354, 355).  To test the feasibility of this strategy, we designed a macrocyclic 
peptide (MAC) that mimics the β-hairpin of CdiA-CTo11
EC869
.  The MAC peptide contains 
residues corresponding to Lys242 – Ser253 of CdiA-CTo11
EC869
, which were connected 
through a δ-linked ornithine residue (Figure 18).  Biolayer interferometry experiments failed 
to detect a binding interaction between MAC and CdiIo11
EC869
; and the MAC peptide was 
unable to promote DNase activity when added in ~103-fold molar excess to the CdiA-
CT/CdiIo11
EC869
 complex in vitro (data not shown).  Despite its low affinity for CdiIo11
EC869
, 
we were able to crystallize the MAC peptide in complex with the immunity protein and solve 
the structure to 2.0 Å resolution by molecular replacement (Figure 19A).  As anticipated, the 
MAC peptide forms a two-stranded β-sheet, though there are only four cross-strand H-bonds 
compared to the five in the CdiA-CT/CdiIo11
EC869
 complex.  The ornithine turn creates a 
bulge that prevents formation of the fifth H-bond (Figure 19B).  The MAC/CdiIo11
EC869
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structure superimposes well with CdiIo11
EC869
 (RMSD of 0.437 Å over all α-carbons), though 
helix α3* is displaced 3.0 Å to create a slightly altered β-hairpin binding pocket (Figure 
19B).  Five MAC peptide side-chains form H-bonds or ion-pair interactions with the 
immunity protein, in contrast to the six direct interactions observed in the CdiA-
CT/CdiIo11
EC869
 complex.  In the CdiA-CT/CdiIo11
EC869
 complex, β-hairpin residue Ser247 
interacts with the immunity protein.  However, the corresponding Ser7 residue within the 
MAC peptide does not interact with CdiIo11
EC869
 (Figure 19C).  Additionally, the side-chain 
conformation of MAC residue Arg10 is altered compared to that of Arg249 in the CdiA-
CT/CdiIo11
EC869
 structure, resulting in a H-bond interaction with the hydroxyl of Ser80 rather 
than the backbone carbonyl of Phe75 in the toxin/immunity structure.  The MAC/CdiIo11
EC869
 
structure establishes that structure-based designed macrocyclic peptides can bind in the 
CdiIo11
EC869
 β-hairpin binding pocket (Figure 19D), forming contacts that mimic those found 
in the CdiA-CT/CdiI complexes. 
C.  Discussion 
CDI toxin/immunity protein pairs are diverse and comprise more than 100 distinct 
families.  Even within a given family, there is considerable sequence variability suggesting 
that toxin/immunity protein families continue to evolve.  This phenomenon is well-illustrated 
by homologues of the CdiA-CT/CdiIo11
EC869
 toxin/immunity protein pair.  Alignment of 26 
closely related toxin domains from this family reveals that nearly all of the secondary-
structure elements are highly conserved (Figure 5A).  The obvious exception is the β4/β5-
hairpin, which mediates the β-augmentation interaction and is the least-conserved element in 
the family.  Loop L1 of the toxin domain is responsible for all other contacts with the 
immunity protein; in contrast to the β-hairpin, this region is well-conserved with five 
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invariant residues (Arg189, Leu190, Pro19, Phe194 and Asp198).  Although loop L1 is 
highly conserved, it interacts with immunity proteins using distinct contacts in the CdiA-
CT/CdiIo11
EC869
 and CdiA-CT/CdiI
YPIII
 complexes.  Loop L1 of CdiA-CTo11
EC869
 engages 
almost exclusively in hydrophobic and van der Waals interactions, whereas the C-terminal 
portion of the CdiA-CT
YPIII
 loop is dominated by direct H-bond and ion-pair interactions 
involving residues Asp201, Ala203 and Thr204.  The differences are striking because these 
three residues are also present in CdiA-CTo11
EC869
, yet do not form the same interactions.  
Similar phenomena are observed for the immunity proteins.  CdiI strand β3* anneals with the 
toxin's variable β5 strand during β-augmentation; accordingly, β3* varies between immunity 
proteins in the family (Figure 5B).  CdiI strands β7*, β8*, β9*, and the intervening loops are 
highly conserved, yet this region interacts with cognate toxins using distinct molecular 
contacts.  In several instances, highly conserved residues engage in direct H-bonds in one 
complex, but fail to make any intermolecular contact in another closely related complex.  
Therefore, even conserved sequence elements can be exploited to discriminate against near-
cognate partners.  The idiosyncratic nature of these interactions most likely explains why 
immunity-binding specificity cannot be switched through a simple exchange of β4/β5-
hairpins between homologous toxins. 
The divergence of toxin/immunity protein interactions was first recognized and 
characterized in a subset of E-class colicins.  Colicins are diffusible protein toxins released 
by some strains of E. coli to kill other competing bacteria (23).  Though colicins and CdiA 
proteins are not related, there are several features common to both competition systems.  One 
striking parallel is the variability of C-terminal toxin domains.  The eight characterized E-
class colicins share nearly identical N-terminal domains, but their C-terminal nuclease 
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domains are distinct with either DNase (E2, E7, E8 and E9), ribosomal RNase (E3, E4 and 
E6), or tRNase (E5) activities (23).  Like CdiA proteins, colicins are always encoded in 
tandem with a specific immunity protein that binds the nuclease domain and blocks its 
activity.  Colicins E2, E7, E8 and E9 carry homologous DNase domains, yet their respective 
immunity proteins do not protect against near-cognate toxins (63, 356).  Structure-function 
analyses show that E-class immunity proteins bind to a contiguous stretch of ~30 residues 
that are highly variable between the different nuclease domains (71, 72, 357).  Similarly, the 
interaction surfaces on the immunity proteins are also variable, but contain a conserved core 
interaction comprised of Tyr54 and Tyr55 (ImmE9 annotation) (71, 78).  This invariant core 
provides significant binding energy, and near-cognate colicin toxin/immunity protein 
interactions often have dissociation constants of 10
-8
 M (358), which are similar in affinity to 
the cognate CdiA-CT/CdiI complexes studied here.  An analogous core interaction centered 
at the tip of the β-hairpin is found in the CdiA-CT/CdiIo11
EC869
 toxin/immunity family.  
Leu246 of the toxin engages in a hydrophobic interaction with an aliphatic residue in the 
immunity protein (Ala131 in CdiIo11
EC869
 and Val141 in CdiI
YPIII
).  Similarly, toxin residue 
Ser247 interacts with a Tyr residue (Tyr84 in CdiIo11
EC869
 and Tyr94 in CdiI
YPIII
) that is 
invariant in the immunity protein family (Figure 5B).  However, these core interactions do 
not provide significant binding affinity for near-cognate toxin/immunity pairs.  A final 
important parallel between the colicin E-class and CdiA-CTo11
EC869
 DNases is that the 
immunity proteins both bind to exosites, leaving the nuclease active site exposed in the 
toxin/immunity complex (23, 177).  The spatial segregation of substrate and immunity 
binding sites presumably provides the flexibility to evolve unique protein-protein interactions 
while retaining catalytic activity.  The fact that two unrelated DNase toxin/immunity pairs 
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appear to be diverging rapidly suggests that this is a general and perhaps universal feature of 
toxin/immunity systems.   
Protein-protein interactions presumably evolve through mutational drift followed by 
reciprocal changes in the binding partner to maintain overall affinity while the underlying 
molecular contacts change.  Riley and colleagues have proposed a diversification-selection 
model to explain the observed diversity in E-class colicin/immunity protein pairs.  According 
to their model, some mutations expand immunity function and allow the newly evolved 
immunity protein to not only protect against its cognate toxin, but also against the colicins 
released by other strains (39, 212).  Such mutations would appear to be rare, but have been 
identified and characterized experimentally (359, 360).  One striking example that supports 
this model is the Asp33Leu mutation in ImmE2 immunity protein, which increases affinity 
for non-cognate colicin E9 more than a 3,000-fold (360).  The advantage conferred by the 
new immunity gene would provide the selective pressure to retain the allele and allow it to 
become fixed in the population.  This in turn allows for subsequent mutations in the linked 
colicin gene.  Further mutations in the colicin are predicted to produce "super-killer" toxins, 
to which the ancestral bacteria are not immune (212).  Thus, the evolved colicin/immunity 
pair kills ancestral cells, thereby allowing fixation of the new pair in the population.  
Multiple iterations of this process are predicted to eventually produce a family of divergent 
toxin/immunity pairs.  Of course, mutations that disrupt the toxin/immunity protein complex 
should be lethal to the cell, so the pressure to retain high-affinity interactions is presumably a 
significant barrier to diversification.  However, colicin/immunity protein complexes have 
some of the highest known binding affinities, with cognate pairs characterized by femtomolar 
dissociation constants (357, 358, 360, 361).  Therefore, even if a mutation results in a 1000-
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fold decrease in affinity, the complex will still have a sub-nanomolar dissociation constant, 
which is sufficient to provide complete protection against toxicity (358, 361).  Thus, the 
extraordinarily high affinity of cognate colicin/immunity protein complexes provides a buffer 
against the potentially lethal effects of mutations that disrupt the toxin/immunity protein 
interface.  In contrast, the CDI toxin/immunity proteins studied here have much lower 
binding affinities with dissociation constants of about 20 nM for cognate pairs.  Therefore, 
CDI toxin/immunity systems must exploit other biophysical mechanisms to avoid self-
intoxication during evolution.  One possible mechanism involves the over-expression of 
immunity proteins relative to the toxins.  The majority (21 of 25) of CdiA-CTo11
EC869
 
homologues presented in Figure 5A are encoded by truncated cdiA gene fragments that lack 
the N-terminal coding sequences required for secretion.  These pseudogene pairs are termed 
"orphan" modules, because they resemble cdiA-CT/cdiI coding sequences that have been 
displaced from full-length cdiA genes (176).  Orphan cdiA-CT reading frames usually lack 
translation initiation signals, whereas the linked orphan cdiI genes have canonical ribosome-
binding sites upstream of the initiating Met codon.  These observations suggest that the 
toxins are expressed at very low levels, but the immunity proteins are highly expressed.  
Under these conditions, the selective pressure to retain immunity function would be relieved 
and allow the immunity gene to undergo drift without lethal consequences.  This hypothetical 
scenario is supported by the observation that non-cognate/mutated immunity proteins can 
fully protect cells when over-expressed (358, 362).  Therefore, we propose that the 
organization of cdiA-CT/cdiI gene pairs into orphan modules serves to accelerate 
toxin/immunity evolution by attenuating toxin expression.  We note that this could be a 
general strategy to generate diversity in inter-bacterial competition systems because similar 
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clusters of orphan gene pairs are associated with rhs genes in type VI secretion systems(176, 
230) and the mafB genes of Neisseria species (211). 
CDI systems are widespread throughout proteobacteria and are most commonly found in 
pathogenic species, such as Yersinia pestis, Neisseria meningitides, and Burkholderia 
pseudomallei (167, 213).  Because CDI
+
 bacteria exchange CdiA-CT toxins with one 
another, it may be possible to induce bacterial suicide with small molecules that specifically 
disrupt CDI toxin/immunity protein binding interactions.  The β-hairpin binding pocket 
within CdiIo11
EC869
 and homologous immunity proteins is an attractive target to test this 
antimicrobial strategy.  Small cyclic peptides that fold into β-hairpins have been used to 
study protein-protein and protein-DNA interactions and in some instances have been used to 
specifically disrupt protein complexes (363, 364).  As illustrated by the MAC/CdiIo11
EC869
 
structure, cyclic β-hairpin mimics can be designed to bind CdiI immunity proteins.  Our 
design could be improved to enhance binding affinity and possibly be utilized as a protein-
protein complex inhibitor by increasing the number of residues or designing additional 
contacts.  Although the current MAC contains pentapeptide strands, we have previously 
reported cyclic β-hairpin mimics containing heptapeptide and nonapeptide β-strands (365, 
366).  Homologous MACs containing larger β-hairpin mimics and designed to achieve more 
contacts may allow rational design of a higher affinity macrocyclic peptide that specifically 
may disrupt toxin/immunity complexes within bacterial pathogens, setting the stage for the 
development of a new class of antibacterials. 
D.  Materials and methods 
1. Bacterial strains and plasmid constructs 
All bacterial strains and plasmids used in this study are presented in Table S2.  All 
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primers used in this study are presented in Table S3.  Yellow fluorescent protein (YFP)-
labeled E. coli EPI100 cells were generated by integrating the yfp coding sequence at the gal 
locus.  First, a genomic integration construct was made by amplifying the kanamycin-
resistance cassette from plasmid pKAN(367) with primers Kan-1/Kan-2, followed by blunt-
end ligation to SmaI-digested plasmid pBluescript.  One plasmid clone was identified with 
the kanamycin-resistance cassette in the opposite orientation as pKAN, and this plasmid was 
termed pNAK.  A fragment of galM was then amplified using primers CH3789/CH3790, and 
the product was ligated to SacI/BamHI-digested plasmid pNAK to produce pCH2500.  A yfp-
galT fragment was amplified from E. coli DA28100 (a gift from Sanna Koskiniemi, Uppsala 
University) using primers CH3787/CH3788, digested with KpnI/EcoRI, then ligated into 
pCH2500 to yield plasmid pCH2503.  The large KpnI/SacI fragment from pCH2503 was 
recombined into E. coli EPI100 cells that harbor plasmid pSIM6 as previously described(291, 
368).  mKate2-labeled target bacteria were generated by integrating the coding sequence of 
mKate2 at the phage HK022 attP site using plasmids pDE1013 and pAH69 as described 
previously(369). 
The coding sequence for CdiA-CT/CdiI
YPIII
 was amplified from Y. pseudotuberculosis 
YPIII genomic DNA with primers YPK0575-Kpn-for/YPK0576-Xho-rev.  The resulting 
product was digested with KpnI/XhoI and ligated to pET21S to generate plasmid pCH10413.  
The CdiA-CTo11
EC869/Δβ4β5 expression construct was generated by replacing the β4/β5-
hairpin coding sequence with a Gly-Ser linker.  The 5´-end of the construct was amplified 
with primers β-deletion-for1/β-deletion-rev1 and the 3´-end with primers β-deletion-for2/β-
deletion-rev2.  The two PCR fragments were ligated at the BamHI site, and the joined 
fragments re-amplified with β-deletion-for1/β-deletion-rev2.  The resulting product was 
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ligated to pET21d using NcoI and XhoI restriction sites to generate pCH10369.  
Catalytically-inactive CdiA-CTo11
EC869
 domains carrying the Asp198Ala mutation and 
heterologous β-hairpin sequences were generated by PCR.  Plasmid pCH10164 was 
amplified with primers EC869-CT-Nco/EC869-Nlact(beta)-rev and EC869-Nlact(beta)-
for/EC869-cdiI-Spe, and the two products combined by overlap extension PCR (OE-
PCR)(370) using primers EC869-CT-Nco/EC869-cdiI-Spe.  The final product was digested 
with NcoI/SpeI and ligated to pET21S to generate plasmid pCH10365.  The same procedure 
was used to introduce the Y. kristensenii β-hairpin by PCR with primers EC869-CT-
Nco/EC869-Ykris(beta)-rev and EC869-Ykris(beta)-for/EC869-cdiI-Spe.  The two products 
were combined by OE-PCR and ligated to pET21S to generate plasmid pCH10175.  The 
coding sequences for CdiI
Ykris
 (ykris0001_10740) and CdiI
Nlact
 (NEILACOT_05636) were 
chemically synthesized (Genscript, Inc.) with flanking restriction sites and ligated to plasmid 
pUC57.  The ykris0001_10740 sequence was sub-cloned into pTrc99KX to generate plasmid 
pCH10103, which was then used as a template for PCR with primers pTrc-seq2/Ykris-cdiI-
Spe-rev.  The resulting product was digested with KpnI/SpeI and ligated to pET21K to 
generate plasmid pCH10170.  The NEILACOT_05636 sequence was subcloned into pCH450 
to generate plasmid pCH10101, which was then used as a template for PCR with primers 
pCH450-for/Nlact-cdiI-Spe-rev.  The resulting product was digested with NcoI/SpeI and 
ligated to pET21S to generate plasmid pCH10172. 
The chimeric CDI system that deploys CdiA-CT
YPIII
 toxin was generated by replacing the 
CdiA-CTo11
EC869
 DNase domain with the corresponding region of CdiA-CT
YPIII
.  Regions 
upstream and downstream of the cdiA-CT/cdiIo11
EC869
 sequence were amplified from plasmid 
pCH9305 using primers DL1527/EC869o11-G173-rev (upstream) and EC93-YPIII-down-
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for/DL2368 (downstream).  The cdiA-CT/cdiI
YPIII
 sequence was amplified from Y. 
pseudotuberculosis YPIII genomic DNA using primers EC869o11-G173-for/EC93-YPIII-
chim-rev.  The three PCR products were combined by OE-PCR using primers 
DL1527/DL2368.  The final product was electroporated together with plasmid pCH10163 
into E. coli strain DY378 as described(175, 177).  Recombinants were selected on yeast 
extract/glucose-agar supplemented with 33 μg/mL chloramphenicol and 10 μM D/L-o-
chlorophenylalanine.  All plasmid constructs were verified by DNA sequence analysis. 
2. Protein purification 
All proteins were over-produced from pET21-derived plasmid using either E. coli 
CH2016 or E. coli BL21-Gold(DE3).  Cells were grown aerobically at 37 °C in LB medium 
containing 150 μg/mL ampicillin.  CdiA-CT/CdiIYPIII expression was induced by the addition 
of 1 mM isopropyl-β-D-thiogalactoside at an OD600 ~0.8 and grown for a further 3-4 h before 
harvesting.  Cells were collected by centrifugation at 5,500 × g for 25 min and then washed 
with resuspension buffer [20 mM sodium phosphate (pH 7.0), 150 mM NaCl].  Cells were 
resuspended and disrupted by sonication on ice in resuspension buffer containing 10 mg/mL 
lysozyme and1 mM phenylmethylsulfonyl fluoride.  Cell debris was removed by 
centrifugation at 18,000 × g for 30 min followed by filtration through a 1.0 μm filter.  
Clarified lysates were loaded onto a Ni
2+
-charged HiTrap column (5 mL; GE Healthcare) or 
Ni
2+
-nitrilotriacetic acid (Ni
2+
-NTA) agarose resin (MCLAB) and washed with resuspension 
buffer supplemented with 10 mM imidazole.  Proteins were eluted with a linear gradient of 
imidazole (10 – 500 mM) in resuspension buffer.  Fractions were collected, combined, and 
concentrated to a volume of ~500 μL using a 10-kDa centrifugal concentrator (Centricon; 
Millipore).  Proteins were further purified by gel filtration on a Superdex 200 column for the 
178 
 
CdiA-CT/CdiI
YPIII
 complex or Superdex 75 for individual immunity proteins (GE 
Healthcare).  Gel filtration columns were equilibrated with 20 mM sodium phosphate (pH 
7.0), 150 mM NaCl using an AKTA FPLC.  Purification of CdiI
Ykris
 and CdiIo11
EC869
 
followed the same protocol, except all buffers contained 20 mM Tris-HCl (pH 7.4) instead of 
sodium phosphate.  CdiA-CT/CdiI
YPIII
, CdiI
Ykris
, and CdiIo11
EC869
 were concentrated to 10, 
12.5 and 7.5 mg/mL (respectively) for crystallization trials. 
The individual His6-tagged CdiI proteins were over-produced from plasmid pET21d 
constructs and purified as described above for CdiIo11
EC869
.  CdiA-CT proteins were isolated 
from co-expressed His6-tagged CdiI proteins by two methods, depending on whether the two 
proteins co-eluted following Ni
2+
-affinity chromatography.  CdiA-CT/CdiI-His6 complexes 
were denatured overnight in 6 M urea and then subjected to Ni
2+
-affinity chromatography in 
buffers containing 6 M urea.  Denatured CdiA-CT toxins were collected from the void 
volume, refolded by dialysis into 20 mM Tris-HCl (pH 8.0), 10 mM NaCl, then concentrated 
on a HiTrap Q anion-exchange column and eluted with a salt gradient, yielding 95% pure 
CdiA-CT protein.  Purified toxins were then exchanged into 20 mM Tris-HCl (pH 7.4), 150 
mM NaCl by gel filtration on a S75 column. 
3. Crystallization and structure determination 
Protein crystals were grown by hanging-drop vapor diffusion, with drops containing a 1:1 
ratio (vol/vol) of protein solution to reservoir liquor.  Crystals were mounted and collected 
under cryo-conditions with the addition of 40% glycerol as cryoprotectant to the reservoir 
solution.  Datasets were collected at 70K at a wavelength of 1.0 Å and images were indexed, 
integrated and reduced using either iMOSFLM (CdiA-CT/CdiI
YPIII
 complex)(371) or the 
HKL2000 suite (CdiI
Ykris
 and MAC/CdiIo11
EC869
)(372).  Initial phases were determined by 
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molecular replacement by autoMR in PHENIX using the CdiA-CT/CdiIo11
EC869
 structure 
(PDB: 4G6U) as a search model.  Initial model building was performed by Autobuild in 
PHENIX.  The final models were built through iterative manual building in Coot and refined 
with phenix.refine.  Data collection and refinement statistics are presented in Table 1.  All 
molecular graphics were prepared with PyMOL(373). 
CdiA-CT/CdiI
YPIII
 crystals were grown from a 10 mg/mL solution and a reservoir 
containing 50 mM HEPES (pH 7.0), 20% PEG 3350, 1% tryptone.  The complex crystallized 
in space group C2 with unit cell dimensions 65.51 Å × 65.51 Å × 71.49 Å and one complex 
per asymmetric unit.  The model contains residues Met174 – Lys297 (numbered from Val1 
of the VENN motif) of CdiA-CT
YPIII
 and residues Asp3 – Lys176 of CdiIYPIII.  CdiA-CTYPIII 
residues Lys182, Lys220, Lys240 and Lys297 were modeled as Ala due to lack of observable 
side-chain density.  Similarly, CdiI
YPIII
 residues Asp3, Lys108, Lys118, Lys148 and Lys176 
were modeled as Ala residues.  The final CdiA-CT/CdiI
YPIII
 model includes 148 water 
molecules resulting in an Rwork/Rfree (%) of 20.5/25.6 (Table 1).  CdiI
Ykris
 immunity 
protein crystals were grown from a 12.5 mg/mL solution over a reservoir containing 0.2 M 
ammonium fluoride, 20% PEG 3350.  The crystal space group was P31 with unit cell 
dimensions 54.448 Å × 54.448 Å × 54.472 Å and one molecule per asymmetric unit.  The 
final model contains CdiI
Ykris
 residues Met1 – Gly165 and 130 water molecules resulting in 
an Rwork/Rfree (%) of 18.1/22.1.  CdiI
Ykris
 residues Lys4, Glu67, Lys96, Lys126 and 
Lys136 were modeled as Ala due to lack of observable side-chain density.  In addition, the 
CdiI
Ykris
-His6 expression construct contained an Ala84Thr mutation. 
The macrocyclic peptide (MAC) that mimics the CdiA-CTo11
EC869
 β-hairpin (Figures 18 
and 19) was prepared according to previously described procedures(354, 374, 375).  MAC 
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peptide (2 mg) was added to 200 μL of 7.5 mg/mL CdiIo11
EC869
 to yield a solution at a ~ 10:1 
peptide:protein ratio.  MAC/CdiIo11
EC869
 co-crystals were grown over two days in 0.2 M 
sodium acetate (pH 5.6), 0.1 M bis-tris propane, pH 6.9, and 20% (wt/vol) PEG 3350, using 
the protein/peptide mixture described.  Initial crystals were of poor quality and resulted in 
highly mosaic diffraction data.  Crystal quality was improved by microseeding(376).  Briefly, 
crystals were harvested into 80 μL of crystallization solution and a seed stock was generated 
using a seed bead (Hampton).  Following optimization, suitable diffraction quality crystals 
were generated using a hanging drop containing 1 μL of seed stock and 1 μL of the 
protein/peptide mixture following a three-fold dilution.  The MAC/CdiIo11
EC869
 complex 
crystallized in space group P21 with unit cell dimensions 34.776 Å × 128.166 Å × 44.953 Å 
(Table 1).  Each asymmetric unit contained two MAC/CdiIo11
EC869
 complexes.  The final 
model contains two molecules of CdiIo11
EC869
 residues Ala2 – Gly167, two macrocyclic 
peptides and 132 water molecules, resulting in Rwork/Rfree (%) of 18.4/23.1.  Residues 
Lys5, Gln43, Glu78, Lys85, Glu93 of one CdiIo11
EC869
 molecule (chain D only), Asp117 and 
Glu139 of both CdiIo11
EC869
 molecules were modeled as Ala due to lack of observable side-
chain density. 
4. Protein analyses 
The secondary structure of purified toxins (0.1 mg/mL in 20 mM Tris-HCl, pH 7.4) was 
analyzed by CD spectroscopy on a Jasco J-720 spectropolarimeter using a 0.1 cm path-
length.  Spectra were collected at 20 nm/min with a 2 nm bandwidth and 4 s response time.  
Three consecutive scans were collected and averaged for each analysis.  CdiA-CT/CdiI 
binding affinities were determined by biolayer interferometry as described previously [7].  
Binding reactions were performed at 25 °C in 20 mM Tris-HCl (pH 7.4), 150 mM NaCl.  
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CdiI-His6 immunity proteins were immobilized onto Ni
2+
-NTA biosensors and exposed to 
cognate or heterologous CdiA-CT toxins at 0.5 – 300 μM.  A reference was subtracted from 
all binding curves before curve fitting.  Curve fitting and data processing were performed 
using BLitz Pro software (ForteBio Inc.). 
5. In vitro analysis of nuclease activities 
The activity of purified CdiA-CTo11
EC869
 and CdiA-CT
YPIII
 were assayed in vitro using 
supercoiled plasmid pUC18 as a substrate.  CdiA-CT (at 1 μM final concentration) was 
incubated with 250 ng of plasmid DNA in 20 mM Tris-HCl (pH 7.5), 100 mM NaCl, 0.1 
mg/mL bovine serum albumin supplemented with 2 mM MgCl2 or ZnCl2 for 1 h at 37 °C.  
Where indicated, purified CdiI-His6 proteins were included at 2 μM final concentration and 
allowed to bind CdiA-CT for 30 min at room temperature prior to adding substrate DNA.  
Reactions were quenched with 10 mM EDTA followed by the addition of 300 μL of 
denaturing solution (4 M guanidine-HCl, 33% 2-propanol).  The reactions were purified over 
silica membrane spin columns (Epoch Life Sciences).  Columns were then washed with 70% 
ethanol, 10 mM Tris-HCl (pH 8.0) followed by elution with 10 mM Tris-HCl (pH 8.0).  
Purified DNA from reactions was run on 1% agarose gels containing ethidium bromide and 
visualized using Bio-Rad Gel Doc 2000. 
6. Competition co-cultures and fluorescence microscopy 
Inhibitor cells (E. coli EPI100 carrying plasmids pCH9305, pCH2409 or pDAL878) and 
target cells (CH8251 carrying plasmids pTrc99a, pCH9315 or pCH848) were grown 
individually in LB media with 33 μg/μL Cm for inhibitors and 150 μg/μL Amp for targets.  
The overnight cultures were diluted into fresh LB medium without antibiotics and grown in 
baffled flasks at 37 °C.  At mid-log phase, the inhibitor and target strains were mixed 
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together at a 1:1 ratio in baffled flasks and a sample was withdrawn to score viable target 
cells as colony forming units (cfu) per mL on LB-agar supplemented with 200 μg/mL 
rifampicin (Rif).  After four hours of co-culture, another sample was taken and viable target 
cells enumerated on Rif-supplemented LB agar.  Viable target cell counts are the mean 
cfu/mL ± the standard error of the mean for three independent experiments.  Competitions 
with fluorescent inhibitor and target bacteria were conducted as described above, except 
YFP-labeled inhibitor CH2550 cells and mKate2-labeled targets cells were used.  Cells were 
diluted into fresh LB medium and grown to late log phase at 30 °C in the dark to maximize 
fluorescence.  Inhibitor and target cells were mixed at a 1:1 ratio in baffled flasks and 
incubated at 37 °C with shaking in the dark for the duration of the experiment.  Samples 
(equivalent to OD600 = 0.2) were removed at the indicated times and cells were collected by 
centrifugation.  Cells were briefly resuspended in freshly prepared 4% formaldehyde in 1 × 
phosphate buffered saline (PBS), and the fixation reaction quenched with 125 mM glycine.  
Fixed cells were washed with 1 × PBS and spotted onto a poly-D-lysine coated slide (Gold 
Seal Fluorescent Antibody Rite-On Slides from Fisher prepared by coating with a 1% poly-
D-lysine solution prior to addition of cells).  Unbound cells were removed gently with 
Nanopure water, and the slides treated with Fluorogel II with DAPI mounting medium 
(Fisher Scientific/EMS) and a coverslip was overlaid prior to imaging.  Images were acquired 
on an Olympus fluorescent microscope with a 100 × oil objective using an Optronics 
MacroFire digital microscope camera.  Lightfield images were captured with a 12 ms 
exposure (gain 2) and DAPI images were acquired in grayscale with a 48 ms exposure (gain 
2).  Fluorescent images were captured in grayscale using a 502 ms exposure/gain 5 (for YFP) 
or a 1 s exposure/gain 5 (for mKate2).  Images were overlaid and false-colored using 
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FIJI(292), and stacked images were cropped to 400 × 400 pixels using GIMP.  The same 
microscope images used to display fluorescence were used to obtain cell length 
measurements.  Cells were manually measured using the line tool in FIJI, and between 175 
and 328 cells from three microscopy fields were measured for each co-culture competition.  
Each object plotted represents a single cell length measurement.  P values were obtained 
using two-tailed unpaired t-tests. 
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Figure 1.  Structure of the CdiA-CT/CdiIo11
EC869
 complex and alignments of toxin and immunity 
homologues. (B) Cartoon representation of the CdiA-CT/CdiIo11
EC869
 complex structure (PDB ID: 4G6U) with 
the toxin and immunity colored green and cyan, respectively. Toxin active-site residues are rendered in space-
filling model and the Zn
2 +
 ion is represented by a purple sphere. (B) Protein sequence alignment of the CdiA-
CTo11
EC869
 nuclease domain and its homologues. Active-site residues are outlined in red boxes, and the β4/β5-
hairpin is outlined in a green box. (C) Protein sequence alignment of the CdiIo11
EC869
 immunity protein and its 
homologues. Residues that form H-bond or ion-pair interactions with CdiA-CTo11
EC869
 are marked with green 
boxes. The location of CdiI
YPIII
 elongated loop (E-L*) is indicated with a magenta bar. For (B) and (C), 
alignments were prepared using Jalview, with progressively darker shades of blue indicating greater residue 
conservation. The secondary-structure elements shown are from the CdiA-CT/CdiIo11
EC869
 complex structure.  
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Figure 2.  The structure of the CdiA-CT/CdiI
YPIII
 complex.  (A) Ribbon representation of the CdiA-
CT/CdiI
YPIII
 complex with toxin and immunity proteins colored orange and purple, respectively. Location of the 
CdiA-CT
YPIII
 β4/β5-hairpin is indicated. (B) Structural superimposition of the β-hairpin binding regions of 
CdiA-CT/CdiIo11
EC869
 and CdiA-CT/CdiI
YPIII
. CdiA-CTo11
EC869
 and CdiIo11
EC869
 are colored green and cyan, 
respectively. CdiA-CT
YPIII
 residues that form a salt-bridge via loop L1 are depicted as sticks. (C) Predicted 
active-site residues of CdiA-CTo11
EC869
 (carbons in green) and CdiA-CT
YPIII
 (carbons in orange). Oxygen and 
nitrogen atoms are colored red and blue, respectively. Residue labels correspond to both toxins. The Zn
2 +
 ion 
was observed in the CdiA-CTo11
EC869
 structure and is shown as a purple sphere. Extended loop (E-L*) of 
CdiI
YPIII
 is labeled in (A) and (B). 
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Figure 3.  Comparison of CdiA-CT catalytic sites.  In both panels EC869 and YPIII carbon atoms are 
depicted in white and grey, respectively, and oxygen and nitrogen atoms are colored red and blue, respectively.   
(A) CdiA-CTo11
EC869
 active site contains a Zn
2+
 ion, depicted by at purple sphere with water molecules depicted 
as smaller red spheres, and interacting bons with Zn
2+
 are depicted as black dotted lines.   (B) CdiA-CT
YPIII
 
active site has no extra density that would create a zinc coordination sphere.  Water molecules are depicted as 
yellow spheres. 
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Figure 4.  Comparison of the β-augmentation interactions.  (A) Ribbon representation of the CdiA-
CT/CdiIo11
EC869
 complex with toxin and immunity proteins are colored green and cyan, respectively. Residues at 
the complex interface involved in direct ion pair or H-bond interactions are shown in stick representation, with 
carbon atoms colored as stated for above: oxygen and nitrogen atoms are colored red and blue, respectively. 
Water molecules at the interface are represented as red spheres. (B) Ribbon representation of the CdiA-
CT/CdiI
YPIII
 complex with toxin and immunity proteins colored orange and purple, respectively. Residues and 
water molecules represented and colored as in (A). 
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Figure 5. Alignments of CdiA-CT/CdiIo11
EC869
 family members. (A) Alignment of DNase toxin domain 
homologues. Residue are numbered according to the CdiA-CTo11
EC869
 sequence beginning with Val1 of the 
VENN peptide motif. The alignment was rendered with Jalview at 30% sequence identity with progressively 
darker shades of purple indicating greater residue conservation. Secondary structure elements correspond to 
CdiA-CTo11
EC869
. CdiA-CTo11
EC869
 and CdiA-CT
YPIII
 residues that form H-bonds/ion-pairs with cognate 
immunity proteins are shown in orange, and residues that form hydrophobic/van der Waals contacts are shown 
in blue. (B) Alignment of immunity protein homologues. Residue numbers and secondary structure elements 
correspond to CdiIo11
EC869
. Residues that interact with toxins are color coded according the scheme described for 
panel A. 
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Figure 6. CdiA-CT
YPIII
 has DNase activity in vitro. Linearized plasmid DNA was incubated with purified (A) 
CdiA-CT
YPK
 or (B) CdiA-CT
Nlact
 in the presence of either Mg
2+
 or Zn
2+
 and then analyzed by agarose gel 
electrophoresis and ethidium bromide staining.  (C) and (D) Reactions were supplemented CdiI immunity 
proteins where indicated. Untreated linearized plasmid substrate was included as controls for the migration of 
undigested DNA.  
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Figure 7.  CdiA-CT
Nlact
 can utilize other metals as co-factors for DNase activity.  Linearized plasmid DNA 
was incubated with purified CdiA-CT
Nlact
 in the presence of the indicated metals and then analyzed by agarose 
gel electrophoresis and ethidium bromide staining.  Reactions were supplemented CdiI immunity proteins 
where indicated. Untreated linearized plasmid substrate was included as controls for the migration of undigested 
DNA. 
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Figure 8. Electrostatic surfaces of CdiA-CT/CdiIo11
EC869
 and CdiA-CT/CdiI
YPIII
 complexes. Electrostatic 
surface representation of CdiIo11
EC869
 (A) and CdiI
YPIII
 (B). Red and blue surfaces correspond to positive and 
negative surface potentials (respectively) and white indicates hydrophobic surfaces. Toxin β-hairpins are show 
in stick representation in the left panels. Right panels are rotated 180° around the y-axis with respect to the left 
panels and the immunity proteins are shown in cartoon representation. 
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Figure 9. CdiIo11
EC869
 and CdiI
YPIII
 confer specific immunity to CDI. (A) Competition co-cultures. Inhibitors 
cells that deploy CdiA-CTo11
EC869
 (from pCH9305) or CdiA-CT
YPIII
 (from pCH2409) were incubated at a 1:1 
ratio with target cells that express CdiIo11
EC869
 (from pCH9315), CdiI
YPIII
 (from pCH848) or no immunity at all 
(none, pTrc99a vector). Viable target cells were quantified as colony-forming units (c.f.u.) per milliliter at the 
beginning of the co-culture and after 4 h. Data represent the average ± standard error of the mean for three 
independent experiments. (B) Fluorescence microscopy of competition co-cultures. YFP-labeled inhibitor cells 
were co-cultured with mKate2-labeled target strains that carry the indicated immunity genes. Cells were stained 
with DAPI to visualize genomic DNA at 0 and 4 h of co-culture. 
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Figure 10.  Target cells become filamentous after inhibition by the CDIo11
EC869
 and CDI
YKris
 systems.  Co-
culture competitions were performed using mock inhibitors or inhibitor cells deploying the CDIo11
EC869
 and 
CDI
YPIII
 systems and target cells carrying an empty vector (none) or a plasmid expressing CdiIo11
EC869
 or 
CdiI
YPIII
.  Cell length values were measured from microscopy images taken of each competition.  Each object 
plotted represents the length of a single cell.  Black bars indicate the mean of each data set.  P values from two-
tailed unpaired t-tests are reported.  ***,  P=<0.0001. 
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Figure 11.  CdiA-CT
YPIII
 and CdiA-CT
Nlact
 are toxic when expressed intracellularly.  Plasmids expressing 
either (A) active CdiA-CT
YPIII
, (B) active CdiA-CT
Nlact
, or inactive point mutations (corresponding to the CdiA-
CTo11
EC869
 residue D198) were co-transformed into E. coli X90 cells with empty pTrc99a or pTrc99a derivatives 
carrying the indicated immunity gene.  Transformants were selected on LB-tetracycline-ampicillin-agar plates 
supplemented with either glucose or arabinose and IPTG as indicated. 
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Figure 12.  CdiA-CT
YPIII
 causes cell filamentation and loss of DNA staining when expressed 
intracellularly. 
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Figure 13.  CdiA-CTo11
EC869
 does not strongly interact with non-cognate immunity proteins in vitro.  
Purified CdiA-CTo11
EC869
 was mixed with purified His6-CdiI proteins and subjected to pulldown using Ni-NTA 
beads.  Input, unbound, and bound (eluted) fractions were analyzed via SDS-PAGE and Coomassie staining. 
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Figure 14. Superimposition of immunity protein homologues. The CdiI
YPIII
, CdiIo11
EC869
, CdiI
Ykris
 and 
CdiI
Nmen
 immunity proteins are depicted in cartoon representations colored in magenta, cyan, gold and gray, 
respectively. The structures of CdiI
Nmen
 (PDB ID: 2GKP) and CdiI
Ykris
 were determined in the absence of bound 
toxin. The location of the β-hairpin binding pocket is indicated and the extended loop (E-L) connecting α1* to 
α2* of CdiIYPIII is labeled. 
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Figure 15. Deletion of the CdiA-CTo11
EC869
 β-hairpin disrupts complex formation. (A) Ribbon 
representation of the CdiA-CT/CdiIo11
EC869
 complex interface. CdiA-CTo11
EC869
, CdiIo11
EC869
 and the β-hairpin 
colored green, cyan and olive, respectively. The Gly-Ser-Gly linker in CdiA-CTo11
EC869/Δβ4β5
 is depicted as a red 
broken line. (B) His6-tagged CdiIo11
EC869
 was co-expressed with CdiA-CTo11
EC869
 or CdiA-CTo11
EC869/Δβ4β5
, 
followed by purification via Ni
2 +
-affinity chromatography and then analysis by SDS/PAGE gel. Relevant 
molecular weight standards are labeled. The flow-through (FT), wash (W) and elution fractions (E) are 
indicated. (C) CD spectra of purified CdiA-CTo11
EC869
 and CdiA-CTo11
EC869/Δβ4β5
. 
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Figure 16. Toxin β-hairpin sequence contributes to complex binding affinity.  (A) Protein sequence 
alignment of the β-hairpin region (boxed) of CdiA-CTo11
EC869
, CdiA-CT
Nlact
 and CdiA-CT
Ykris
. CdiA-CTo11
EC869
 
residues that interact with CdiIo11
EC869
 are shown in green. Red residues indicate sequence differences with 
respect to CdiA-CTo11
EC869
.  (B) CdiIo11
EC869
-His6 was co-expressed with CdiA-CTo11
EC869
 containing the β-
hairpins from either N. lactamica or Y. kristensenii then purified by Ni
2 +
-affinity chromatography and analyzed 
by SDS-PAGE. The molecular mass standards are indicated in kilodaltons (kDa). The flow-though (FT) and 
wash fractions (W1 and W2) are indicated followed by elution with imidazole gradient.  (C) CD spectra of 
purified CdiA-CTo11
EC869/Nlact
 and CdiA-CTo11
EC869/Ykris
 show similar secondary-structure content compared to 
wild-type CdiA-CTo11
EC869
.  
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Figure 17. Electrostatic surface potential of toxin β-hairpin chimeras. (A) Electrostatic surface 
representation of CdiIo11
EC869
 with the toxin β-hairpin in cartoon and sticks colored green (left panel). The right 
panel is rotated 180 around the y-axis with respect to the left panel. The immunity protein is depicted as 
cartoon representation and the toxin β-hairpin is rendered as an electrostatic surface representation. (B) and (C) 
Models of CdiA-CT
Nlact
 and CdiA-CT
Ykris
 β-hairpins docked onto CdiIo11
EC869
 immunity protein. The models are 
viewed in the same orientation as the right image in panel A. The β-hairpins are rendered as electrostatic surface 
representations, with red and blue representing positive and negative surface potentials (respectively) and white 
indicating hydrophobic surfaces. 
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Figure 18. The macrocyclic peptide mimic of the β-hairpin from CdiA-CTo11
EC869
.  The β-hairpin in this 
synthetic peptide mimics the β-hairpin that forms the basis of the interaction face between CdiA-
CT/CdiIo11
EC869
.  The synthetic construct corresponds to residues lysine 242 through serine 253 of CdiA-
CTo11
EC869
. 
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Figure 19. Structure of the MAC-CdiIo11
EC869
 complex.  (A) Crystal structure with CdiIo11
EC869
 depicted as 
orange ribbons and MAC displayed as sticks, carbon, nitrogen, oxygen and ornithine carbons colored magenta, 
blue, red and pink, respectively. The MAC 2Fo − Fc electron density map is shown in a gray mesh and 
contoured at 1.0 σ. (B) Structural superimposition of MAC [colored same as (A)] and the CdiA-CT/CdiIo11
EC869
 
complex. Only residues Lys242–Ser253 of the CdiA-CTo11
EC869
 β-hairpin are shown (green). CdiIo11
EC869
 is 
colored teal and helix α3* is labeled. (C) MAC interacts with CdiIo11
EC869
 through a network of H-bonds and ion 
pairs. Interacting bonds are shown as black dotted lines. CdiIo11
EC869
 β-strands that H-bond with MAC (β3* and 
β7*) are shown as sticks. (D) Surface representation of the CdiICT-MAC structure, oriented as in (A) and (B), 
depicting the complementarity of MAC and CdiIo11
EC869
. 
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Table 1.      X-ray diffraction data and atomic refinement. 
 
 CdiA-CT/CdiI
YPIII
 CdiI
Ykris
 MAC/CdiIo11
EC869
 
Space group C2 P31 P21 
Unit cell dimensions    
 a, b, c (Å) 65.5, 65.5, 71.5 54.4, 54.4, 54.4 34.8, 128.2, 45.0 
 β (°) 92.18  112.73 
pH of crystallization 
condition 
7.0 7.4 6.0 
Protein concentration 
(mg/mL) 
10 12.5 7.5 
Dataset    
Wavelength (Å) 1.0 1.0 1.0 
Resolution range 46.49–2.1 50.0–1.8 50.0–2.0 
Unique reflections (total) 18,152 16,618 23,561 
Completeness (%)
a
 99.4 (98.3) 99.7 (100) 96.5 (92.1) 
Redundancy
a
 3.5 (3.5) 5.4 (5.5) 3.1 (3.1) 
Rmerge
a and b
 0.059 (0.460) 0.161 (0.607) 0.076 (0.485) 
I/σ(I)a 10.0 (1.6) 9.48 (3.1) 11.1 (3.1) 
NCS copies 1 1 2 
Other ions 2 Cl
−
 — 2 Cl− 
Model refinement    
Resolution range (Å) 46.49–2.09 23.58–1.80 34.81–2.00 
No. of reflections 
(working/free) 
18,149/1851 16,580 (1673) 23,526 (2004) 
No. of protein atoms 2308 1283 2596 
No. of water molecules 148 130 132 
No. of CT-MAC atoms — — 222 
Missing residues 1–173, 298 (CdiA) None 1, 168, 169 
 1–2 (CdiI)   
Rwork/Rfree
c
 (%) 20.5/25.6 18.1/22.1 18.4/23.1 
rmsd    
 Bond lengths (Å) 0.003 0.007 0.009 
 Bond angles (°) 0.694 0.998 1.222 
Ramachandran plot    
 Most favorable region (%) 95.25 98.77 97.13 
 Additional allowed region 
(%) 
4.75 1.23 2.87 
 Disallowed region 0 0 0 
PDB code 4ZQU 4ZQV 4ZQW 
Rfree was computed identically except where all reflections belong to a test set of 10% randomly selected data. 
a.  Statistics for the highest-resolution shell are given in brackets. 
b.  Rmerge = ∑|I − 〈I〉|/∑〈I〉. 
c.  Rwork = ∑|Fo − Fc|/∑ Fo.  
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Table 2.  Dissociation constants (μM) of CdiA-CT and CdiI interactions determined 
using biolayer interferometry. 
 
 CdiA-CTo11
EC869
 
CdiA-
CTo11
EC869/Ykris
 
CdiA-CTo11
EC869/Nlact
 
CdiIo11
EC869
 0.018 ± 0.007 46 ± 36 0.18 ± 0.10 
CdiI
Ykris
 5.0 ± 0.4 24 ± 14 5.8 ± 3 
CdiI
Nlact
 82 ± 18 3.2 ± 2 0.17 ± 0.09 
 
 
Table 3. Direct hydrogen bonds and ion pairs between CdiA-CT/CdiI toxin/immunity 
proteins. 
 
 
CdiA-CT toxin
 
CdiI immunity Distance (Å) 
EC869o11    
Main-Side 
 
 
Side-Side 
 
 
 
 
 
 
 
Lys242 NZ 
Arg249 NH2 
Glu250 O 
Asp187 OD2 
Lys242 NZ 
Tyr244 OH 
Glu243 OE1 
Glu243 OE2 
Glu243 OE2 
Glu243 OE2 
Ser247 OG 
Glu250 OE1 
Glu250 OE2 
Glu250 OE2 
Glu250 OE2 
Glu250 OE1 
Ile137 O 
Phe75 O 
Thr31 OG1 
Arg71 NE 
Asn138 OD1 
Lys128 NZ 
Arg122 NE 
Arg122 NE 
Lys109 NZ 
Arg122 NH2 
Glu130 OE1 
Arg122 NH2 
Arg122 NH2 
Thr31 OG1 
Asn12 ND2 
Lys109 NZ 
2.73 
2.72 
3.65 
2.82 
3.90 
3.99 
3.15 
3.70 
3.33 
3.10 
3.36 
3.18 
3.39 
3.82 
3.08 
3.12 
YPIII    
Main-Side 
 
 
Thr250 O 
Lys243 NZ 
Glu242 OE2 
Asn30 ND2 
Pro133 O 
Leu147 N 
3.89 
2.85 
3.72 
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Side-Side 
Ala203 O 
Thr204 O 
Thr204 O 
Met255 O 
Lys243 NZ 
Lys195 NZ 
Lys195 NZ 
Arg202 NH1 
Lys243 NZ 
Asp201 OD1 
Asp201 OD2 
Arg28 NE 
Arg28 NE 
Arg28 NH2 
Arg28 NH1 
Ser132 OG 
Glu137 OE1 
Glu137 OE2 
Ser29 OG 
Asp121 OD2 
Arg69 NH1 
Arg69 NH2 
2.92 
3.43 
3.43 
2.79 
2.55 
2.68 
3.01 
2.99 
3.05 
2.71 
3.09 
 
 
Table 4. Bacterial strains and plasmids.   
 
Strain or 
plasmid 
Description
a
 Reference or 
source 
Strains   
BL21-
Gold(DE3) 
E. coli B F
–
 ompT hsdS(rB
–
 mB
–
) dcm
+
 gal λ(DE3) 
endA, Tet
R
 
Agilent 
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, 
leu)7697 galU galK λ– rpsL nupG, StrR 
Epicentre 
EPI100 pir
+
 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, 
leu)7697 galU galK λ– rpsL nupG pir+(DHFR), StrR 
Tp
R
 
Epicentre 
X90 
F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) rifr 
thi-1, Rif
R
  
(377) 
DY378 W3110 λcI857 ∆(cro-bioA) (378) 
DA28100 galK::sYFP2opt-cat 
Dan 
Andersson 
CH2016 X90 (DE3) ∆rna ∆slyD::kan, RifR KanR (379) 
CH2550 EPI1100 galK::sYFP2opt-kan This study 
CH2567 MC4100 mKate::cam Str
R
 Cm
R
 This study 
CH8251 MC4100 rif
r
, Str
R
 Rif
R
 (177) 
Plasmids 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 
GE 
Healthcare 
pTrc99KX Derivative of pTrc99A that contains KpnI restriction (380) 
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site immediately downstream of the ribosome-binding 
site, Amp
R
 
pCH450 
pACYC184 derivative with E. coli araBAD promoter 
for arabinose-inducible expression, Tet
R
 
(381) 
pSIM6 
Heat-inducible expression of the phage λ Red 
recombinase proteins, Amp
R
 
(291) 
pET21S 
pET21d derivative with SpeI restriction site for in-
frame fusion to His6 coding sequences, Amp
R
 
(176) 
pDE1013 pEndy1013-mKate2::cat (369) 
pNAK 
pBluescript derivative with FRT-flanked kanamycin-
resistance cassette, Amp
R
 Kan
R
 
This study 
pDAL878 
Constitutive expression of cdiA
EC93
-(∆CT), in which 
the toxin-encoding sequence has been deleted, Cm
R
 
(176) 
pCH10164 
Constitutive expression of chimeric cdiA
EC93
-
CT(D198A)o11
EC869
 and cdiI o11
EC869
. The Asp198Ala 
mutation inactivates the DNase domain. Cm
R
 
(177) 
pCH848 pTrc99KX::cdiI
YPIII
, Amp
R
 This study 
pCH2409 
Constitutive expression of chimeric cdiA
EC93
-CT
YPIII
 
and cdiI
YPIII
 genes, Cm
R
 
This study 
pCH2500 pNAK::galM´, Amp
R
 Kan
R
 This study 
pCH2503 pNAK::galT´-yfp-galM´, Amp
R
 Kan
R
 This study 
pCH9305 
Constitutive expression of chimeric cdiA
EC93
-CTo11
EC869
 
and cdiIo11
EC869
 genes, Cm
R
 
(177) 
pCH9315 pTrc99A::cdiIo11
EC869
, Amp
R
 (177) 
pCH9938 
pUC57::NEILACOT_05636 encoding CdiI
Nlact
 from 
Neisseria lactamica ATCC 23970, Amp
R
 
This study 
pCH9940 
pUC57::Ykris_10749 encoding CdiI
Ykris
 from Yersinia 
pseudotuberculosis ATCC 33638, Amp
R
 
This study 
pCH10101 pCH450::NEILACOT_05636, Tet
R
 This study 
pCH10103 pTrc99KX::Ykris_10749, Amp
R
 This study 
pCH10163 
Cosmid pCdiA-CT/pheS* that carries a kan-pheS* 
cassette in place of the E. coli EC93 cdiA-CT/cdiI 
coding sequence. Used for allelic exchange and 
counter-selection. Cm
R
 Kan
R
 
(177) 
pCH10170 
pET21-derivative that expresses CdiI
Ykris
-His6 from Y. 
kristensenii ATCC 33638, Amp
R
 
This study 
pCH10172 
pET21-derivative that expresses CdiI
Nlact
-His6 N. 
lactamica ATCC 23970, Amp
R
 
This study 
pCH10175 
pET21-derivative that expresses CdiA-
CT(D198A)o11
EC869
 containing the β4/β5 hairpin from 
CdiA-CT
Ykris
, Amp
R
 
This study 
pCH10365 
pET21-derivative that expresses CdiA-
CT(D198A)o11
EC869
 containing the β4/β5 hairpin from 
CdiA-CT
Nlact
, Amp
R
  
This study 
pCH10367 
pET21-derivative that expresses CdiI
YPIII
-His6 from  
from Y. pseudotuberculosis YPIII, Amp
R
 
This study 
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pCH10369 
pET21-derivative that expresses CdiA-CTo11
EC869/Δβ4β5
 
lacking the β4/β5 hairpin, AmpR 
This study 
pCH10407 
pET21-derivative that expresses CdiA-CT/CdiIo11
EC869
-
His6 complex from E. coli EC869, Amp
R
 
(177) 
pCH10413 
pET21-derivative that expresses CdiA-CT/CdiI
YPIII
-
His6 complex from Y. pseudotuberculosis YPIII, Amp
R
 
This study 
a
Abbreviations: Amp
R
, ampicillin-resistant; Cm
R
, chloramphenicol-resistant; Kan
R
, kanamycin-resistance; Rif
R
, 
rifampicin-resistant; Tet
R
, tetracycline-resistant; Tp
R
, trimethoprim-resistant 
 
Table 5. Oligonucleotides used in this study. 
 
Oligonucleotide Sequence Reference 
Kan-1 (CH106) 5´ -  TGT GTA GGC TGG AGC TGC TTC (367) 
Kan-2 (CH107) 5´ - CAT ATG AAT ATC CTC CTT AGT TCC (367) 
galM-Bam-for 
(CH3789) 
5´ - CGC GGA TCC CGG AAG AGC TGG This study 
galM-Sac-rev 
(CH3790) 
5´ - TCT GAG CTC AGG GCA AAC AGC ACC This study 
galT-Kpn-for 
(CH3787) 
5´ - CAC GGT ACC ATT TGG GCA AAT AGC TTC C This study 
yfp-Eco-rev 
(CH3788) 
5´ - CT GAA TTC GCG GCC GCT TCT AGA This study 
YPK0575-Kpn-
for 
(CH2447) 
5´ - TTT GGT ACC ATG GTA GAG AAT AAT TAT 
CTA AAC TCC 
This study 
YPK0576-Xho-
rev  
(CH2448) 
5´ - TTC CTC GAG ACC TTT ACA GCG ACT CAA 
TGC CAG 
This study 
YPK0576-Kpn-
for  
(CH2449) 
5´ - TGA GGT ACC ATG AAC GAT ATA GTA AAA 
AG 
This study 
YPK0576-Xho-
rev2 (CH2790) 
5´ - TTT CTC GAG TTA ACC TTT ACA GCG This study 
Nlact-cdiI-Spe-
rev 
(CH2345) 
5´ - AAA ACT AGT CTT ACA ATA ACT TAG This study 
Ykris-cdiI-Spe-
rev 
(CH2346) 
5´ - AAA ACT AGT GCC TTT ACA GCG GC This study 
Trc-seq2 
(CH823) 
5´ - GTT CTG GCA AAT ATT CTG AAA TGA GC This study 
ara seq (CH943) 
5´ - GAT TAG CGG ATC CTA CCT GAC GCT TTT 
TAT CGC 
This study 
β-deletion-for1 
5´ - GCC CAA TGG GCA CAA ACC AGT CTC TGA 
CCT TCG AT 
This study 
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β-deletion-rev1 
5´ - GCG GAT CCG CTT TTA AAC TTA GCC GCA 
GCA TCG ATG 
This study 
β-deletion-for2 
5´ - GCG GAT CCG GCA CTT CAT CAA TGA TCT 
CTA ACA GGG 
This study 
β-deletion-rev2 
5´ - GCC TCG AGA CTA GTA CCT TTG CAG CGA 
CTC AAG 
This study 
EC869-CT-Nco 
5´ - ATT CCA TGG GCA CAA ACC AGT CTC TGA 
CCT TCG 
(177) 
EC869-cdiI-Spe 
5´ - TCT ACT AGT ACC TTT GCA GCG ACT CAA 
GGC CAG 
(177) 
EC869-
Nlact(beta)-for 
(CH2341) 
5´ - AAA ACT TAC TCT CTT TCT GGT GTT GAG 
TTA ACT TCA TCA ATG ATC TC 
This study 
EC869-
Nlact(beta)-rev 
(CH2342) 
5´ - CTC AAC ACC AGA AAG AGA GTA AGT TTT 
AAA CTT AGC CGC AGC ATC G 
This study 
EC869-
Ykris(beta)-for 
(CH2343) 
5´ - CAT ACA CAT ACT CTT TCA GGC GAA CAG 
TTA ACT TCA TCA ATG ATC TC 
This study 
EC869-
Ykris(beta)-rev 
(CH2344) 
5´ - CTG TTC GCC TGA AAG AGT ATG TGT ATG 
AAA CTT AGC CGC AGC ATC G 
This study 
DL1527 
(CDI204) 
5´ - GAA CAT CCT GGC ATG AGC G (177) 
EC869o11-G173-
rev (CH3640) 
5´ - CCC AAC ATA ATC CTC CCA CGG CAT ACC This study 
EC869o11-G173-
for (CH3641) 
5´ - GGT ATG CCG TGG GAG GAT TAT GTT GGG  This study 
EC93-YPIII-
chim-rev 
(CH2689) 
5´ - GGT CTG GTG TCT AAC CTT TGG GTT AAC 
CTT TAC AGC GAC TCA ATG C 
This study 
EC93-YPIII-
down-for 
(CH2690) 
5´ - GCA TTG AGT CGC TGT AAA GGT TAA CCC 
AAA GGT TAG ACA CCA GAC C 
This study 
DL2368 
(CDI205) 
5´ - GTT GGT AGT GGT GGT GCT G (177) 
Restriction enzyme sites are underlined. 
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VI. EF-Tu is a general co-factor required for inhibition by a subset of 
contact-dependent inhibition systems from Gram-negative bacteria 
This work was done in collaboration with Argonne National Laboratory (Darien, Illinois) 
as well as with Allison Jones, Fernando Garza-Sánchez, Grant Gucinski, and David Low 
(University of California, Santa Barbara). 
A. Background 
CdiA-CT domains inhibit target cells by disrupting essential cellular components such as 
RNA and DNA or destroying the integrity of the inner membrane.  Many CdiA-CTs function 
independently and do not require other protein cofactors for activity, the need for which can 
be assessed by performing in vitro activity assays with purified proteins and substrates.  If a 
CdiA-CT is toxic in co-culture assays or when expressed intracellularly but not in vitro, then 
a cofactor may be required.  This approach was used to identify the cofactor required by 
CdiA-CT
Ec536
, which has tRNase activity inside cells but not when purified and added to total 
RNA in vitro.  Further investigation revealed a role for CysK, which is a biosynthetic 
enzyme that catalyzes the second step in the conversion of serine to cysteine during cysteine 
biosynthesis (214, 215, 217).  CdiA-CT
Ec536
 physically interacts with CysK, and this 
interaction is required for tRNase activity both in vitro and in vivo.  The C-terminal 4 
residues (GYGI) of CdiA-CT
Ec536
 interact with CysK in a manner that mimics the interaction 
between CysK and the tail of its cofactor CysE (220).  This complex forms a heterotrimer 
with CdiI
Ec536
 and crystallizes as a dimer of heterotrimers (Robert Morse, Christina Beck, 
Christopher Hayes, and Celia Goulding, unpublished data).   
That the CysK/CdiA-CT
Ec536
 interaction so closely mimics a biosynthetic interaction with 
physiological relevance outside of CDI suggests evolution of CdiA-CT
Ec536
 to “hijack” the 
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structure of CysK, although the exact contribution of CysK in positioning CdiA-CT
Ec536
 in an 
optimal position to cleave tRNA subtrates has yet to be revealed.  Given the diversity of CDI 
toxins across Gram-negative bacteria, we wondered whether other CdiA-CT families require 
protein cofactors for inhibition or whether this is a unique trait of CdiA-CT
Ec536
.  Using both 
biochemical and genetic approaches, we have discovered a role for the translation factor EF-
Tu in the activity of CdiA-CT from different families and species.. 
B. Results 
1. Transposon mutagenesis fails to reveal cofactors required for activity of three 
CdiA-CTs from E. coli EC869 
We constructed cosmids in which the CdiA-CT from EC93 was replaced with the main 
CdiA-CT/CdiI sequence or orphan CdiA-CT/CdiI modules (EC869o5 and EC869o10) from E. 
coli EC869 at the conserved VENN tetrapeptide motif.  These peptides encode functional 
toxins, and inhibition can be blocked by expression of the cognate immunity (Figure 1A).  
We then performed transposon mutagenesis experiments in which a library of mariner-
mutagenized E. coli targets were co-cultured with strains expressing each CDI
+
 cosmid.  
Surviving cells were selected and mixed with a fresh inhibitor culture; this process was 
repeated iteratively to enrich for the presence of CDI-resistant target cells.  At the end of 
three rounds of enrichment, no increase in resistance was observed in target cells co-cultured 
with CDIo5
EC869
 or CDIo10
EC869
 (data not shown).  The target cells co-cultured with CDI
EC869
 
showed an increase in resistance, although the pool did not become completely resistant.  We 
note that the colony morphology of surviving cells was markedly different than the input 
population, indicating some upregulation of capsule production (data not shown).   
Two colonies (CT1-3 and CT1-7) isolated from this enrichment process were isolated, 
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and the kanamycin resistance marker linked to the mariner transposon was moved into a 
fresh CDI
S
 background using P1 phage transduction.  Transductants were co-cultured with 
CDI
EC869
 cells to test for genetic linkage of the CDI
R
 phenotype.  When tested as individual 
monocultures, the transposon isolates showed a partial CDI
R
 phenotype compared to wild-
type cells (Figure 1B).  Each transductant showed the same level of partial resistance (Figure 
1B, labels marked “x” to indicate transductant as opposed to original mutant).  We identified 
the location of the CT1-3 and CT1-7 transposons using arbitrary PCR to amplify the 
transposon/genomic DNA junction.  CT1-3 contained a transposon in uhpB, and the 
transposon in CT1-7 was determined to be upstream of the open reading frame for uvrY.  
UhpB is part of the UhpABC system that regulates the expression of UhpT, a sugar-
phosphate transporter and can sense and transport glucose-6-phosphate into the cell (342, 
382).  UvrY is part of a two-component system with BarA that is involved in growth 
adaptation to different carbon sources (383, 384).  This two-component system also regulates 
the non-coding RNAs CsrA and CsrB, which ultimately control a suite of activities including 
metabolism, biofilm formation, flagella, and virulence of some uropathogenic E. coli strains 
(385-388).  We reasoned that these membrane complexes might serve as transporters for 
CdiA-CT
EC869
 during delivery, so we constructed single-gene knockouts of uhpB, uvrY, and 
associated genes from their respective operons and pathways.  These strains were used as 
target cells in co-culture assays with CDI
EC869
.  As indicated by the cell viability counts, none 
of the clean deletion strains were tested showed significant resistance to CDI
EC869
 (Figure 
1C).  Therefore, none of these proteins are bonafide members of the CDI
EC869
 pathway, and it 
is likely that compounding factors from the transposon mutagenesis experiments influenced 
the resistance of these cells. 
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2. Mutations in tsf confer resistance to CdiA-CTEc869 
Subsequent enrichment experiments were performed using UV-mutagenized target pools, 
which yielded a CDI
Ec869
-resistant strain with a mutation in tsf at codon 202, changing a 
small, uncharged alanine residue to a bulky, negatively-charged glutamic acid (Allison Jones 
and David Low, unpublished data).  tsf encodes elongation factor EF-Ts, which is a guanine-
nucleotide exchange factor (GEF) involved in the translation cycle in which EF-Tu delivers 
aminoacyl-tRNAs (aa-tRNAs) to the ribosome (389).  During translation, a ternary complex 
of GTP, EF-Tu, and aa-tRNA docks with the A site of the ribosome.  Codon recognition 
leads to GTP hydrolysis, and the resulting GDP:EF-Tu complex is released.  In order to 
complete another cycle of aa-tRNA delivery, EF-Tu must be recharged with GTP; release of 
GDP is facilitated by the GEF activity of EF-Ts (389-391).  EF-Tu then associates with GTP 
and can form another ternary complex.   
Bacterial EF-Ts contains four domains:  an N-terminal domain, the core domain, a 
dimerization domain that contains a coiled-coil motif, and a C-terminal domain (390, 392, 
393).  The coiled-coil motif, in which the CDI-resistant Ala202Glu mutation was identified, 
mediates dimerization between EF-Tu:EF-Ts complexes in the crystal structure, but the 
physiological relevance of this tetramer is unclear (393).  While the coiled-coil domain is 
conserved throughout bacteria and chloroplasts, it is noticeably absent from mammalian EF-
Ts proteins (392).  This suggests that this motif plays some essential albeit unknown role in 
prokaryotic translation. While the coiled-coil domain is not essential for cell viability or GEF 
activity of EF-Ts, activity is reduced in a coiled-coil deletion mutant (390, 392).  Mutants 
lacking the coiled-coil motif also display a growth defect when rapidly dividing, but not at 
lower growth rates (392).  This is most likely due to the decreased GEF activity and a 
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subsequent reduction of EF-Tu turnover, which results in slower than maximal growth.  Cells 
lacking the entire coiled-coil domain are also resistant to inhibition by CDI
Ec869 
(Allison 
Jones and David Low, unpublished data).   
Binding data using purified CdiA-CT
Ec869
 revealed that this toxin tightly interacts with 
EF-Tu but not EF-Ts in vitro (Fernando Garza-Sanchez, Allison Jones, Christopher Hayes, 
and David Low, unpublished data).  The EF-Ts Ala202Glu and Δcoiled-coil mutants are also 
resistant to inhibition by CdiA-CT
NC101
 and CdiA-CT
96.154
, two other toxins from E. coli 
strains (Allison Jones and David Low, unpublished data).  Taken together, this suggests that 
a genetic or biochemical interaction with EF-Tu, EF-Ts, or translation machinery may be a 
general feature of some classes of CDI toxins.  To further investigate this hypothesis, we 
used a combination of genetic and biochemical approaches to identify additional CdiA-CTs 
that interact with EF-Tu and EF-Ts. 
3. CdiA-CTKp342 has a genetic interaction with tsf but does not interact with EF-Tu 
or EF-Ts in vitro 
Given the magnitude of distinct CdiA-CT families in E. coli alone (170), we wondered 
whether additional CdiA-CTs had a genetic requirement for tsf.  We employed a co-culture 
assay to rapidly identify additional CdiA-CTs unable to inhibit tsf mutants (Table 1).  
Individual CdiA-CT/CdiI modules were fused to the CdiA core from E. coli EC93; these 
constructs retained identical receptor-binding domains.  To facilitate data interpretation, we 
calculated the fold inhibition of tsf Ala202Glu and Δcoiled-coil strains relative to wild-type 
E. coli targets and color-coded each value (Figure 3A).  As predicted, CdiA-CT
NC101
 and 
CdiA-CT
EC869
 did not inhibit tsf mutants.  Well-characterized nuclease toxins such as CdiA-
CT
Dda3937
 and a homolog of CdiA-CT
Ec536
 were used as negative controls, and both were able 
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to inhibit all target strains, regardless of tsf allele (Figure 3A).  CdiA-CT
Dda3937
 is a CDI toxin 
from Dickeya dadantii 3937 that degrades DNA (194), and CdiA-CT
Ec536
 is a general tRNase 
that requires CysK for activity (193).  From this screen, we found that CdiA-CT
Kp342
, a toxin 
from Klebsiella pneumonia 342, was able to inhibit wild-type cells but not tsf mutants.  The 
EF-Ts and Δcoiled-coil strains had approximately 100-fold higher cell viability than wild-
type E. coli targets when co-cultured with the CDI
Kp342
 inhibitor strain.  Interestingly, none 
of the toxins that have a genetic connection to tsf are closely related to each other, as 
determined by pairwise sequence comparisons (Figure 3B). 
Because CdiA-CT
Kp342
 shares a genetic interaction with CdiA-CT
Ec869
, we next wished to 
determine whether this similarity extends to the biochemical relationship between CdiA-
CT
Ec869
, EF-Tu, and EF-Ts.  We first asked whether EF-Tu or EF-Ts co-purified with CdiA-
CT
Kp342
 when the toxin was overexpressed inside E. coli cells.  Using a CdiA-CT/CdiI
Kp342
-
His6 overexpression construct, we trapped CdiI
Kp342
-His6 using Ni-NTA beads and used 
denaturing washes to elute CdiA-CT
Kp342
 along with any proteins that might be bound to the 
CdiA-CT/CdiI-His6 complex.  A single band migrating at approximately 28 kDa on an SDS-
PAGE gel was detected using this procedure (Figure 3A); this corresponds to the predicted 
size of CdiA-CT
Kp342
.  This species was the sole protein detected, and no additional proteins 
corresponding to EF-Tu or EF-Ts were observed. 
The CdiA-CT
Kp342
 variant used in this experiment was expressed and purified in complex 
with a tagged form of CdiI
Kp342
 using nickel agarose beads.  If EF-Tu or EF-Ts interact with 
this toxin, it is possible that the location of this His6 tag could interfere with co-factor 
binding.  Alternatively, the presence of the immunity protein bound to CdiA-CT
Kp342
 could 
occlude a co-factor binding site, preventing detection of this interaction.  Therefore, we asked 
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whether CdiA-CT
Kp342
 interacts with EF-Tu in vitro in the absence of the immunity protein.  
Untagged and His-tagged variants of CdiA-CT
Kp342
 were overexpressed, purified, and mixed 
with either untagged or His6-tagged EF-Tu or EF-Ts, then added to Ni-NTA beads.  
Fractions were collected and analyzed via SDS-PAGE and Coomassie staining.  No 
interactions between CdiA-CT
Kp342
 and EF-Tu were observed under any of the conditions 
tested.  Furthermore, His-tagged CdiA-CT
Kp342
 constructs did not pull down any proteins 
when added to an E. coli S30 lysate (Figure 3B).  CdiA-CT
Kp342
 is able to bind purified 
CdiI
Kp342
 in vitro, indicating that this toxin refolds correctly undergoing denaturation during 
the purification process (Figure 3B). 
4. EF-Ts regulates intracellular activity, not translocation of CdiA-CTs 
An overarching goal of studying CDI cofactors is to understand how they influence 
CdiA-CT activity.  Delivery of nuclease CdiA-CTs into target cells encompasses three basic 
steps:  1) recognition and binding of CdiA at the outer membrane, 2) translocation across the 
outer membrane, periplasm, and inner membrane into the cytoplasm, and 3) carrying out 
toxic function upon reaching the cytoplasm (157, 167, 173, 193, 194).  Therefore, mutations 
in tsf could theoretically influence any of these steps.  One could imagine a scenario in which 
mutations in tsf affect the translation of multiple proteins, and that these proteins are involved 
in different steps of the CDI pathway for given CdiA-CTs.  Because CdiA-CT
EC869
 and 
CdiA-CT
Kp342
 both genetically interact with tsf but have different biochemical interactions 
with EF-Tu, the step in CDI affected by tsf mutations is not necessarily the same for all 
toxins.   
We first considered whether tsf mutations could affect the first step in CDI delivery, 
which is binding an outer membrane receptor at the target cell surface.  All CDI
 
chimeras 
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constructed in this study were made by replacing the native EC93 CdiA-CT at the VENN 
tetrapeptide with the CdiA-CT/CdiI sequence of choice.  Therefore, the receptor-binding 
domain of CdiA, which lies in the middle of the primary sequence, is unchanged in all 
constructs.  CdiA truncations containing the receptor-binding domain but lacking any CdiA-
CT sequence still bind to target cells (225), indicating that this event is functionally separate 
from toxin translocation.  As such, it is unlikely that tsf mutations would disrupt receptor 
recognition given that this occurs in a toxin-independent manner.  We therefore presume that 
this first step in CDI is not disrupted by tsf mutations. 
Next, we considered that the translocation step across the periplasm and inner membrane 
may be affected by tsf mutations.  As discussed in Chapter 2, we have recently shown that 
the N-terminal domain of CdiA-CTs dictates the specific inner membrane protein required 
for delivery into target cells.  Because EF-Ts is essential for translation of proteins, it is 
possible that mutations in tsf affect translation rates, and that this could differentially impact 
IMP synthesis.  In turn, this could alter the levels of IMPs acting as receptors for CdiA-CT 
toxins, and decreased levels of specific IMPs required for CdiA-CT import could result in 
increased resistance against particular toxins.  To probe whether this hypothesis is feasible, 
we performed sequence analysis on the CdiA-CTs that interact either genetically or 
biochemically with EF-Tu and EF-Ts to identify any underlying homology that may be 
responsible for these co-factor requirements.  We compared the N-terminal domains from the 
set of CdiA-CTs that require wild-type tsf for inhibition of target cells and found that they 
have little to no sequence conservation (Figure 4A).  In general, CdiA-CT sequences are 
bipartite, and N-terminal domains sort independently from C-terminal domains (167, 173, 
176).  We next looked for tsf-independent CdiA-CTs that share an N-terminal domain but not 
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a C-terminal domain with tsf-dependent CdiA-CTs, reasoning that these related toxins would 
be translocated via the same pathway (based on N-terminal domain similarity) but would 
have different cytotoxic activities (as dictated by the C-terminal domain).  Therefore, if tsf 
mutations disrupted translocation, both toxins with a shared N-terminal domain would be 
affected.  If tsf mutations affected activity, then N-terminal domain homology would not be 
important, and toxins with different C-terminal domains would differentially inhibit tsf cells.  
We chose to use CdiA-CT
Kp342
, which was identified from our co-culture competition screen, 
and CdiA-CT
NC101
, which was previously found to require wild-type tsf for inhibition 
(Allison Jones and David Low, unpublished data).  
The N-terminal domain of CdiA-CT
NC101
 is similar to that of a toxin from Dickeya zeae 
(CdiA-CT
Dzeae
), and the N-terminal domain of CdiA-CT
Kp342
 is similar to the same region of 
a CdiA-CT from Yersinia kristensenii 33638 (CdiA-CT
Yk33638
) (Figure 4B and C).  The C-
terminal activity domains of each toxin are distinct regardless of N-terminal domain 
homology.  We compared inhibition data from each toxin against the same set of wild-type 
and tsf cells previously used to identify CdiA-CT
Kp342
.  While CdiA-CT
NC101
 and CdiA-
CT
Kp342
 inhibit wild-type but not tsf cells, both N-terminal domain partners inhibit all tested 
genotypes regardless of tsf allele (Figure 4D and E).  This suggests that tsf mutations do not 
disrupt translocation of these toxins, or inhibition would be linked to N-terminal domain 
identity.  Therefore, it is likely that EF-Ts is directly involved in modulating the activity of 
these CdiA-CT domains once delivered to the cytoplasm. 
If EF-Ts is required for intracellular activity, then toxin molecules directly produced in 
the cytoplasm (as opposed to delivered from a CDI
+
 inhibitor cell) should also be inactive in 
tsf mutant backgrounds.  Conversely, if tsf mutations produce a defect in translocation but do 
218 
 
not affect CdiA-CT activity, cells expressing mutant EF-Ts should still be sensitive to 
internally-produced toxin.  Delivery of CdiA-CTs into a separate target cells can be bypassed 
using an intracellular expression system.  To test whether wild-type tsf is needed for 
intracellular activity, we cloned CdiA-CT/CdiI
NC101
 into a controllable degradation system in 
which the immunity protein is linked to an ssrA(DAS) tag that is degraded by the ClpXP 
protease (268).  We transformed this construct into wild-type cells and cells expressing the 
EF-Ts Ala202Glu and Δcoiled-coil variants along with an empty plasmid vector or a plasmid 
expressing untagged CdiI
NC101
 (Figure 5A) and monitored the growth of these strains by 
measuring OD600 values over time (Figure 5B).  Expression of CdiA-CT
NC101
 inhibits cells, 
and inhibition is blocked by co-expression of the immunity protein.  Cells with mutated tsf 
alleles are resistant to internal expression of CdiA-CT
NC101
, indicating that EF-Ts is required 
for the proper intracellular function of this toxin. 
5. CdiA-CTO32:H37 co-purifies with EF-Tu 
Thus far, we have identified several CdiA-CTs that interact with translation machinery in 
different ways.  CdiA-CT
Ec869
 requires wild-type tsf to inhibit target cells and interacts with 
EF-Tu in vitro.  CdiA-CT
NC101
 and CdiA-CT
96.154
 both require wild-type tsf to inhibit cell 
growth (Allison Jones and David Low, unpublished data).  CdiA-CT
Kp342
 requires wild-type 
tsf for inhibition, but does not interact with EF-Tu or EF-Ts in vitro.  Therefore, we 
wondered whether additional CdiA-CTs physically interact with these co-factors in vitro, and 
whether these cofactors were required for activity via the same mechanism as CdiA-CT
Ec869
.  
As part of an ongoing structure/function collaboration with Argonne National Laboratory 
(Darien, Illinois), we discovered that a CdiA-CT from E. coli O32:H37 co-purified with a 
protein migrating at approximately 43 kDa (Figure 6A and B), which is close to the size of 
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EF-Tu (43.2 kDa).  CdiA-CT
O32:H37
 is the toxin domain (predicted size 15.8 kDa) associated 
with a full-length CdiA protein found in a strain of E. coli associated with diseases in dairy 
cattle (394).  Two of these bands correspond to the predicted gel mobility of CdiA-CT
O32:H37
 
and CdiI
O32:H37
.  The third band is present at an equimolar amount to CdiA-CT
O32:H37
 and 
CdiI
O32:H37
 and has an apparent size of approximately 43 kDa (Figure 6A).  This protein and 
CdiA-CT
O32:H37
 co-elute under denaturing conditions (Figure 6B), suggesting that it interacts 
with either CdiA-CT
O32:H37
 or CdiI
O32:H37
.  Based on size, abundance, and previously-
characterized interactions between CdiA-CTs and translation machinery, we surmised that 
the third band that co-purifies with CdiA-CT
O32:H37
 could be EF-Tu. 
To ascertain whether the EF-Tu is required for activity of CdiA-CT
O32:H37
 in the same 
manner as CdiA-CT
Ec869
, we first determined the activity of CdiA-CT
O32:H37
 inside cells.  
CdiA-CT
O32:H37
 was fused to the structural domain of CdiA
EC93
, and cells expressing the 
resulting CDI
+
 cosmid were mixed with targets carrying either an empty plasmid vector or 
cdiI
O32:H37
.  After 1 h of co-culture, target cells lacking the immunity were inhibited 
approximately 100-fold, while cells expressing CdiI
O32:H37
 did not lose viability (Figure 7A).  
Mutation of a conserved histidine residue to an alanine (His71Ala) ablated toxicity of target 
cells.  We examined RNA from these co-cultures and looked for evidence of degradation 
using Northern blot probes to tRNA and rRNA species.  RNA cleavage products were 
detected using probes that recognize tRNA2
Thr
, tRNA
Gln
, and tRNA2
Arg
, as well as a probe for 
23S ribosomal RNA (Figure 7B).  This activity was blocked by expression of CdiI
O32:H37
. 
We next purified the CdiA-CT
O32:H37
/EF-Tu complex to examine in vitro activity of this 
toxin.  We mixed either 100 nM or 1 µM of this complex with total guanidine isothiocyanate-
extracted cellular RNA and examined the reactions using ethidium bromide staining and 
220 
 
Northern blots to observe degradation products.  This purified complex was able to degrade 
RNA in vitro, as evidenced by the degradation of high molecular weight bands corresponding 
to 23S and 16S ribosomal RNA as well as the appearance of additional degraded RNA 
species (Figure 7C, top panel).  In vitro activity against tRNA
Gln
 is also evident in the 
Northern blot analysis (Figure 7C, bottom panel).  The inactive CdiA-CT
O32:H37
 H71A/EF-Tu 
complex did not have in vitro activity against RNA.  Interestingly, although CdiA-CT
Ec869
 
requires EF-Ts for complete cleavage of substrates in vitro, the activity of the re-folded EF-
Tu/ CdiA-CT
O32:H37
 complex was not enhanced by the addition of EF-Ts (Figure 7C, top 
panel, compare middle two lanes to two lanes on the right).  This suggests that if EF-Tu is 
required, CdiA-CT
O32:H37
 may utilize this cofactor in a mechanistically-distinct way as 
compared to CdiA-CT
EC869
.  Additional work on separating CdiA-CT
O32:H37
 from EF-Tu to 
further elucidate the activity of this toxin is ongoing. 
Both CdiA-CT
Ec869
 and CdiA-CT
O32:H37
 interact with EF-Tu in some capacity, but appear 
to do so in different ways.  Therefore, we wished to determine whether CdiA-CT
O32:H37
 had 
the same genetic interaction with tsf as CdiA-CT
Ec869
.  We mixed cells expressing CDI
O32:H37
 
with wild-type target cells as well as cells expressing the EF-Ts Ala202Glu and Δcoiled-coil 
mutations and measured viability of target cells after 3 h of co-culture.  All target strains 
were inhibited approximately 100-fold, indicating that CdiA-CT
O32:H37
 does not require EF-
Ts the same way as CdiA-CT
Ec869
 in vivo or in vitro (Figure 8).  The same target cell lines 
were also co-cultured with CDI
Ec869
 as a positive control, and CDIo11
EC869
 (a DNase that does 
not require tsf for in vitro or in vivo activity (177, 202)) was included as a negative control.  
As expected, target cells with tsf mutations were resistant to inhibition by CDI
Ec869
 and were 
inhibited to wild-type levels by CDIo11
EC869
 (Figure 8). 
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6. CdiA-CTO32:H37 does not interact with EF-Tu or EF-Ts in vitro 
CdiA-CT
Ec869
 interacts with EF-Tu when mixed together in vitro as purified components.  
Therefore, we wished to determine whether the CdiA-CT
O32:H37
/EF-Tu complex could be 
reconstituted outside of cells.  We purified an untagged inactive CdiA-CT
O32:H37
 His178Ala 
mutant and mixed it with purified EF-Tu carrying an N-terminal His6-TrxA fusion.  CdiA-
CT
O32:H37
 eluted in the unbound fraction (Figure 9A), indicating that this protein was not 
bound to EF-Tu in vitro.  We then repeated these experiments in a variety of reaction 
conditions including Tris and sodium phosphate buffers, varying concentrations of salts, and 
in the presence of whole-cell lysates to determine whether a molecule like Mg
2+
 or RNA was 
required for binding (Figure 9).  However, we were unable to recapitulate the complex 
purified from intact cells.  We next tried using fusion proteins with different N- or C-terminal 
tags to decrease the probability that binding was blocked due to steric hindrance from the 
location of the His6/His6-TrxA epitope (Figure 9B, C, and D).  Again, the CdiA-
CT
O32:H37
/EF-Tu complex could not be formed under any in vitro conditions. 
We then considered the differences in experimental conditions that could lead to 
purification of a complex from whole cells but an inability to reconstitute this complex in 
vitro.  One possibility is that the native complex includes CdiA-CT
O32:H37
 and EF-Tu in 
addition to CdiI
O32:H37
, as the initial CdiA-CT
O32:H37
/EF-Tu complex was isolated from cells 
expressing both CdiA-CT
O32:H37
 and CdiI
O32:H37
-His6.  To test this, we purified all three 
proteins and repeated in vitro binding assays (Figure 10).  We first showed that a stable 
complex forms between CdiA-CT
O32:H37
 and CdiI
O32:H37
-His6 in vitro (Figure 10A, left 
lanes), indicating that these proteins are correctly folded after purification.  We then mixed 
these purified proteins with untagged EF-Tu.  All three proteins were present in the bound 
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fraction, indicating that some ternary complex formed (Figure 10A, right lanes).  CdiI
O32:H37
-
His6 does not interact with EF-Tu in the absence of CdiA-CT
O32:H37
 (Figure 10B).   
A second possibility is that EF-Tu plays some role in protein folding during CDI.  The 
current CDI model posits that CdiA-CTs are unfolded during translocation into target cells, 
meaning they must refold in the correct confirmation to carry out activity.  Chaperone 
activities have been described for both eukaryotic and prokaryotic EF-Tu (395-398).  It is 
therefore possible that as CdiA-CT domains translocate across the inner membrane into the 
cytoplasm, an unfolded portion interacts with EF-Tu, facilitating re-folding of the entire 
delivered toxic peptide into an activity-competent conformation.  To test whether EF-Tu acts 
as a chaperone for CdiA-CT
O32:H37
, we purified tagged His10- and His6-TrxA-CdiA-
CT
O32:H37
 constructs under denaturing conditions, ensuring the protein remained unfolded.  
We then mixed these unfolded samples with a concentrated solution of native EF-Tu and 
immediately incubated the protein mixtures in dialysis buffer to permit refolding of 
denatured CdiA- CT
O32:H37
.  After dialysis, we performed a pulldown assay using nickel-
agarose resin to trap the tagged CdiA-CT
O32:H37
 constructs.  After these steps, Ef-Tu was 
detected in the bound fraction of both CdiA-CT
O32:H37
 constructs (Figure 10C and D).  We 
also re-folded an aliquot of these toxin elutions independently (away from EF-Tu) and tested 
them in binding assays after dialysis.  Neither construct pulled down EF-Tu when dialyzed 
separately (Figure 10E).   
Although this suggests that EF-Tu may chaperone the folding of CdiA-CTO32:H37, 
enforcing complex formation between these proteins, we observed similar results when we 
carried out the same experiments with two negative controls.  We performed the same 
dialysis procedure using a tagged variant of CdiA-CT
Ec536
, which does not require EF-Tu as a 
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co-factor and instead uses the cysteine biosynthesis pathway enzyme CysK for activity (193).  
We also included His6-TrxA-CdiA-CTo11
Ec869
, a tagged form of a DNase toxin that does not 
require any additional co-factors for activity (177, 202).  After the co-dialysis and protein 
pulldown steps, some EF-Tu was found in the bound fraction of both negative control 
reactions, indicating that EF-Tu may indiscriminately interact with unfolded proteins (Figure 
10F and G).  This may be exacerbated by the high concentrations of proteins used in these 
assays, and this may mask any differences in binding affinity between EF-Tu and various 
CdiA-CTs. 
C. Discussion 
The data presented here describe CdiA-CTs from E. coli and Klebsiella pneumoniae that 
interact, either genetically or biochemically, with the translation factors EF-Tu and EF-Ts.  
Interestingly, none of these toxins have strong sequence homology to each other in either the 
N-terminal or C-terminal domains (Figure 4A).  Two hypotheses could explain this 
observation.  The first is that perhaps these toxins share common structural motifs that are 
involved in interacting with these co-factors.  We previously published a study showing that 
the E. coli toxin CdiA-CTo11
EC869
 and the Burkholderia pseudomallei toxin CdiA-CTII
1026b
 
have unrelated primary sequences (less than 15% identity) but nearly identical core structures 
(177).  Therefore, it is possible that the CdiA-CTs that interact with EF-Tu and EF-Ts share 
structural homology that is crucial for these interactions but that is simply not definable 
without crystallographic analysis.  Detailed structure-function studies could reveal binding 
domains or motifs that cannot be identified by primary sequence gazing.  A second 
possibility is that these toxins share no common structural or binding features, but that each 
evolved the ability and necessity to interact with EF-Tu or EF-Ts in a unique way.  All of the 
EF-Tu/EF-Ts-dependent toxins with characterized activities have been found to be RNases, 
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and it is interestingly that no known DNase or pore-forming CdiA-CT domains use either of 
these co-factors for activity.  Perhaps this requirement represents a common feature of 
substrate recognition or activity carried out by toxins that interact with translational 
machinery.  An attractive hypothesis, especially for the tRNase toxins, is that interacting with 
components of the translational machinery help position these toxins near their tRNA 
substrates.  This interaction between EF-Tu and the specific CdiA-CTs described here could 
also facilitate substrate recognition, binding, or activity.  Because the canonical role of EF-Tu 
is to bring aminoacylated tRNAs to the ribosome during translation, interacting with EF-Tu 
might simply be a means by which tRNase domains can localize near their targets.  It 
remains to be empirically determined whether EF-Tu/EF-Ts-dependent toxins interact 
preferentially with the aminoacylated tRNA form that would be delivered to the ribosome, 
although in vitro activity assays suggest that purified toxin can cleave charged and uncharged 
substrates. 
CdiA-CT
Kp342
 has a genetic interaction with tsf, but does not interact with EF-Ts or EF-
Tu in vitro.  It is possible that it requires some other cellular co-factor for binding, but this is 
unlikely as binding was tested in whole-cell S30 lysates.  While it is formally possible that 
purification and refolding results in an improperly-folded toxin, this is extremely unlikely 
because CdiA-CT
Kp342
 binds its cognate immunity in vitro.  Furthermore, all CdiA-CTs 
tested thus far have been successfully unfolded and refolded during purification (167, 169, 
174, 175, 202).  An attractive alternate hypothesis is that the lack of in vitro interaction is 
suggestive of the role EF-Ts plays in activity.  The physiological function of EF-Ts is to 
catalyze guanine nucleotide exchange to recycle EF-Tu during delivery of tRNAs to the 
ribosome during translation (389, 391).  While EF-Ts mutants lacking the coiled-coil domain 
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can still catalyze GDP turnover, its ability to do so is decreased (392).  Perhaps the GDP 
turnover activity performed by EF-Ts is essential for the (yet-to-be-determined) activity of 
CdiA-CT
Kp342
.  Disrupting this domain could block activity of this toxin yet not be 
detrimental enough to halt cell growth.  However EF-Ts contributes to the activity of CdiA-
CT
Kp342
, we presume that this role is catalytic and not structural based on the lack of strong in 
vitro interactions.  Another possibility is that EF-Ts and CdiA-CT
Kp342
 do have a specific 
binding interaction, but that this binding is weak and not detectable using a crude bait-prey 
assay approach.  Future work could involve cross-linking experiments or more sensitive 
interaction studies to precisely determine the contribution of EF-Ts to the activity of CdiA-
CT
Kp342
. 
While CdiA-CT
O32:H37
 does not share the genetic tsf interaction with CdiA-CT
Kp342
 and 
CdiA-CT
EC869
, it does co-purify with EF-Tu, thus fitting within the broad classification of 
toxins that interact with EF-Tu or EF-Ts.  These differences may be indicative of different 
mechanisms of action against cellular substrates.  It is interesting to note that the cleavage 
products produced by CdiA-CT
O32:H37
 are not identical to the fragments produced by CdiA-
CT
EC869
 or another CdiA-CT from E. coli NC101 that requires both EF-Tu and EF-Ts for 
activity.  Both of these (EF-Tu)-dependent toxins cleave the tRNA acceptor stem near the 
end of the CCA tail (Fernando Garza-Sanchez, Grant Gucinski, Christopher Hayes, and 
David Low, unpublished data).  However, the cleavage pattern produced by CdiA-CT
O32:H37
 
resembles that of CdiA-CT
Ec536
, which cleaves the anticodon loop of tRNA substrates (174, 
193).  If EF-Tu is required for activity of CdiA-CT
O32:H37
, perhaps this toxin interacts with 
EF-Tu using a different interface, contributing to the difference in tRNA cleavage patterns. 
An alternative explanation for the relationship between CdiA-CT
O32:H37
 and EF-Tu is that 
226 
 
these do not form a stable complex required for activity, but rather a transient catalytic 
complex that is stabilized through addition of the immunity protein CdiI
O32:H37
.  The co-
purification between toxin and EF-Tu was first observed using a construct that also expresses 
the immunity protein.  Ternary complex formation is also observed using purified 
components in vitro.  Perhaps a weak interaction occurs between EF-Tu and CdiA-CT
O32:H37
 
inside the cell, but CdiI
O32:H37
 stabilizes it as part of the mechanism of immunity protection.  
This would remove some EF-Tu from the cellular pool available for translation, but given the 
high intracellular concentration of EF-Tu, the amount bound to CdiA-CT
O32:H37
 would 
presumably be low enough as to maintain the overall rate of protein synthesis.  A number of 
non-canonical activities have been ascribed to EF-Tu in both prokaryotic and eukaryotic 
organisms (262, 395-401).  Therefore, there is precedence for pools of EF-Tu being used for 
non-translation purposes.  Perhaps by “locking” CdiA-CTO32:H37 and EF-Tu together in a 
stable complex, CdiI
O32:H37
 completely prevents dissociation and thus tRNase activity.  
CdiI
O32:H37
 is an interesting protein by itself, as it is a small, cysteine-rich peptide (6 of 81 
residues) that coordinates an iron atom using 4 cysteines in a well-conserved fold (Argonne 
National Laboratory, preliminary data).  An additional cysteine residue is located in a loop on 
the opposite face of the protein and could facilitate the formation of disulfide bridges or aid 
in multimerization.  This is apparent during in vitro handling of this protein, as it readily 
forms dimers and multimers that are somewhat resistant to destabilization even in the 
presence of DTT and under SDS-PAGE gel conditions (Julia Willett and Christopher Hayes, 
unpublished data).   
Regardless of the specific functional relationship between these CdiA-CTs, the toxins 
described in this chapter comprise a group of diverse proteins that interact with translational 
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machinery in different ways.  Recent studies on type 6 secretion systems show that this 
interaction extends beyond the scope of CdiA-CT domains to other forms of bacterial 
inhibition.  The type 6 secretion system (T6SS) effector Tse6 from Pseudomonas aeruginosa 
is a glycohydrolase that blocks cell growth by degrading NAD
+
 and NADP
+
 (262).  In P. 
aeruginosa cells, Tse6 interacts with other T6SS proteins and, surprisingly, GDP-bound EF-
Tu.  Through analysis of crystal structures and activity assays, the authors concluded that EF-
Tu is required for entry of this toxin into cells (262).  This result is surprising, especially 
considering the syringe-like model of T6SS effector injection into target cells (240, 241, 243, 
251).  It was previously thought that T6SS toxins acting in the cytoplasm were injected 
through both membranes and released (240, 402), but the association of Tse6 with EF-Tu 
suggests that this delivery process may occur with some mechanistic subtleties, and that EF-
Tu could help import Tse6 into the cytoplasm during delivery.  Though not related to T6SS, 
another study using P. aeruginosa showed that a pool of methylated EF-Tu localizes to the 
cell membrane of this bacteria, where it is interacts with host epithelial cells during infection 
of the respiratory system (399). 
Additional examples of non-canonical EF-Tu usage have been shown in other bacteria, as 
well.  In the Gram-positive organism Bacillus subtilis, EF-Tu localizes to the inner face of 
the cell wall, where it interacts with the prokaryotic actin homolog MreB and influences the 
fidelity of cell shape (401).  In Francisella tularensis, a subset of EF-Tu is found at the 
external face of the outer cell membrane, where it interacts with host-produced nucleolin 
during infection (400).  Surface-bound EF-Tu from Streptococcus pneumoniae interacts with 
complement proteins, including Factor H and plasminogen, resulting in cleavage of 
fibrinogen, C3, and C3b and pathogen survival against host immune responses (403).  
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Involvement in bacterial inhibition systems is yet another example of a moonlighting 
function outside of the well-characterized functions typically associated with EF-Tu.   
What is apparent from our studies is that EF-Tu and EF-Ts do not contribute to the 
delivery of toxins into the cytoplasm of target cells, based on experiments performed with 
our current understanding of translocation.  This is in opposition to the T6SS effector Tse6, 
which requires EF-Tu for import into target cells (262).  The preliminary data showing 
connections between a variety of toxins and translational machinery may be indicative of 
some evolutionary pressure or benefit conferred by these co-factors.  This is interesting to 
consider in terms of toxin evolution, as these toxins have presumably never existed in an 
environment that contains CDI systems but lacks EF-Tu.  Because these CdiA-CTs are 
tRNases, interacting with EF-Tu or EF-Ts would presumably position them near their 
substrates.  The process of translation is conserved across all domains of life, and EF-Tu 
proteins are highly conserved throughout bacteria.  Therefore, utilizing this protein as a co-
factor or chaperone as opposed to a protein specific to E. coli or gammaproteobacteria would 
allow for a greater organismal diversity of theoretical targets.  Cells would have virtually no 
chance to evolve resistance to EF-Tu/EF-Ts-dependent toxins without influencing some 
aspect of their own translation processes.  Considering many elements of CDI systems are 
linked to horizontal gene transfer through their presence on genomic or pathogenicity islands 
(170), perhaps using an essential, well-conserved protein co-factor enables them to 
seamlessly adapt to transfer across species without loss of activity. 
Many questions about the specific relationship between CdiA-CTs, EF-Tu, and EF-Ts 
remain to be answered.  However, it can be concluded that a subset of toxins associated with 
diverse bacterial inhibition systems have evolved to use translational machinery for activity.  
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These co-factors may help delivered toxins efficiently find their target in the complex 
cytoplasmic milieu.  Future biochemical and structural studies will be needed to precisely 
delineate the contribution of these translational components to the specific inhibitory 
activities of CdiA-CTs. 
D. Materials and Methods 
1. Plasmid construction 
All strains, plasmids, and cosmids are listed in Table 2.  Oligonucleotide sequences are 
listed in Table 3.  All plasmids and cosmids were verified by sequencing (University of 
California, Berkeley).  Strains containing tsf mutations were a gift from Allison Jones and 
David Low (University of California, Santa Barbara).  The pUC57 plasmid constructs used 
as template DNA for the amplification of CdiA-CT/CdiI modules was graciously provided by 
Argonne National Laboratory (Darien, IL).  Plasmid-borne chimeric CDI systems were 
constructed by allelic exchange of the counter selectable pheS* marker from plasmid 
pCH10163 as described previously (177).  The various cdiA-CT/cdiI sequences were 
amplified by PCR by using the following primer pairs:  Escherichia coli 97.0246, 
CH3562/CH3564; E. coli DEC9E, CH3562/CH3563; E. coli EC1738, CH3565/CH3566; E. 
coli EC869, CDI209/CDI208; E. coli EC93 cdi2, CH3822/CH3823; E. coli STEC_O31, 
CH3176/CH3569; E. coli O32:H37, CH3567/CH3568; Dickeya dadantii CT2, 
CH3513/CH3514; D. dadantii CT3, CH3515/CH3516; Klebsiella pneumoniae 342, 
CH3517/CH3518; Yersinia intermedia, CH3745/CH3746; Y. mollaretti, CH3747/CH3748; 
and Providencia alcalifaciens, CH3743/CH3744.  The E. coli O32:H37 H71A mutation was 
constructed by amplifying the N-terminal sequence of CdiA-CT
O32:H37
 with primers CH3567 
and CH3897.  This fragment was purified and fused to the rest of the CdiA-CT/CdiI coding 
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sequence via megaprimer PCR using primer CH3568.  Each cdiA-CT/cdiI fragment was 
fused to upstream and downstream homology regions amplified from the cdiA
EC93
 gene. The 
cdiA
EC93
 upstream homology fragment was amplified by using primers DL1527/DL2470, and 
the downstream fragment was amplified with primers DL1663/DL2368.  The three products 
(cdiA-CT/cdiI, upstream cdiA
EC93
, and downstream cdiA
EC93
) were then fused to each other 
through overlapping-end PCR (OE-PCR) by using primers DL1527/DL2368. The final DNA 
product (100 ng) was electroporated together with plasmid pCH10163 (300 ng) into E. coli 
strain DY378 cells as described previously (11).  Clones with recombinant plasmids were 
selected on yeast extract glucose-agar supplemented with 33 µg/mL chloramphenicol and 10 
mM d/l-p-chlorophenylalanine.  The Dickeya zeae 1594 chimera was a gift from Grant 
Gucinski, the Yersinia kristensii 33638 chimera was a gift from Greg Ekberg, and the E. coli 
536/Ruminococcus lactaris chimera was a gift from Christina Beck (University of California, 
Santa Barbara). 
Constructs for overexpression and purification of proteins were constructed as follows.  
The CdiA-CT/CdiI module from Klebsiella pneumoniae 342 was amplified with primers 
CH3962 and either CH3685 (for construction of His6-tagged pET21 constructs) or CH3570 
(for constructs with a native immunity gene).  The PCR products were treated with 
appropriate restriction endonucleases (NcoI/SpeI for the CH3962/CH3685 PCR product and 
KpnI/XhoI for the CH3962/CH3570 PCR product) and were ligated to pET21 plasmid 
vectors that had been treated with the same enzymes.  cdiI
Kp342
 was amplified using primers 
CH3965 and CH3685.  PCR products were digested with KpnI and SpeI and were ligated to 
a pET21 backbone treated with the same enzymes.  The CdiA-CT/CdiI module from E. coli 
O32:H37 was amplified using primer CH3896 and either CH3898 (for constructs with a C-
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terminal His6 tag) or CH3571 (for native immunity sequences).  The CH3896/CH3898 PCR 
product was treated with NcoI and SpeI and was ligated to a pET21b vector treated with the 
same enzymes.  The CH3896/CH3571 PCR product was treated with KpnI/XhoI and ligated 
to a KpnI/XhoI-treated pET21 vector.  CDI
O32:H37
 variants carrying the His71Ala mutation 
were amplified from pCH12768 and treated with the same restriction endonucleases for 
cloning.  pET21b plasmids were used as vectors for all constructs carrying C-terminal His6 
tags or N-terminal His6-TrxA fusions.  The kanamycin-resistant pET21db plasmid was used 
to fuse N-terminal His10 tags, where appropriate.  The native cdiI
O32:H37
 construct was 
amplified using primers CH3603 and CH3571, digested using KpnI/XhoI, and ligated to a 
pTrc99AKX backbone.  The CdiA-CT/CdiI
NC101
 expression construct used for in vitro 
activation growth curves was a gift from Grant Gucinski. 
2. Transposon mutagenesis and isolation of mutants 
The mariner transposon was introduced into E. coli CH10229 cells through conjugation 
with E. coli MFDpir donor cells carrying plasmid pSC189. Donor and recipient cells were 
grown to mid-log phase in lysogeny broth (LB) medium supplemented with 150 µg/mL 
ampicillin and 30 µM diaminopimelic acid (donors) or 33 µg/mL chloramphenicol 
(recipients). Donors (∼6.0 × 108 cfu) and recipients (∼3 × 108 cfu) were mixed and collected 
by centrifugation for 2 min at 6,000 × g in a microcentrifuge. The supernatant was removed 
by aspiration and the cell pellet resuspended in 100 µL of 1× M9 salts. Cell mixtures were 
spotted onto 0.45-µm nitrocellulose membranes, and the filters were then incubated on LB 
agar (without inversion) for 4 h at 37 °C. The cells were then harvested from the filters by 
using 2 mL of 1× M9 salts. Transposon insertion mutants were selected by plating 10-fold 
serial dilution on LB-agar supplemented with 50 µg/mL of kanamycin. 
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More than 20,000 colonies from each transposon library were collected from the agar 
plates in 1× M9 salts and inoculated into 50 mL of LB medium in a 250-mL baffled flask. 
CDI
+
 inhibitor strains were grown in a parallel 50 mL LB medium culture. Both cultures 
were grown at 37 °C until mid-log phase, then mixed at approximately a 10:1 ratio and 
cultured for 3 h with shaking at 37 °C. Viable target cells from the transposon mutant library 
were enumerated as cfu counts per milliliter on LB agar supplemented with 50 µg/mL of 
kanamycin. The survivors of the first round of CDI competition were harvested from the 
plates with 1× M9 salts and used to inoculate 50 mL LB medium culture for a second round 
of CDI selection; this process was repeated to yield a third round of competition.  Individual 
clones were then isolated and the CDI
R
 phenotype confirmed in competition co-cultures.  The 
transposon mutations were then transferred into CDI-sensitive cells by bacteriophage P1-
mediated transduction, and the resulting transductants were tested for a CDI
R
 phenotype. 
Transposon insertion locations were identified using a two-step arbitrary PCR procedure.  
In the first set of reactions, CH2255/CH2020, CH2258/CH2020, CH2255/CH2022, and 
CH2258/CH2022 were with chromosomal DNA templates isolated from target mutant clones 
used to amplify the transposon/chromosome junctions.  The second set of PCRs used the first 
PCR products as templates along with primer pairs CH2256/CH2021 (for reactions done with 
CH2255) and CH2259/CH2021 (for reactions done with CH2258) to selectively amplify only 
DNA fragments containing the transposon.  Sequencing reactions were performed with 
primers CH2257 (for reactions done with primers CH2255 and CH2256) and CH2270 (for 
reactions were done with primers CH2258 and CH2259).  Nucleotide sequencing reads were 
mapped to the E. coli reference genome using NCBI BLAST to identify genomic locations of 
transposon insertions. 
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3. Growth competition assays 
Competition co-culture assays were carried out as previously described (175, 177).  
Briefly, inhibitor cells (E. coli EPI100 carrying CDI expression constructs) and target cells 
(E. coli MC4100 carrying pTrc99a derivatives) were grown in LB medium supplemented 
with appropriate antibiotics overnight at 37 °C. The next day, cells were inoculated into fresh 
LB medium without antibiotics in baffled flasks. Individual cultures were grown with 
shaking until early log phase, and then the populations were mixed at a 1:1 ratio in fresh pre-
warmed LB in baffled flasks.  A sample of each co-culture was taken at initial mixing to 
enumerate viable target cells as cfu counts per milliliter. The co-cultures were incubated with 
shaking for 3 h at 37 °C. Viable target cell counts are presented as the average ± SEM of 
three independent competition experiments. 
4. Activation of CdiA-CT toxins inside E. coli cells 
E. coli MG1655 cells (WT and tsf mutants) were co-transformed with an empty pTrc99a 
vector or a derivative expressing cdiI
NC101
 and empty pCH450 or a derivative that expresses 
the CdiA-CT/CdiI
NC101
-DAS protein pair.  Transformants were selected overnight on LB 
agar supplemented with 150 µg/mL Amp, 15 µg/mL Tet, and 0.4% glucose. The following 
day, transformants were inoculated into 25 mL of LB medium supplemented with Amp and 
Tet, and glucose. Cells were grown to mid-log phase and then diluted to an OD600 of 0.05 in 
fresh LB supplemented with Amp and Tet to allow low levels of expression from both 
plasmids. Cell growth was monitored by measuring the OD600 of the culture every 30 min 
for 5 h. The presented growth curves show the average ± SEM for three independently 
performed experiments.  
5. Protein purification 
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Cells carrying pET21 derivatives (CH2016 carrying pET21b constructs or CH6247 
carrying pET21db constructs) were grown in baffled flasks with shaking at 37 °C in LB 
medium with 50 µg/mL kanamycin or 150 µg/mL ampicillin until OD600 0.4-0.6, at which 
point 1.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce protein 
expression for ~3 hours before harvesting.  Cells were pelleted by centrifugation in a Sorvall 
RC 5B centrifuge at 6,000 rpm for 15 min at 4 °C, and pellets were stored at -80 °C for 
future use.  Cells overexpressing His6-tagged immunity proteins and CdiA-CT/CdiI 
complexes with C-terminal His6 tags were resuspended in non-denaturing buffers (20 mM 
sodium phosphate (pH 7.0), 150 mM NaCl, and 1 mM PMSF or 20 mM Tris-HCl (pH 7.0), 
150 mM NaCl, and 1 mM PMSF) and were lysed using a French press (2 passes at 20,000 
psi).  Lysates were cleared by centrifugation (15,000 × g in a Sorvall RC 5B centrifuge at 4 
°C) and were mixed with nickel agarose beads (1 uL Ni
2+
-NTA resin per 1 mL of original 
culture volume) for 1 h at 4 °C.  Resin was washed with resuspension buffer supplemented 
with 20 mM imidazole (pH 8.0), and His6-tagged proteins were eluted using resuspension 
buffer plus 250 mM imidazole (pH 8.0).  Elution fractions were immediately dialyzed against 
2 liters of resuspension buffer and were quantified after dialysis by measuring absorbance at 
280 nm.  
Denaturing urea lysis buffer (8 M urea, 150 mM NaCl, 10 mM Tris-HCl (pH 8.0), 1 mM 
PMSF) was used to resuspend cell pellets from cultures overexpressing constructs with N-
terminal His6 or His6-TrxA epitopes fused to CdiA-CTs.  Cells were broken with a freeze-
thaw cycle at -80 °C.  Lysates were cleared and applied to Ni
2+-
NTA resin as described 
above.  Wash steps were performed with urea lysis buffer supplemented with 20 mM 
imidazole, and proteins were eluted into urea lysis buffer plus 250 mM imidazole.  Proteins 
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were refolded against 2 liters of non-denaturing resuspension buffer quantified by measuring 
absorbance at 280 nm. 
6. Protein-protein interaction assays 
Binding interactions between CdiA-CT domains, CdiI proteins, EF-Tu, and EF-Ts were 
assessed by bait-prey assays.  Proteins fused to His6 or His6-TrxA epitopes were used as 
“bait” (tagged constructs labeled in all figures).  Untagged “prey” proteins were added to a 
final concentration of 5 uM in reaction buffer for 30 min at 4 °C.  An “input” aliquot was 
removed for analysis via SDS-PAGE, and Ni
2+
-resin was added for 1 h at 4 °C to trap tagged 
proteins and any in vitro complexes that formed during the incubation.  Tubes were 
centrifuged at 3000 rpm for 5 minutes in a tabletop centrifuge to collect the Ni
2+
-NTA beads, 
and the supernatant was removed as the “unbound” fraction.  Resin was washed 4 times with 
reaction buffer plus 20 mM imidazole, and “bound” proteins were eluted into reaction buffer 
supplemented with 250 mM imidazole.  All fractions were analyzed by SDS-PAGE (10% 
acrylamide at 110 V for 1 h, unless otherwise indicated) and stained with Coomassie brilliant 
blue dye. 
7. RNA isolation and analysis 
Cultures of E. coli X90 cells in logarithmic phase (OD600 0.4 – 0.6) were flash-fixed in 
ice-cold methanol, and cells were collected by centrifugation in a Sorvall RC 5B centrifuge 
at 15,000 × g for 15 min at 4 °C.  Cell pellets were frozen at −80 °C, and RNA was isolated 
by guanidine isothiocyanate-phenol extraction as described previously (379).  10 μg of this 
total RNA preparation was mixed with the indicated concentrations of purified proteins an 
reaction buffer for 1 h at 37 °C, and the reactions were once again extracted with guanidine 
isothiocyanate-phenol to remove protein species before electrophoresis.  RNA was resolved 
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on denaturing 8 M urea/10% (wt/vol) polyacrylamide gels and then electrotransferred onto 
nylon membrane (Nytran Supercharge).  The indicated RNA species were detected by 
Northern blot hybridization by using radiolabeled oligonucleotides as probes.  Blots were 
visualized on a Bio-Rad PhosphorImager by using Quantity One software. 
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Figure 1.  Transposon mutagenesis fails to produce strains resistant to three CdiA-CT toxins from E. coli 
EC869.  (A) CDI
EC869
, CDIo5
EC869
, and CDIo10
EC869
 and their corresponding CdiI proteins are functional 
toxin/immunity complexes.  Inhibitor cells expressing each cosmid were mixed with wild-type cells or targets 
expressing the cognate immunity.  Viable target cells were scored at 0 and 3 h.  (B) Mutants isolated after 3 
rounds of enrichment co-cultures with CDI
EC869
 are partially CDI
R
.  Transposons were moved into fresh cell 
backgrounds to test genetic linkage (targets labeled with “x” are transductants).  (C) Clean knockouts of uhpB, 
uvrY, and related genes were tested for resistance to CDI
EC869
.  Target cell viability was measured at 0 and 3 h. 
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Figure 2.  CDI
Kp342
 does not inhibit tsf mutants.  (A) For the 19 toxins tested, the relative inhibition of wild-
type cells compared to tsf mutants (genotypes indicated at the top of the table) were color-coded such that green 
indicates higher viability and red indicates more inhibition.  Wild-type viability values were adjusted to 1 for 
each set of co-culture assays.  (B) Pairwise identity comparisons were performed to determine conservation 
between toxins that require wild-type EF-Ts for inhibition.  Protein sequences were aligned using Clustal 
Omega, and pairwise comparison values were calculated using the SIAS pairwise alignment server (found at 
http://imed.med.ucm.es/Tools/sias.html).  
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Figure 3.  CdiA-CT
Kp342
 does not interact with EF-Tu or EF-Ts in vitro.  (A) The CdiA-CT/CdiI
Kp342
-His6 
complex was natively purified and bound to nickel agarose beads.  CdiA-CT
Kp342
 and any bound co-factors 
were eluted with denaturing washes and analyzed via SDS-PAGE.  (B) Tagged and untagged variants of CdiA-
CT
Kp342
 and EF-Tu were used for bait-prey assays.  To show proper re-folding of CdiA-CT
Kp342
 after 
purification, a binding assay with this protein and CdiI
Kp342
-His6 was performed. 
  
240 
 
 
Figure 4.  Mutations in tsf do not contribute to translocation of CdiA-CTs.  (A) Pairwise comparisons of 
the N- and C-terminal domains of tsf-dependent CdiA-CTs reveal little conservation in either region.  Sequence 
alignment of (B) CdiA-CT
Kp342
 and CdiA-CT
Yk33638
 and (C) CdiA-CT
NC101
 and CdiA-CT
Dzeae
 show conservation 
in the N-terminal translocation domains.  The toxin domains aligned in (B) and (D) were fused to CdiA and 
delivered into the target cells indicated in (D) and (E) during co-culture assays.  Target cell viability was 
measured at 0 and 3 hours.  Data represented the mean of three independent experiments ±SEM. 
241 
 
 
Figure 5.  Wild-type EF-Ts is required for intracellular activity of CdiA-CT
NC101
.  (A) Experimental 
design.  Plasmids expressing CdiA-CT
NC101
 or CdiI
NC101
 are expressed inside wild-type and tsf mutant E. coli 
background to decouple delivery from activity.  (B) Cell densities as measured by OD600.  Intracellular 
expression of CdiA-CT
NC101
 inhibits wild-type E. coli (orange line) as compared to growth of a strain carrying 
empty plasmid vectors (dark purple line, top).  Expression of the immunity gene rescues growth (light purple 
line compared to orange line).  Expression of the toxin permits growth in both tsf mutant backgrounds (light and 
dark green lines). 
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Figure 6.  CdiA-CTO32:H37 co-purifies with EF-Tu.  (A) The CdiA-CT/CdiI
O32:H37
 module was expressed 
as a complex inside cells and purified under native conditions using a C-terminal His6 tag fused to CdiI
O32:H37
.  
An aliquot of the purified fraction was analyzed via SDS-PAGE.  The major CdiA-CT, CdiI, and EF-Tu species 
are labeled.  Bands marked with an asterisk (*) are presumably dimers and multimers of CdiI
O32:H37
-His6.  In 
(B), the same CdiA-CT/CdiI
O32:H37
-His6 complex was expressed inside cells and was bound to nickel-agarose 
beads under native conditions.  Denaturing conditions in 6M guanidine buffer were done to denature CdiA-
CT
O32:H37
 and any associated proteins.  
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Figure 7.  CdiA-CTO32:H37 is an RNase.  (A) Cells expressing wild-type CDI
O32:H37
 or a variant at the 
putative active site residue H71A were used in co-culture assays with target cells carrying the indicated empty 
vector or cdiI constructs.  Target cell viability was measured at 0 and 1 h.  Disrupting the histidine at position 
71 ablates activity.  (B) CDI
O32:H37
 cleaves RNA in co-culture assays with target cells.  Total RNA was 
harvested from the competitions shown in (A) and analyzed via Northern blots using probes to the indicated 
tRNA and rRNA species.  The sizes of full-length and cleaved RNA products are indicated.  (C) The CdiA-
CT
O32:H37
/EF-Tu complex was purified under denaturing conditions and refolded before mixing with total 
guanidine isothiocyante-extracted cellular RNA in vitro.  Samples were split into equal parts for ethidium 
staining and Northern blot analysis. 
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Figure 8.  CDI
O32:H37
 inhibition of target cells is not affected by mutations in EF-Ts.  Inhibitor cells 
carrying CDI+ cosmids as labeled were mixed with target cells with the indicated target cells.  Viable target 
cells were measured at 0 and 3 h.  Data presented is representative of 2 independent experiments. 
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Figure 9.  CdiA-CT
O32:H37
 does not interact with EF-Tu or EF-Ts in vitro.  (A) Purified CdiA-CT
O32:H37
 and 
His6-TrxA-TEV-(EF-Tu) were mixed together in the absence or presence of MgCl
2+
 and total purified RNA.  
(B) The protein constructs used in (A) were mixed with EF-Ts to test whether the presence of EF-Ts facilitated 
complex formation.  (C) An EF-Tu construct with a C-terminal His6 tag and no extra N-terminal domain was 
mixed with purified CdiA-CT
O32:H37 
in vitro.  (D) A whole-cell S30 lysate from cells expressing a C-terminal 
His6-tagged EF-Tu construct was mixed with CdiA-CT
O32:H37
, and (EF-Tu)-His6 was selectively removed from 
the lysate using nickel agarose beads. 
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Figure 10.  EF-Tu may be involved in binding both CdiA-CT
O32:H37
 and CdiI
O32:H37
 or in chaperoning the 
folding of CdiA-CT
O32:H37
 upon delivery into cells.  (A) CdiA-CT
O32:H37
 and CdiI
O32:H37
 interact in vitro, and a 
ternary complex is formed in the presence of EF-Tu.  (B) His6-CdiI
O32:H37
 and EF-Tu do not interact in vitro in 
the absence of CdiA-CT
O32:H37
.  Purified His10-CdiA-CT
O32:H37
 (C) and His6-TrxA-TEV-CdiA-CT
O32:H37
 (D) 
interact with EF-Tu when unfolded and dialyzed in the presence of native EF-Tu.  The same denatured protein 
preparations used in (C) and (D) were folded away from EF-Tu and used in parallel binding assays as shown in 
(E).  As negative controls, CdiA-CTo11
EC869
 (F) and CdiA-CT
Ec536
 (G) – which do not interact genetically with 
tsf nor do they require EF-Tu or EF-Ts for in vitro activity – were unfolded and refolded in the presence of EF-
Tu before being subjected to a pulldown assay using nickel agarose beads. 
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Table 1.  CdiA-CTs tested for genetic interaction with tsf. 
Organism Activity 
E. coli 97.0246 Unknown 
E. coli DEC9E Unknown 
E. coli EC1738 Unknown 
E. coli EC869-1 tRNase, specific for tRNAGln (172) 
E. coli EC93cdi2 Unknown 
E. coli NC101 
tRNase (Grant Gucinski and Christopher Hayes, 
unpublished data) 
E. coli STEC_O31 
RNase (Julia Willett and Christopher Hayes, 
unpublished data) 
Dickeya dadantii CdiA-CT2 Unknown 
Dickeya dadantii CdiA-CT3 Unknown 
Dickeya dadantii EC3937 DNase (194) 
Dickeya zeae 1594 Unknown 
Klebsiella pneumoniae 342 Unknown 
Photorhabdus luminescens TTO1 
DNase (Julia Willett and Christopher Hayes, 
unpublished data) 
Yersinia intermedia Unknown 
Yersinia kristensenii 
General RNase (Greg Ekberg, Grant Gucinski, Celia 
Goulding, and Christopher Hayes, unpublished data) 
Yersinia mollaretti Unknown 
Yersinia pestis Pestoides A Unknown 
Providencia alcalifaciens Unknown 
E. coli 536/Ruminococcus lactaris 
tRNase, general (Christina Beck and Christopher 
Hayes, unpublished data) 
 
Table 2.  Bacterial strains and plasmids used in this study. 
 
Strain  Description
a
 Reference 
X90 F´ lacI
q
 lac´ pro´/ara ∆(lac-pro) nal1 argE(amb) rifr thi-1, RifR   
EPI100 
F
–
 mcrA ∆(mrr-hsdRMS-mcrBC) φ80dlacZ∆M15 
∆lacXcZ∆M15 ∆lacX recA1 endA1 araD139 ∆(ara, leu)7697 
galU galK λ– rpsL nupG pir+(DHFR), StrR TpR 
Epicentre 
MG1655 F
–
 λ– ilvG– rfb-50 rph-1  
CH2016 X90 (DE3) Δrna ΔslyD::kan, KanR  
CH8251 MC4100 rif
r
, Rif
R
 (173) 
DL8705 
MG1655 ara::spec, araBAD genes replaced by a spectinomycin 
resistance cassette 
Allison 
Jones and 
David Low 
DL8730 
MG1655 ara::spec tsf Ala202Glu, araBAD genes replaced by a 
spectinomycin resistance cassette and single point mutation in 
codon 202 of tsf changing alanine to glutamic acid 
Allison 
Jones and 
David Low 
DL8731 MG1655 ara::spec tsf Δcoiled-coil, araBAD genes replaced by Allison 
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a spectinomycin resistance cassette and clean deletion of the 
coiled-coil domain (helixes 10 and 11) in tsf 
Jones and 
David Low 
Plasmid  Description
a
 Reference 
pCH481 pET21b, cloning vector, Amp
R 
 
pCH1272 pET24db::relE, cloning vector, Amp
R
 Dan Bolon 
pCH1417 
Constitutive expression of chimeric cdiA
EC93
-CT
Y. Pestoides A
 and 
cdiI
Y. Pestoides A
 genes, Cm
R
 
 
pCH2260 
Constitutive expression of chimeric cdiA
EC93
-CT
97.0246
 and 
cdiI
97.0246
genes, Cm
R
 
This study 
pCH2261 
Constitutive expression of chimeric cdiA
EC93
-CT
EC1738
 and 
cdiI
EC1738
, Cm
R
 
This study 
pCH2262 
Constitutive expression of chimeric cdiA
EC93
-CT
O32:H37
 and 
cdiI
O32:H37
, Cm
R
 
This study 
pCH2274 
pTrc99aU2::cdiI
O32:H37
, expresses  cdiI
O32:H37
 under an IPTG-
inducible promoter, Amp
R
 
This study 
pCH2275 
Constitutive expression of chimeric cdiA
EC93
-CT
DEC9E
 and 
cdiI
DEC9E
, Cm
R
 
This study 
pCH2408 
Constitutive expression of chimeric cdiA
EC93
-CT
STEC_O31
 and 
cdiI
STEC_O31
, Cm
R
 
This study 
pCH6275 
pUC57::cdiA-CT/cdiI
DEC9E
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
DEC9E
 alleles, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6276 
pUC57::cdiA-CT/cdiI
97.0246
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
97.0246
 alleles, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6277 
pUC57::cdiA-CT/cdiI
EC1738
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
EC1738
 alleles, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6278 
pUC57::cdiA-CT/cdiI
STEC_O31
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
STEC_O31
 alleles, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6279 
pUC57::cdiA-CT/cdiI
NC101
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
NC101 
alleles, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6281 
pUC57::cdiA-CT/cdiI
O32:H37
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
O32:H37
 alleles, Amp
R
  
Argonne 
National 
Laboratory, 
this study 
pCH6286 
pUC57::cdiA-CT/cdiI
P. lum TTO1
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
 P. lum TTO1
 alleles from 
Photorhabdus luminescens, Amp
R
  
Argonne 
National 
Laboratory, 
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this study 
pCH6289 
pUC57::cdiA-CT/cdiI
Kp342
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
Kp342 
alleles from Klebsiella 
pneumonia 342, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6290 
pUC57::cdiA-CT/cdiI
Ymoll
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
Ymoll 
alleles from Y. mollaretii 
43969, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6300 
pUC57::cdiA-CT/cdiI
Palca
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
Palca 
alleles from P. 
alcalifaciens 30120, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6302 
pUC57::cdiA-CT/cdiI
Yint
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
Yint
 alleles from Y. 
intermedia, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6303 
pUC57::cdiA-CT/cdiI
Yk33638
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
Yk33628 
alleles from Y. 
kristensenii 33638, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH6306 
pUC57::cdiA-CT/cdiI
PestA
, high-copy expression construct 
containing untagged cdiA-CT/cdiI
PestA 
alleles from Y. pestis 
Pestoides A, Amp
R
 
Argonne 
National 
Laboratory, 
this study 
pCH7445 pWEB-TNC, cosmid vector, Amp
R
 Cm
R
 This study 
pCH10163 
Cosmid pCdiA-CT/pheS* that carries a kan-pheS* cassette in 
place of the E. coli EC93 cdiA-CT/cdiI coding sequence. Used 
for allelic exchange and counter-selection. Cm
R
 Kan
R
 
 
pCH11009 
Constitutive expression of chimeric cdiA
EC93
-CT
EC3937
 and 
cdiI
EC3937
, Cm
R
 
This study 
pCH11434 
Constitutive expression of chimeric cdiA
EC93
-CT
NC101
 and 
cdiI
NC101
, Cm
R
 
This study 
pCH11948 
Constitutive expression of chimeric cdiA
EC93
-CT
Kp342
 and 
cdiI
Kp342
, Cm
R
 
This study 
pCH11949 
Constitutive expression of chimeric cdiA
EC93
-CT
Plum
 and 
cdiI
Plum
, Cm
R
 
This study 
pCH11950 
Constitutive expression of chimeric cdiA
EC93
-CT
DdaCT2
 and 
cdiI
DdaCT2
, Cm
R
 
This study 
pCH11951 
Constitutive expression of chimeric cdiA
EC93
-CT
DdaCT3
 and 
cdiI
DdaCT3
, Cm
R
 
This study 
pCH12241 
Constitutive expression of chimeric cdiA
EC93
-CT
Yk33638
 and 
cdiI
Yk33638
, Cm
R
 
This study 
pCH12351 
Constitutive expression of chimeric cdiA
EC93
-CT
Yint
 and cdiI
Yint
, 
Cm
R
  
This study 
pCH12389 Constitutive expression of chimeric cdiA
EC93
-CT
Ec536-Rlact
 and This study 
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cdiI
Rlact
, Cm
R
 
pCH12398 
Constitutive expression of chimeric cdiA
EC93
-CT
EC93cdi2
 and 
cdiI
EC93cdi2
, Cm
R
 
This study 
pCH12491 
Constitutive expression of chimeric cdiA
EC93
-CT
Dzeae1594
 and 
cdiI
Dzeae1594
, Cm
R
 
This study 
pCH12715 
pET21::cdiA-CT/cdiI
O32:H37
-His6, overproduces the CdiA-
CT/CdiI
O32:H37
-His6 complex under control of the T7 promoter, 
Amp
R
 
This study 
pCH12717 
pET21::cdiA-CT/cdiI
O32:H37 H71A
-His6, overproduces the 
inactive CdiA-CT/CdiI
O32:H37 H71A
-His6 complex under control 
of the T7 promoter, Amp
R
 
This study 
pCH12721 
pET21::His6-trxA-cdiA-CT/cdiI
O32:H37
, overproduces the 
inactive His6-TrxA-CdiA-CT/CdiI
O32:H37
 H71A complex under 
control of the T7 promoter, Amp
R
 
This study 
pCH12750 
pET21::cdiI
O32:H37
-His6, overproduces the CdiI
O32:H37
 protein 
under control of the T7 promoter, Amp
R
 
This study 
pCH12768 
Constitutive expression of chimeric cdiA
EC93
-CT
O32:H37 H71A
 and 
cdiI
 O32:H37
, Cm
R
 
This study 
pCH12847 
Constitutive expression of chimeric cdiA
EC93
-CT
Ymoll
 and cdiI
 
Ymoll
, Cm
R
 
This study 
pCH12848 
Constitutive expression of chimeric cdiA
EC93
-CT
Palca
 and cdiI
 
Palca
, Cm
R
 
This study 
pCH12852 
pET21db::His10- cdiA-CT/cdiI
O32:H37 H71A
, overproduces the 
inactive His10-CdiA-CT/CdiI
O32:H37
 H71A complex under 
control of the T7 promoter, Kan
R 
This study 
pCH12861 
pET21::cdiA-CT/cdiI
Kp342
-H6, overproduces the CdiA-
CT/CdiI
Kp342
-His6 complex under control of the T7 promoter, 
Amp
R
 
This study 
pCH12863 
pET21::His6-trxA-cdiA-CT/cdiI
Kp342
, overproduces the His10-
TrxA-CdiA-CT/CdiI
Kp342
 complex under control of the T7 
promoter, Amp
R
 
This study 
pCH12898 
pET21::cdiI
Kp342
-His6, overproduces the CdiI
Kp342
-His6 protein 
under control of the T7 promoter, Amp
R
 
This study 
pCH12910 
pET21db::His10- cdiA-CT/cdiI
Kp342
, overproduces the His10-
CdiA-CT/CdiI
Kp342
 complex under control of the T7 promoter, 
Kan
R
 
This study 
a
Abbreviations: Amp
R
, ampicillin-resistant; Apr
R
, aprimycin-resistant; Cm
R
, chloramphenicol-resistant; Erm
R
, 
erythromycin-resistant; Kan
R
, kanamycin-resistance; Rif
R
, rifampicin-resistant; Tet
R
, tetracycline-resistant; 
Zeo
R
, zeocin-resistant. 
 
Table 3.  Oligonucleotides used in this study. 
 
Oligonucleotide Sequence
a
 Reference 
CDI208 (EC869-cdiI-rev) 
5' - CTA ACC TAC TGC CTC AAA 
AAA ACT TTC C - 3' 
This study 
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CDI209 (EC869-CT-for) 
5' - TAT CTG AGT AAA GCC CAG 
AAA GCT C - 3' 
This study 
CH3176 (NC101-CT(OE)-
for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT ACC TGA GCG TGT 
CTG AAA AGA CAG – 3’ 
This study 
CH3513 (3937CT2-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT TCC TGA ACA AAG 
GAA GAC CG – 3’ 
This study 
CH3514 (3937CT2-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GTT AAC TCC ACT TCC ATT 
TTA TGA TCA AAT – 3’ 
This study 
CH3515 (3937CT3-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT ATC TGA GCA GTA 
CGG ACA AGA GC – 3’ 
This study 
CH3516 (3937CT3-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GTT AAG GCT GGT AAT CTT 
CAT ATT CC – 3’ 
This study 
CH3517 (Kpn342-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT CGT TGG CGG GCG 
ATC AG – 3’ 
This study 
CH3518 (Kpn342-mid-rev) 
5'- GGT CTG GTG TCT AAC CT TGG 
GTT ATC TAA TGA CAG AGC TAC 
TTT TTA TTT – 3’ 
This study 
CH3562 (DEC9E/97.0246-
mid-for) 
5' - CAG GTA GGA ACT CGG TTG 
AGA ATA ATA TGC TGA ACG TGA 
TAG CCA C - 3' 
This study 
CH3563 (DEC9E-mid-rev) 
5' - GGT CTG GTG TCT AAC CTT 
TGG TTA GGT CCA TCC GAG AGA 
GCC - 3'  
This study 
CH3564 (97.0246-mid-rev) 
5' - GGT CTG GTG TCT AAC CTT 
TGG TTA GGC AAG TAG CTC TAA 
TTT TGC - 3' 
This study 
CH3565 (EC1738-mid-for) 
5' - CAG GTA GGA ACT CGG TTG 
AGA ATA ATT ATC TGA GCA GTA 
AGC - 3' 
This study 
CH3566 (EC1738-mid-rev) 
5' - GGT CTG GTG TCT AAC CTT 
TGG CTA TTT CTT GAT TCC TAA 
ACG G - 3' 
This study 
CH3567 (O32:H37-mid-for) 
5' - CAG GTA GGA ACT CGG TTG 
AGA ATA ATG CGC TGG GTA AC - 
3' 
This study 
CH3568 (O32:H37-mid-rev) 
5' - GGT CTG GTG TCT AAC CTT 
TGG TTA CTG TTC GTT AAA TC 
TCG TTT C - 3' 
This study 
CH3569 (STEC_O31-mid-
rev) 
5' - GGT CTG GTG TCT AAC CTT 
TGG TTA GGA TGG GAT TTT AGA 
This study 
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CAG TAA TT - 3' 
CH3570 (pUC57-univ-rev-
Xho) 
5' - AAA CTC GAG GCC TCT GCA 
GTC G - 3'  
This study 
CH3571 (pUC57-univ-for-
Xho) 
5' - AAA CTC GAG TCG CGA ATG 
CAT C - 3' 
This study 
CH3603 (O32:H37-cdiI-Kpn-
for) 
5' - AAA GGT ACC ATG AAT AAT 
GGT TC - 3'  
This study 
CH3685 (Kp342-cdiI-Spe-
rev) 
5'- TGA ACT AGT TCT AAT GAC 
AGA GC 
This study 
CH3743 (Palc-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT TTT TAT CAG CGA 
CAA AAA ATG A – 3’ 
This study 
CH3744 (Palc-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GTT AAA AAT AAA TTA ATA 
AAT GAT TTTT GTA CAT TAC C – 3’ 
This study 
CH3745 (Yint-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT ATC TCA ATG CCA 
GTG ATA AGA – 3’ 
This study 
CH3746 (Yint-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GCT AAA CCA GCT TTA ATA 
GCT TCA – 3’ 
This study 
CH3747 (Ymol-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATA ACC TTA GTT TTG 
GCA AAG G – 3’ 
This study 
CH3748 (Ymol-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GTT AAG CAG GTA ATT TAG 
TCA GTA AAT C – 3’ 
This study 
CH3822 (EC93-CT2-mid-for) 
5'- CAG GTA GGA ACT CGG TTG 
AGA ATA ATT CAC TCA GTG ATG 
GCT GGA AC – 3’ 
This study 
CH3823 (EC93-CT2-mid-rev) 
5'- GGT CTG GTG TCT AAC CTT 
TGG GTT AAC GAT AAA AAC GAT 
TTA ATA TCA ATA TGA TGA – 3’ 
This study 
CH3897 (O32:H37-H71A-
rev) 
5' - GGA AAC TCT TTT CCA GCT 
TTT GTC CAA TGC C - 3'  
This study 
CH3898 (O32:H37-cdiI-Spe-
rev) 
5' - TTT ACT AGT CTG TTC GTT 
AAA TGC TCG - 3' 
This study 
CH3962 (Kp342-CT-
Kpn/Nco-for) 
5' - TTT GGT ACC ATG GTT GAG 
AAT AAC TTG GCG G - 3' 
This study 
CH3965 Kp342-cdiI-Kpn-for 
5' - TTT GGT ACC ATG TTC ATA 
GAA AAT AAG CC - 3'  
This study 
DL1527 5´ - GAA CAT CCT GGC ATG AGC G   
DL1663 
5´ - CCC AAA GGT TAG ACA CCA 
GAC C 
 
DL2368 5´ - GTT GGT AGT GGT GGT GCT G  
DL2470 5´ - ATT ATT CTC AAC CGA GTT  
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CCT ACC TG 
 
  
254 
 
VII. CDI systems as synthetic biology tools 
This research was conducted in collaboration with Beatrice Ramm and Drew Endy at 
Stanford University, who performed the reversibility studies and the time-lapse microscopy.  
I constructed many of the strains used throughout this study, performed the co-culture assays 
and additional microscopy, and wrote a significant portion of the manuscript. 
A. Introduction 
The complexity of higher-order organisms often makes it difficult to understand the 
source of arising patterns in cell populations. A simplified system that is easy to manipulate 
and quantify can provide valuable information on the underlying design principles of 
biological pattern formation.  To understand higher-order developmental patterns, the field of 
synthetic biology has taken an interest in programming pattern formation using bacteria.  
Synthetic biology and computational modeling using bacterial systems have contributed to 
our knowledge of two and three-dimensional patterning in response to morphogens (404, 
405) and physical parameters such as cell shape (406), modeling of multicellular behavior 
(407, 408), and edge detection (409). In eukaryotic systems, synthetic biology has been 
utilized to understand how Notch-Delta signaling controls patterning during development 
(410-412).  A goal of synthetic biology is to create well-defined systems that can be precisely 
manipulated with the end goal of controlling cell growth or gene expression in a multicellular 
community.  Such studies on bacterial interactions can also contribute to our knowledge of 
complex microbial communities such as biofilms.   
As perhaps the best-studied Gram-negative bacterium, Escherichia coli is simple to 
engineer, and formed patterns can be observed in detail using time-lapse microscopy (TLM) 
(413).  As a result, E. coli is an ideal unicellular tool for modeling patterning in a population. 
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Though E. coli is genetically tractable and is easy to manipulate under laboratory conditions, 
natural bacterial environments are much more complex. To navigate this population space, 
bacteria have evolved myriad ways to compete and communicate with other microbes in their 
surroundings, some of which have been adapted for use in synthetic biology systems.  
Quorum sensing is a well-studied form of bacterial communication that uses small molecules 
like oligopeptides and N-acyl homoserine lactones (AHLs) to coordinate group behaviors on 
a population level by regulating biofilm development, growth of microbial communities, and 
host-microbe interactions (16, 19, 414).  As a synthetic biology tool, quorum sensing has 
been used to regulate cell growth in a variety of ways, including controlling pattern 
development (405, 409, 415, 416), encoding genetic oscillators (417), and creating synthetic 
ecosystems (418, 419).  The use of these diffusible molecules simulates developmental 
morphogen gradients used by eukaryotic organisms to direct cell differentiation and growth.  
However, building more complex cell-cell communication schemes based on quorum sensing 
systems is difficult because of cross-talk and overlap between ligand and receptor families 
(420, 421).  Recent efforts to diversify existing communication schemes include the 
introduction of decoupled DNA messaging (421) or the proposition of a contact-dependent 
communication form based on conjugation (422). 
In addition to communication systems based upon diffusible compounds, bacteria can 
interact using a variety of contact-dependent systems that require physical interaction 
between two cells.  Bacteria utilize pili, adhesins, and effector secretion systems to interact 
with other cells or surfaces, and, in some cases, deliver toxic effectors into prokaryotic and 
eukaryotic targets (130, 243, 245, 248, 402, 423-428).  Contact-dependent growth inhibition 
(CDI) is a type 5 secretion system and a form of bacterial competition by which CDI
+
 cells 
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can inhibit the growth of target cells following physical contact with a receptor and delivery 
of a toxic peptide (156, 167, 169, 173, 175, 194).  CDI was first described in Escherichia coli 
strain EC93, which was isolated from a rat gut and could inhibit the growth of E. coli K-12 
cells upon physical contact (156). This inhibitory activity was localized to a three-gene locus 
encoding cdiBAI.  CdiA and CdiB comprise a two-partner secretion system in which CdiB 
facilitates the surface display of the large exoprotein CdiA.  Upon recognition of a target cell 
via binding the outer membrane receptor BamA (157), the C-terminal region of CdiA 
(termed CdiA-CT) presumably undergoes a proteolytic cleavage event and can be delivered 
to target cells, resulting in inhibition of growth (172, 194, 429).  Inhibitory activity of CdiA-
CTs is blocked by CdiI, an immunity protein that physically binds and inactivates the toxin 
(169, 175, 177, 193, 202).   
CDI systems are widespread across Gram-negative bacteria, and CDI systems have been 
identified in a variety of α-, β-, and γ-proteobacteria including plant pathogens (Dickeya spp. 
and Erwinia pyrifoliae), animal pathogens (Moraxella catarrhalis), and human pathogens 
(Klebsiella pneumoniae, Yersinia pestis, and uropathogenic E.coli (168, 170).  More than 
16% of sequenced E. coli genomes contain a CDI gene cluster (213), and CDI systems are 
remarkably diverse even among closely-related strains. Almost 30 distinct families of CDI 
toxins have been identified in E. coli alone (170).  CdiA-CTs characterized include toxins 
that act as DNases (177, 194), ionophores (158), general tRNases (193), specific tRNases 
(169, 172), and ribosomal rRNases (175), and a variety of other toxin/immunity pairs have 
been bioinformatically predicted (199, 200).  CDI can influence group behavior of bacterial 
communities, and expression of CDI systems leads to cell aggregation and enhanced biofilm 
formation (159, 430).   
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To our knowledge, the potential of bacterial contact-dependent forms of communication 
and competition have not been explored for synthetic biology purposes.  CDI systems may be 
an ideal platform for the development of synthetic biology tools because they are modular, 
can influence the growth of specific target populations, and are capable of delivering cargo to 
another cell.  Previous work demonstrated that cells inhibited by a pore-forming CdiA-CT 
can resume growth after toxicity is neutralized by expression of CdiI (158).  This 
reversibility may enable long-term experiments with on/off cycles of CDI toxin expression.  
Additionally, given the vast distribution of cdi genes throughout gammaproteobacteria and 
range of CdiA-CT activities, the array of available CDI systems constitutes a great wealth of 
potential tools.  Here, we sought to determine whether reversibility of inhibition was a 
feature of other CDI systems and whether these inhibition systems could be used to construct 
synthetic biology tools to study cell growth and pattern formation in bacterial communities.  
As CDI activity is dependent on physical contact, these systems could be harnessed as a way 
to control cell growth and patterning in multicellular populations without the need for 
diffusible signaling compounds.  We present the development of CDI-based synthetic 
biology tools and show that they can be used to reversibly control cell growth in culture and 
to influence cellular morphology within a bacterial population.   
B.  Results 
1. Tunable control of cell growth rates by CdiA-CT/CdiI expression 
Reversible growth inhibition mediated by CdiA-CT/CdiI pairs could be useful for 
constructing dynamic growth rate systems to control the growth of cells over time.  To 
achieve this, such a system should have tight control of toxin expression (i.e., no change in 
growth rate of cells without induction of toxin), a range of changes in growth rate, the ability 
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to rescue growth defects by expression of the respective immunity gene, and reversibility of 
growth inhibition. Previous work demonstrated the reversibility of inhibition from a pore-
forming toxin (158), so we wanted to test the reversibility of other classes of CdiA-CTs.  We 
reasoned that low levels of RNase activity may be reversible to some degree if protein 
synthesis can resume after inactivation of the toxin and selected four previously-
characterized CdiA-CT/CdiI pairs to evaluate using these criteria:  CdiA-CT
ECL
 from 
Enterobacter cloacae (16s rRNase) (175), CdiA-CT
Ec869
 from E. coli (tRNase specific for 
tRNA
Gln
) (172), CdiA-CTII
Bp1026
 (cleaves tRNA
Ala
) (169), and CdiA-CT
Ec536
 from E. coli 
(general tRNase) (193).  We first asked whether a range of cellular inhibition could be 
achieved by varying expression of these toxins.  To study the effects of these toxins on 
growth rate, we cloned these four CdiA-CT/CdiI pairs into growth control plasmids in which 
CdiA-CT is expressed under control of the L-arabinose-inducible PBAD promoter (ara), and 
CdiI expression is regulated by the anhydrotetracycline-inducible promoter PLtetO-1 (atc) 
(431).  We transformed the four resulting pGC::CdiA-CT/CdiI constructs into E.coli 
DH5αZ1 and monitored growth of these strains by measuring the optical density at 600 
nanometers (OD600) over time.  CdiA-CT and CdiI expression were regulated by varying 
arabinose (0 – 0.1%) and atc (0 or 200 ng/mL) concentrations in the media.  Non-inducing 
conditions did not result in any growth rate changes as compared to cells carrying a control 
plasmid. 
Of the four CdiA-CT/CdiI pairs tested, three did not meet the criteria for tunable growth 
control systems (Figure 1).  Growth rates of cells expressing CdiA-CT
Ec536
 and CdiA-
CTII
Bp1026b
 toxins do not appear to be tunable in this system, as even low levels of arabinose 
resulted in complete growth inhibition (Figure 1C and E).  With high toxin induction, 
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expression of the respective cdiI genes for these systems does not completely block 
inhibition (Figure 1D and F).  Expression of CdiA-CT
EC869
 appears to be leaky, as uninduced 
cells (no arabinose) show a growth defect at late stages of growth (Figure 1G).  Furthermore, 
CdiI
EC869
 does not fully rescue inhibition at the highest levels of toxin induction (Figure 1H).  
Previous studies have shown these CdiA-CT/CdiI modules to be functional, and these 
immunity proteins can neutralize CdiA-CT toxicity in liquid co-culture experiments and in 
vitro (169, 172, 193).  We presume that in our system, cdiI expression is lower than that of 
the cdiA-CT genes and that full protection from toxicity could be achieved for all CdiA-
CT/CdiI pairs by tuning the expression levels of the respective constructs. 
We identified the 16S rRNase CdiA-CT
ECL 
as the most promising candidate for 
controllable growth rate systems (Figure 2).  Without toxin induction, E.coli DH5αZ1 cells 
carrying pGC::CdiA-CT/CdiI
ECL
 grow at the same rate as cells harboring the control plasmid 
(Figure 2B, black and pink lines).  Low levels of toxin induction (Figure 2B, blue line) slow 
cell growth, and higher levels of arabinose lead to an arrest of growth as measured by OD600 
(Figure 2B, green and brown lines).  Full induction of cdiI
ECL
 does not affect cell growth in 
the absence of toxin induction (Figure 2C, black and pink lines). When CdiA-CT
ECL
 is 
expressed at low levels, CdiI
ECL
 rescues growth almost to control levels (Figure 2C, blue 
line). With increasing arabinose concentrations, CdiI
ECL
 partially rescues growth, resulting in 
a lower growth rate but not full attenuation (Figure 2C, green and brown lines). 
2. Control of cell growth rates by CdiA-CTs is reversible 
To determine if the change in growth rate observed with the induction of pGC::CdiA-
CT/CdiI
ECL
 is reversible, we performed a re-growth experiment (Figure 2D).  Cells carrying 
the CdiA-CT/CdiI
ECL
 expression plasmid or a control plasmid vector (Figure 2E) were grown 
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in media either lacking arabinose or with the lowest inducing condition (0.001% ara). In 
phase 1, pGC::CdiA-CT/CdiI
ECL
 cells grown in arabinose showed a decrease in growth rate, 
consistent with our growth curve results shown in Figure 2B (Figure 2D, left panel).  After 
the untreated cells reached stationary phase, both populations were washed to remove 
inducing agent, and cell density was diluted to an OD600 of 0.01 (Figure 2D, transition 
between left and middle panels).  In phase II, each initial population was grown in media 
either lacking inducer or media with 0.001% ara (Figure 2D, middle panel).  The cells 
supplemented with arabinose showed a similarly suppressed growth as cells in phase I.  Cells 
without inducer recovered growth, eventually reaching the same final OD600 of 1.0 as control 
cells (Figure 2D, middle panel), but showed a significantly longer lag phase than control cells 
or cells grown without inducer in phase I.  The cells which showed recovered growth in the 
absence of arabinose were washed, diluted, and split into cultures with varying arabinose 
concentrations (Figure 2D, right panel).  Cells that had been previously inhibited by CdiA-
CT expression and recovered by CdiI were once again inhibited by expression of CdiA-
CT
ECL
.  Cells without inducer grew comparably to phase I and the negative control (Figure 
2D, compare left and right panels).  The lag phase of cells was shorter again and can be 
compared to the lag phase of phase I or the negative control.  These results demonstrate that 
growth inhibition of cells can be achieved by inducing expression of CdiA-CT
ECL
, and that 
this inhibition is reversible when the cognate CdiI is expressed.  Cells inhibited by CdiA-
CT
ECL
 are capable of re-growing like untreated cells and can undergo several cycles of 
reversible inhibition.   
3. Homogeneous control of growth inhibition by CdiA-CTECL at a single-cell level 
Expression of the PBAD promoter in a population of E. coli DH5αZ1 cells is not 
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homogeneous, and it is regulated by an all-or-none response to induction in each cell (432).  
Intermediate expression of the target gene at a population level is not caused by intermediate 
expression levels in single cells, but instead represents a distribution of high and low 
expression.  However, systems have been developed for homogeneous expression using the 
PBAD promoter, ensuring that intermediate inducer levels lead to intermediate gene 
expression in all cells (433).  E. coli strain BW27786 lacks the high-affinity arabinose 
transport operon AraFGH, is deficient in arabinose metabolism, and constitutively expresses 
the low-affinity arabinose transporter AraE from the chromosome.  PBAD induction in this 
strain leads to an even gene expression response from all cells (433).  Therefore, we tested 
whether this strain could control cell growth rates at a single-cell level over a range of 
inducer concentrations using pGC::CdiA-CT/CdiI
ECL
.  As BW27786 does not contain the 
tetR gene needed for the regulation of PLtetO-1, cells were co-transformed with pGC::CdiA-
CT/CdiIECL or the empty control plasmid as well as pTS1127, which encodes 
constitutively-expressed tetR.  These strains were grown under control and inducing 
conditions, and growth rates were assessed with OD600 measurements.  As with DH5αZ1, 
growth of BW27786 cells carrying the control plasmid were not influenced by different 
arabinose concentrations or by atc addition (Figure 3C and D).  Cells carrying pGC::CdiA-
CT/CdiI
ECL
 showed normal growth in the absence of inducer (Figure 3A).  Lower arabinose 
concentrations (1×10
-6
% and 1×10
-5
% (w/v)) did not have an effect on growth rate. 
Intermediate concentrations of arabinose (5×10
-5
%, 7.5×10
-5
% and 1×10
-4
% (w/v)) slowed 
cell growth considerably (Figure 3A).  Cells subjected to high levels of inducer (0.001% and 
0.01% (w/v)) stopped growing after 2 hours but seemed to resume growth after 7 hours.  
Induction of cdiI gene expression had no detrimental effect on cell growth (data not shown).  
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Growth inhibition caused by low levels of CdiA-CT induction could be rescued by co-
expression of CdiI, but CdiI does not protect against toxicity at high levels of CdiA-CT 
expression (Figure 3B).  These results suggest that systems which permit homogeneous gene 
expression are suitable for controlling growth rates at a population and single-cell level. 
4. Controlling colony morphology with CDI 
We have previously reported the DNase activity of an orphan CdiA-CT from E. coli 
O157:H7 EC869 (CdiA-CTo11
EC869
), a Shiga toxin-producing strain isolated from cattle (177, 
434).  Cells that have been inhibited by CdiA-CTo11
EC869
 have damaged nucleoids and are 
often elongated and filamentous (173, 177, 202).  The physical effects of this CDI system are 
striking, but it is possible that these morphology changes are an artifact of forced contact 
between inhibitors and targets during growth in shaking broth. Therefore, we wanted to 
observe the effects of CdiA-CTo11
EC869
 in real time using time-lapse microscopy (TLM) to 
determine whether these physical changes occur in a more natural environment, such as two 
cell populations growing towards each other.  TLM has previously been used to monitor 
patterning in bacterial communities and T6SS toxicity between bacteria (402, 427).  As a 
preliminary test, we performed growth competitions in liquid culture using the media 
conditions used for TLM experiments.  GFP-labeled CDI
+
 inhibitor cells carrying a plasmid 
constitutively expressing CDIo11
EC869
 were mixed with mKate2-labeled target cells 
transformed with either a plasmid encoding cdiIo11
EC869
 or an empty vector (Figure 4).  As 
previously demonstrated, wild-type target cells lose viability upon mixing with CDIo11
EC869
 
inhibitors, and this growth inhibition is blocked by expression of cdiI (Figure 4A).  
Microscopy images reveal that susceptible target cells become elongated and filamentous 
after competition in liquid media (Figure 4B), consistent with our previously-reported 
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phenotype.  Cells expressing cdiIo11
EC869
 retain normal morphology (Figure 4B). 
TLM was then used to observe the phenotypic effects of inhibition of these target cells in 
real time. The same CDI
+
 inhibitor and target strains used for the liquid competitions were 
applied to an agarose pad at a low density, and image locations were chosen where cells from 
both populations were positioned close to each other.  When CDIo11
EC869
 inhibitor cells 
collided with susceptible target cells, the targets elongated at the interface of the two 
colonies, smoothing the collision border with filamentous cells aligned parallel to the 
inhibitor/target cell interface (Figure 5A).  In contrast, contact between CDIo11
EC869
 inhibitor 
cells and immune targets expressing cdiIo11
EC869
 did not induce morphological changes in 
target cells at the interface (Figure 5B).  Examination of the border between CDI
+
 and cells 
expressing cdiIo11
EC869
 shows mixing of the two populations, as evidenced by the 
intermingling of GFP-labeled CDI
+
 cells and mKate2-labeled target cells (and vice versa).  
These invaginations lead to a rough, jagged colony interface (Figure 5B).  Conversely, 
filamentation of susceptible target cells after interaction with CDIo11
EC869
 cells leads to a 
smooth border between the two populations (Figure 5A).  Elongated cells exclude CDI
+
 
inhibitor cells, preventing them from invading the target cell population. Therefore, we 
conclude that filamentation of target cells is a relevant physical consequence of inhibition by 
the CDIo11
EC869
 system, and that morphological changes associated with this system can be 
harnessed to alter the boundary between growing cell populations. 
We next wished to determine whether we could combine reversibility of cell inhibition 
and morphology changes in a CDI-based synthetic biology system.  As we demonstrated 
earlier, expression of CdiA-CT
ECL
 can be used to modulate cell growth over several cycles 
(Figures 2 and 3).  We performed liquid co-culture competition assays with target cells 
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expressing cdiI
ECL
 and an empty plasmid vector and visualized cellular morphology after 
mixing to determine whether delivery of this toxin was also associated with changes in target 
cell morphology.  Delivery of CdiA-CT
ECL
 to targets did not change the overall cell 
morphology during inhibition (Figure 6B), so it is unlikely that using this toxin for reversible 
inhibition would alter cell morphology during patterning.  Taken together, these data suggest 
that CdiA-CTs have unique properties that can be harnessed for synthetic biology purposes, 
but that a combinatorial approach using reversible inhibition to create cyclic alterations in 
cell morphology may not be feasible.   
5. An inducible CDI system to control cell growth and colony morphology 
CdiA-CTs are delivered rapidly during CDI, and toxin activity can be observed in target 
cells before a decrease in viable target cells is observed (172).  Because of the physical 
requirements of TLM, cells are incubated together for upwards of 30 minutes before imaging 
begins.  During this time, freely-diffusing target cells can come into contact with CDI
+
 cells 
and inhibition can occur before the first images are acquired.  This is an imperfect setup for 
studying morphological and physiological changes that accompany delivery of CDI toxins 
into target cells as well as for precise control of colony growth and patterning.  To address 
this, we utilized an IPTG-inducible CDIo11
EC869
 system to enable tighter control of toxin 
delivery (Figure 7).  In the absence of IPTG, cdiA is not expressed, and co-culture of these 
inhibitor cells with susceptible target cells does not result in growth inhibition (Figure 6A) 
nor in morphological changes of target cells (Figure 7B and C).  Upon addition of IPTG, 
CdiA is expressed, resulting in target cell filamentation (Figure 7B and C) and inhibition 
(Figure 7A).  However, the plasmid encoding the cdiIo11
EC869
 gene contains an IPTG-
inducible promoter, and overexpression of this immunity protein is lethal to cells (Figure 8).  
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Therefore, we used another CDI
R
 strain that lacks yciB, a gene encoding a putative inner 
membrane protein required for delivery of CdiA-CTo11
EC869
 into target cells (173).  When co-
cultured with IPTG added to the media, ΔyciB cells are not inhibited (Figure 7A) and do not 
display any morphological defects (Figure 7B and C).  We again performed TLM with 
mKate2
+
 wild-type and ΔyciB targets (Figure 9) and did not observe filamentation in the 
CDI-resistant ΔyciB cells.  As with immune cells and the constitutive CDIo11
EC869
 system, 
growth of IPTG-CDIo11
EC869
 and yciB cells on agarose pads resulted in intercalation of the 
two populations (Figure 9B).  Therefore, cell morphology can be controlled by CDI systems 
by altering expression of either cognate CdiI proteins or inner membrane proteins required 
for delivery. 
6. The modularity of CDI systems expands potential synthetic biology applications  
CDI is a simple process in that inhibition is mediated by a three-gene locus.  This is in 
stark contrast to the elaborate T6SS apparatus, which consists of a dozen or more subunits 
(133, 240, 243, 256, 402).  Delivery of CdiA-CT domains into target cells can be 
manipulated by altering a single protein at either the outer or inner membrane of target cells.  
Given the diversity of translocation pathways used by CdiA-CT toxins to enter the cell and 
the multiple morphological outcomes of inhibition by CdiA-CTs, it is plausible that specific 
subpopulations of cells in a complex environment could be individually manipulated using 
CDI systems.  As a proof of concept, we carried out tri-population co-culture assays in which 
GFP
+
 CDIo11
EC869
 cells were mixed with both mKate2
+
 wild-type targets and BFP
+
 targets 
expressing cdiIo11
EC869
 (Figure 10).  As expected, only the CDI-sensitive mKate2
+
 target cells 
show the filamentatous phenotype that is a hallmark of inhibition by this toxin.  BFP
+
 cells 
carrying a plasmid-borne copy of cdiIo11
EC869
 are protected from inhibition, and do not 
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elongate or change morphology.  Thus, CDI systems can be used to selectively influence 
individual populations within a mixed culture, increasing the applicability of these as 
synthetic biology tools. 
C.  Discussion 
Controlling colony morphology and cell growth is a necessary step towards engineering 
complex microbial consortia that mimic the complexity of biofilms and other microbial 
communities in terms of communication, competition, and species variety.  Furthermore, 
development and maintenance of complex microbial systems requires coordination of 
activities between many cells, making them attractive candidates for studying principles of 
multicellular tissues and organisms.  Here, we present new methods for reversibly controlling 
bacterial cell growth and influencing morphology of subpopulations of cells in a microbial 
community based on principle components of bacterial contact-dependent growth inhibition 
systems.  Manipulating these variables in a contact-dependent way using a single species of 
bacteria such as E. coli could prove useful as a simplified way to model environments of 
greater complexity (435).  
Previously, Aoki et al. demonstrated that inhibition by the pore-forming CdiA-CT
EC93
 is 
reversible when the cognate CdiI immunity protein is expressed (158).  Here, we show that 
growth inhibition of E. coli by CdiA-CT
ECL
, which cuts 16S rRNA (175), is reversible in a 
similar manner.  Growth of E. coli DH5αZ1 cells is suppressed by low levels of toxin, and 
growth could be fully recovered when the inducing agent was removed.  The CdiA-CT
ECL
 
growth suppression module was still functional and could inhibit growth when seeded into 
fresh media containing inducing agents.  Therefore, the ability of cells to recover from 
inhibition is likely not due to the accumulation of inactivating mutations in pCdiA-CT
ECL
 and 
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instead represents a bonafide reversible growth inhibition system.  
Of the CdiA-CT/CdiI pairs we tested, CdiA-CT/CdiI
ECL
 was best able to reversibly 
regulate the growth of E.coli. The 16S rRNase activity of CdiA-CT
ECL
 may contribute to its 
ability to reversibly control growth for two reasons.  First, 16S rRNase activity can be 
imagined to have a “balanced” effect on cell growth; that is, when 16S rRNA is degraded, 
synthesis of all proteins will be affected equally since this activity affects general translation 
machinery and not the levels of specific tRNAs.  In contrast, the activity of specific tRNases 
such as CdiA-CT
EC869
, which cleaves tRNA
Gln
 molecules (172), might result in unbalanced 
protein production based on amino acid content.  General tRNases are, in theory, a good 
candidate for controllable growth systems, as induction of these toxins would also affect 
protein synthesis almost homogenously.  However, even low expression of the general 
tRNase CdiA-CT
Ec536
 halted growth in an irreversible manner. This may be because recovery 
requires synthesis of many tRNAs instead of only 16S rRNA.   
A second reason that 16S rRNase activity from CdiA-CT
ECL
 may reversibly control cell 
growth is that it mimics natural growth regulation in E. coli.  Cell growth rate is coupled to 
protein synthesis, with the production of rRNAs as the rate-limiting step (436, 437).  In E. 
coli, rRNA transcription occurs from 7 operons and is under the control of multiple 
regulatory systems (437).  16S rRNA is subject to further processing by cellular RNases 
during maturation (438), and RNA stability studies show that 16S rRNA levels fluctuate with 
nutrient availability and growth phase (439, 440).  Furthermore, toxins from classical toxin-
antitoxin addiction modules interact with 16S rRNA.  RelE interacts with 16S rRNA in order 
to cleave mRNA transcripts, and the Doc toxin binds 16S RNA but does not cleave mRNA 
(441).  Therefore, low expression levels of CdiA-CT
ECL
 may cleave 16S rRNA in a manner 
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that mimics rRNA processing during starvation conditions, allowing the cell to recover when 
toxin activity is neutralized by production of the cognate CdiI or removal of an inducing 
agent from the media. 
Previous studies characterizing CDI systems have examined growth inhibition in well-
aerated liquid cultures using rich broth (167, 169, 172, 173, 175, 177, 193, 194).  Under these 
conditions, CDI
-
 target cells are in constant contact with CDI
+
 cells by virtue of physical 
shaking.  Analysis of target cell morphology by microscopy after liquid culture with 
CDIo11
EC869
 reveals that a majority of target cells have damaged nucleoids and display the 
elongated, filamentous phenotype that is the hallmark of inhibition by this toxin (177, 202).  
However, this might not be an accurate representation of how this CDI system inhibits 
targets in a natural system.  Using TLM, we were able to examine populations of CDI
+
 and 
CDI
-
 cells as they collide during surface growth, which is a better spatial representation of 
natural bacterial environments.  
The results from our TLM experiments indicate that inhibition and phenotypic evidence 
of CDI toxin delivery in stationary environments does not occur throughout the entire 
population.  As CDI
+
 and CDI
-
 cells collide, target cells at the interface elongate.  These cells 
physically block off internal layers of target cells, encapsulating untouched targets and 
preventing a lethal interaction with invading CDI
+
 inhibitors (Figures 5A and 9A).  In this 
way, intoxicated target cells that stretch across the CDI
+
/CDI
-
-cell interface act as a “border 
patrol” that protects internal cells from inhibition.  The spatial constraints of surface growth 
prevent constant contact between all cells.  When CDI
+
 cells encounter “self” immune cells, 
the populations can mix, as evidenced by crossover of GFP
+
 cells to the mKate2-labeled 
target population (Figures 5B and 9B).  These results are in agreement with computational 
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models predicting the emergence of discrete domains created by interactions between CDI
+
 
and CDI
-
 cells (442).  In the future, analyzing CDI in stationary conditions using TLM as 
opposed to shaking batch co-cultures may provide a better assessment of CDI function in 
natural environments. 
The microscopy results presented here have important implications for CDI biology.  In 
natural populations, filamentation as a response to CdiA-CT delivery could be a mechanism 
by which CDI
-
 cells exclude invading CDI
+
 strains to protect their niche. Alternatively, it 
could be a means by which CDI
+
 cells can create a boundary between “self” and “non-self” 
populations to establish a community.  Anderson et al. found that CDI systems in 
Burkholderia pseudomallei influenced biofilm structures by excluding “non-self” cells from 
pillar structures (443), and CDI systems are important to maintain structure during biofilm 
development in a variety of bacteria (225, 430).  Morphological changes can influence the 
way bacteria communicate, form multicellular structures, or survive potentially lethal stresses 
(417, 435, 444-447).  For example, filamentation can help pathogens like uropathogenic E. 
coli evade host innate immune responses during infection and Burkholderia pseudomallei 
survive antibiotic treatment (445, 448).  Previous computational studies have incorporated 
morphological terms in systems describing bacterial communities composed of multiple cell 
types (406, 449).  
The usefulness of contact-dependent methods for patterning and multicellular computing 
has been modelled computationally (422, 442).  Here, we experimentally demonstrate that a 
toxin used for contact-dependent growth inhibition can reversibly control growth of cells and 
that CDI toxins can alter cell morphology upon delivery into targets.  The ability to 
reversibly control bacterial growth using CdiA-CT
ECL
 could be a useful tool to dynamically 
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control colony morphologies. CDI systems could be utilized to create defined, self-contained 
subpopulations within larger synthetic microbial ecologies. The development of reporters to 
measure delivery of CdiA-CT into target cells could be used to create a precise edge detector 
within a complex population of bacteria. The ability to control colony growth and 
morphology using these toxin/immunity pairs could be combined with other patterning tools 
and algorithms to build complex bacterial networks, engineer biofilms, and study gene 
expression in multicellular systems.   
Using CDI systems to control cell growth and patterning has several advantages. CdiA-
CT/CdiI pairs can be separated from the structural domains required for delivery, allowing 
for intracellular expression. This provides a platform for controlling cell growth independent 
of interactions with surrounding cells, as these growth control modules can be activated by 
addition of exogenous inducing agents or by light-regulated gene expression (408, 450).  
Fine-tuning of gene expression models allows for homogenous control of growth regulators, 
ensuring equivalent toxin doses across a system.  The delivery of CDI toxins is also tunable 
at several steps, allowing for the construction and control of complex microbial consortia in 
which subpopulations can be targeted by one CDI system but resistant to another.  We have 
demonstrated that delivery of CdiA-CT domains requires a specific inner membrane protein 
for each toxin.  Therefore, knockout strains that lack the requisite inner membrane protein for 
delivery of a given toxin is specifically resistant to inhibition by that CDI system, but not 
other CdiA-CTs (173).  Unlike quorum sensing, in which there is cross-talk between AHL 
receptors, the tight levels of control provided by CDI delivery pathways may provide a better 
method to engineer complex microbial populations.  Given the species-specificity observed 
with CdiA-receptor interactions (159), contact between subpopulations of cells can be 
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controlled simply by replacing a target cell receptor with an allele containing polymorphisms 
that prevent interaction with CdiA.  Receptor-independent, homotypic interactions between 
CdiA proteins, and thus, different subpopulations, can also be controlled by expression of 
different cdiA alleles (225).  CdiA-CT/CdiI domains are modular (157), and inhibition by 
different CdiA-CTs results in a variety of cell morphologies (158, 177) (Figures 4, 5, and 6).  
Groups of CDI
+
 cells within a complex community could be constructed such that delivery of 
phenotype-altering toxins could occur in specific subpopulations, generating multiple 
morphologies.  Finally, CdiI proteins can be expressed independently of their cognate CdiA-
CTs, allowing for creation of groups of cells that are resistant to a particular CDI
+
 strain 
while maintaining susceptibility to other CDI toxins in the community.  Because CDI 
systems are touch-dependent, control of growth or a patterning response is not dependent on 
the diffusion of an inducing agent, such as AHLs or other small molecules, and can thus be 
controlled with higher precision. This modularity provides a platform for the construction of 
expansive bacterial communities in which subpopulations of cells can interact with each 
other in a tightly-controlled, contact-dependent manner. 
CdiA-CTs with RNase and pore-forming activity (158) have the ability to reversibly 
control toxicity. It is possible that the toxicity of other CdiA-CTs with RNase activity is also 
reversible.  Given the strict cognate/non-cognate interactions between CdiA-CTs and CdiI 
proteins, using multiple reversible CdiA-CT/CdiI pairs could allow for construction of 
oscillating cell populations in liquid culture.  CDI systems could also be harnessed for 
delivery of heterologous cargo that regulates gene expression or cell metabolism, leading to 
changes in patterning or cell morphology.  Delivery of such effectors could be controlled at 
both the outer and inner membranes of target cells, enabling delivery and response in a 
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specific target population.  However, we note that preliminary attempts to deliver 
heterologous cargo proteins using CdiA scaffolds have been unsuccessful, suggesting that 
there may be biological constraints on what can be delivered using CDI.  Incorporating 
elements of CDI systems into existing bioengineering platforms will provide a variety of new 
tools for synthetic biology and modeling.  
D.  Materials and Methods 
1. Plasmid and strain construction 
All plasmids, cosmids, and bacterial strains are listed in Table 1.  All oligonucleotides are 
listed in Table 2.  All plasmids and cosmids were verified by sequencing (University of 
California, Berkeley).  The four growth control plasmids pGC::CdiA-CT/CdiI express cdiA-
CT under the control of the promoter PBAD (i0500) and the corresponding antitoxin cdiI 
under the control of PLtetO-1.  Promoter and coding sequences are separated by the ribozyme-
based insulator parts RiboJ and SccJ (451) and the bicistronic junctions BCD2 and 
Gene10_LeuL (452) as translation initiation elements. We separately amplified the cdiA-CT 
and cdiI coding regions using the following primer pairs and plasmid templates:  E. coli 536, 
BR1/BR2 and BR3/BR4 on pCH10540; ECL, BR15/BR16 and BR17/BR18 on pCH10445; 
EC869, BR19/BR20 and BR21/BR22 on pCH10525; and Bp1026b, BR23/BR24 and 
BR25/BR26 on pCH10415.  We amplified the J64100 backbone using the primers 
TS433/TS455 and the promoter region from plasmid TS1465 with the primers TS349/TS460.  
The four linearized templates (cdiA-CT, cdiI, J64100 backbone, and TS1465 promoter) were 
then combined using Golden Gate Assembly [69] to yield the plasmids pGC::CdiA-
CT/CdiI
Ec536
, pGC::CdiA-CT/CdiI
ECL
, pGC::CdiA-CT/CdiI
EC869
 and pGC::CdiA-
CT/CdiIII
Bp1026b
.  We obtained the control plasmid pGC by cutting J64100 with XbaI and 
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SpeI and self-ligating.  The cosmid pCH12502 allows for IPTG-inducible expression of 
CDIo11
EC869
 and was a gift from Zach Ruhe (University of California, Santa Barbara). 
The chromosomal insertions in fluorescent strains CH12735 (mKate2) and CH2699 
(sfGFP) were constructed using the integration vectors TS1013 and TS1014 and the 
corresponding helper plasmid pAH69 (453).  TS1013 and TS1014 are enhanced versions 
(454) of the original integration vectors (453), encoding the fluorescent proteins mKate2 and 
sfGFP under the control of the constitutive promoter J23119 (369), respectively. 
2. Growth experiments 
We chemically transformed the pGC::CdiA-CT/CdiI constructs or a control plasmid into 
E.coli DH5αZ1.  Overnight cultures were grown 12 – 16 hours at 37°C with shaking and 
were diluted into fresh LB media supplemented with chloramphenicol (25 µg/mL).  200 µL 
of each dilution was transferred to a clear-bottom 96-well plate (Greiner Bio-One).  We 
prepared fresh serial dilutions of L-arabinose (Calbiochem) and anhydrotetracycline (Sigma-
Aldrich) and added 2 µl of the respective dilution where appropriate to reach the final 
arabinose concentrations of 0.1% - 1×10
-6
% (w/v) and 200 ng/ml atc.  Plates were sealed 
with a gas-permeable Aeraseal sealing film (Excel Scientific) and incubated at 37 °C, 80 % 
humidity, and 460 rpm in a LT-X plate shaker. OD600 was measured hourly using the 
Spectramax i3 (Molecular Devices). Each condition was tested in triplicate. All experiments 
were at least repeated once. 
To test reversibility of growth inhibition, we repeated the growth experiments final 
arabinose concentrations of 0 % and 0.001 % (w/v).  When cells grown without arabinose 
reached stationary phase, we transferred the liquid into Eppendorf tubes.  After centrifugation 
for 3 min at 3000 rpm in a tabletop centrifuge, we resuspended the cells in fresh LB without 
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inducer.  After three washes, the OD600 of each sample was measured, and cells were diluted 
to an OD600 of 0.01 in a final volume of 200 µl of fresh LB media.  We split the cells that 
originally received arabinose into two groups.  One received the same concentration of 
arabinose, and the other culture was treated with a buffer control.  After another growth 
cycle, the procedure was repeated, and the cells that did not receive arabinose treatment were 
split into two groups for subsequent growth.  To test the plasmid pGC::CdiA-CT/CdiI
ECL
 in 
the strain BW27786, we chemically co-transformed pGC::CdiA-CT/CdiI
ECL
 or a vector 
control with the plasmid pTS1127, which constitutively expresses tetR. Growth curves were 
recorded as described above. 
3. Liquid competitions 
Overnight cultures of inhibitor cells (EPI100 carrying pWEB-TNC, pCH7874, pCH9305, 
pCH12502, or pCH10445) and target cells (MC4100 carrying pTrc99a or cdiI derivatives or 
MC4100 ΔyciB::kan carrying pTrc99a) were grown overnight in LB media or M9 
supplemented media (M9 salts (Sigma), 1 mM thiamine hydrochloride (Sigma), 0.2% 
casamino acids (Acros Organics), 2 mM MgSO4 (EMD reagents), 0.1 mM CaCl2 (Sigma), 
and 0.4% glycerol (Fisher Scientific)) with antibiotics.  Cells were diluted in fresh media and 
were grown to mid-log phase at 37 
o
C with shaking.  For co-culture experiments, cells were 
mixed at a 1:1 inhibitor:target ratio in fresh pre-warmed media supplemented with 1 mM 
IPTG where indicated.  At various timepoints, aliquots were removed, diluted in M9 salts, 
and plated onto LB-agar or M9-agar supplemented with 200 ug/mL rifampicin to enumerate 
viable target cells.  Data is represented as viable target cells per milliliter of culture, and 
values shown are the mean ± SEM from three independent replicates. 
For competitions with fluorescently-labeled cells, inhibitors (CH2699 carrying pWEB-
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TNC, pCH9305, pCH12502, or pCH10445) and targets (CH2567 or CH1273 carrying 
pTrc99a derivatives) were grown in either LB or M9 supplemented media at 30 
o
C with 
appropriate antibiotics. Cells were mixed at a 1:1 ratio in pre-warmed LB, and aliquots were 
removed at various timepoints to assess phenotypes via epifluorescence microscopy. Agarose 
pads were made using M9 supplemented media (as described above, with 1.5 % (w/v) 
UltraPure™ Low Melting Point Agarose (Life Technologies)) and were cut into 1 cm2 pads 
for imaging.  10 µL of each competition mixture was removed from the shaking flask, mixed 
with DAPI II plus Fluorogel (EMS), and applied to an agarose pad.  A coverslip was added, 
and the slides were incubated at room temperature for 10 minutes to allow cells to settle 
before viewing.  Images were acquired using an Olympus fluorescent microscope with a 
100x oil objective and an Optronics MacroFire digital microscope camera.  Lightfield images 
were taken with a 12 millisecond exposure (gain 2), and DAPI images were acquired with a 
47.8 millisecond exposure (gain 2).  Fluorescent field images were acquired with a gain of 5 
and either a 502 millisecond exposure (sfGFP and BFP) or a 1 second exposure time 
(mKate2).  All images were acquired in grayscale and were false-colored using the FIJI 
image suite (292).  Overlays were cropped to 200x200 pixels using GIMP. 
4. Time-lapse Microscopy 
Time-lapse microscopy was performed as previously described (455).  We prepared 
agarose pads for imaging with M9 supplemented media plus 100 µg/ml carbenicillin.  Time-
lapse microscopy of low-density colliding microcolonies was performed as followed.  
Inhibitors (CH2699 carrying the cosmid pCH9305, which constitutively expresses 
CDIo11
EC869 
(177)) and targets (CH2567 either carrying empty pTrc99a or pCH9315 
(cdiIo11
EC869
)) were grown for 12 – 16 h in LB media at 37°C with shaking.  Cultures were 
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diluted to an OD600 of 0.01 in fresh supplemented M9 media, grown to mid-log phase (OD600 
0.3-0.5), and diluted again to an OD600 of 0.015.  0.5 µl of each diluted strain was spotted 
onto an agarose pad for imaging.  For time-lapse microscopy at higher cell density, we used 
the inhibitor strain CH2699 carrying pCH12502 (IPTG-inducible expression of CDIo11
EC869
) 
and susceptible or immune targets (CH2567 or CH12735 (ΔyciB::kan), respectively).  Both 
target strains carried pTrc99a and expressed mKate2 from the chromosome.  Overnight 
cultures were diluted, grown to mid-log phase, and diluted again to an OD600 of 0.1.  
Inhibitors and targets were mixed, and 1 µl was applied to an agarose pad supplemented with 
1 mM IPTG.  Non-fluorescent control cells (CH8251) were also prepared and imaged for 
each replicate to correct for autofluorescence of cells. 
All images were acquired with a 60x Plan Apo oil immersion objective (NA 1.4) using a 
Nikon Eclipse TE2000-E inverted microscope equipped with Perfect Focus.  The Lambda-
XL (Sutter Instruments) served as an epifluorescence light source, and a halogen bulb 
provided phase contrast illumination.  The open-source software µmanager (version 1.3.43) 
(456) controlled the CoolSnap HQ2 CCD camera (Photometric), the MS 2000 motorized 
stage (ASI instruments), and shutters.  Sample temperature was constantly kept at 37 °C 
using an environmental chamber with heat control (World Precision Instruments).  
Fluorescent images were taken using the 89006 filter set from Chroma Technology 
Corporation.  ImageJ (457) was used for image processing.  An image series from one 
position was imported into ImageJ, and the brightness of images as a whole was adjusted 
such that non-fluorescent cells imaged on a separate pad were not visible.  All images from 
the same day and same imaging channel were set to the same display range.  False color 
images were generated by merging the fluorescent channels and the phase-contrast images. 
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Figure 1.  CdiA-CT
Ec536
, CdiA-CTII
Bp1026b
, and CdiA-CT
EC869
 do not reversibly inhibit cells.  E. coli 
DH5αZ1 cells were grown in the presence of (A) arabinose and (B) arabinose and anhydrotetracycline and do 
not show any growth defect with either treatment.  Expression of (C) CdiA-CT
Ec536
, (E) CdiA-CTII
Bp1026b
, and 
(G) CdiA-CT
EC869
 inhibit the growth of cells when expressed intracellularly.  Of these, only CdiA-CT
EC869
 
inhibits cells growth in a titratable manner (compare pink, blue, and green/tan lines.  Expression of the cognate 
CdiI protein partially blocks toxicity of (D) CdiA-CT
Ec536
 and (F) CdiA-CTII
Bp1026b
, but not (H) CdiA-CT
EC869
.  
Values are the mean ± SD of three independent samples. 
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Figure 2.  Iterative expression of CdiA-CT
ECL
 can reversibly control cell growth.  (A) Schematic of the 
inducible cdiA-CT and cdiI modules.  CdiA-CT
ECL
 is under control of the arabinose-inducible PBAD promoter, 
and CdiI
ECL
 is expressed from the anhydrotetracycline-inducible promoter PLtetO-1.  (B) Inducing CdiA-CT
ECL
 
expression by increasing the arabinose concentration slows cell growth as measured by OD600.  (C) Expression 
of CdiI
ECL
 fully rescues inhibition of E. coli DH5αZ1caused by low levels of CdiA-CTECL induction and 
partially rescues inhibition caused by full induction of CdiA-CT
ECL
.  Values shown are the mean ± SD of three 
independent samples.  (D) Growth inhibition by CdiA-CT
ECL
 is reversible (left panel).  E. coli DH5αZ1 cells 
expressing CdiA-CT
ECL
 (induced with 0.001% arabinose, blue lines) are inhibited compared to non-inducing 
conditions (pink lines).  Growth recovers when arabinose is removed (transition from blue line, left panel, phase 
I to pink line, left panel, phase II) and can be re-suppressed by addition of arabinose (blue line transition from 
phase I to phase II, left panel).  E. coli DH5αZ1 grows normally in the presence of arabinose without the CdiA-
CT
ECL
 module (right panel).  Values are the mean ± SD of three independent samples. 
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Figure 3.  Expression of CdiA-CT
ECL
 inhibits growth when homogenously expressed in strain BW27786.  
(A) Growth rates of cells expressing CdiA-CT
ECL
 under control of the PBAD promoter were measured using 
different concentrations of arabinose to induce gene expression.  Suppression of the growth inhibition 
phenotype at the highest inducer concentrations (pink and purple lines) is observed after 7 h of culture.  (B) 
Expression of CdiI
ECL
 by addition of 200 ng/mL anhydrotetracycline reduces toxicity at intermediate arabinose 
conditions (compare kelly green, olive green, and yellow lines to panel (A)).  Growth of BW27786 carrying 
empty plasmid vectors is not affected by the presence of (C) arabinose or (D) arabinose and anhydrotetracycline 
in the media.  Values are the mean ± SD of three independent samples. 
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Figure 4.  Constitutive expression of CDIo11
EC869
 leads to target cell filamentation.  (A) Cells carrying a 
constitutively-active CDIo11
EC869
 system or a vector control were mixed with wild-type E. coli cells or cells 
carrying a plasmid expressing cdiIo11
EC869
.  Viable target cells were measured at 0 and 4 h.  (B) GFP-labeled 
CDIo11
EC869
 cells were mixed with mKate2-labeled target cells in shaking liquid culture.  At 0, 3, and 4 h 
timepoints, aliquots were spotted onto agarose pads and observed using epifluorescence microscopy.  CDI-
sensitive target cells (left) become filamentous after co-culture with inhibitors, while immune cells (right) do 
not display any cell morphology defects. 
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Figure 5.  Cells filament in response to inhibition by CDIo11
EC869
, creating a smooth border between the 
inhibitor and target populations.  (A) GFP-labeled CDIo11
EC869
 inhibitor cells were mixed with mKate2-
labeled wild-type E. coli target cells carrying a pTrc99a vector control on a stationary agarose pad.  Images 
from initial contact (0 minutes, upper panels) and the result of collision (144 minutes, lower panels) are 
displayed as a merged GFP/mKate2 field.  Target bacteria are independently visualized in the enlarged 
grayscale images (right panels).  Filamentous cells can be observed at the border of the mKate2
+
 population.  
(B) The inhibitor strain from (A) was mixed on stationary agarose pads with mKate2-labeled target cells 
expressing CdiI
ECL
.  The merged GFP/mKate2 fields are shown for initial contact (0 minutes, upper panels) and 
after competition (144 minutes, lower panels).  mKate2-labeled cells at 144 minutes are shown in grayscale in 
the enlarged images.  No filamentation or morphological changes are observed.  Scale bars are 10 µm.  
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Figure 6.  Inhibition of target cells by CDI
ECL
 does not alter target cell morphology.  (A) Cells expressing 
CDI
ECL
 were mixed with targets carrying an empty vector or a plasmid expressing cdiI
ECL
 at a 1:1 ratio in M9 
supplemented media.  Viable target cells were enumerated at 0 and 4 h.  Reported values are the average ± SEM 
for three independent experiments.  (B) GFP
+
 CDI
ECL
 cells were mixed with the unlabeled target cells used in 
the experiments for (A).  Cell morphology at 0 and 4 h was visualized via microscopy.  CDI
ECL
 does not alter 
target cell morphology despite decreasing viability by several logs.  The morphology of inhibited target cells 
(left panels) is identical to that of immune target cells (right panels). 
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Figure 7.  Target cell filamentation can be controlled using IPTG-inducible CDIo11
EC869
.  (A)  Inhibitor 
cells carrying an IPTG-inducible CDIo11
EC869
 system or a control plasmid were mixed with wild-type or ΔyciB 
target strains in the presence and absence of IPTG.  Wild-type cells are only inhibited when CDI expression is 
induced with IPTG.  Viable target cells were enumerated at 0 and 4 h.  Values reported are the mean ± SEM for 
three independent experiments.  GFP
+
 IPTG-CDIo11
EC869
 cells were mixed with mKate2-labeled wild-type target 
cells (B) or ΔyciB target cells (C).  Filamentation and DNA degradation is only observed in wild-type cells with 
induction of CDIo11
EC869
 by IPTG.  No filamentation or evidence of cellular damage was observed in ΔyciB 
cells, even in the presence of IPTG. 
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Figure 8.  Overexpression of the immunity protein CdiIo11
EC869 
in the absence of CdiA-CTo11
EC869
 is toxic 
to cells.  Cells carrying the pTrc99a::cdiIo11
EC869
 construct were grown in LB media with the indicated 
concentration of IPTG.  Images were taken after 3 h of growth.  Elongated cells are present in all samples 
except for the untreated culture, but no evidence of DNA degradation is observed.  Images are 20x20 µm.    
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Figure 9.  Inner membrane proteins can be utilized to influence population morphology with IPTG-
CDIo11
EC869
.  (A) GFP
+
 IPTG-CDIo11
EC869
 cells were mixed with mKate2
+
 targets and imaged after 240 minutes 
(4 h).  Target cells elongate at the inhibitor/target interface, preventing mixing of the populations and smoothing 
the interface between the populations.  Both populations are shown in the overlaid green/red images (left 
panels).  mKate2-labeled target populations are shown in grayscale (center and right panels).  Scale bars are 10 
µm.  Left panels show a 3x magnification of the full-field (center) images.  (B) mKate2
+
 cells lacking the inner 
membrane protein required for translocation are not inhibited, and populations intermingle over the course of 
the 240 minute competition.  The border between GFP
+
 and mKate2
+
 cells is jagged, as opposed to the smooth 
interface observed in (A). 
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Figure 10.  Subpopulations of cells in a complex environment can be targeted using CDI systems.  GFP-
labeled CDIo11
EC869
 cells were mixed with immune BFP-labeled cells expressing cdiIo11
EC869
 and CDI-sensitive 
mKate2
+
 target cells in shaking liquid culture and were spotted onto agarose pads for imaging.  Only the 
mKate2-labeled target cells undergo filamentation, while the immune BFP
+
 population remains 
morphologically unchanged.  Representative images from two independent experiments are shown. 
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Figure 11.  Applications of CDI-based synthetic biology tools.  Two possible methods to differentially 
control subpopulations of cells are diagrammed.  As shown in (A), a three-cell system composed of sensitive 
and immune target cells could be used to make zones of green and blue cells while excluding red cells, which 
block invading green cells by filamentation after inhibition by CdiA-CTs like CdiA-CTo11
EC869
.  (B) shows how 
multiple toxins and target cells could be utilized to built synthetic biology tools of increasing complexity. 
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Table 1.  Bacterial strains and plasmids used in this study. 
 
Strains 
  
DH5αZ1 
Δ(argF-lac)169, φ80dlacZ58(M15), ΔphoA8, 
glnX44(AS), λ-, deoR481, rfbC1, gyrA96(NalR), 
recA1, endA1, thiE1, hsdR17, laci
q
, PN25-tetR, Sp
R
 
(431) 
BW27786 
Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, Δ(araH-
araF)570(::FRT), ΔaraEp-532::FRT, 
φPcp13araE534, Δ(rhaD-rhaB)568, hsdR514 
(433) 
MC4100 
F- araD139 Δ(argF-lac)U169 rpsL150 relA1 
flbB5301 deoC1 ptsF25 rbsR, Str
R
 
(458) 
CH2567 MC4100 rif
R
 mKate2::cat (202) 
CH2699 MC4100 rif
R
 GFP::kan This study 
CH8251 MC4100 rif
R
 (173) 
CH9404 MC4100 rif
R
 ΔyciB::kan (173) 
CH12735  MC4100 rif
R
 ΔyciB::kan mKate2::cat This study 
DA28102 
galK::mTagBFP2opt-cat, constitutive expression of 
BFP at the gal locus 
Sanna Koskiniemi 
Plasmids 
  
J64100 Regulated ColE1 origin, CmR 
Registry of 
Standard 
Biological Parts 
pSB4A5 Low copy pSC101 origin, AmpR 
Registry of 
Standard 
Biological Parts 
pGCCtrl Control plasmid, CmR This study 
pGC::CdiA-
CT/CdiI
UPEC536
 
Expression of cdiA-CT
UPEC536
 under the control of 
PBAD and cdiI
UPEC536
 under the control of PLtetO-1, 
Cm
R
 
This study 
pGC::CdiA-
CT/CdiI
ECL
 
Expression of cdiA-CT
ECL
 under the control of 
PBAD and cdiI
ECL
 under the control of PLtetO-1, Cm
R
 
This study 
pGC::CdiA-
CT/CdiI
EC869
 
Expression of cdiA-CT
EC869
 under the control of 
PBAD and cdiI
EC869
 under the control of PLtetO-1, 
This study 
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Cm
R
 
pGC::CdiA-
CT/CdiI
Bp1026b
 
Expression of cdiA-CT
 1026b
 under the control of 
PBAD and cdiI
1026b
 under the control of PLtetO-1, 
Cm
R
 
This study 
pTS1127 
pSB4A5 expressing tetR under the control of the 
constitutive promoter J23100, Amp
R
 
Pakpoom 
Subsoontorn 
pTS1465 
Expression of superfolder GFP under the control of 
PBAD and of mKate2 under the control of PTET, Cm
R
 
Pakpoom 
Subsoontorn 
pTS1013 
HK022 integration vector expressing mKate2 under 
the control of the promoter J23119, Cm
R
 
Pakpoom 
Subsoontorn 
pTS1014 
HK022 integration vector expressing 
superfolderGFP under the control of the promoter 
J23119, Cm
R
 
Pakpoom 
Subsoontorn 
pAH69 CRIM helper plasmid encoding integrase HK022 (453) 
pCH9305 
Constitutive expression of chimeric cdiA
EC93
-
CT
EC869o11
 and cdiI
EC869o11
 genes, Amp
R
 
(177) 
pCH9433 
Constitutive expression of chimeric cdiA
EC93
-
CT
Bp1026b
 and cdiI
Bp1026b
 genes, Cm
R (172) 
pCH10445 
Constitutive expression of cdiA
EC93
-CT
ECL
 and 
cdiI
ECL
 genes, Cm
R
 
(175) 
pCH10525 
Constitutive expression of cdiA
EC93
-CT
EC869o5
 and 
cdiI
EC869o5
 genes, Cm
R
 
(172) 
pCH10540 
Constitutive expression of cdiA
EC93
-CT
Ec536
 and 
cdiI
UPEC536
 genes, Cm
R
 
(172) 
pCH12502 
IPTG-inducible expression of cdiA
EC93
-CT
EC869o11
 
and cdiI
EC869o11
, Amp
R
 
This study 
pTrc99a IPTG-inducible expression plasmid, Amp
R
 GE Healthcare 
pCH9315 pTrc99a::cdiI
EC869o11
, Amp
R
 (177) 
pCH9000 pTrc99a::cdiI
ECL
, Amp
R
 (175) 
pCH7874 
Derivative of pDAL660Δ1-39 in which the cdiA-
CT/cdiI region has been deleted, Cm
R 
Amp
R 
 
(194) 
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Table 2.  Oligonucleotide sequences used in this study. 
 
Oligonucleotide Sequence 
TS349 5’ – GCT GAG GGT CTC ATG CGA TAA TGT TTA GTC 
ATG CTA GCC ATG – 3’ 
TS433 5’ – TAC AAA GGT CTC TTA ACT CTA GAA GCG GCC 
GCG AAT TC – 3’  
TS455 5’ – AAT TAG GTC TCA CTA GTA GCG GCC GCT GCA 
G – 3’ 
TS460 5’ – TAC AAA GGT CTC AGC ATG ATT AAG ATG TTT 
CAG TAC GAA AAT TGC – 3’ 
BR1_UPEC536_cdiI_fw 5’ – CCT GAA GGT CTC AGT TAT CAT CAG TGG TGG 
TGG TGG TGG – 3’ 
BR2_UPEC536_cdiI_rev 5’ – ATA TAT GGT CTC ACG CAT TCA TCT GGA GCT 
GAT TTA ATG ATT ACC TTA CGT AAA TTG ATT GGA 
AAC ATC AAT ATG AC – 3’ 
BR3_UPEC536_cdiACT_fw 5’ – CGT TAA GGT CTC GAT GCT AAG GAG GTT TTC 
TAA TGG TTG AGA ATA ATG CGC TGA GTC TGG – 3’ 
BR4_UPEC536_cdiACT_rev 5’ – ATT AAC GGT CTC GCT AGT ACT CTA GTA TCA 
TAT TCC ATA TCC TTT CAA GGC TGA TTC TAT TT – 
3’ 
BR15_ECL_cdiI_fw 5’ – AGC GAT GGT CTC AGT TAT CAG TTG TTA AGA 
CTA TGA TAA AAA TCT AAA ACA CTA TTT – 3’ 
BR16_ECL_cdiI_rev 5’ – CAT TTC GGT CTC TCG CAT TCA TCT GGA GCT 
GAT TTA ATG TTT GGA ATA TTC TCT AAA GGT 
GAA CCA GT – 3’ 
BR17_ECL_cdiACT_fw 5’ – CAC TCC GGT CTC CAT GCT AAG GAG GTT TTC 
TAA TGT CGC TGG CAC TGG TTG C – 3’ 
BR18_ECL_cdiACT_rev 5’ – TCG CAA GGT CTC ACT AGT ACT CTA GTA CTA 
GTC CTT AAT CCT GTT TAG TCC GC – 3’ 
BR19_EC869_cdiI_fw 5’ – TAG CTC GGT CTC CGT TAT CAC TAA CCT ACT 
GCC TCA AAA AAA CTT TCC – 3’ 
BR20_EC869_cdiI_rev 5’ – GGA GCT GGT CTC ACG CAT TCA TCT GGA GCT 
GAT TTA ATG AAA TTA ACT GTA GAT AGC GTT 
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ATT AAT GAA CC – 3’ 
BR21_EC869_cdiACT_fw 5’ – CCT TGC GGT CTC TAT GCT AAG GAG GTT TTC 
TAA TGT ATC TGA GTA AAG CCC AGA AAG CTC – 3’ 
BR22_EC869_cdiACT_rev 5’ – TAC TGC GGT CTC ACT AGT ACT CTA GTA TTA 
TTT ATA CAA CGC ATG CTT TAA TAC TGG ATA – 3’ 
BR23_1026b_cdiI_fw 5’ – GGA TGA GGT CTC CGT TAT CAT CAC CTC CGG 
TAT TCG TTA TCT TG – 3’ 
BR24_1026b_cdiI_rev 5’ – CTG AAA GGT CTC ACG CAT TCA TCT GGA GCT 
GAT TTA ATG GCA ATT GAC TTG TTT TGC TAT CTC 
TCA – 3’ 
BR25_1026b_cdiACT_fw 5’ – TGC TCA GGT CTC GAT GCT AAG GAG GTT TTC 
TAA TGG GCT CTT TAT CAG GCA AGC C – 3’ 
BR26_1026b_cdiACT_rev 5’ – ACC TGG GGT CTC GCT AGT ACT CTA GTA TTA 
ATT CCC CTT TGG CTT TAT GAT GGT – 3’ 
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VIII. Conclusion 
Bacteria are ubiquitous in nature.  The density and complexity of the microscopic world 
necessitates tools to help these cells acquire nutrients, communicate with neighboring 
microbes, and fend off direct competitors, all while replicating and establishing a niche in a 
host organism or another environment.  These needs are evidenced by the diversity of 
inhibition and competition systems that have been discovered in prokaryotic organisms.  
Both contact-independent and contact-dependent bacterial competition systems have been 
classically envisioned as a means by which an inhibitor cell (or population of inhibitor cells) 
can gain an advantage over nearby susceptible cells, thus promoting their own growth or the 
growth of sibling cells over surrounding microbes. 
This thesis has explored aspects of contact-dependent growth inhibition (CDI) systems in 
E. coli in an effort to understand the process by which these systems deliver CdiA-CT toxin 
domains into neighboring cells, how these effector domains exert toxicity, and how these 
systems are involved in general bacterial physiology.  Chapter II presented genetic evidence 
towards the mechanism by which CdiA-CT toxins translocate across the inner membrane of 
target cells during delivery.  Chapter III illustrated a physiological role for one such inner 
membrane protein, YciB, which we demonstrate is required for metal tolerance in E. coli in 
addition to CdiA-CT delivery.  In Chapter IV, we examined CDI from the viewpoint of a 
target cell and discussed insertion element transposition as a way to confer transient 
resistance to certain toxins.  This type of target cell stress response may contribute to the 
physiology of these systems in natural environments.  Chapter V presented work 
investigating the basis of CdiA-CT diversification across bacterial genomes, specifically 
focusing on a family of toxins related to the DNase toxin CdiA-CTo11
EC869
.  This work shows 
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how CdiA-CT/CdiI pairs evolve at the toxin-immunity interface while retaining a conserved 
core structure.  In Chapter VI, we discussed new data on a co-factor involved in the activity 
of two CDI toxins.  This protein, EF-Tu, is a well-characterized translation factor that has 
recently been implicated in the delivery of a type 6 secretion system toxin in Pseudomonas 
aeruginosa.  Finally, in Chapter VII, we stepped outside the physiological role of CDI to use 
these modular toxin-immunity domains as synthetic biology tools.  Taken together, this thesis 
highlights how a seemingly-simple three gene locus encodes an inhibition system of 
remarkably complexity. 
Future research will continue to investigate how these bacterial competition systems 
interact with and inhibit other cells, and this work will refine our understanding of the 
biological role of CDI in microbial environments.  In this concluding chapter, we discuss 
some research questions of significant interest in the field of CDI.  A notable observation 
regarding is that every facet of CDI studied thus far has had implications not only for these 
inhibition systems, but for fundamental aspects of bacterial physiology.  The processes 
required for biogenesis and surface display of CdiA, delivery of toxins, and carrying out 
inhibitory activity is inherently intertwined with research areas such as protein translocation 
across membranes, translation, metabolism, microbial stress responses, and evolution.  A 
deeper understanding of the mechanisms involved in CDI will undoubtedly provide a fresh, 
interesting perspective on well-studied principles of microbiology. 
A. Outlook on the mechanisms of CdiA-CT delivery 
1. Rethinking the model of CdiA biogenesis 
The current understanding of the biogenesis of CdiA is based on the model of FHA 
protein orientation in Bordatella pertussis, which proposes that the C-terminus of the protein 
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projects away from the cell surface, while the N-terminal region anchors the protein to the 
cell surface (148).  However, this model has several logistical flaws.  First, CdiA and FHA 
proteins are exceptionally large (200-600 kDa), and the C-terminal toxin domains of CdiA 
are relatively small (20-30 kDa) (167, 170).  Therefore, presenting the “business end” of this 
protein into extracellular space is a bold, somewhat risky option given the possibility of 
degradation by extracellular proteases.  However, it is possible that the native conformation 
of CdiA is such that the C-terminal toxic domain is protected from the extracellular milieu by 
the folding of another yet-uncharacterized domain upstream in CdiA into a pseudo-chaperone 
domain that shields CdiA-CT until delivery, much like how the RHS repeat domains in 
ABC-type toxins form a “cage” around the delivered effector domain (233).  Additionally, 
the receptor binding region of CdiA lies in the middle of the primary sequence (157, 159, 
225).  It is not immediately obvious why this would be the optimal domain localization if the 
C-terminus is secreted from the cell first, considering that receptor binding must occur for 
toxin delivery. 
Perhaps a more parsimonious explanation is that the current model of CdiA presentation 
is inverted.  CdiA requires the Sec machinery for co-translational secretion into the periplasm 
of CDI
+
 cells, and the N-terminus is transported into the periplasm before the C-terminus.  If 
the N-terminus of CdiA is also secreted via CdiB before the C-terminus, this could 
conceivably be a mechanism by which the extracellular portion of CdiA, presumably 
containing the receptor-binding domain, could sample the surface of nearby cells to ensure 
that there is an appropriate target in the vicinity that can receive the CdiA-CT domain.  This 
orientation could also protect CdiA-CT from extracellular degradation by selectively 
releasing this domain from the periplasm of producing cells after receptor binding occurs, 
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ensuring its immediate delivering into an awaiting cell.  A number of periplasmic chaperones 
are required to keep domains in other T5SSs unfolded in the periplasm before export out of 
the cell (459, 460), so it is plausible that a similar system could protect CdiA-CT from the 
activity of periplasmic peptidases or retain the effector in a delivery-competent state until 
delivery into a target cell can occur.  This model could also rationalize the lack of 
periplasmic-acting CdiA-CT toxins identified thus far.  It is interesting to considering that in 
contrast to T6SS effector domains and colicins, no known CdiA-CTs degrade periplasmic 
components like peptidoglycan.  CdiI proteins are produced in the cytoplasm and have no 
signal peptides or export signals to localize them to the periplasm for protection against 
incoming toxins. 
2. Target cell recognition 
The first outer membrane receptor identified for CDI systems was BamA, an essential 
outer membrane protein involved in outer membrane protein biogenesis (157, 190).  Detailed 
studies revealed that CdiA makes contact with the surface-exposed extracellular loops of 
BamA, which have little sequence homology across species (159).  The CdiA/BamA 
interaction is species-specific; only BamA protein from E. coli supports binding of E. coli 
EC93 CdiA and subsequent delivery of CdiA-CTs and target cell inhibition (159).  This 
specificity profile dictates potential CDI interactions and restricts the inhibitory potential of 
the E. coli EC93 CDI system to other E. coli strains, thereby constraining the range of target 
bacteria that are susceptible to attack by E. coli CDI systems.  This raises the question of 
what benefit is derived from only targeting sibling cells instead of different species that may 
be competing for space and nutrients in the same niche.   
Preliminary data suggests that distinct classes of CdiA protein may utilize different outer 
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membrane receptors (Zach Ruhe, Christina Beck, David Low, and Christopher Hayes, 
unpublished data).  The ability of CDI systems to target different outer membrane proteins or 
structures increases the number of ways that CDI
+
 cells can interact with surrounding 
targets.  This interplay may be complicated by expression patterns of proteins that serve as 
CDI receptors, as outer membrane proteins are known to be regulated by a variety of factors 
(461-464).  Outer membrane proteins are targeted by phage (191), colicins (23), and host 
immune systems and are under constant selective pressure (465, 466).  CDI systems that 
target specific outer membrane proteins or cell surface structures are conceivably another 
form of selective pressure that can shape the content of surface-exposed residues of outer 
membrane proteins.  Interestingly, cell surface modifications such as production capsule can 
block CDI (157), suggesting that the inhibitory or communication potentials of these systems 
are subject to regulation on multiple levels at the outer membrane. 
3. Processing and delivery across the inner membrane 
For the nuclease CdiA-CT toxins, delivery into the cytoplasm of target cells is a 
requirement for target cell inhibition.  The work presented in Chapter II sheds light on unique 
toxin/inner membrane protein relationships involved in this process.  However, the precise 
mechanistic details of moving these proteinaceous cargoes across the lipid bilayer inner 
membrane are far from clear.  DNase colicins are predicted to interact with the anionic lipid 
head groups via positively-charged residues (81, 85).  Colicin D and related klebicins require 
LepB, an inner membrane peptidase, for translocation, and this interaction presumably brings 
the toxins close enough to the inner membrane to facilitate transport through FtsH or another 
pathway (91, 101, 103, 467).  Therefore, it is plausible that CdiA-CT domains could 
translocate across the inner membrane via similar mechanisms.  The inner membrane 
proteins we identified may take the place of LepB, bringing these toxins close enough to the 
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lipid face to initiate the final translocation steps.  One model for translocation is that after 
CdiA-CT domains gain proximity to the inner membrane by binding or interacting with a 
membrane receptor, they transverse through the inner membrane at the protein/lipid 
interface. 
Evidence of another aspect of toxin translocation across the inner membrane comes from 
the T6SS in Pseudomonas aeruginosa.  Tse6, a toxin with cytotoxic NAD(P)
+
-ase activity.  
This toxin requires the translation elongation factor EF-Tu for delivery into the cytoplasm, 
presumably via a ratchet-like mechanism in which EF-Tu interacts with an exposed 
hydrophobic patch of Tse6 and pulls the toxin across the inner membrane (262).  Like 
colicins, Tse6 is predicted to interact to with the inner membrane via positively-charged 
residues.  It is known that the proton motive force is required for CdiA-CT translocation, 
regardless of the intracellular activity of the toxin (172).  A fragment of CdiA containing the 
CdiA-CT is delivered to the periplasm after the initial BamA recognition event occurs at the 
outer membrane.  This fragment can be stably retained in this compartment in the absence of 
pmf, but complete translocation across the inner membrane into the cytoplasm requires pmf 
(172).  Perhaps CdiA-CT movement across the inner membrane shares commonalities with 
both colicin import and T6SS delivery, and intrinsic association of CdiA-CTs with the inner 
membrane recruits other cellular factors that harness pmf to complete the delivery process. 
Though we have been unable to demonstrate direct binding between CdiA-CTs and the 
inner membrane proteins required for delivery of these toxic domains, what is known is a 
genetic link between the N-terminal half of CdiA-CTs and their inner membrane 
translocation pathway.  It is clear from our study presented in Chapter II that the CdiA-CT N-
terminal domain dictates the delivery of these toxins across the inner membrane.  These N-
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terminal regions are typically poorly resolved in crystal structures of CdiA-CTs (175, 177) 
and are presumably more labile than their attached cytotoxic domains.  Current studies using 
NMR and membrane-association techniques are underway in an effort to determine whether 
these N-terminal domains have affinity for their required inner membrane proteins or the 
inner membrane itself.  A combinatorial approach using structural, genetic, and biochemical 
approaches will be required to fully understand the role of CdiA-CT N-terminal domains in 
toxin translocation during CDI as well as the biochemical rules that govern the “mixing and 
matching” of N-terminal translocation domains and C-terminal cytotoxic domains in CdiA-
CTs.  We note that while we have been able to swap translocation and cytotoxic domains 
between some CdiA-CT toxins, not all constructs have yielded a functional CDI system.  A 
better understanding of the interactions between the N- and C-terminal domains as well as 
between the N-terminal domain and translocation pathway components will allow us to 
understand why some, but not all, N-terminal/C-terminal combinations support CDI. 
In addition to the mechanistic details of membrane translocation during delivery, another 
aspect of CdiA-CT translocation that is poorly understood is the processing of CdiA that 
occurs during these steps.  CdiA proteins are highly conserved up until the VENN 
tetrapeptide that demarcates the start of the CdiA-CT domain (167).  One scenario that 
explains the conservation of this motif is that these residues are involved in a critical step of 
CdiA-CT delivery.  If a processing event that liberates the toxin domain is required for 
inhibition, then the VENN residues might facilitate this chemistry.  Preliminary experiments 
show that mutation of the terminal asparagines to alanine residues results in a loss of 
inhibition, suggesting that they are indeed important for the overall process of CDI (Julia 
Webb, Grant Gucinski, David Low, and Christopher Hayes, unpublished data).  CdiA-CT 
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domains found in Burkholderia pseudomallei are demarcated by a SNVELYN motif instead 
of the VENN tetrapeptide commonly found in gammaproteobacterial CDI systems.  Though 
not identical, the residues in the Burkholderia motif could still presumably support 
autoproteolytic activity during delivery.  Several questions about the precise mechanism of 
delivery remain to be answered.  What is the specific role of the VENN motif, and is it 
catalytic?  Are cleavage mechanisms involved in delivery of CdiA-CT domains conserved 
across all CDI systems?  
Identifying the delivered domain of CdiA-CT could aid in the clarification of processing 
steps that occur during delivery.  However, attempts to “fish out” a delivered CdiA-CT 
fragment from inside target cells has been ongoing and unsuccessful, presumably in no small 
part affected by the small number of CdiA-CT molecules that are delivered to a single target 
cell.  Also compounding identification of this domain is the experimental requirement of a 
two-cell system; it has so far not been possible to inhibit cells using purified extracellular 
doses of CdiA.  This distinguishes CDI from colicins and other related secreted toxins, which 
can be readily purified and added exogenously to cells.  A possible solution would be the use 
of two-dimensional gels to increase resolution and identify delivered fragments.  Another 
option would be to utilize an alternative delivery method based on technology used for 
vaccine development, where “ghost” cells are made by expressing low levels of phage lysis 
proteins (468).  These cells are devoid of DNA and RNA but retain the overall cell rigidity 
and shape.  This allows for the surface display of high molecular weight antigens, such as 
those used for vaccine development.  If these “cells” could display CdiA and facilitate 
delivery to target cells, this might remove some of the protein background from experiments 
aimed at identifying the delivered cytotoxic CdiA-CT fragment.   
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B. The role of CDI in bacterial environments 
1. Regulation of cdi loci 
The strain in which CDI was first identified, E. coli EC93, was initially of interest 
because it was the dominant intestinal isolate from a rat colony.  Its characterized CDI 
system is constitutively active and presumably contributed to the outgrowth of this strain 
over other gut microbes.  Interestingly, sequencing data revealed that this strain carries a 
second cdi locus that is genetically intact but not active under laboratory conditions (Stephen 
Poole, David Low, and Christopher Hayes, unpublished data).  This suggests that some level 
of regulatory control governs the differential expression of these systems.  We have 
examined cdi loci from a number of other bacteria, including Dickeya dadantii, Enterobacter 
cloacae, and clinical isolates of E. coli, and have found that expression of these systems is 
typically repressed under laboratory conditions, necessitating the construction of inducible 
promoters to enable the study of these operons. 
Little is known about what regulates the expression of CDI systems.  In Burkholderia, 
quorum sensing systems regulate expression of cdi loci (469-471).  Perhaps other CDI loci 
are also negatively or positively regulated by quorum sensing or small signaling molecules 
produced by other bacteria.  A regulatory role for quorum sensing in expression of CDI genes 
would ensure that these large genes and gene products are not produced until neighboring 
cells are near enough to be targeted.  Given the metabolic load required to produce CdiA 
proteins (which range from 300-600 kDa across species), this could be a clever way to 
conserve cellular resources until the activity of CDI systems is needed.   
The relationship between CDI regulation and other microbial communication or 
competition systems is also unknown.  Work from the T6SS field shows that these systems 
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can be activated by attack from T6SS systems produced by other cells or membrane 
perturbations from T4SS pili and antibiotics (260).  However, in these examples, the T6SS 
machinery is already assembled and fires in response to signals from other cells.  Given the 
receptor-mediated process of CdiA/target cell recognition, it is unlikely that a signal from a 
neighboring cell would trigger this process.  Expression of type 3 secretion systems (T3SS) 
in enteropathogenic E. coli is intertwined with non-ribosomal peptide production by 
Streptomyces species (472).  T3SS effectors are can be chimeric, like CDI toxins, and these 
systems are thought to diversify by recombination mechanisms similar to Rhs-CT or CdiA-
CT domain swapping (473).  CDI systems are commonly found in bacteria with quorum 
sensing systems, additional secretion systems for effector delivery, pili and other surface 
adhesins, and the ability to produce compounds that inhibit other cells, so it is possible that 
cdi expression is co-regulated along with these other communication and competition 
systems.  In some uropathogenic E. coli, the cdi genes are encoded on pathogenicity island 2 
(PAI-2), which contains a number of other virulence factors such as iron-uptake systems, 
toxin secretion systems, and pili (474).  These genes are differentially regulated during 
various stages of host colonization or infection to optimize virulence.  Therefore, it is likely 
that the expression of CDI systems on these mobile islands would be controlled in a similar 
fashion.  Similarly, it is well known that plant pathogens regulate a variety of adhesion and 
virulence factors upon association with a host (475).  HecA, an adhesin from Dickeya 
dadantii that we now know to be a CdiA protein (175, 476), is essential for aggregation and 
host cell death during Dickeya infections.  It is likely that CDI systems in pathogens with 
complex virulence factor arrays or pathogenicity islands is highly regulated and linked to the 
expression of other genes essential for virulence. 
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2. CdiA-CT activities can alter target cell morphology 
While the canonical CDI model presents this system as a “killing” mechanism utilized by 
bacteria, it is interesting to consider a more subtle role for these genes in light of the work 
presented in Chapters IV and VII.  We demonstrated in Chapter IV that spontaneous CDI-
resistant mutants can arise in a population subjected to selective pressure from a CdiA-CT 
with DNase activity, CdiA-CTo11
EC869
.  This resistance was in large part due to the 
transposition of insertion elements into yciB, a gene encoding an inner membrane protein 
required for the delivery of this toxin.  Additional nonsense mutations and small deletions in 
yciB also conferred resistance to this toxin.  The diversity of IS element insertions in yciB in 
each pool of resistant target cells cannot be explained simply by a basal level of stochastic 
movement of these mobile elements, as the normal transposition rates of these sequences is 
extremely low (348).  Furthermore, the large-scale transposition of IS elements into yciB was 
not observed in mutants resistant to a tRNase toxin delivered through the same inner 
membrane protein, suggesting that these transposition events are directly linked to the DNA 
damage induced by delivery of CdiA-CTo11
EC869
.  Together, this suggests that although the 
delivery of CdiA-CTo11
EC869
 into target bacteria is eventually lethal for a vast majority of the 
population, the kinetics of this toxicity allow for some behavioral response by target cells.  
Interestingly, we observed increased transposition of IS elements even in cell backgrounds 
lacking RecA, the ssDNA-binding protease that activates the SOS pathway in response to 
DNA damage by inactiving LexA, a transcriptional repressor (41).  This suggests that 
mobilization of IS elements in response to DNA damage mediated by CdiA-CTo11
EC869
 may 
be stimulated via a RecA-independent mechanism. 
Co-culture experiments have shown that sublethal amounts of tRNA cleavage products 
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accumulate in target cells before a loss in viability can be measured (172).  The laboratory 
conditions in which these experiments are carried out is severe, with target and inhibitor cells 
growing together in a confined space with constant mixing and aeration.  This forces 
interactions between these two populations that may not be representative of CDI in a natural 
environment.  While this provides a rich environment to study the activities of CdiA-CTs and 
the genetics required for CDI import by target cells, this may not be ideal for understanding 
the subtle consequences of low levels of toxin delivery.   
The response to CDI by target cells seems markedly different than that of the outcome of 
inhibition by T6SSs.  Many T6SS effectors are periplasmic-acting effectors that, when 
delivered into neighboring bacteria, result in a dramatic rounded phenotype and subsequent 
cell lysis – an obviously irreversible event.  Conversely, many CdiA-CTs act in the 
cytoplasm and cleave nucleic acid targets.  The work in Chapter VII shows that the activity 
of at least one CdiA-CT, a 16S RNase from Enterobacter cloacae, is irreversible.  A previous 
study showed that the toxicity associated with the pore-forming CdiA-CT
EC93
 could be 
reversed by expression of the cognate immunity protein.  Taken together, these data suggest 
that cells can recover from a small amount of CdiA-CT activity (for a subset of toxins, at 
least), but there exists some threshold past which cell death is inevitable.  Sub-inhibitory 
concentrations of antibiotics and other toxic molecules can influence gene expression (448, 
477, 478).  Specific cellular responses, including induction of the SOS response pathway, are 
associated with low levels of DNA damage (41).  During the SOS response, cells halt growth 
and repair DNA breaks before dividing.  This cascade of events is possible because the cell is 
able to detect DNA damage events that are not immediately lethal, giving the cell time to 
respond.  Perhaps sub-lethal amounts damage induced by CdiA-CTs have physiological roles 
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outside of eventual lethality. 
As shown in Chapters II and V, the activity of some CdiA-CTs, like CdiA-CTo11
EC869
, 
results in the filamentation of target cells (177, 202).  Cell elongation to a lesser degree has 
also been observed after delivery of CdiA-CT
EC93
 (158).  These morphological changes 
suggest that gene expression changes take place after delivery of a toxin.  Given the 
importance of atypical phenotypes in protection from host immune response during some 
bacterial infections (445), it is intriguing to hypothesize that CDI systems can perhaps 
influence the phenotype of surrounding cells (and survival of the community as a whole) by 
delivering low doses of toxins to invoke a physiological stress response.  Perhaps these 
morphological responses are less important in our well-aerated shaking laboratory co-culture 
conditions but are more relevant to natural populations.  Dynamic control of phenotypes and 
sulA-mediated filamentation of uropathogenic E. coli are essential for virulence in a host 
(445).  During infection, UPEC can undergo multiple rounds of differentiation into filaments, 
which help evade the host immune system and protect the bacteria from phagocytosis (445-
447).  Furthermore, bacterial filaments contribute to evolution of antibiotic resistance in sub-
MIC conditions (446, 479).  Filamentation can be triggered by a variety of environmental 
factors, including host and predator signals, quorum sensing, and low doses of antimicrobial 
compounds (446). 
3. Kin selection and the influence of CDI on bacterial populations 
Given the importance of atypical phenotypes to bacterial survival, it is intriguing to 
hypothesize that CDI systems can influence survival of the entire bacterial community by 
delivering low doses of toxins to invoke a physiological stress response.  As shown in 
Chapter VII, filamentation of target cells upon contact with a CDIo11
EC869
 inhibitor creates 
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pockets of target cells physically shielded from inhibitors by elongated cells.  In a mixed 
population, perhaps this elongation response helps promote the survival of bacterial 
communities during scenarios in which filamentation is advantageous.  In a urinary tract 
infection, this could be coupled to kin selection – by delivering toxins to neighboring E. coli 
cells, a filamentation response could help UPEC cells survive while also removing non-self 
cells from the population.  This may be a dual role for CDI that promotes fitness in a given 
environment. 
Computational modeling suggests that CDI may be important for establishing niches or 
zones of CDI
+
 bacteria in natural environments.  Blanchard et al. showed that in simulations 
of CDI
+
 and CDI
-
 populations in liquid culture, one group of cells will “win” over time (442).  
If inhibition from CDI systems is strong enough, then this provides a growth advantage, and 
CDI
+
 cells will outgrow the susceptible target cells.  However, if the fitness effect of 
expressing CDI systems is too great, then CDI
-
 cells will overtake the niche despite delivery 
of toxic peptides by CDI
+
 cells.  In models of stationary environments, distinct zones of CDI
+
 
and CDI
-
 cells are created, and patches of CDI
-
 cells can survive even in the presence of cells 
expressing CDI.  Perhaps the morphology changes described above contribute to this 
patterning and niche development during bacterial growth.  These stationary simulations may 
be a good proxy for how CDI systems influence naturally-occurring bacterial populations.  
The time-lapse microscopy presented in Chapter VII shows that target cells in contact with a 
growing population of CDIo11
EC869
 inhibitors filament, but that this event forms a border 
between the invading CDI
+
 cells and the rest of the susceptible population.  One could 
imagine that in a natural bacterial environment, the sacrifice of this outer border of cells 
would enable survival of the shielded internal cells.   
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CDI systems can be involved policing the composition of bacterial communities on 
multiple levels.  First, at the outer-most level of the surface receptor, CdiA proteins 
discriminate between cells expressing the correct receptor.  CdiA is sensitive to both different 
species (the extracellular loops in BamA vary across species (159), and Burkholderia LPS 
moieties are different than those displayed in other species (192)) and outer membrane 
proteins within the same species (based on recognition of different outer membrane proteins 
by different classes of CdiA).  Once identity has been established at the outer membrane, 
translocation initiation can occur.  After toxin delivery, a second level of control occurs at the 
level of the immunity protein.  E. coli cells may carry the correct outer membrane receptor 
but lack an immunity gene, and would therefore be inhibited.  This could help winnow a 
complex environment down to the most dominant strain by direct cell inhibition and killing, 
or delivery of specific toxins could influence the population through gene expression and 
morphological changes.  Additionally, it is possible that CdiA-CT/CdiI complexes could 
exert their own secondary effects in immune cells.  The CdiA-CT/CdiIo11
EC869
 complex binds 
DNA (177), and in a cell, this could influence gene expression upon delivery and formation 
of this complex.  An interesting question to ask from the perspective of immunity protection 
is what happens when two cells of the same species, both expressing CDI systems with 
different toxins, deliver into one another but do not carry the immunity gene required for 
protection?  Perhaps the benefits the community as a whole gains from CDI systems would 
allow subsets of cells to persist instead of the end result being death of both populations.  
CdiA is also involved in intercellular adhesion between sibling cells via a domain that is 
distinct from the receptor-binding domain.  These activities may help form beneficial 
bacterial networks or biofilms in a toxin-independent manner, increasing their fitness.  Both 
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the receptor-mediated and CdiA-mediated, receptor-independent abilities of CdiA may allow 
CDI
+
 cells to detect “self” or sibling cells in a mixed environment (225).  Similar 
mechanisms of kin selection are known to increase fitness in a population (480).   
C. Structural and biochemical features of CdiA-CTs 
Apart from elucidating the regulatory features of CDI systems, another focus of future 
research will be on the precise mechanism of CdiA-CT activities inside the cell.  Evidence 
from the CDI system in uropathogenic E. coli strain 536 combined with the data presented in 
Chapter VI indicate that some CdiA-CTs require a co-factor or permissive factor for activity 
(193).  Our data suggests that multiple toxins utilize EF-Tu and EF-Ts, but perhaps for 
different purposes.  Taken together, the data on CdiA-CT
O32:H37
 and CdiA-CT
Kp342
 suggests 
that a variety of CdiA-CTs have some biochemical or genetic interaction with EF-Tu and/or 
EF-Ts, but that these individual relationships may be unique.  Targeting a well-conserved 
protein as a co-factor makes some amount of evolutionary sense.  Because EF-Tu and EF-Ts 
are highly conserved across bacteria, a toxin requiring these for delivery or activity would 
have to undergo a minimal amount of evolution if transferred into the genome of another 
organism.  The usage of conserved co-factors may allow for greater spread of toxin/immunity 
modules throughout bacteria while retaining the ability to rapidly inhibit neighboring 
bacteria.  To date, all characterized CdiA-CTs are pore formers, DNases, or RNases.  
However, extensive bioinformatic analysis by Zhang and Aravind predict many more 
functions for CdiA-CTs, including deaminases and peptidases (199, 200, 232, 481).  Given 
the vast array of CdiA-CTs (more than 20 distinct families of toxins in E. coli alone (170)), it 
is likely that examination of additional crystal structures will reveal novel features about CDI 
biology. 
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Structural analysis and molecular modeling will also elucidate how inactivation by 
immunity proteins specifically blocks toxic activity.  Thus far, we have discovered examples 
of CdiI proteins that neutralize their cognate toxins by directly occluding the active site 
residues as well as CdiI proteins that bind an exosite away from where the catalytic activity 
occurs (175, 177).  While active site occlusion is a readily-interpretable form of inactivation 
via immunity proteins, it is more difficult to understand the mechanisms of exosite 
inactivation.  Structural studies have also revealed unique prokaryotic folds, such as the β-
complementation that forms between CdiA-CTs and CdiI proteins in the EC869 superfamily 
of DNase toxins (177, 202).  This toxin/immunity interface provides a rich surface to study 
the evolution of CdiA-CT/CdiI modules as they spread throughout bacteria.  Riley and other 
colicin biologists have proposed that diversification of bacteriocins occurs at the 
toxin/immunity interface, where mutations in the immunity that retain high-affinity binding 
to the colicin are matched by mutations in the toxin (38, 39, 212).  Similar evolutionary 
forces likely contribute to the diversity of CdiA-CT/CdiI pairs.   
While many aspects of the mechanisms involved in CDI remain unclear, what is 
increasingly apparent is that CDI and related systems are important in a variety of cellular 
processes in bacteria, from kin selection to biofilm formation to gene regulation in host 
organisms.  Future work will not only reveal fine mechanistic detail regarding the delivery 
and activity of these systems, but will also contextualize them in the big-picture scope of 
bacterial physiology within complex communities.  That every “answer” obtained in this 
work raises more questions speaks to the rich future of research on contact-dependent growth 
inhibition systems in bacteria. 
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